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Abstract 
The aim of this project is to synthesise and investigate potential enantioselective 
membrane carriers for the enantioseparation of racemic drugs. Tetramethoxy-
resorcinarene is a potential enantioselective membrane carrier because it possesses a 
chiral cavity. This project proposes to enhance the binding of the tetramethoxy-
resorcinarene by partial enclosure of the cavity via synthetic installation of a crown 
ether bridge that spans from distal positions over the cavity of the resorcinarene. In the 
synthesis, a key intermediary product was a distally-functionalised tetramethoxy-
resorcinarene, since it would prevent proximal-bridging and pave the way for the 
bridge to selectively attach at distal positions of the resorcinarene. 
The first strategy towards the distally-functionalised tetramethoxyresorcinarene aimed 
to spatially enforce distal selectivity on the resorcinarene through the direct attachment 
of a rigid bridge of identical length to the resorcinarene. A calixarene was chosen to 
serve as the rigid bridge due to its similar dimensions to the resorcinarene, as well as 
the existing literature methods to readily produce a distally-functionalised calixarene. 
Imine linkages were chosen to link the rigid bridge to the resorcinarene because the 
reactions to form these are reversible and would reduce the possibility of oligomeric 
products. The synthesis of both tetraaldehyde- and tetraamino- resorcinarene 
precursors were both accomplished in three steps from the starting resorcinarene, 
according to literature procedures. The corresponding distal dialdehyde- and diamino- 
calixarene rigid-bridges were respectively synthesised in two and five steps from 
tetrahydroxycalixarene. The imine coupling of both the resorcinarenes with their 
corresponding calixarene rigid bridges was investigated. The results were however 
lacking in success, giving ambiguous and inconclusive 1H NMR spectra. Considering 
these unpromising results, together with the effort required in synthesising the 
resorcinarene and calixarene precursors, this strategy was deemed to be impractical 
and was abandoned. 
The second strategy towards the distally-functionalised tetramethoxyresorcinarene 
precursor was a partially-selective lithiation of the aromatic ring followed by 
quenching, as was described in the literature for an octamethoxyresorcinarene. In order 
to apply this lithiation to the tetramethoxyresorcinarene, the phenols were first 
protected with benzyloxy and methoxymethyl groups. Under the lithiation conditions, 
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the benzyloxyresorcinarene appeared to decompose, while the 
methoxymethylresorcinarene yielded the entire range of partially-functionalised 
products with no selectivity. As a proof of concept, the tetramethoxyresorcinarene was 
O-alkylated with ethoxy groups, then subjected to the lithation delivering the distally-
functionalised product in 36% yield, after separation from starting material. These 
results suggest that the selective lithiation is not widely applicable being only 
successful for alkoxyresorcinarenes with an alkyl group that is similar to a methyl. 
The third strategy towards the distally-functionalised precursor was through direct, 
partially-selective protection of the tetramethoxyresorcinarene phenols. The reaction 
with TBDMS-Cl and potassium tert-butoxide in tetrahydrofuran successfully 
delivered the distally-functionalised resorcinarene in a best yield of 31%. All other 
partially-protected resorcinarenes were also produced and these were readily isolated 
and characterised. Furthermore, this reaction was scalable, and through this simple 
single-step reaction, the key intermediary product of a distally-functionalised 
resorcinarene was produced in gram-quantities. Due to the instability of the TBDMS 
protecting groups, the TBDMS groups were replaced with benzyloxy groups via two 
additional high-yielding steps. 
With gram-quantities of the key intermediary product, the distal-bridging of the 
tetramethoxyresorcinarene was a success. Three sizes of the distally-bridged crown 
resorcinarenes were synthesised in good yields ranging from 49-70%. Removal of the 
benzyloxy protecting groups was accomplished in quantitative yield to furnish the 
target dihydroxy crown 5-7 resorcinarene products in a total of five steps from the 
starting resorcinarene. All six of these crown resorcinarenes were characterised by 
NMR, and some by X-ray crystallographic methods. To investigate these crown 
resorcinarenes as enantioselective membrane carriers, camphorsulfonate 
diastereomers were made and separated for all three derivatives, enabling the crown 
resorcinarenes to be obtained as single enantiomers. In total, twelve distally-bridged 
crown resorcinarenes in three different sizes (crown 5-7), and in three different types 
(dibenzyloxy, dihydroxy, dicamphorsulfonate) were synthesised and characterised.  
The twelve distally-bridged crown resorcinarenes, together with three synthesised bis-
crown 5-7 resorcinarenes, were investigated as membrane carriers for salbutamol. The 
membrane transport experiments found that all crown resorcinarenes were enhancing 
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the transport of salbutamol to varying degrees. However, all of these crown 
resorcinarenes were transporting salbutamol at a low rate. To examine the possibility 
of enantioselective transport, single enantiomers of one of the best membrane carriers 
were obtained from the hydrolysis of the respective camphorsulfonate diastereomers. 
Membrane transport of salbutamol by these single enantiomers unfortunately showed 
no enantioselectivity according to chiral HPLC analysis. Nevertheless, this work offers 
a proof of concept, being the first demonstration of salbutamol transport across a 
membrane mediated by a membrane carrier. Optimisation of the chiral resorcinarene 
and membrane transport conditions may provide the breakthrough of an 
enantioselective membrane carrier. 
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1 Introduction 
 
 
Some of the content presented in this chapter has been published in a peer reviewed 
book cited below: 
Tan, D. A.; Mocerino, M., in Calixarenes and Beyond, Neri, P.; Sessler, J. L.; Wang, 
M.-X., Eds. Springer International Publishing: Cham, 2016; pp 235-253.  
DOI: 10.1007/978-3-319-31867-7_10 
 
Chiral molecules are molecules that have mirror images that are not superimposable. 
The different mirror images of chiral molecules are known as enantiomers and an 
equimolar mixture of enantiomers is known as a racemic mixture. The potential for 
the undesired enantiomer of a chiral molecule to cause harm is well known.1, 2 This is 
of concern wherever chiral organic molecules are made to interact with living 
organisms, whether in agriculture, fragrances, cosmetics or medicine. Medicines are 
particularly important, because of their common widespread use, dependence, and the 
potential risk to human lives. Chiral drugs consisted of 40-50% of the drugs marketed 
around 2013.1 Furthermore, newly-approved chiral drugs are a majority, accounting 
for 73% of globally-approved drugs between 2001-2010.3 The issue of racemic 
mixtures of chiral drugs came to the spotlight in the infamous case of thalidomide 
where pregnant women in the 1950s were administered a racemic mixture of the drug 
to relieve their morning sickness. Tragically, the (S) enantiomer of thalidomide caused 
major deformations in the infants, which resulted in many of their deaths as well as 
many handicapped survivors.4 This example clearly illustrates the issue: one 
enantiomer produces the therapeutic effect, but the other enantiomer impacts the body 
differently in a manner which may be undesirable. Some drugs today have undesirable 
enantiomers, but are still administered as racemic mixtures.1 This is because the side-
effects due to the undesirable enantiomer are not as serious and are often overlooked, 
but are nevertheless a nuisance. Therefore, removal of the undesirable enantiomer of 
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these drugs could remove the undesirable side-effects, and also halve the dosage. This 
would improve the quality of the therapeutic treatment for the many patients taking 
the drug. 
The issue of negative side effects is not universal for all chiral drugs, since some chiral 
drugs are still being approved as racemic mixtures. In some cases, the advantage of a 
single enantiomer drug over a racemic mixture is unclear, or that both enantiomers 
contribute to the therapeutic effect.1 This is evident in the selection of common racemic 
drugs listed in Table 1.1.1, 5-7  
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Table 1.1 A selection of common and current racemic drugs.  
Name Application (S) enantiomer (R) enantiomer 
OH
OH
OH
NH
Salbutamol8-10 
Treatment of 
asthma 
Associated with 
pro-inflammaotry 
effects 
Relaxes airway 
muscles 
F3C
O N CH3
H
Fluoxetine5 
Anti-
depressant 
More potent than 
(R) 
Metabolised 
faster 
NC
O
N
F
Citalopram5 
Anti-
depressant 
More potent than 
(R)* 
Possible 
antagonist of (S)
H3CO
N
OH
Venlafaxine5 
Anti-
depressant Both enantiomers are useful 
N
OH
NH
S
O
O
CH3
H
Sotalol1 
Treatment of 
abnormal heart 
rhythms 
Both enantiomers are useful 
O N
OH H
Propanolol1 
Treatment of 
abnormal heart 
rhythms 
Both enantiomers are useful 
Cl
NH
O
 
Ketamine1 
Anaesthetic 
and analgesic 
More potent than 
(R)* 
Associated with 
hallucinogenic 
effects 
*Single enantiomer commercially available  
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In fact the infamous thalidomide, being racemized in the body,11 has been approved 
by the U.S. Food and Drug Administration for the treatment of leprosy.12 Therefore, 
the potential risks of racemic mixtures of chiral drugs is case-dependent, and requires 
individual consideration. Nevertheless, statistics from Agranat et al. have shown that 
of the 73% of globally-approved chiral drugs, 87% were approved as single 
enantiomers.3 This demonstrates that there is a strong preference for enantio-pure 
drugs, and that there are already existing methods for obtaining drugs in single 
enantiomers on industrial scales. But the fact that some common drugs, with 
enantiomer-induced side-effects, are still sold today as racemic mixtures indicates a 
need for improvement – the need for these drugs to be industrially-obtained as single 
enantiomers.  
1.1 Asymmetric synthesis and chiral resolution 
A single enantiomer of a desired chiral molecule could be obtained by extraction from 
nature. However, this requires that the molecule, is available in nature in substantial 
concentrations, and can be extracted in an industrially-viable process. This is often not 
the case, hence synthetic methods have been employed. There are two main methods 
to producing chiral molecules as a single enantiomer: asymmetric synthesis and chiral 
resolution. Asymmetric synthesis is the synthesis of a chiral molecule as a single 
enantiomer. Enantio-pure molecules may be obtained from nature for use as 
precursors, but the necessary transformations also need to preserve chirality. 
Asymmetric synthesis can also be performed on achiral starting materials which are 
more readily available, albeit a longer synthetic process. A well-known example of 
this is the asymmetric synthesis of menthol, developed by Noyori, who was awarded 
the 2001 Nobel Prize in Chemistry in recognition of his work. Alternatively, chiral 
resolution is the separation of enantiomers obtained from a racemic product of regular 
symmetric synthesis. The suitability of either method is dependent on a number of 
factors including, the properties of the molecule, its application, its synthesis, its ability 
to be scaled up for the industry, and the associated costs. The advantage of asymmetric 
synthesis is that only the desired enantiomer is formed, so there is no wastage. 
However, the fact that only a few chiral molecules have been synthesised by 
asymmetric methods on industrial scales illustrates the difficulty.13 It may be more 
feasible to resolve a racemic mixture from a regular symmetric synthetic process, or 
perhaps from a natural product if available. If there was a requirement for both 
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enantiomers, chiral resolution of a racemic mixture would be applicable. Otherwise, 
the undesired enantiomer could be discarded if it is cheap, or may be possibly 
converted to the desired enantiomer, by establishing a dynamic equilibrium between 
the enantiomers via a catalytic entity.14 All in all, both methods require a chiral entity 
to accomplish enantiopurity of a chiral molecule. This may give rise to beneficiary 
overlaps between the two methods, which are both useful for obtaining enantiopurity, 
given the uniqueness of chiral molecules. This project aims to contribute to the method 
of chiral resolution. The methods of chiral resolution can be classified into the 
following categories: diastereomeric resolution, crystallisation resolution, kinetic 
resolution, capillary electrophoresis, chromatography, and membrane-based 
separation.15 
1.1.1 Resolution of diastereomers  
The difficulty in chiral resolution arises from the enantiomers having the same physical 
properties. However, enantiomers can be converted into diastereomers which have 
different solubility and other physical properties which result from the existence of 
multiple chiral centres within the same molecule. The difference in the physical 
properties of diastereomers could enable easier separation by conventional 
crystallisation or chromatography. Separation of diastereomers from enantiomers can 
be thought of in three steps: (1) conversion of the enantiomers to diastereomers by 
attachment of a chiral moiety to the enantiomeric mixture, (2) separation of the 
diastereomers, (3) removal of the chiral moiety from the separated diastereomers to 
recover the pure enantiomers. The key factor to the separation of enantiomers via 
diastereomers is the chiral moiety; the chiral moiety may be expensive, difficult to 
determine, and needs to be enantio-pure and removable.15 Although diastereomers 
have different properties, they are still isomers and hence their physical properties may 
be similar, causing difficulty in their separation. The difference in diastereomers is 
affected by the chiral moiety they are made from, so a chiral moiety that would render 
a significant difference in the resulting diastereomers needs to be determined. This 
determination may be difficult because it is typically done through experimental 
screening. Nevertheless, these issues have been resolved in some cases, enabling chiral 
resolution by diastereomeric crystallisation of some drugs at industrial scales. An 
example of this is (S)-naproxen, a common anti-inflammatory drug, that is industrially 
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resolved in >95% ee through the enantioselective formation of an insoluble 
diasteromic salt with N-alkylglucamine serving as the chiral moiety.16 
1.1.2 Crystallisation resolution 
Crystallisation resolution is the selective crystallisation of an enantiomer from a 
racemic solution. Since its discovery by Pasteur in 184817 the concept has been used 
to resolve enantiomers from small to large scales. In this method, the enantiomers in a 
racemic mixture become separated by aggregating into enantio-pure crystals. This is 
able to occur because the enantio-pure crystals make up conglomerates which are 
overall racemic, thus the overall racemic character is preserved. Selective 
crystallisation of an enantiomer can then be effected by introducing a seed crystal of 
the desired enantiomer which causes the respective enantio-pure crystals in the 
conglomerates to crystallise out of solution.18 Though this method of chiral resolution 
is simple and economical, its widespread application to chiral molecules is limited 
since only 5-10% of chiral molecules are able to form crystalline conglomerates.15  
1.1.3 Kinetic resolution 
Kinetic resolution separates enantiomers by exploiting the different reaction rates of 
the enantiomers with a chiral catalyst. Of a racemic mixture, one enantiomer has a 
favourable orientation with the chiral catalyst and reacts, while the other enantiomer 
should remain unreacted. Complete conversion of a racemic mixture into a single 
enantiomer can be achieved by dynamic kinetic resolution. In this method, a 
racemisation equilibrium is established between the two enantiomers by a suitable 
process such as by catalysis, or heating. With the racemisation equilibrium in place, 
the desired enantiomer is reacted through a chiral catalyst, producing an enantio-pure 
product (Scheme 1.1). This causes the undesired enantiomer to be racemised through 
a shift in the equilibrium, and the resultant desired enantiomer then reacts with the 
chiral catalyst.14 Theoretically, the end result is that the entire racemic reactant is 
converted into an enantio-pure product. In situations where the chiral catalyst is not 
entirely enantioselective, it is critical for the racemisation process to be rapid to avoid 
the formation of product of the undesired enantiomer. The chiral catalyst may be a 
chemical or an enzyme catalyst. Although enzymes have been shown to be fairly 
versatile chiral catalysts, with high resolving efficiencies, the main drawbacks are that 
enzyme modification techniques are lacking, and that enzymes are susceptible to 
degradation.14 Therefore, it is necessary for the chiral catalyst and the racemisation 
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process to be compatible. Kinetic resolutions are possible on industrial scales, but 
industrial applications are currently very limited and a work in progress.19, 20 
Racemisation
Reactant (S)
Reactant (R)
Product (S)
Chiral
catalyst
 
Scheme 1.1 Schematic illustrating chiral resolution through dynamic kinetic resolution. 
Microbial systems have been known to use enzymes to entirely convert a racemic 
mixture, to the desired enantiomer.14 This occurs because the enzyme is able to 
selectively react with the undesired enantiomer, converting it to the desired 
enantiomer. There is no need to establish an equilibrium between the enantiomers, and 
no overall transformation of functional groups in this process. Therefore, this is simply 
a deracemization of a racemic mixture, and is similar to dynamic kinetic resolution, 
but more convenient. This method is in its infancy, and the limitations associated with 
the use of enzymes need to be dealt with. 
1.1.4 Chromatography 
Chromatography is a well-established and general method for separating mixtures of 
compounds. The application of chiral molecules to stationary phases is also well-
established, and has enabled the resolution of most racemic mixtures to be achieved 
with the generality of this method. As a result, chromatography is the most common 
technique used for chiral resolution. However, at industrial scales, chromatography 
often becomes expensive and inefficient, with a discontinuous operation.15 Nevertheless, 
these obstacles have been overcomed to an extent that has allowed chromatography to 
be a common method for resolving enantiomers at industrial scales.  
Simulated moving bed (SMB) chromatography is a well-established method to resolve 
enantiomers at industrial scales. Since the first multi-tonne SMB was installed in 1997, 
the technology has improved and expanded, with several installations currently 
operating around the world.21 Escitalopram (the S-enantiomer of Citaloplam) is one 
such drug to be resolved by this method. The principle of separation of the moving bed 
in SMB is that the racemic mixture is loaded at the mid-point of a column that has the 
‘stationary’ phase moving in the opposite direction to the mobile phase. The faster 
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eluting enantiomer is carried along with the mobile phase, and collected, while the 
slower eluting enantiomer is carried along with the ‘stationary’ phase, and collected. 
This enables enantiomers, which would closely-elute by regular elution 
chromatography, to be completely separated by moving bed chromatography. In 
practice, the principle of the moving bed is simulated (SMB) by continuously loading 
the racemic mixture onto the middle of a series of columns which are connected in 
series in a closed cycle. The stationary phase of these columns remains stationary, but 
the opposite motion of the stationary phase relative to the mobile phase is simulated 
by continuously moving the input of the racemic mixture as well as the two collection 
points of the separated enantiomers, in a motion that is opposite to the direction of the 
mobile phase. Advantages of these over regular HPLC are that a racemic mixture can 
be continuously resolved, and that the solvents can be recycled, once the analytes have 
been recovered. Currently, the main drawbacks of SMBs are: the requirement of a 
mathematical model for the design, optimisation and control of SMBs with the need 
for improvement of this process; the need for better chiral stationary phases with 
higher capacity; the need for solvent usage and energy consumption to be reduced; and 
the need to address other environmental concerns. 
Supercritical fluid chromatography (SFC) is another chromatographic method that has 
been demonstrated to separate enantiomers, with potential industrial applications. SFC 
uses the same standard columns as HPLC, but makes use of supercritical carbon 
dioxide as the mobile phase. Supercritical carbon dioxide has liquid-like densities and 
dissolving capabilities, while also having gas-like viscosities and diffusion properties, 
thus making it an advantageous mobile phase. With SFC, resolution times could be 
faster, the solvation power of the mobile phase could be adjusted by adjusting the 
pressure of carbon dioxide, and a reduction of organic solvent usage would be 
certain.21 However, the adoption of SFC has been hindered by a number of problems, 
including safety and cost issues associated with the temperature and pressure required 
to obtain supercritical carbon dioxide. Furthermore, there may be solubility issues, 
since carbon dioxide is relatively non-polar. Nevertheless, these issues are being 
resolved, and SFC is already being utilised in industry.22-24 There is a current effort to 
resolve some issues of SMB by incorporation of SFC.21-24  
1.1.5 Capillary electrophoresis 
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Chiral resolution by capillary electrophoresis has been proposed as an alternative to 
liquid chromatography because of the potential to increase separation efficiency, 
reduce analysis time, lower the amounts of mobile phase and buffers required, and the 
possible use of a wide variety of chiral mobile phase additives.25 Research into 
capillary electrophoresis is largely in development, with the intention of it being an 
analytical tool rather than for large scale separation. 
1.1.6 Membrane-base separation 
The principle of membranes for separation is most commonly encountered as a simple 
separation of solids from a liquid by filtration through a membrane. The membrane 
only allows liquid to pass through, thus separation is based on the size of the particles. 
This principle of membrane-based separation has been expanded for potential 
separation based on a variety of other properties, including chirality, through the 
development of different membranes.15, 26 To conveniently enable a variety of 
membranes to be used, membrane-based separations are often performed in apparatus 
as illustrated in Figure 1.1. Two aqueous phases are separated by an organic phase 
which serves as a membrane. The organic phase could be a plasticiser in a supported 
liquid membrane, or a solvent in bulk liquid membrane. Membranes could be designed 
to be selective alone, or could contain a chiral agent. Membrane agents are molecules 
which permanently reside in the membrane, while the mixture to be separated is loaded 
in the source aqueous phase. Separation would be performed by the membrane agent 
which should selectively allow passage of a component of the mixture, from the source 
aqueous phase, through the organic membrane, to the receiving aqueous phase. 
Eventually an equilibrium between the source and receiving phases will be reached. 
Therefore, equilibrium principles apply, and further separation can be achieved by 
driving the equilibrium forward through establishing a concentration or pH gradient 
across the source and receiving phases. Membrane-based separation is not as well-
established as chromatography, but there is a great potential for this method, due to its 
simple operating mechanism that offers many advantages such as: being low cost, 
energy saving, environmentally friendly, high capacity, continuous operation, easy to 
maintain, operate and to scale up to industrial scales.15 For these merits, this project 
aims to utilise membrane-based separation for the chiral resolution of racemic 
mixtures, ultimately at industrial scales, through the employment of enantioselective 
membrane agents. However, the design and synthesis of an appropriate 
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enantioselective membrane agent is the main obstacle. Though it may not be a 
requirement,27 it is thought that a potential enantioselective membrane agent should 
possess a cavity that is chiral and able to achieve an appropriately weak binding so that 
the guest molecule can be carried across the membrane and released.28 
        
Figure 1.1  Chiral resolution via enantioselective calixarene transport agent in supported liquid 
membrane or U-shaped bulk liquid membrane apparatus. Image from Tan and 
Mocerino.29 
1.2 Cavity molecules as chiral selectors 
1.2.1 Cyclodextrins 
Cyclodextrins are bowl-shaped macrocycles that are made up of glucose subunits, and 
can be simply obtained by the enzymatic conversion of starch.30 The cyclodextrin bowl 
has a hydrophobic cavity which is able to contain a variety of different molecules as 
widely reported in the literature.31-38 The chiral cavity of cyclodextrins has been 
employed as the stationary phase or additive in SMB chromatography,39 gas 
chromatography, HPLC, capillary electrophoresis and capillary zone electrophoresis 
for the chiral resolution of a variety of natural products.40 Cyclodextrins are commonly 
available, and have advantageous properties such as being water soluble, relatively 
non-toxic, stable in solution, non-UV absorbing, and ionisable.25, 41 For these reasons, 
cyclodextrins have been most commonly researched as chiral selectors for capillary 
electrophoresis. An example of this is the carboxy methyl-β-cyclodextrin used by Li 
and co-workers to resolve enantiomers of salbutamol and sotalol.42 As shown in their 
results (Figure 1.2), four analytes were resolved from each other, and further 
resolution of enantiomers of each analyte was also shown. The enantiomers of 
salbutamol and sotalol were completely resolved, while chiral resolution of the other 
two analytes, 2-amino-1-phenyl-ethanol and 1-(4-methoxyphenyl)-2-
(methylamino)ethanol, was incomplete. β-Cyclodextrin was also tested, but showed 
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significantly inferior enantioseparation compared to the carboxy methyl counterpart. 
Further analysis provided evidence that the negatively-charged carboxylate groups of 
carboxy methyl-β-cyclodextrin were providing stronger interactions via electrostatic 
interactions and hydrogen bonding with the analyte guests resulting in better chiral 
recognition. 
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Carboxy methyl-ß-cyclodextrin, R = CH2COOH  
Figure 1.2  Separation of four analytes and their enantiomers via carboxy methyl-β-cyclodextrin in 
capillary electrophoresis. Image from Li et al.42 
Given the success of cyclodextrins as chiral resolving agents, and the advantages of 
membrane-based separation, the potential of cyclodextrins to acts as an 
enantioselective transport agents have been investigated by Stancu et al.43 A heptakis 
(2,3,6-tri-o-acetyl)-β-cyclodextrin membrane carrier was shown to transport 
tryptophan, phenylalanine, tyrosine and their respective methyl esters across a bulk 
liquid membrane. The most successful transport was for tryptophan and phenylalanine 
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methyl esters which were transported in over 75% yield during a 24 hour period. This 
was most likely due to the complementary structure, together with the increased 
hydrophobicity of the two amino acids. However, in all experiments, the cyclodextrin 
showed poor enantioselectivity, transporting significant amounts of both enantiomers. 
The best enantioselectivity of 16% ee was recorded for phenylalanine. 
1.2.2 Crown ethers 
Crown ethers are macrocyclic molecules made up of ethylene glycol subunits. The 
oxygen atoms of a crown ether are available hydrogen bond acceptors, enabling the 
cavity inside the ring of a crown ether to participate in binding interactions of smaller 
guest species. Although the parent structure of a crown ether renders an achiral cavity, 
functional groups about the ring of a crown ether can be arranged in a manner that 
imparts chirality to the cavity. A chiral crown ether as such has been utilised by 
Steffeck et al., for the chiral resolution of racemic mixtures of secondary amine drugs 
by HPLC.44 The crown ether used was either enantiomer of  (18-crown-6)-2,3,11,12-
tetracarboxylic acid, which was immobilised onto the silica gel stationary phase by 
covalent bonds (Figure 1.3). The crown ether was believed to cause retention of the 
secondary amines by hydrogen bonding of the hydrogen atoms of the amine to the 
crown ether oxygen atoms, as well as electrostatic attraction between the protonated 
amine to the carboxylate of the crown ether stationary phase. The different affinities 
of the enantiomers toward the chiral crown ether stationary phase led to different 
retention of the enantiomers that was sufficient for their resolution.   
O
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Figure 1.3 Chiral crown ether stationary phase for chiral resolution of secondary amines by 
HPLC.44 
Crown ethers have also been a part of enantioselective membrane transport agents. 
Using a U-shaped apparatus (Figure 1.1), Breccia et al. showed that their crown-
guanidinium membrane carrier (Figure 1.4) was able to efficiently transport 1.2 % of 
zwitterionic tryptophan amino acid over a short period of 1.5 hours, with up to 80% ee 
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for the L-enantiomer.45 The enantioselectivity of the carrier was enabled by its chiral 
structure, effected by the specific orientations of the aza-crown ether and the 
naphthalene substituents on the bicyclic guanidinium moiety. Through molecular 
dynamics studies, the guanidinium moiety of the carrier was shown to hydrogen bond 
with the carboxylate group of the zwitterionic L-tryptophan, whilst the ammonium 
group of the amino acid was bound in the cavity of the aza-crown ether through 
alternating hydrogen bonds to the ether oxygen atoms. The naphthalene group of the 
carrier was envisioned to interact with the side chain of the amino acid. However, it 
was reported to be slightly oscillating in solution at room temperature, indicating that 
it was largely not participating in the binding and recognition of the amino acid. 
L-tryptophan zwitterion
N
N + NH O O
N
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OO
O
OO H
NH3
N
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O O
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PF6-
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Figure 1.4 Aza-crown ether guanidinium efficiently transported the L-tryptophan zwitterion in up 
to 80% ee.45 
1.2.3 Calixarenes 
The versatile ability of calixarene derivatives to act as hosts for a variety of smaller 
guest species as well as membrane transport has been widely demonstrated in the 
literature.28, 46-52 This is because calixarenes are relatively large bowl-shaped 
molecules that are readily synthesised and functionalised. Figure 1.5 illustrates a range 
of conformations calixarenes and their derivatives may adopt. Calixarenes may 
interconvert between conformations if not rigidly held together by steric forces, 
hydrogen bonding or by other intramolecular interactions.53 As depicted in Figure 1.6, 
only a calixarene in the cone confirmation is bowl-shaped and possesses a cavity. A 
calixarene in the cone confirmation has a narrower (bottom) rim as well as a wider 
(upper) rim. The wider rim of a calixarene may be selectively and variously 
functionalised to enable the calixarene cavity to engage in a range of interactions with 
smaller guest molecules. This range of interactions can be adjusted to be charged or 
neutral, and may lead to the cavity being selective for a particular type of guest 
molecule, depending on the configuration and the type of functional groups on the 
wider rim.  
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Figure 1.5 Some conformations of calixarenes.54 Resorcinarene terminology in parentheses.55 
Cavity
Wider rim
Narrower rim  
Figure 1.6 Calixarenes are bowl-shaped molecules possessing a cavity. 
An example that illustrates the influence of functional groups on the binding of 
calixarenes is the membrane transport studies by Adhikari et al.28 Knowing that certain 
calixarenes are able to bind choline and tetraalkylammonium molecules, a potential 
application of this principle to membrane carriers was investigated. The investigation 
aimed to utilise the choline functional group to act as a ‘handle’ to facilitate binding 
between a particular calixarene host, and a fluorophore guest. A choline handle was 
attached to various fluorophore molecules, which were tested as guests to be 
transported across a liquid membrane by a couple of known choline-binding 
calixarenes acting as experimental membrane carriers. The highest transport of 11% 
was achieved with tetraphosphonic acid calixarene as carrier for the FITC-choline 
guest (Figure 1.7), over a period of 200 hours.  
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Figure 1.7 The membrane transport of the FITC-choline guest was facilitated by maintaining a 
charge balance through exchange of H+ to and from the tetraphosphonic acid 
calixarene.28 
The binding was mainly effected by the ionic attractions between the negatively 
charged tetraphosphates of the calixarene, and the positively charged ammonium of 
the guest. Transport of the guest was facilitated by maintenance of charge balance 
through an exchange of a H+ from a phosphonic acid of the calixarene host with the 
source and receiving phases. Since this main interaction occurred at the wider rim of 
the calixarene, the electron-rich calixarene cavity may have also been able to hold the 
ammonium guest via a cation-π attraction as depicted in Figure 1.8.  
 
Figure 1.8 Binding and releasing of the FITC-choline guest by the tetraphosphonic acid calixarene 
membrane carrier. Reprinted with permission from Adhikari et al., Eur. J. Org. Chem. 
2014, 2014 (14), 2972-2979 (graphical abstract). Copyright John Wiley & Sons 2014.28 
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However, the resorcinarene cavitands (A-C, Table 1.2) that were also known for 
binding choline moieties exhibited no transport ability. These resorcinarene cavitands 
showed good binding by preliminary NMR studies, which were a contrast to the 
successful calixarene membrane carrier, which appeared to be a weak binder during 
NMR tests. Indeed, the resorcinarene cavitands which appeared to be strong binders, 
simply extracted the guests out of the source phase, never to be released again to either 
of the aqueous phases. This demonstrates the importance for a calixarene to have the 
appropriately weak binding for the guest, to be a successful membrane carrier. The 
appropriate weak binding may be obtained by adjustment of the functional groups 
present on the calixarene. 
Table 1.2 The appropriately weak binding of a calixarene host is crucial to its success as a 
membrane carrier.28 
Calixarene 
Host 
O O
O
O
OO
O
O
R R
RR
N
NH N
N
H
N
NHN
N
H
R' R'
R'R' A: R' = H, R = C11H23B: R' = H, R = C5H11
C: R' = CH2COOEt, R = C11H23
D: calix[4]arene, R' = tBu, R = CH2COOH
E: calix[6]arene, R' = tBu, R = CH2COOH
F: calix[4]arene, R' = CH2PO2(OH)OiPr, R = nPr
OROR OR
R' R'
OR
R' R'
 
NMR Strong binding Weak binding 
Transport No Yes 
 
Looking to their end goal of the delivery of drugs through cell walls by endocytosis, 
Adhikari et al. have extended their membrane transport studies by replacing the FITC 
portion of the guest, with drug molecules such as tryptophan, acetaminophen, 
ibuprofen, dimethylresveratrol and bentiromide.52 Moreover, different binding 
moieties, other than choline, in the form of ionisable amine moieties in unaltered 
neurotransmitters such as dopamine and serotonin were also tested as guests. 
Calixarenes D and F were shown to transport all of the aforementioned guests to 
varying degrees as highlighted in Table 1.3. 
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Table 1.3 Transport of drug-choline conjugates and neurotransmitters via calixarenes D and F. 
Experiments were conducted with varying pH of the receiving phase; the best results are 
highlighted here.52  
Guest 
Guest in 
source 
phase  
(mM) 
Guest transported (%) 
Background Calixarene D 
Calixarene 
F 
Tryptophan-choline 0.5 6.83 [a] 63.36 [a] 43.13 [a] 
Acetaminophen-choline 0.5 0.75 
[a] 
0.72 [n] 4.47 
[a] 2.07 [n] 
Ibuprofen-choline 0.5 9.05 [a][n] 27.02 [a] 50.38 [a] 
Dimethylresveratrol-
choline 0.5 1.57 [a] 4.08 [a] 5.34 [a] 
Bentiromide-choline 0.5 2.05 
[a] 
1.23 [n] 11.68 
[a] 8.66 [n] 
Dopamine 5.0 1.86 
[a] 
2.04 [n] 3.72 
[a] 45.04 [n] 
Serotonin 5.0 0.00 [n] 6.98 [n] 29.50 [n] 
[a] The receiving phase was acidic. [n] The receiving phase was neutral. Transport experiments were 
conducted over a 72 hour period. 
The position of the functional groups at the wider rim of a calixarene can enable the 
calixarene to act as a selective membrane carrier for a particular molecule. An example 
of this is the work by Duggan and co-workers who have demonstrated selective 
membrane transport of fructose from a mixture with glucose, mediated by cavitand 
boronic acids.56 Boronic acids are known for the ability to selectively transport 
carbohydrates across lipid membranes, while cavitands are known to be 
conformationally-rigid calixarenes. Therefore, cavitands with boronic acids would 
present prime candidates as membrane carriers for carbohydrates. The synthesis of 
mono-, proximal-, distal-, tri-, and tetra- cavitand boronic acids was accomplished, and 
the five cavitands were tested for the potential to selectively transport fructose over 
glucose through a solid supported liquid membrane. The results (Table 1.4) show that 
all five cavitand boronic acids were selective membrane carriers for fructose. In 
particular, the distal cavitand boronic acid showed the best selectivity, while its 
proximal isomer showed increased transport for both fructose and glucose. This 
observation clearly shows that the rate and selectivity of the transport was impacted 
by the positioning of the boronic acids about the wide rim of the cavitand. The increase 
in glucose transport was thought to be due to the glucose being able to form two ester 
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linkages between the boronic acids at the proximal positions of the cavitand, while at 
the distal positions, the two boronic acids would be too far apart, preventing the 
glucose from forming the two ester linkages. This rationale would also explain the 
marked increase in transport of the two sugars by the tri bronic acid derivative.  
Table 1.4 Selective membrane transport of fructose from a mixture with glucose, mediated by 
various cavitand boronic acids.56 
O OOO O OOO
H B(OH)2HH
C5H11 C5H11 C5H11C5H11     
O OOO O OOO
H B(OH)2H(HO)2B
C5H11 C5H11 C5H11C5H11     
O OOO O OOO
(HO)2B B(OH)2HH
C5H11 C5H11 C5H11C5H11     Mono   Proximal   Distal 
O OOO O OOO
(HO)2B B(OH)2B(OH)2H
C5H11 C5H11 C5H11C5H11     
O OOO O OOO
(HO)2B B(OH)2B(OH)2(HO)2B
C5H11 C5H11 C5H11C5H11      Tri       Tetra 
Cavitand 
boronic acid 
Transport yield % over 5 hours Ratio Fructose Glucose 
Mono 0.029 0.004 6.5 
Proximal 0.038 0.004 10.6 
Distal 0.054 0.013 4.2 
Tri 0.164 0.029 5.7 
Tetra 0.105 0.016 6.4 
 
The effect of the size of the calix[n]arene on the transport of tryptophan methyl ester 
across a liquid membrane was studied by Oshima et al.57 Of the carboxymethyleneoxy 
derivatives of tetramer, hexamer, and octamer of p-tert-octylcalix[n]arene, the best 
transport rate was recorded with the hexamer (Figure 1.9), followed by the octamer, 
while the tetramer showed essentially no transport. With the calix[6]arene derivative, 
quantitative transport of the tryptophan methyl ester was achieved under a pH gradient. 
The success of the calix[6]arene over other sizes was attributed to the C6-symmetrical 
structure which enabled a complementary tripodal hydrogen bonding of the protonated 
amino group of the tryptophan methyl ester with the six carboxylic acids of the 
narrower rim of the calix[6]arene. It was thought that the remainder of the tryptophan 
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methyl ester was binding within the hydrophobic cavity of the calix[6]arene. The 
transport of phenylalanine methyl ester, tyrosine methyl ester, and tryptophan by this 
calix[6]arene derivative was also studied. Phenylalanine methyl ester transported 
similarly to tryptophan methyl ester, but the free tryptophan amino acid showed 
neglible transport. These results indicate that the hydrophobicity of the guests was 
critical for their transport by the calix[6]arene.  
OO O
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COOH COOH
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Figure 1.9 Structure of the p-tert-octyl carboxylic acid calix[6]arene membrane carrier for 
tryptophan methyl ester guest.57 
One of the relatively few examples of a calixarene being tested as a membrane carrier 
for chiral resolution is the work by Durmaz and Sirit et al. In their three publications, 
non-chiral p-tert-butylcalixarene was distally-O-alkylated at the narrower rim with 
enantio-pure α-hydroxy amide,49 aminonaphthol,50 aminoalcohol58 moieties. A total of 
sixteen calixarene derivates were prepared and tested as enantioselective membrane 
carriers in a U-tube apparatus, for the methyl esters of phenylalanine, phenylglycine, 
and tryptophan. The best result was achieved with amino alcohol calixarene (Figure 
1.10), which transported phenylalaine methyl ester in the highest recorded transport 
flux with 52% ee. The best ee of 53% was recorded with another amino alcohol 
calixarene for tryptophan methyl ester, but had a far lower transport flux of 3% of the 
best result. All calixarene derivatives tested generally had a significantly lower 
transport flux for the tryptophan methy ester compared to the other amino acid methyl 
esters. It was thought that the enantioselectivity was the result of hydrogen bonding, 
π-π stacking binding interactions, and structural rigidity or flexibility between the host 
and guest. 
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Figure 1.10 The amino alcohol calixarene derivative which transported L-phenylalanine methyl 
ester in 52% ee.58 
The calixarenes, in the enantioseparation experiments by Durmaz and Sirit et al., were 
simply functioning as a scaffold for the chiral moieties. However, since a key feature 
of a calixarene is its cavity, this project aims to achieve enantioselective transport 
through the use of the cavity of the calixarene. A few other studies have shown that 
the chiral cavities of some calixarenes can achieve some chiral recognition.59, 60 
However, the key requirement is to obtain a calixarene with the appropriate a chiral 
cavity. 
1.2.4 Chiral resorcinarenes 
Resorcinarenes are a subclass of calixarenes. Compared to calixarenes, resorcinarenes, 
derived from resorcinol subunits, tend to have more functionality at the wider rim. If 
the configuration of the functional groups at the wider rim is chiral, then the cavity is 
chiral (axially chiral), and so the resorcinarene has the potential to be an 
enantioselective host for chiral guest molecules. Axial chirality arises when one or 
more moieties are arranged about a molecule either in a clockwise or anticlockwise 
fashion, and thus the molecule does not need to have a chiral centre. Calixarenes with 
chiral cavities are known, but the specific arrangement required often complicates their 
synthesis.61, 62 
The first enantioselective synthesis of an axially-chiral resorcinarene was reported by 
Heaney and co-workers in 1999. Starting with a Mannich reaction between octaphenol 
resorcinarene and the (R) enantiomer of an α-methylbenzylamine derivative, 
tetrakis(dihydro-1,3-benzoxazine) resorcinarene was produced in 77% yield, with very 
high distereoselectivity (Scheme 1.2).63 The key to the diastereoselectivity of this 
reaction was due to the particular arrangement of the benzoxazine groups around the 
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resorcinarene. This was caused by the formation of four hydrogen bonds between the 
phenols and the oxygen of the benzoxazine group on the neighbouring aromatic ring, 
together with the steric interactions of the chiral amines. The crystalline 
tetrakis(dihydro-1,3-benzoxazine) resorcinarene product was stable over long periods 
of time, however the diastereoselectivity would be lost when placed in solution with a 
trace amount of acid. The acid would cause the benzoxazine ring to open, and re-form; 
and on reformation, there are two possible ortho phenols to react with, hence leading 
to loss of diastereoselectivity.64 Therefore, preservation of the diastereoselectivity was 
achieved by methylating the other ortho phenol of the tetrakis(dihydro-1,3-
benzoxazine) resorcinarene. With the diastereoselectivity secured, the benzoxazine 
ring was opened by simply refluxing in formic acid. Finally, reduction of the α-
methylbenzylamine chiral moiety converted the diastereomerically-pure resorcinarene 
to its pure enantiomer.63 
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Scheme 1.2. Enantioselective synthesis of an axially-chiral resorcinarene via diastereoselective 
Mannich reaction.63 
In 2000, McIldowie and co-workers synthesised an axially-chiral 
tetramethoxyresorcinarene in a single step from starting subunits (Scheme 1.3).65 
Borontrifluoride, a strong Lewis acid, facilitated the cyclisation of the aldehyde and 3-
methoxyphenol subunits, to regioselectively construct the axially-chiral resorcinarene 
in high yields, as a racemic mixture. Out of the many possible regioisomers, the 
axially-chiral regioisomer was essentially the only product. The particular regioisomer 
obtained enabled four hydrogen bonds to be formed between phenols and methoxy 
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groups at the wider rim, causing the resorcinarene to adopt the cone conformation. 
Assembly of the resorcinarene could also be accomplished with long-chain aliphatic 
aldehydes, thus increasing its solubility in organic solvents.65 Furthermore, separation 
of the axially-chiral resorcinarene enantiomers from the resultant racemic mixture has 
been accomplished by Buckley et al. in good yields, through diastereomic separation.66 
In this procedure, the four phenols of the resorcinarene enantiomers were converted to 
camphorsulfonates to give the resorcinarene as a diasteromic mixture. Separation of 
the diastereomers of tetracamphorsulfonate resorcinarene was then achieved by 
column chromatography, and hydrolysis of all camphorsulfonates from each 
diastereomer afforded the enantiomerically-pure axially-chiral tetramethoxy-
resorcinarene.  
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Scheme 1.3 One-step synthesis of an axially-chiral resorcinarene.65 
Therefore, this tetramethoxyresorcinarene appears to have the key features of a 
potential enantioselective membrane carrier, which this project aims to investigate. 
However, the major remaining obstacle is that the cavity of the tetramethoxy-
resorcinarene is likely too open and has not enough binding interactions for the guest 
to be retained during transport. This work proposes to bind guests inside the cavity of 
tetramethoxyresorcinarene by partially-enclosing the cavity through installation of a 
bridge over the wider rim from distal aromatic rings. 
1.3 Bridged calixarenes 
Calixarenes that are distally-bridged on the narrower rim are common in the 
literature.67-71 The crown ether bridged calixarene synthesised by Ungaro and co-
workers in 1995 is one of many examples.48 Selective distal functionalisation of a 
calixarene on the narrower rim was first achieved by treating tetrahydroxycalixarene 
with 1.1 equivalents of potassium carbonate base with an octyl halide (Scheme 1.4). 
Simple alkylation of the remaining two distal phenols by pentaethylene glycol 
ditosylate furnished the crown ether-bridged calixarene in the 1,3-alternate 
 23 
 
conformation. The calixarene crown ether was then shown to be a membrane transport 
agent selective for caesium ions over sodium ions. Such a system has been utilised by 
the U.S. Department of Energy to remove caesium ions from more than 11 million 
litres of radioactive waste.72, 73 
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Scheme 1.4 Selective distal bridging of calixarene at the narrower rim. 
Distal selectivity is a key requirement for selective distal-bridging of calixarenes. The 
simple two-step procedure developed by Ungaro and co-workers has been responsible 
for the many narrow-rim, distally-bridged calixarenes reported in the literature. The 
mechanism of the distal selectivity of the phenol alkylation is illustrated in Scheme 
1.5. After the first phenol is alkylated, the distal phenol is most favourable for 
subsequent deprotonation because the resultant phenoxide is stabilised by two 
hydrogen bonds formed from the two phenols on adjacent aromatic rings. Therefore, 
the second alkylation occurs on the distal phenol.74  
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Scheme 1.5  Mechanism of the selective distal alkylation of tetraphenol calixarene at the narrower 
rim. 
This mechanism of distal selectivity is only applicable to the narrower rim of 
calixarenes where the hydrogen bonding stabilisation is enabled by the phenols being 
in proximity to each other. Therefore, the popular method for distal bridging 
calixarenes does not directly apply to the wider rim of calixarenes. Unfortunately, a 
bridge at the narrower rim in the cone conformation does not make use of the cavity, 
which is a key attribute of a calixarene. Generally, the calixarene portion in these 
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narrow-rim bridged calixarenes simply serves as a scaffold. Nevertheless, distal 
bridging over the wider rim has been accomplished by transferring the distal selectivity 
from the narrower rim to the wider rim via the stronger para-activating effect of the 
remaining two phenols, as reported in the literature.74-76 
The first characterisation of calixarenes with a distal bridge at the wider rim was 
reported by Bӧhmer and co-workers in 1988.77 In their pioneering work, distally-
bridged calixarenes were synthesised by the TiCl4-catalysed Friedel-Crafts alkylation 
of α,ω-(p-hydroxypheny1)alkanes with bis(bromomethy1)phenols  (Scheme 1.6). 
TiCl4 was thought to also act as a template for the cyclisation. Calixarenes with various 
aliphatic bridge lengths were synthesised, but with lower yields. Calixarenes with 
bridges of eight carbons and longer were observed to be in the cone conformation, but 
shorter bridges resulted in the cone conformation becoming pinched. The cyclisation 
reaction with a shorter bridge of four carbons was not successful.  
+
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CH3 CH3
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Scheme 1.6 Pioneering synthesis of distally-bridged calixarene by Bӧhmer and co-workers.77 
To study the effect of the bridge length and rigidity on the synthesis of a distally-
bridged calixarene, Zeng et al. have tried various diacid chlorides to form diester 
linkages with a distal-diol calixarene (Scheme 1.7).78 Each experiment was conducted 
at dilute concentrations and produced multiple products which were separated by 
column chromatography into three main fractions. The yields of the three fractions of 
the various trials are shown in (Table 1.5). At these conditions, it is evident that the 
longer bridge with an eight-carbon chain gives the highest proportion of distally-
bridged calixarene. This could be attributed to the increasing flexibility of the longer 
chain,78  and perhaps the reduction of strain on the calixarene cone conformation. It is 
also evident that that the distally-bridged calixarene was the predominant product for 
all tests, except for the teraphthalate, which may have suffered from steric strain / 
hindrance due to its rigidity. The reactions were also attempted at higher 
concentrations, producing a greater proportion of calixarene oligomer products, as 
well as trace amounts of shorter-bridged calixarene dimers. Thus as expected, a higher 
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concentration of the reactants increases the chance of intermolecular reactions between 
calixarenes at the expense of intramolecular reactions within calixarenes. 
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Scheme 1.7 Synthesis of distally-bridged calixarenes via diester linkages. Experiments to explore 
the impact of bridge length and rigidity.78 
Table 1.5 Yields of the three main fractions from various calixarene bridging experiments. 
Bridge Yield determined by HPLC (%) 
n Distally-bridged calixarene Calixarene dimer 
Calixarene oligomer 
mixture 
1 55.6 0 41.0 
2 39.8 17.4 42.8 
3 41.3 23.7 35.0 
4 42.2 25.5 32.3 
6 66.5 0 33.5 
8 82.2 0 17.8 
phenyl 0 34.5 [a] 45.4 [a] 
[a] isolated yield (not determined by HPLC) 
In a related reaction, Cacciapaglia and co-workers constructed a distally-bridged 
calixarene with acetal linkages (Scheme 1.8).79 The outcome of this reaction was also 
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similar to Zheng et al. in that the reaction produced multiple calixarene products which 
were separated by column chromatography into three main fractions: distally-bridged 
calixarene, calixarene dimer and calixarene oligomer mixture. This work was part of 
an investigation into the synthesis of dynamic 'living' polymers which could be 
manipulated by concentration, to selectively give a particular product or oligomer at 
equilibrium. In this case, it was envisioned that the creation of a dynamic family of 
cyclic calixarene oligomers linked by formaldehyde acetals would be enabled by the 
reversible formation of the acetal linkages of the calixarene products upon the addition 
of a catalytic amount of acid. However, when a catalytic amount of trifluoroacetic acid 
was added to all three acetal calixarene fractions, a distally-bridged ether calixarene 
formed instead. This was thought to proceed via a benzylic carbocation on the 
calixarene that could be formed by the acid-catalysed cleavage of one of the acetal 
bonds. The resultant hemiacetal and stabilised p-propoxy benzyl carbocation would 
then react in an intramolecular reaction, eliminating formaldehyde and forming the 
unreactive distal ether bridge. This mechanism would explain the observation that all 
acetal calixarenes, regardless of the type of acetal linkage, resulted in the same distal 
ether bridge when treated with acid. 
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Scheme 1.8 Synthesis of acetal-bridged calixarenes and their decomposition into distally-bridged 
ether calixarene upon treatment with acid.79 
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A very similar calixarene with the short distal ether bridge has also been synthesised 
by Arduini et al. in 30% yield, beginning from the same distal diol calixarene (Scheme 
1.9).80 The 1H NMR spectrum of the product provided evidence that the ether-bridged 
calixarene was rigid, adopting a highly-distorted flattened-cone conformation. The 
protons of the aromatic rings involved in the bridge appeared at a significantly lower 
chemical shift (~δ 5.7), which suggested their shielding by the un-bridged proximal 
aromatic rings. The intermolecular bridging product, a calixarene pair linked by two 
acetal bridges, was also produced, but as a minor product. Interestingly, the 
intermolecular reaction could be favoured by reacting the distal diol calixarene with a 
distal dichloromethyl calixarene with caesium hydroxide as base, to give the calixarene 
pair product in 50% yield. 
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Scheme 1.9 Synthesis of distal ether bridged calixarene.80 
The intramolecular bridging on the wider rim of the calixarenes was further studied by 
Arduini et al. with a McMurry reductive coupling between the formyl groups of 
various formyl calixarenes (Scheme 1.10).81 The reductive coupling of distal 
diformylcalixarene afforded a distally-bridged calixarene with a diol bridge, after 5 
hours, which could be further reduced to an alkene after 16 hours. A similar result was 
also reported by Lhoták and Shinkai in separate work.82 Arduini et al. also explored 
the possibility for the coupling to occur between formyl groups on proximal aromatic 
rings of tri and tetraformylcalixarenes. With both these calixarenes, only the distal 
formyl groups showed coupling, while the remaining formyl groups were reduced to 
methyl groups. 
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Scheme 1.10 Distal bridging of formyl calixarenes via intramolecular McMurry reductive coupling.81 
Another calixarene with a short distal bridge is the siloxane-bridged calixarene 
synthesised by Hudrlik et al.83 The synthesis of this calixarene was accomplished in 
four steps, as described in Scheme 1.11. The distal selectivity on the wider rim of the 
calixarene was obtained through a selective bromine to lithium exchange, followed by 
quenching with methanol, as described by Larsen and Jørgensen.84 
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Scheme 1.11 Synthesis of distally-bridged siloxane calixarene.83 
In another example, Zajícová et al. reported a distally-bridged calixarene obtained 
from the reductive coupling of a distal dialdoxime calixarene (Scheme 1.12).75 The 
distal selectivity of the starting dialdoxime calixarene was obtained by the stronger 
para-directing effect of distal phenols at the narrower rim. The reductive coupling 
afforded the diamine product in a rather low yield of 26%, which was attributed to 
decomposition of the product under aerobic conditions. However, it was discovered 
that the product easily formed a stable aminal with acetone. Therefore, immediate 
chromatography of the diamine product with acetone afforded the aminal of the 
distally-bridged diamine calixarene in 90% yield. The scope of the reductive coupling 
was investigated with a number of dialoximine calixarene derivatives with various 
substituents at both rims of the calixarene, as well as a calixarene in the 1,3-alternate 
conformation (Figure 1.11). In all these other cases, no distally-bridged calixarene 
was detected, alluding to the sensitivity of the reductive coupling to the conformation 
of the starting dialoximine calixarene. A crystal structure of an amide derivative of the 
distally-bridged calixarene showed that the short bridge, of two carbons, forced the 
supporting aromatic rings to be bent into the cavity, causing the calixarene to take the 
pinched cone conformation.  
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Scheme 1.12 Distal bridging of dialdoxime calixarene via reductive coupling.75 
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Figure 1.11 Reductive coupling with other dialdoxime calixarene derivatives failed to give the 
distally-bridged product.75 
While investigating the synthesis of phenanthrene calixarenes via photochemical 
cyclisation, Barton85 synthesised a distally-bridged calixarene with a cyclobutane 
bridge (Scheme 1.13). The photolysis of tetra-stilbene calixarene produced a highly 
complex mixture of cyclisation products including the distally-bridged cyclobutane 
calixarene, which was isolated in 1% yield by HPLC. Deducing that the bridging does 
not occur on the proximal aromatic rings, Hüggenberg et al. attempted the same 
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photochemical cyclisation on proximal di-stilbene calixarene.86 As anticipated, the 
proximal di-phenanthrene calixarene was produced as three diastereomers in 67% 
yield, without any bridged calixarene. It is interesting that the bridging only occurred 
on the distal aromatic rings, rather than on proximal. 
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Scheme 1.13 Photochemical [2+2] cycloaddition of tetra-stilbene calixarene to give distal 
cyclobutane-bridged diphenanthrene calixarene.85 
Liu et al., while exploring the synthesis of cage-like compounds, reported another 
unexpected distal bridging of calixarenes by intramolecular coupling.87 The aim was 
to couple two tetraalkynylcalixarenes via a reversible intermolecular zirconocene 
coupling to form a cage-like structure. However, the intramolecular coupling was 
prevalent, and a two-carbon distally bridged calixarene formed instead (Scheme 1.14). 
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Scheme 1.14 Zirconocene coupling of tetraalkynylcalixarene leads to distal bridging of calixarene.87 
A distally bridged calixarene with the shortest possible bridge has been synthesised by 
Struck et al.88 The distal methylene-bridged calixarene was reported to be exclusively 
formed by the reaction shown in Scheme 1.15. The ‘collapsed’ cone conformation of 
the product was evident by signals at δ 5.6 in the 1H NMR spectrum. These signals 
were attributed to the protons of the bridging aromatic ring, which had become 
shielded by the neighbouring non-bridging aromatic rings. 
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Scheme 1.15 Synthesis of distal methylene bridged calixarene.88 
It is noteworthy from the preceding examples that it is possible to span across the wider 
rim of the calixarene with short bridges. This is possible because the calixarene in the 
cone conformation is not entirely rigid, despite the steric bulk of the four substituents 
on the narrower rim. In such a scenario, the cone calixarene oscillates between two 
pinched cone conformers, enabling the calixarene to adopt a highly-distorted, pinched 
cone conformation where the pair of distal aromatic rings involved in bridging are 
pinched close enough together to form the short bridge. The vibrational motion also 
allows the other pair of unbridged distal aromatic rings to be forced outwards from the 
cavity.  
Seeing the potential utilisation of this phenomenon, Düker and co-workers have 
experimented with the synthesis of tetrathiafulvene bridges across the wider rim of 
calixarenes for the construction of redox-active molecular architectures.89 Their aims 
were to attach the tetrathiafulvene bridges on the proximal or distal aromatic rings of 
a calixarene and their results are summarised in Scheme 1.16. Dual tetrathiafulvene 
bridges on proximal aromatic rings of the calixarene were synthesised in good yields, 
however bridging the tetrathiafulvene across distal aromatic rings was unsuccessful 
for calixarene derivatives in both the 1,3-alternate and cone conformations. The lack 
of success may be due to the conditions used as the bridging reactions were carried out 
at room temperature. Under these conditions, there may not be sufficient oscillation 
energy to bring the distal rings close enough to be bridged. Interestingly, when the 
propanitrile groups were relocated along the length of the tetrathiafulvene, the distal 
bridging was possible, although a calixarene dimer was also produced (Scheme 1.17). 
It is notable that the distal bridging was accomplished along the length of 
tetrathiafulvene, being a rigid, planar molecule of a fixed length. This may suggest that 
tetrathiafulvene is the same length as the diameter of the wider rim of a calixarene in 
the cone conformation. 
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Scheme 1.16 Synthesis of bridged calixarenes with tetrathiafulvene derivatives.89 
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Scheme 1.17 Distal bridging of calixarene with tetrathiafulvene.89 
The potential application of calixarenes to function as biomimetic receptors has led 
Casnati et al. to design distally-bridged calixarenes with peptide bridges. The aim was 
to use the hydrophobic cavity of the calixarene in conjunction with the hydrogen 
bonding of the peptide bridge to enable binding of guest molecules. Starting with a 
distally-functionalised diacid chloride calixarene, the cavity of the calixarene was 
bridged over by two alanine residues linked together by a nitrogen atom (Scheme 
1.18).90 The distally-bridged N-linked peptidocalixarene was shown to bind D-Ala-D-
Ala (Figure 1.12), thus mimicking the mode of binding of the vancomycin group of 
antibiotics. Studies indicated that a proton transfer from the carboxylic acid group of 
the guest to the amino group of the calixarene pseudopeptide bridge generated a salt 
which was thought to be the key binding interaction, besides the hydrogen bonding 
between NH and CO groups. It was speculated that the hydrophobic calixarene cavity 
may have hosted the methyl group of the non-terminal alanine residue.91 
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Scheme 1.18 Synthesis of distally-bridged (L, L) peptidocalixarene.90 
 
 
Figure 1.12 Distally-bridged peptidocalixarene mimics the mode of binding of vancomycin 
antibiotics by binding D-Ala-D-Ala by the suggested binding mechanism. Reprinted 
with permission from Casnati et al, Acc. Chem. Res. 2003, 36 (4), 246-254. Copyright 
American Chemical Society 2003.91 
However, some peptidocalixarenes are poor receptors due to intramolecular hydrogen 
bonding between amino acid residues within the molecule. This is caused by the 
peptidocalixarene being conformationally flexible. Therefore, to increase 
conformational rigidity, Sansone et al. have placed a rigid aromatic spacer between the 
two amino acid residues in a distally-bridged peptidocalixarene that adopted a pinched 
cone conformation (Scheme 1.19).92 This peptidocalixarene was shown to bind 
anionic guests, having the best affinity for benzoate. From investigations, it appeared 
again that a proton transfer had occurred, and that the resultant carboxylate anion was 
electrostatically attracted to the amide protons of the bridge of the peptidocalixarene 
(Figure 1.13). π-π Stacking between the aromatic rings also appeared to contribute to 
the binding.91 
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Scheme 1.19 Synthesis of distally-bridged peptidocalixarene linked with a rigid aromatic spacer.92 
 
 
Figure 1.13 Proposed binding of benzoate by distally-bridged peptidocalixarene. Reprinted with 
permission from Casnati et al, Acc. Chem. Res. 2003, 36 (4), 246-254. Copyright 
American Chemical Society 2003.91  
Distal bridging of calixarenes has also been performed on resorcinarenes. An 
interesting example is the thiocrown resorcinarenes synthesised by Konishi et al. by 
the bridging of distal dibromoresorcinarene with 2-mercaptoethyl ether, propane-1,3-
dithiol, and ethane-1,2-dithiol (Scheme 1.20).93 The octahydroxy thiacrown 
resorcinarene product was reportedly difficult to purify, hence the conversion to 
octaacetates for characterisation. Despite the various bridge lengths, all the thiocrown 
resorcinarenes were determined to be in the pinched cone conformation, by analysis 
of the 1H-NMR chemical shifts and molecular modelling. The bridging was also 
attempted with rigid dithiols such as 2,6-dimercaptomethylpyridine or m-
xylylenedithiol, but to no success. The distal dibromoresorcinarene starting material 
was obtained by the careful, direct bromination of octahydroxyresorcinarene with 
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limited N-bromosuccinimide. Though this bromination reaction is simple, it was not 
completely selective for the distal product, since 9 % of the obtained product was 
proximal dibromoresorcinarene.94  
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Scheme 1.20 Synthesis of distally-bridged thiacrown resorcinarenes with three bridges of varying 
length. OAc substituents have been omitted for clarity93 
Shivanyuk et al. had developed a method for regioselectively obtaining the starting 
distal tetratosylate resorcinarene from the reaction of octahydroxyresorcinarene with 
triethylamine followed by four equivalents of tosyl chloride in dry acetonitrile 
(Scheme 1.21).95, 96 Selectivity was likely to due to the observed precipitate which 
formed when the triethylamine was added to the resorcinarene. Addition of the 
sulfonylating agent to the precipitate needed to be performed quickly and followed by 
rapid stirring of the reaction mixture to avoid the formation of complicated mixtures.  
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Scheme 1.21 Mechanism of selective distal tetrasulfonylation of octaphenol resorcinarene.93, 94 
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By this method, other distally-bridged resorcinarenes have been synthesized by 
Shivanyuk et al. who used aliphatic diamines to bridge distal tetratosylate 
resorcinarenes by the formation of benzoxazine linkages from a Mannich condensation 
with formaldehyde (Scheme 1.22).97 The cavity of the crown ether-bridged 
resorcinarene was actually chiral due to the positions of the two benzoxazine linkages. 
However, no attempt was made to separate the enantiomers. The impact of a shorter 
bridge on the distal-bridging Mannich condensation was also investigated. Based on 
the conformation from the crystal structures of the previous chiral benzoxazine 
resorcinarenes, bridging should not be possible with shorter diamines. Contrary to 
expectation, the distal bridging was accomplished with ethylene diamine, but the 
shorter bridge forced the benzoxazine linkages to form on the phenols that were closer 
together, producing the other possible regioisomer which is not chiral. Both these 
distally-bridged resorcinarene regioisomers took on the boat conformation. 
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Scheme 1.22 Synthesis of axially-chiral distally-bridged tetratosylate resorcinarene via benzoxazine 
linkages. Substituents have been omitted for clarity.97 
In similar work, the Mannich condensation was also used by Arnott et al. to distally-
bridge tetratosylate resorcinarene with various diamines in good yields of 47-80% 
(Scheme 1.23).98 Various derivatives of these distally-bridged resorcinarenes were 
then tested for potential to act as enantioselective asymmetric catalysts for the 
alkylation of benzaldehyde with dimethyl zinc (Table 1.6).99, 100 Addition of 
functionality to the bridge, in the form of a dioxane and dimethoxy acetals, was 
explored for potential coordination to zinc. The different acetals caused a reversal in 
enantioselectivity. Modifications such as changing the tosylate to smaller mesylate 
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groups, or to ester groups resulted in a reversal of enantioselectivity as well. 
Lengthening, or functionalising the bridge with a dimethoxy acetal also reversed the 
enantioselectivity. These reversals of enantioselecitivity were indicative that the 
modifications were causing a significant change in conformation of the bridged 
resorcinarene. Moreover, it appears that the longer alkyl chains, despite being on the 
narrower rim, had an influence on the cavity, which resulted in the increased the 
enantioselectivity. In all tests, the ability of the bridged resorcinarene for 
enantioselective catalysis was limited to about 50% ee. Arnott et al. have suggested a 
hypothetic mechanism based on Noyori’s model to explain this limitation.100 
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Scheme 1.23 Distal bridging of tetratosylate resorcinarene.98 
  
 40 
 
Table 1.6 Studies into the potential enantioselective alkylation of benzaldehyde with diethylzinc 
in the presence of distally-bridged resorcinarene derivatives.96, 97 
H
O OH
H
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% R/S 
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In almost all the examples presented so far in this review, the distal-bridging of 
calixarenes at the wider rim has been accomplished on calixarenes that have already 
been distally functionalised. However, if bridging were to be performed on a non-
distally-functionalised calixarene with four equally-reactive subunits, multiple 
bridged-calixarene products are possible. Reinhoudt and co-workers have 
demonstrated this with flexible crown ether bridges on a cavitand.101 In this work, a 
cavitand with four equally-reactive phenol subunits was treated with 1.2 equivalents 
of pentaethyleneglycol ditosylate to give three differently-bridged crowncavitand 
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products (Scheme 1.24). The bridging reaction was performed with various solvents 
and bases, and the yields of each crowncavitand are shown in Table 1.7. It is evident 
that the proximally-bridged crowncavitand can be selectively produced in 33% yield, 
but with a significant amount of unreacted starting cavitand. The distally-bridged 
crowncavitand could only be obtained in trace yields of 2-3 % as part of a mixture of 
all three crowncavitands products. This example with a cavitand suggests that directly 
bridging a resorcinarene containing four equally-reactive subunits, with a flexible 
bridge, would produce either a proximally-bridged calixarene, or a mixture of bridged 
calixarene products. 
O
O
OO
O
O
O O
R
RR
R
O
O
O
O
O
O
OO O
O
OO
OO
O
O
O O
O
O
R R
RR
O
OH
O
OHO
O O
O
O
O
OO
O
O
O O
R
RR
R
OH
OH
OH
OH
O
O
OO
O
O
O O
R
RR
R
O
O
OH
OH
O
O
OO
O
O
O
TsOO
OTs
+ BaseSolvent
70°C
R = C5H11
1.2 equiv
Proximal DistalDouble proximal  
Scheme 1.24 Bridging of tetrol cavitand with pentaethyleneglycol ditosylate to form three different 
crowncavitand products.101 
 
Table 1.7 Reaction with various solvents and bases, and the yields of each crowncavitand product. 
Solvent Base 
Yield (%) 
Starting 
cavitand Proximal 
Double 
proximal Distal 
DMF NaH 21 33 0 0 
DMF Na2CO3 22 18 0 0 
DMF K2CO3 22 2 8 2 
DMF Cs2CO3 40 2 10 2 
CH3CN NaH 3 13 0 3 
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Bridging calixarenes on the wider rim with crown ethers has also been explored by 
Nissinen and co-workers in their synthesis of tetramethoxyresorcinarene crown 
ethers.102 Tetramethoxyresorcinarene was treated with caesium carbonate base for 15 
minutes, followed by 2 equivalents of the tetraethylene glycol ditosylate to produce 
proximally-bridged bis-crown tetramethoxyresorcinarene in 31 % yield (Scheme 
1.25). When the deprotonation time with caesium carbonate was extended to 60 
minutes, the bis-crown tetramethoxyresorcinarene was produced in 10% yield along 
with the proximally-bridged mono-crown by-product in 13% yield.103 Both the mono-
crown and this bis-crown tetramethoxyresorcinarenes adopted the boat conformation. 
The bis-crown tetramethoxyresorcinarene was shown to bind potassium, rubidium, 
caesium, and silver ions.104-106 The binding of silver ions was reversible, and was utilised 
to deliver silver ions to bacteria resulting in cell death and an anti-bacterial effect.105 
The mono-crown tetramethoxyresorcinarene, having a larger cavity, was not able to 
bind alkali metal cations. Nevertheless, the mono-crown was an optimal host for an 
acetylcholine (neurotransmitter) guest, binding through interactions between the 
crown ether with the ammonium portion, as well as hydrogen bonding between the 
two phenols with the acetate group of the guest. The distal mono-crown tetramethoxy-
resorcinarene was not reported, signalling a tendency for flexible bridges to form on 
proximal aromatic rings of a calixarene with equally-reactive subunits.  
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Scheme 1.25 Synthesis of proximally-bridged crown ether tetramethoxyresorcinarenes.102 
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1.4 Outlook and research objectives 
Calixarenes have been well studied and have proven to be suitable for industrial 
applications. However, axially-chiral calixarenes and resorcinarenes in particular, 
despite having potential for enantiorecognition, remain relatively unexplored. 
Although multiple methods for distally-bridging calixarenes and resorcinarenes exist 
in the literature, these methods are not applicable to the entire range of diverse 
calixarene derivatives. Furthermore, achieving selective distal bridging can be 
challenging, and the aforementioned example has shown that this is particularly true 
for the tetramethoxyresorcinarene – proximal bridging seems to be favoured. Scheme 
1.26 outlines the three main strategies for achieving distal-bridging of the 
tetramethoxyresorcinarene. In particular, a distally-functionalised resorcinarene would 
serve as a key intermediate that would enable the distal-bridging to proceed smoothly.  
 
Scheme 1.26 The three main routes to achieving distal-bridging of tetramethoxyresorcinarene. 
The synthesis of this key intermediate was explored in preliminary work involving 
multiple strategies.107 A selective deprotection approach was investigated by partial 
hydrolysis of tetramethanesulfonate- and tetrabenzoate- derivatives of the 
tetramethoxyresorcinarene using 2 equivalents of sodium hydroxide (Scheme 1.27). 
However, the hydrolysis reactions delivered the partially-hydrolysed products in a 
non-selective manner.  
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Scheme 1.27 Attempted distal functionalisation of tetramethoxyresorcinarene by selective hydrolysis. 
The selective deprotection was also attempted on the tetrabenzoate resorcinarene using 
DIBAL, a sterically bulky reducing agent (Scheme 1.28). In these reactions, 4 to 22 
equivalents of DIBAL were used, producing asymmetrical resorcinarenes without the 
target C2-symmetrical distally-functionalised resorcinarene.  
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Scheme 1.28 Attempted distal functionalisation of tetramethoxyresorcinarene by selective reduction. 
Other than selective deprotection, another approach investigated in this preliminary 
work was distal functionalisation by selective bromine-lithium exchange, as reported 
for calixarenes84 and cavitands.108-110 A prerequisite to this approach is the bromination 
of the ortho position of the tetramethoxyresorcinarene. However, direct bromination 
with N-bromosuccinimide (NBS) or bromine, respectively gave a mixture of 
incompletely brominated or unknown products (Scheme 1.29).  
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Scheme 1.29 Attempted bromination of tetramethoxyresorcinarene. 
The bromination was also attempted on a O-protected tetramethoxyresorcinarene via 
lithiation with butyllithium then quenching with NBS (Scheme 1.30) in a similar 
procedure to the literature.111 However, the reaction produced a complex mixture. 1H 
NMR spectroscopy of D2O quenching studies indicated that the butyllithium was 
causing decomposition of the protecting group as well as the resorcinarene.   
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Scheme 1.30 Attempted bromination of O-protected tetramethoxyresorcinarene. 
From these preliminary investigations, the uniqueness of the tetramethoxy-
resorcinarene has been realised. It seems that the synthesis of a distally-functionalised 
tetramethoxyresorcinarene requires a new procedure that is unknown to the literature. 
Therefore, the objective of this project is to continue the development of the practical 
synthesis of a distally-functionalised tetramethoxyresorcinarene, with the aim of 
distal-bridging. Crown ethers would be appropriate candidates for the bridge, due to 
their well-known ability to act as hydrogen-bond acceptors, and their availability in 
various lengths. If successful, the distally-bridged crown resorcinarene can then be 
investigated as a potential enantioselective membrane carrier for the chiral resolution 
of certain racemic drugs. 
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2 Distal functionalisation of resorcinarene by a calixarene 
rigid bridge 
A method to achieve direct distal-functionalisation of the tetramethoxyresorcinarene 
is through attachment of a rigid bridge of the appropriate length. This would be a 
molecule which is rigid and has exactly the same length as the diameter of the 
resorcinarene wider rim. The idea is that such a rigid bridge would directly attach to 
the resorcinarene at the distal positions, with the rigidity and length of the bridge being 
key to giving distal selectivity. This idea is illustrated in Scheme 2.1 where the 
tetramethoxyresorcinarene has been simplified into four grey squares which represent 
the four equally-reactive aromatic ring subunits (A in Scheme 2.1). In principle, direct 
attachment of the rigid bridge to the resorcinarene would give intermediate (B) where 
one end of the rigid bridge has attached to the resorcinarene. The other end of the rigid 
bridge would be spatially prevented from approaching proximal positions, unlike 
flexible bridges102, 103 or the standard protecting groups.107 Thus, the attachment of the 
other end of the rigid bridge should occur at the distal position of the resorcinarene, 
leading to selective formation of product (C). The remaining two aromatic rings of 
product (C) could be protected to give product (D), then the rigid bridge could be 
cleaved, like a protecting group, to give product (E) which would be the key 
intermediate of a distally-functionalised resorcinarene. As discussed in Scheme 1.26, 
a distally-functionalised resorcinarene is a key intermediate because it would be able 
to accept any bridge to furnish the desired distally-bridged resorcinarene, product (F). 
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Scheme 2.1 Illustration of the distal bridging of tetramethoxyresorcinarene by a rigid bridge. 
The preceeding examples, by Zheng et al. (Scheme 1.7) and Düker et al. (Scheme 1.16 
and Scheme 1.17) show that the length of the bridge affects the proportion of the 
variously-bridged calixarene products. Therefore, the ideal rigid bridge needs to be a 
molecule that is of the same length as the wider rim of the resorcinarene. A molecule 
that has the same dimensions as the resorcinarene would be another calixarene in the 
cone conformation. There are multiple methods documented in the literature for 
distally-functionalising calixarenes.112 For these reasons, a distally-functionalised 
calixarene would ideally serve as the rigid bridge for the resorcinarene. Furthermore, 
though the rigid bridge idea is novel for distally-functionalising a calixarene, the 
feasibility of the calixarene rigid bridge idea has been demonstrated in the literature 
by the formation of hemicarcerands. Hemicarcerands were first synthesised by Cram 
and co-workers by linking two calixarenes together at the wider rim to give a cage-
like calixarene dimer (hence the carcerand naming, to incarcerate).113-121 Scheme 2.2 
provides a few examples of the synthesis of carcerands and hemicarcerands in the 
literature. A di-imine linkage between the two bowls is proposed, because examples 
in the literature have shown that the formation of hemicarcerands by di-imine linkages 
is high-yielding and reversible, preventing the formation of oligomeric bridging by-
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products.113, 114 Moreover, imine linkages can be cleaved by hydrolysis, enabling the 
calixarene rigid bridge to be removed. These examples in the literature with 
calixarenes, should be applicable to the tetramethoxyresorcinarene since it has the 
same macrocyclic calixarene skeleton. 
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Scheme 2.2 Examples of the synthesis of carcerands / hemicarcerands in the literature.113, 118, 119, 122 
To experimentally prepare for this strategy, amine or aldehyde groups first need to be 
installed onto the tetramethoxyresorcinarene, as well as the respective calixarene 
(Scheme 2.3). The wider rim of the tetramethoxyresorcinarene has potentially two 
positions for functionalisation – the phenol and the ortho carbon of the aromatic ring. 
The amine and aldehyde groups should ideally be directly installed onto the bowls, 
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with minimal or no spacer atoms in between, to maintain the dimensions of the bowls 
for the selective distal coupling. 
R R R R
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OR ROO ORR
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been omitted for clarity  
Scheme 2.3 Amine and aldehyde resorcinarene and calixarene starting materials required for the 
rigid bridge strategy. 
The functionalisation of the tetramethoxyresorcinarene is detailed in the first two 
sections: Section 2.1 describes functionalisation at the ortho position, while Section 
2.2 describes the functionalisation of the phenolic position. The synthesis of a relevant 
calixarene rigid bridge, and the investigations into its coupling to the 
tetramethoxyresorcinarene is covered in Sections 2.3 and 2.4. 
2.1 Functionalisation of the ortho position of the resorcinarene 
The most direct method to install amines and aldehydes onto the resorcinarene is by 
electrophilic aromatic substitution on the activated aromatic carbon that is ortho to the 
phenol and methoxy groups. In principle, this can be achieved by nitration of 
tetramethoxyresorcinarene (1) followed by reduction of the nitro group to give the 
amine, or by direct formylation to give the aldehyde (Scheme 2.4). 
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Scheme 2.4 Possible installation of nitro or aldehyde groups on the ortho position of 
resorcinarene (1).  
(1) 
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2.1.1 Nitration 
The nitration of calixarenes has been well-documented in the literature.127, 135-137 
However, the nitration of resorcinarenes has been scarcely reported, which is rather 
surprising for a theoretically simple reaction. The tetranitro octahydroxyresorcinarene 
has been reported in the literature, but was synthesised from pre-nitrated resorcinol 
subunits, rather than by nitration of the resorcinarene macrocyle.123-125 Tetramethoxy-
resorcinarene should be readily nitrated at the ortho position, since it is activated for 
electrophilic aromatic substitution by the electron-donating hydroxy and methoxy 
groups. Therefore, the nitration of the starting resorcinarene (1) was investigated, first 
with concentrated nitric acid and glacial acetic acid, with dichloromethane as the 
solvent (Scheme 2.5). With the nitrating agent in vast excess (75-100 eq), the reaction 
was conducted at various conditions from 0°C to room temperature, and from 40 
minutes to 6 hours, but the outcome of these experiments yielded essentially the same 
complex mixture apparent by TLC and 1H NMR spectroscopy. In the 1H NMR spectra 
of these reactions, the group of peaks at 6.5 and 8 ppm, representing the two aromatic 
protons, were consistently integrating in a 1:1 ratio, which was a clear indicator that 
the substitution of one of the aromatic protons was not occurring at all. Furthermore, 
the appearance of peaks at 11 ppm were likely indicators of the presence of phenols 
hydrogen-bonded to nitro groups, but the appearance of apparent doublet of doublets 
around 6.1 ppm was unexpected and puzzling.  
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Scheme 2.5 Investigation into the nitration of the ortho position of resorcinarene (1). 
The nitration was also conducted at milder conditions using nitric acid on silica,126 but 
the outcome appeared to be essentially the same. After subjecting some of the crude 
mixture to column chromatography, one of the products was isolated. The 
chromatographed product was recrystallised from chloroform-MeOH to form slightly-
yellow crystals. The 1H NMR spectrum of the recrystallised product, shown in Figure 
2.1, indicated it to be a pure material, with peaks reminiscent of a C4-symmetrical 
resorcinarene. However, the absence of the benzylic triplet around 4.3 ppm, and the 
appearance of a triplet at 2.9 ppm was the main inconsistency with a resorcinarene.  
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Figure 2.1 NMR spectra of the unknown resorcinarene nitration product recorded in CDCl3: 1H 
spectrum (top), DEPT-135 and 13C spectra (bottom). 
Other notable differences in the 1H NMR spectrum was the appearance of a peak at 
11.1 ppm, and the downfield shift of one of the aromatic peaks to 8.6 ppm, both of 
which may suggest the presence of a hydrogen-bonded phenol and a nitro group. The 
absence of the benzylic methine was also evident on the 13C NMR and DEPT-135 
spectra which recorded no CH peak around the usual 33 ppm. The appearance of a 
peak at 199 ppm indicated the presence of a carbonyl group. The IR spectrum 
confirmed the presence of a hydroxy group, however no characteristic carbonyl peak 
was recorded around 1700 cm-1. Perhaps the carbonyl was in conjugation with the 
aromatic ring, and has overlapped with C=C peaks around 1600 cm-1. Based on the 
NMR and IR data, two isomeric structures (Figure 2.2) for the unknown product were 
proposed. Further evidence supporting the proposed product was provided by HRMS 
which recorded a main peak corresponding to its mass. A search of the literature shows 
that these are not known compounds. 
OHO
OO2N
C3H7
OOH
OO2N
C3H7  
Figure 2.2 Proposed structures for the unknown resorcinarene nitration product. 
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This theoretically-simple nitration of an activated aromatic ring has yielded some 
unexpected and confusing results. Hence a more thorough search of the literature was 
performed. A search of the literature for “resorcinarene nitration” yielded only one 
match which appears to confirm the suspicion that the nitration of resorcinarenes is in 
fact a far more difficult and complex process than one would expect. In this literature 
work, Botta and co-workers were investigating the complexation of highly-reactive 
NO+ in the cavities of resorcinarenes.127 It was discovered that when a greater excess 
of NO+ was used, the resorcinarene unexpectedly reacted to form two new products. 
These products were fully characterised and were revealed to be products from the 
ring-opening of the resorcinarene macrocycle caused by the insertion of a nitro group 
on one of the aromatic rings (Scheme 2.6). Simulation by computational methods 
provided substantial evidence that these products were formed by an ipso electrophilic 
addition of NO+ on the resorcinarene macrocycle, which was catalysed by another 
complexed NO+.  
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Scheme 2.6 Unexpected ring-opening of the resorcinarene macrocycle via ipso electrophilic attack 
by NO+.127 
Therefore, the results obtained from the nitration of tetramethoxyresorcinarene seem 
to confirm the work by Botta and co-workers. Both of the proposed isomers in Figure 
2.2 could possibly be formed by a similar mechanism as proposed by them, where the 
resorcinarene macrocycle could open and fragment through ipso electrophilic addition 
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by NO2+ (Scheme 2.7). The resultant benzylic alcohol could become oxidised by the 
nitric acid to give a ketone conjugated with the aromatic ring.  
Further investigation is required to develop these preliminary results into a more 
conclusive outcome of the nitration of tetramethoxyresorcinarene. The nitration 
reaction needs to be repeated, followed by careful chromatographic separation of the 
products. The isolated products would need to be fully characterised, with a crystal 
structure being ideal. However, regarding the investigation into the direct 
functionalisation of the resorcinarene ortho position, there is much evidence to show 
that this nitration reaction has delivered a completely different outcome than desired. 
Therefore, regarding this investigation, the direct nitration of the resorcinarene was 
abandoned. 
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Scheme 2.7 Proposed mechanism for the ring-opening of the resorcinarene (1) macrocycle by ipso 
nitration. 
2.1.2 Attempted synthesis of ortho-formylated resorcinarene 
2.1.3 Rieche formylation 
The next part of the investigation focuses on installing aldehyde groups on the ortho 
position of the tetramethoxyresorcinarene. Di-O-alkylated calixarenes have been 
conveniently formylated in high yields through the Rieche formylation which involves 
the generation of an electrophile from the activation of 1,1-dichloromethyl methyl 
ether with tin(IV) chloride.69, 128 Under these conditions, only the two non-O-alkylated 
aromatic rings of the calixarene were formylated. Nevertheless, tetra O-alkylated 
calixarenes have been formylated by a similar procedure, albeit in a lower yield.80 
 55 
 
These examples indicate that the Rieche formylation is more successful on calixarenes 
with aromatic rings activated with a hydroxy substituent. According to this rationale, 
tetramethoxyresorcinarene (1), should readily undergo formylation at the ortho 
position since it is activated by both hydroxy and methoxy substituents.  
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Scheme 2.8 Attempted formylation of tetramethoxyresorcinarene under Rieche conditions. 
Tetramethoxyresorcinarene (1) was reacted under Rieche formylation conditions 
(Scheme 2.8), as per the literature, to give a brown-black crude product which had a 
1H NMR spectrum showing the resorcinarene signals as broad humps. A hydrogen-
bonded phenol was clearly visible as a single peak at 11.38 ppm; this was confirmed 
by its disappearance upon addition of D2O. A broad group of signals at 10.25 ppm 
were indicative of the presence of the formyl group. This may suggest that the 
formylation of the resorcinarene had proceeded, but not to completion. However, the 
broad humps of resorcinarene signals together with the black colour of the crude 
product suggests some decomposition of the resorcinarene may have occurred. 
Moreover, the TLC was a complete streak, thus preventing any chromatographic 
separation. In face of these results, it was decided to focus efforts on a different 
formylation method. 
2.1.4 Duff formylation 
The other method in the literature for the formylation of calixarenes is by the Duff 
formylation. By this method, calixarenes129 as well as resorcinarenes130 have been 
formylated. The Duff fomylation of octahydroxyresorcinarene was accomplished in 
48% yield by Szumna and co-workers using hexamethylenetetramine in trifluoroacetic 
acid via microwave irradiation.130 
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Scheme 2.9 Attempted formylation of tetramethoxyresorcinarene under Duff conditions. 
(1) 
(1) 
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Reaction of tetramethoxyresorcinarene (1) under the same conditions (Scheme 2.9) as 
described by Szumna and co-workers,130 gave a crude product of mass that was double 
the theoretical yield, and appeared to be a complex mixture by 1H NMR spectroscopy. 
The TLC of the crude mixture, though slightly streaked, indicated absence of the 
starting resorcinarene (1), and two major product spots at higher Rf, other than baseline 
material. In preparation for chromatography, the baseline material was removed by 
filtering the crude product through a plug of silica. However, in this process, 70% of 
the mass was lost. Nevertheless, TLC confirmed the presence of the two remaining 
product spots, with most of the baseline material being removed. To isolate the two 
product spots, a portion of the remaining material after the silica plug was subjected 
to preparative TLC. The preparative TLC was highly streaked when visualised under 
UV, but under ambient light, three yellow bands were apparent. These were collected 
as separate fractions, but totalled to only 16% of the original mass that was applied to 
the preparative TLC. TLC of the fractions indicated that co-elution had persisted 
through each fraction. It seems that the chromatographic separation on the TLC did 
not carry through to the preparative TLC. This result, together with the low mass 
recovery may be due to decomposition of the material on the silica. The partially-
separated compounds were analysed by 1H NMR spectroscopy and showed multiple 
aldehyde signals for all products. The signals around 6.4 ppm associated with the ortho 
aromatic proton had a relatively lower integration compared to the signals of the other 
aromatic proton. This again may suggest that the formylation was occurring but not 
proceeding to completion. Given the unpromising results, particularly the suspected 
decomposition of the products on silica, it was decided to abandon the resorcinarene 
formylation. In their brief review of resorcinarene formaylation, Szumna and co-
workers noted many unsuccessful attempts by other research groups to formylate 
resorcinarenes, observing that formylations of macrocyclic scaffolds are theoretically 
simple, but practically difficult.130  
2.1.5 Mannich 
Since direct installation of nitro and aldehyde groups onto the ortho position of  
resorcinarene (1) has been rather unsuccessful, the reported131 functionalisation of this 
position with a Mannich base may provide an alternative strategy. A Mannich base on 
the ortho position of the resorcinarene could be quarternised into the amine salt, then 
substituted with an appropriate nucleophile by SN2 substitution (Scheme 2.10). 
 57 
 
Gutsche et al. has reported success with this idea with tetrahydroxycalixarenes, having 
substituted the dimethylamino group with various nucleophiles including azides and 
nitriles.132 If this were applicable for tetramethoxyresorcinarene (1), then it would 
provide access to an amine or aldehyde group at the ortho position via full or partial 
reduction of the azide or nitrile. 
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Scheme 2.10 Potential strategy for installing amines or aldehydes onto the ortho position of 
resorcinarene via nucleophilic substitution of the Mannich base. 
After some experimentation and modification to the brief literature report,131 the 
desired dimethylamine Mannich base resorcinarene (2) was afforded in good yield and 
purity using potassium carbonate, N,N,N',N'-tetramethylmethylenediamine and acetyl 
chloride in dry acetonitrile under microwave irradiation at 110°C for 10 minutes. The 
reported yield of 70% may actually be quantitative as apparent from a small-scale 
reaction. The rather difficult and inconsistent crystallisation of the product was the 
likely cause of the product loss. The successful electrophilic aromatic substitution of 
the ortho hydrogen with a Mannich base was confirmed by the dimethylamine peak at 
2.21 ppm and 44.4 ppm on the respective 1H and 13C NMR spectra (Appendix A – 1). 
The 1H NMR spectrum provided clear evidence that this was a substitution, in that 
only one aromatic hydrogen peak was present. The methylene between the aromatic 
(1) 
(2)
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ring and the nitrogen appeared as an AB pair at 3.53 and 3.66 ppm in the 1H spectrum, 
which correlated via HSQC spectroscopy, to the peak at 56.3 ppm in the DEPT-135 
spectrum. 
Investigations into the nucleophilic substitution by the quarternisation of the Mannich 
base of (2) via Gutsche and Nam’s132 procedure produced complex mixtures for both 
azide and nitrile nucleophiles. The Mannich base resorcinarene (2) was not entirely 
soluble in DMSO. The 1H NMR spectra of the crude products showed that the 
resorcinarene signals had become broad humps. The TLC, being fairly streaked, 
suggested that unreacted resorcinarene (2) was present amongst multiple products. 
Therefore, there was no clear sign that any target product had been formed, and given 
the lack of success in these preliminary investigations, this route was abandoned. 
2.2 Functionalisation of resorcinarene phenols 
Since the functionalisation of the resorcinarene ortho position yielded no success, the 
investigation moved on to functionalisation of the resorcinarene phenols. A search of 
the literature provided a method for installing aldehyde or priamry amine groups onto 
the tetramethoxyresorcinarene by conversion of the phenols.133 This however 
necessitates as longer synthetic procedure (Scheme 2.11) compared to direct nitration 
or formylation of the resorcinarene aromatic ring. In this synthetic procedure, the 
phenols of the tetramethoxyresorcinarene are converted to nitriles via a Buchwald-
Hartwig cyanation of the triflated phenols. The reduction of the nitrile group on the 
resorcinarene provides access to the desired aldehydes or primary amines.  
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Scheme 2.11 Conversion of resorcinarene phenols to nitriles for subsequent reduction to aldehydes or 
primary amines.  
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The first step of this synthesis is the conversion of the phenols of tetramethoxy-
resorcinarene (1) into trifluoromethanesulfonates. This conversion has been reported 
by Heaney and co-workers134 who employed microwave irradiation to achieve a more 
rapid reaction. After some experimentation on the procedure, the desired 
trifluoromethanesulfonate resorcinarene was conveniently afforded in high yield and 
purity using potassium carbonate with N-phenylbis(trifluoromethanesulfonimide) in 
acetonitrile under microwave irradiation for 15 minutes at 110°C. It was discovered 
that the microwave reaction was best performed with a small amount of acetonitrile at 
high concentrations, since the bulk of the target product conveniently crystallises 
directly from the reaction mixture. This does not necessitate the usual work up 
procedure, because the product can be directly filtered from the reaction mixture, 
washed with water to remove the potassium carbonate, then oven-dried. By this 
method, some target product remains dissolved in the acetonitrile mother liquor, but a 
yield of 90% is achieved. Complete recovery of the product from the acetonitile mother 
liquor is difficult and may not be worthwhile. Another advantage to this method is the 
ability to perform a large-scale reaction with up to 2.6 grams of resorcinarene (1) in 
the limitations of a relatively small microwave vial. Evidence that the desired 
trifluoromethanesulfonate resorcinarene (3) was obtained was provided by the 13C 
NMR spectrum which showed a quartet at 118.7 ppm which is attributed to the carbon 
of the trifluoromethyl group (Appendix A – 3). A recently published alternative 
synthetic procedure employing triflic anhydride and pyridine in dichloromethane may 
be more convenient since it offers essentially quantitative yield without the need for 
formal purification.135 
With substantial quantities of the trifluoromethanesulfonate (3) prepared, the 
Buchwald-Hartwig cyanation was then conducted using zinc cyanide and lithium 
chloride with tetrakistriphenylphosphine palladium in dimethylfomamide, following 
the procedure by Mattay and co-workers.133 From initial attempts, it was discovered 
that special attention needs to be taken to ensure that the lithium chloride was 
anhydrous, and that the tetrakistriphenylphosphine palladium catalyst was properly 
active. To counter these issues, prior to the reaction, the lithium chloride, together with 
the solid reactants were placed in the reaction flask and dried in the oven overnight. 
Moreover, the palladium catalyst was carefully stored in a Schlenk flask under 
nitrogen. With these countermeasures in place, the cyanation of (3) proceeded 
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smoothly and was completed within 2 hours, according to TLC monitoring. After 
column chromatography, the target nitrile resorcinarene (4) was recovered in an 
excellent yield of 99%, confirming the literature. The nitrile group in resorcinarene (4) 
was confirmed by the C≡N stretch in the IR spectrum, as well as a peak at 118 ppm in 
the 13C NMR spectrum which could be distinguished from the quarternary aromatic 
carbon peaks by HMBC spectroscopy (Appendix A – 4). 
With the nitrile resorcinarene (4) prepared, Mattay and co-workers have shown that, 
on a small scale, the iso-butyl derivative of the nitrile resorcinarene could be partially 
reduced by DIBAL-H to give the aldehyde, or fully reduced to the primary amine by 
lithium aluminium hydride to give the primary amine (Scheme 2.12).133 
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Scheme 2.12 Reduction of nitrile resorcinarene to aldehydes or primary amines.  
The reduction of nitrile resorcinarene (4) by DIBAL-H in diethyl ether followed by 
quenching with sodium potassium tartrate as per the procedure by Mattay and co-
workers gave a low yield of target aldehyde resorcinarene (5). A potential source of 
product loss was during the quenching of the DIBAL-H at the end of the reaction, 
which turns the reaction mixture into a gelatinous white precipitate which was difficult 
to dissolve. The gel likely ensnares some of the product preventing it from being 
extracted by organic solvents. It was realised that the formation of the gel could be 
avoided by quenching with an excess of dilute hydrochloric acid, followed by 
prolonged stirring. The amount of crude product afforded from this method suggested 
a good yield, with a TLC that indicated only baseline material other than the desired 
product. Filtration through a plug of silica afforded the target target aldehyde 
resorcinarene (5) in excellent purity, as shown by 1H NMR spectroscopy, which clearly 
evidenced the aldehyde with a peak at 10.3 ppm (Appendix A – 6). The aldehyde was 
further confirmed on the 13C NMR spectrum with a peak at 191 ppm, as well as on the 
(5)
(6)
(4) 
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IR spectrum with a C=O stretch and the disappearance of the C≡N stretch. However, 
the amount of target product (21%) afforded after filtration through a plug of silica 
was much lower than the crude material. A Mićović136, 137 work up and also a basic 
work up of the DIBAL-H reaction were also attempted, but no desired product was 
recovered. 
Regarding the reduction of the nitrile resorcinarene to give the primary amine, the 
procedure by Mattay and co-workers employed lithium aluminium hyride in ether 
followed by work up with sodium potassium tartrate. However, nitrile resorcinarene 
(4), under these conditions, gave a low yield of incompletely reduced tetranitrile 
resorcinarene products, as indicated by the many small peaks on the 1H NMR 
spectrum, as well as a small nitrile peak on the IR spectrum. Attempts to reduce the 
nitrile groups by hydrogenation with Raney Nickel and hydrazine returned only the 
starting nitrile resorcinarene (4). In the literature, nitrile calixarenes have been easily 
reduced to the corresponding amines by borane.138 Applying the borane procedure to 
nitrile resorcinarene (4) yielded the target product as indicated by the 1H NMR 
spectrum, but with broad peaks. Attempts to purify the product by recrystallisation and 
acid/base reprecipitation were of no effect. Therefore, attention was returned to 
reduction by lithium aluminium hydride. Changing the work up from sodium 
potassium tartrate to the Mićović136, 137 work up, with washing of the aluminium salts 
with dichloromethane, drastically improved the yields. However, the 1H NMR and IR 
spectra indicated that the reduction had still not proceeded to completion. Therefore, 
the material was subject to reduction reaction again at the same conditions. The small 
peaks on the 1H NMR spectrum of the product were significantly less, indicating that 
the reaction had proceeded further, but still not to completion. During the 
experimentation, it was realised that the target amine resorcinarene (6) was not very 
soluble in ether, but completely soluble in tetrahydrofuran. Therefore, the reduction 
using lithium aluminium hydride was performed in tetrahydrofuran at reflux overnight. 
After a Mićović work up, the target amine resorcinarene (6) was furnished in good 
yields without needing further purification. Amine resorcinarene (6) was fully 
characterised, with the amine group being confirmed by a N-H stretch in the IR 
spectrum. The methylene of the primary amine appeared on the 1H NMR spectrum as 
an AB pair at 3.54 and 3.79 ppm, while in the DEPT-135 spectrum the peak at 43.8 
ppm was attributed to it (Appendix A – 6). 
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2.3 Coupling of tetraaminoresorcinarene with dialdehydecalixarene 
With sufficient quantities of tetramethoxyresorcinarene furnished with both aldehyde 
and amine functional groups, the next step was to synthesise a distal aldehyde or amine 
calixarene to serve as the rigid bridge. 
The most convenient synthesis of a calixarene, that is distally-functionalised at the 
wider rim with either an aldehyde or amine, is distal aldehyde calixarene (9). This 
calixarene can be synthesised by the procedure by Bonini et al.,128 as outlined in 
Scheme 2.13. According to this literature procedure, the distal two hydroxy groups of 
starting tetrahydroxycalixarene (7) were propylated to decrease the para-activating 
effect of the distal two aromatic rings, while also keeping the calixarene in a fairly 
rigid cone conformation.139 The dipropoxy-calixarene (8) was confirmed by a triplet 
and multiplet in the aliphatic region of the 1H NMR spectrum, while in the aromatic 
region, there was a doubling of signals due to the change from C4 to C2 symmetry 
(Appendix A – 7). Formylation of the remaining two OH-activated aromatic rings of 
the dipropoxycalixarene (8) under Rieche conditions conveniently furnished the distal 
aldehyde calixarene (9) in quantitative yield, which was confirmed by the C=O stretch 
in the IR spectrum, and a 1H NMR spectrum which matched the literature (Appendix 
A – 8). 
OH OHO OH H OH OHO OPr Pr
Br OH OHO OPr Pr
O HH O
O Cl
Cl
SnCl4
CHCl3
-15 °C to RT
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100%
K2CO3
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Reflux, 24 h
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Scheme 2.13 Synthesis of a distal dialdehyde calixarene. 
With a distal dialdehyde calixarene prepared, the coupling of tetraaamino-
resorcinarene (6) and (9) by imine linkages was investigated (Scheme 2.14). A 
preliminary reaction at a dilution of 1 mg/mL using molecular sieves while refluxing 
in dichlormethane, at similar conditions to the literature,113 gave an 1H NMR spectrum 
with broad humps, which was inconclusive. Therefore, to enable monitoring of the 
reaction by 1H NMR spectroscopy, a small scale reaction was conducted in an NMR 
tube in CDCl3. 
(7) (8)  (9) 
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Scheme 2.14 Investigation into the coupling of tetraaminoresorcinarene (6) with dialdehyde 
calixarene (9). 
Immediately after the two were combined, the starting dialdehyde calixarene (9) was 
clearly evident on the 1H NMR spectrum, but the tetraaminoresorcinarene (6) was 
essentially not observed, other than two broad lumps in the hydrocarbon region. Excess 
tetraaminoresorcinarene (6) was added to the NMR solution, and after overnight, the 
dialdehyde (9) peaks which had been sharp became broad humps on the 1H NMR 
spectrum, while the tetraamine (6), being in excess, was clearly visible. Of note was 
the disappearance of the calixarene aldehyde peak, as well the appearance of two tiny 
bumps at 8.26 and 8.69 ppm, which may correspond to the imine and phenol of the 
product(s). A more concentrated NMR solution of (6) and (9) in a 1:1 ratio yielded 
similar results where signals associated with an imine were present on NMR spectra, 
but were tiny or broad. In light of these inconclusive results, it was decided to explore 
the imine coupling in a different manner by swapping the the aldehyde groups from 
the calixarene to the resorcinarene, and vice-versa for the amine groups. 
2.4 Coupling of tetraaldehyderesorcinarene with diaminocalixarene 
The goal for the next part of the investigation was to synthesise a distal diamino-
calixarene to act as a rigid bridge, instead of a dialdehyde calixarene. A distal diamino-
calixarene could be prepared through multiple methods. 
  
(9) 
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2.4.1 Diaminocalixarene method 1 
The same synthetic strategy for dialdehyde calixarene (9) would provide the most 
convenient path to obtaining a distal diaminocalixarene (Scheme 2.15).  
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Scheme 2.15 Synthesis of distal diaminocalixarene (11). 
The nitration of dipropoxycalixarene (8) has been documented by Struck et al. using 
sodium nitrate and a catalytic amount of lanthanum nitrate hexahydrate in concentrated 
hydrochloric acid, to give dinitrodipropoxycalixarene (10) in 56% yield after column 
chromatography.113 However, due to the availability of reagents, the nitration using 
concentrated nitric acid and glacial acetic acid was preferred. The nitration under these 
conditions has been reported in the literature by Liang et al., but no experimental 
procedure was provided.140 Nevertheless, based on similar nitration procedures in the 
literature,141, 142 dinitrodipropoxycalixarene (10) was successfully synthesised in 58% 
yield using nitric acid and glacial acetic acid in dichloromethane. The 1H NMR 
spectrum showed a downfield shift of a singlet in the aromatic region, which indicated 
the presence of the electron-widthdrawing nitro group (Appendix A – 9). The 1H NMR 
spectrum and melting point were consistent with Struck’s data. An alternative nitration 
procedure utilising nitric acid on silica126 also successfully deliverered calixarene (10) 
in similar yield. Compared to using nitric acid and acetic acid, this procedure was more 
convenient in that the silica could simply be filtered off from the reaction mixture, and 
the filtrate concentrated for chromatography.  
The nitro groups of calixarene (10) were then reduced by Raney nickel and hydrazine 
monohydrate to furnish the diamino calixene (11) according to the procedure by Struck 
et al.113 The 1H NMR spectrum of the product obtained after work up appeared fairly 
pure. The signal in the aromatic region had shifted upfield from 8.0 to 6.5 ppm, 
evidencing the conversion of the nitro group to the electron-donating amine group 
(Appendix A – 9). The 1H NMR spectrum was identical to the literature.113  
(8) (10)  (11) 
 65 
 
The diaminocalixarene (11) however, appeared as a light-red solid, which was an 
unexpected colour for such a compound. Nevertheless, the imine coupling of this 
material with tetraformylresorcinarene (5) was attempted under the conditions 
reported by Struck et al. (Scheme 2.16). Mini-work ups of the reaction mixture were 
taken and analysed by 1H NMR spectroscopy. The spectra indicated the presence of 
the tetraformylresorcinarene (5), but the signals for the diaminocalixarene (11) were 
unclear, appearing to have broadened. 
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Scheme 2.16 Attempted imine coupling of diaminocalixarene (11) and tetraformylresorcinarene (5). 
Monitoring of the coupling reaction in CDCl3 at room temperature by 1H NMR 
spectroscopy confirmed the gradual broadening of the diaminocalixarene (11) signals, 
while the signals for the tetraformylresorcinarene (5) were essentially intact. This 
provided clear evidence that the diaminocalixarene (11) was at fault. In fact, the 1H 
NMR spectrum of a sample of (11) that had been kept in storage for nine months had 
shown significant peak broadening, which was indicative of decomposition. Even the 
1H NMR spectrum of freshly prepared (11) exhibited slight peak broadening and 
integration discrepancy. These observations, together with the unexpected red colour, 
agree with the reasoning made by Struck et al. that the instability of diaminocalixarene 
(11) was due to the decomposition of the aminophenols to quinone systems.113 Struck 
et al. also reported lower yields for the imine coupling reactions involving (11), 
suspecting that the acidic phenolic protons were interfering with the imine coupling. 
Therefore, it appears necessary to protect the phenol groups of the diaminocalixarene. 
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2.4.2 Diaminocalixarene method 2 
Diaminotetrapropoxycalixarene has been reported in the literature by the synthetic 
procedure in Scheme 2.17.143, 144 The downside of this method is that it is not high-
yielding and efficient, because the distal nitration of tetrapropoxycalixarene produces 
multiple products that have to be separated by column chromatography. A search of 
the literature does not present any other procedure for obtaining the 
diaminotetrapropoxycalixarene. 
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Scheme 2.17 Literature synthetic procedure for diaminotetrapropoxycalixarene.143, 144 
The logical method to overcome the nitration selectivity issues is to synthesise dinitro-
calixarene (10), then alkylate the remaining distal nitrophenols (Scheme 2.18).  
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Scheme 2.18 Theoretical alternative route to diaminotetrapropoxycalixarene. 
This may seem trivial at first glance, but a search of similar calixarene alkylation 
reactions in the literature reveals that the calixarene flips conformation during 
alkylation to give calixarene products in the partial cone / 1,3-alternate 
conformations.145-148 The alkylation of calixarene phenols on the narrower rim has 
been shown to be affected by the metal cation of the base, the alkyl halide, and the 
solvent.149 Considering this, the alkylation of dinitrocalixarene (10) was attempted 
under various other conditions (Table 2.1). 
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Table 2.1 Alkylation of dinitrodipropoxycalixarene (10) under various conditions. Comparison of 
outcomes from this investigation to the literature. 
 
O2N
OH
NO2
OHO OPr Pr O2N
O
NO2
OO OPr Pr
R R
RX
Base
Solvent
O2N
O O OPr Pr
O2N
O
R
R
NO2NO2
O
O O
O
RR
PrPr
OEt
O
R =
R =
R =
Cone
Partial Cone
1,3-Alternate
R =  
RX Base Solvent Outcome 
I  
K2CO3 MeCN Cone + partial cone 
NaH DMF No reaction 
Na2CO3 MeCN Cone + partial cone + unknown 
Cs2CO3 DMF 1,3-alt (26%) + Partial cone (67%)145 
Br OEt
O
 
Na2CO3 MeCN Cone (12) (41%) + partial cone (13) (23%) 
K2CO3 MeCN Partial cone (44%)146 
Br  
NaH DMF No reaction 
K2CO3 MeCN 
Cone (14) (5%) 
+  partial cone (15) (24%) 
+ 1,3-alt (16) (21%) 
I  Cs2CO3 DMF 1,3-alt (17%) + Partial cone (70%)148 
 
In the propylation reactions, the calixarene conformations in the crude product were 
determined based on literature 1H NMR spectra of the known compounds.144, 145 
Dinitrocalixarene (10) did not react with iodopropane and sodium hydride presumably 
due to the rather poor nucleophilicity of the nitro phenoxide, which may instead allow 
the iodopropane to undergo elimination by sodium hydride to give propene gas.  
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The alkylation of dinitrocalixarene (10) was also attempted with other alkylating 
agents. In the literature, the tetra-alkylation of p-tert-butylcalixarene with ethyl 
bromoacetate by sodium carbonate in acetone was reported to give the tetra-alkylated 
calixarene product with retention of the cone conformation.149 Based on this, 
dinitrocalixarene (10) was alkylated with ethyl bromoacetate under similar reaction 
conditions as the literature, but gave two calixarene products. These were separated by 
preparative TLC and identified to be the di-alkylated calixarene in both the cone (12) 
(41%) and partial cone (13) (23%) conformations. The alkylation with ethylbromo 
acetate was confirmed by the ester carbonyl group being evident in both conformers 
by the C=O stretch in both IR spectra, as well as the peaks at about 169 ppm in both 
13C NMR spectra. The partial cone conformer (13) was differentiated from the cone 
conformer (12) by additional peaks in the NMR spectra, which are attributed to the 
loss of C2 symmetry (Appendix A – 9). The cone conformer (12) was easily identified 
by the single AB pair in the 1H NMR spectrum, which represented the methylene 
bridges of the calixarene macrocycle. The partial cone conformer (13) has been 
described by Regayeg et al.,146 but the cone conformer (12) appears to be unknown to 
the literature. 
Dinitrocalixarene (10) was also alkylated with allyl bromide, since allyl bromide 
cannot readily eliminate to form propene gas under alkaline conditions. It was 
surprising that no reaction was observed by TLC and 1H NMR when dinitrocalixarene 
(10) was treated with excess sodium hydride and allyl bromide. However, with 
potassium carbonate, the reaction with allyl bromide produced multiple products, 
which were isolated by preparative TLC and identified to be cone (14) (5%), partial 
cone (15) (24%), and 1,3-alternate (16) (21%) conformers of the diallylcalixarene. The 
allyl group was confirmed in each conformer by the multiplets around 5.5-6.5 ppm in 
the 1H NMR spectra, together with the CH2 peaks at 117 ppm in the DEPT-135 spectra 
(Appendix A – 13). Applying the same rotational symmetry rationale on the NMR 
spectra, the partial cone could be identified from the other two C2-symmetrical 
conformers. In the 1H NMR spectrum, the AB pair characteristic to the cone conformer 
enabled it to be distinguished from the 1,3-alternate conformer. A search of the 
literature reveals that none of the three conformers are known, with the closest match 
being a calixarene in the 1,3-alternate conformation, having p-tert-butyl groups on the 
propoxy aromatic rings.150  
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In the 1H NMR spectra of the partial cones (13) and (15), the six aromatic protons on 
the two equivalent propoxy aromatic rings appear as three signals integrating for two 
protons each (Figure 2.3). They appear as a doublet of doublets, a triplet, and an 
unresolved doublet of doublets (designated as a multiplet). The opposite orientations 
of the adjacent nitro aromatic rings of the partial cone causes the protons meta to the 
propoxy group to be non-equivalent. The signals for these meta protons appear as a 
doublet of doublets because there is ortho and meta coupling between the non-
equivalent protons on the ring. The signal for the proton para to the propoxy group 
appears as a triplet which could be considered as a doublet of doublets with 
coincidentally identical coupling constants from the two non-equivalent meta protons. 
 
Figure 2.3 The 1H NMR spectrum of the parital cone calixarene (15) showing the aromatic protons 
on the propoxy aromatic rings which are splitting each other due to their non-
equivalence. 
However, for the cone calixarenes with greater symmetry, one would expect the 
aromatic protons on the propoxy aromatic rings to appear as a doublet and a triplet in 
the 1H NMR spectrum. In the 1H NMR spectra of the cone calixarenes (12) and (14), 
a doublet was present, however the expected triplet appeared as a doublet of doublets 
(Figure 2.4). Since the only other signal that was split was the expected doublet, this 
doublet of doublets was unexpected. Perhaps it was due to conformational effects of 
the calixarene, hence the 1H NMR spectrum of (12) was recorded at 50°C. However, 
at this elevated temperature, instead of coalescing to a triplet, the doublet of doublets 
became better-resolved. The possibility of a solvent effect was probed by recording 
the 1H NMR spectrum in acetone-d6 instead of CDCl3, however the doublet of doublets 
was still apparent. The appearance of these doublet of doublets was surprising and 
could not be explained. 
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Figure 2.4 The 1H NMR spectrum of cone calixarene (12) recorded in CDCl3 showing the aromatic 
protons on the propoxy aromatic rings which surprisingly appear as a doublet and a 
doublet of doublets. 
From this investigation (Table 2.1), the alkylation of dinitrocalixarene (10) under 
various conditions produced mixtures of conformers where the cone conformation of 
the calixarene was never fully retained. This result confirms the trend in the literature. 
Unfortunately, this apparently simple strategy, does not readily provide a tetra-
alkylated distal diaminocalixarene in the cone conformation, as required for the imine 
coupling reaction.   
2.4.3 Diaminocalixarene method 3 
The previous methods for synthesising a distally-functionalised calixarene relied on 
the selective distal alkylation of the phenols on the narrow rim for distal selectivity. 
As discovered from the previous attempt, the issue with this method, is that alkylation 
of the remaining two hydroxy groups affects the conformation of the calixarene, 
causing conformers other than the desired cone conformer to be produced. This issue 
could be circumvented by tetra-alkylating the calixarene phenols, then employing a 
selective bromine-lithium exchange,84 which is another well-documented method for 
distally-functionalising the wider rim of calixarenes. The application of this method 
for this purpose utilises the bromine as protecting groups, which enables the selective 
nitration of the remaining distal two aromatic rings (Scheme 2.19). However, the 
nitration and subsequent reduction to the amine is unknown to the literature for the 
particular dibromocalixarene. Similar work in the literature suggests that the entire 
synthetic strategy should be fairly high-yielding and convenient.84, 143, 144, 151-154 
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Scheme 2.19 Proposed synthetic strategy for diaminotetrapropoxycalixarene. Yields are based on 
literature examples.84, 143, 144, 151-154 
To prepare for the selective bromine-lithium exchange, the starting tetrahydroxy-
calixarene (7) was first tetrapropylated to permanently protect the hydroxy groups, and 
to also lock the calixarene in the cone conformation.139 Under the standard literature 
conditions described by Mendez-Arroyo et al,151 issues with complete propylation of 
the calixarene were encountered, despite using excess base and alkylating agent. It was 
often the case that the reaction appeared to be completed by TLC, but upon work up 
and trituation, 1H NMR analysis clearly showed that starting calixarene was still 
present. The propylation was only completed when the material was subjected to 
reaction again. The best yield obtained of 78% was significantly lower than the 92% 
yield reported by Mendez-Arroyo et al. The propylation was confirmed by the 
appearance of a triplet and a multiplet in the aliphatic region of the 1H NMR spectrum 
(Appendix A – 18). A sharp AB pair (δ 3.15 and 4.46) of the methylene groups of the 
macrocycle confirmed the locking of calixarene (17) in the cone conformation.  
Next, tetrabromination of (17) with N-bromosuccinimide in butanone conveniently 
furnished (18) in near quantitative yield. A single singlet in the aromatic region of the 
1H NMR spectrum confirmed that complete bromination was achieved (Appendix A 
– 18). The selective bromine-lithium exchange was then performed on 
tetrabromocalixarene (18) according to the procedure by Larsen and Jørgensen84 to 
give the dibromocalixarene (19) in the expected yield of 93%. The use of sufficient 
butyllithium is imperative to the selectivity of the dilithiation reaction. For this reason, 
a slight excess (2.5 eq) of butyllithium was used. This did not have an impact on the 
reaction outcome, which agrees with the observation by Larsen and Jørgensen. The 
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distal debromination was confirmed by the appearance of an additional apparent 
singlet in the aromatic region of the 1H NMR spectrum, integrating for two hydrogens 
(Appendix A – 19).  
The nitration of the distal dibromocalixarene (19) should be selective for the non-
brominated distal aromatic rings to give calixarene (20). Up till this stage, all 
calixarenes synthesised were known compounds, with their synthesis being well 
described in the literature. However, dibromodinitrocalixarene (20) is not a known 
compound, and its synthesis was in fact more challenging than anticipated. In the 
literature, the nitration of O-alkylated and non-O-alkylated calixarenes has been 
reported,144, 152-154 but none of the usual procedures for nitrating calixarenes appeared 
to give the target product (Table 2.2). After much experimentation, the target product 
was achieved by nitration using ‘claycop’ (copper nitrate on clay)155 in the presence of 
a few drops of anhydrous nitric acid. Nitration by this method appeared to be 
capricious, with the 1H NMR spectrum of the crude product from some reactions 
showing a complex mixture of products without the target product. Purification by 
chromatography was necessary to remove other unknown calixarene by-products, 
which were likely responsible for the relatively low yield of 21%. The dibromodinitro-
calixarene (20) was evidenced by the two singlets of equal integration in the aromatic 
region of the 1H NMR spectrum (Appendix A – 19).  
Table 2.2. Nitration of dibromocalixarene (19) under various nitration conditions.  
OPr PrOO O
H HBrBr
Pr Pr
O2N
OPr
NO2
PrOO O
Br Br
Pr Pr
Nitration
  
Nitrating agent Acid Solvent Outcome 
HNO3 (70%) CH3COOH DCM No reaction 
HNO3 (100%) CH3COOH DCM Complex mixture 
KNO3 CF3COOH DCM Mixture 
KNO3 AlCl3 DCM Decomposition 
HNO3 Silica DCM No reaction 
Cu(NO3)2 + 
HNO3 (100%) 
Montmorillonite 
clay DCM 
Target product (20) (21%) 
+ unknown by-products 
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Finally, the reduction of the nitro groups by Raney Nickel and hydrazine143 proceeded 
smoothly to furnish the pure diaminotetrapropoxycalixarene (21) after work up 
(Scheme 2.20). The success of the reduction was apparent by the appearance of a broad 
amine peak in the 1H NMR spectrum, and the replacement of the signal at 7.63 with 
one at 5.98 ppm which evidences the switch from an electron-withdrawing nitro to an 
electron-donating amine (Appendix A – 20). 
O2N
OPr
NO2
PrOO O
Br Br
Pr Pr
NH2
OPr
NH2
PrOO O
Br Br
Pr PrRaney Ni
H2NNH2
MeOH 
reflux, overnight
100%   
Scheme 2.20 Reduction of dinitrocalixarene (20) to give diaminocalixarene (21). 
With a sufficient quantity of the diaminocalixarene (21) prepared, its imine coupling 
with tetraaldehyde resorcinarene (5) was then investigated (Scheme 2.21) at a dilution 
of 1 mg/mL under similar conditions to the literature.113 The reaction mixture appeared 
as a yellow colour, characteristic of an aromatic Schiff base, but the 1H NMR spectrum 
of a portion of the reaction mixture showed that the peaks associated with the diamino-
calixarene (21) had all become broad humps, while the peaks of the tetraaldehyde-
resorcinarene (5) were clearly intact. To gain more insight, the same reaction was 
conducted in an NMR tube to allow monitoring of the reaction by 1H NMR 
spectroscopy. The 1H NMR spectra indicated that, upon mixing of tetraaldehyde (5) 
and diamino (21), the same phenomenon was occurring rapidly within 30 minutes. In 
the hope that the reversible imine linkages would rearrange to form the desired 
product, portions of the NMR solution were diluted many times, but to no effect.  
N N
O O OOHCCHOO
C3H7 C3H7 C3H7 C3H7
OPr PrOO O
Br Br
Pr Pr
O
O O OO
C3H7 C3H7 C3H7 C3H7
O OO
+
NH2
OPr
NH2
PrOO O
Br Br
Pr Pr
  
Scheme 2.21 Investigation into the coupling of tetraaldehyde resorcinarene (5) with 
diaminocalixarene (21). 
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As a simple test, aniline was added to a solution of tetraaldehyderesorcinarene (5) in 
CDCl3. After 20 minutes, the 1H NMR spectrum recorded an absence of starting 
resorcinarene and an appearance of the expected imine, as represented by the peak at 
8.9 ppm. However, in the reaction between (5) and (21), no imine peak was definitively 
observed in any of the 1H NMR spectra. Perhaps steric hinderance, particularly in 
regards to the bromine atoms, may have impeded the coupling of the calixarene and 
resorcinarene in the envisaged manner. 
From the overall investigations into the calixarene rigid bridge strategy, the target 
resorcinarene-calixarene imine was never definitively observed, with the data being 
inconclusive. The signals for both the amine calixarene and amine resorcinarene 
appeared to broaden in the 1H NMR spectra of their respective coupling reactions, 
while the signals of the corresponding aldehyde appeared to be intact. This has not 
been understood, although it signals that the fault lies with the amine coupling partner.  
A possible reason for the lack of success may be the conformations of the calixarene 
and resorcinarene. In general, solid state crystal structures demonstrate that the 
calixarenes would most likely be in the cone conformation, while the resorcinarenes 
would likely adopt the boat conformation. However, this reaction was in solution, not 
in the solid state, hence there would be conformational mobility of both the calixarene 
and resorcinarene which should permit their coupling. Nevertheless, despite the 
conformational mobility in solution, the calixarene and resorcinarene would still 
gravitate to their preferred conformations, and this may prevent the ideal fit required 
for the envisioned coupling. Moreover, steric hinderance may have also played a role 
by impeding the coupling between the calixarene and resorcinarene.  
All in all, taking into consideration the significant effort to synthesise the aldehyde and 
amino resorcinarenes and calixarenes for this coupling step, together the lack of 
progress, the decision was made to entirely abandon this strategy of a calixarene rigid 
bridge to focus efforts on more promising strategies. 
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2.5 Experimental 
2.5.1 General methods 
NMR spectra were recorded on a Bruker UltraShield Avance 400 spectrometer (400 
MHz for 1H, 100 MHz for 13C). All chemical shifts were reported in parts per million 
(ppm). NMR spectra were calibrated to their respective solvents:156 chloroform-d 
(CDCl3, δ 7.26 ppm; 13C, δ 77.16 ppm); DMSO-d6 (CD3SOCD3, δ 2.50 ppm; 13C, δ 
39.52 ppm); acetone-d6 (CD3COCD3, δ 2.05 ppm; 13C, δ 29.84 ppm). Multiplicity was 
assigned as follows: s = singlet, d = doublet, t = triplet, q = quartet, sxt = sextet, br = 
broad. 
A PureSolv MD5 solvent purification system from Innovative Technology 
Incorporated was used for the purification and drying of the following solvents: 
tetrahydrofuran, dimethylformamide, acetonitrile, diethyl ether, dichloromethane. 
Reactions were subjected to microwave irradiation in a Biotage Initiator+ (0 – 400 W, 
2.45 GHz). IR spectra were acquired on a Perkin Elmer Spectrum 100 with ATR 
attachment and a scan range from 650 – 4000 cm-1. Melting points were determined 
using an Electrothermal IA9300 melting point apparatus. For melting points where the 
solvent of crystallisation was not quoted, the solvent was removed under reduced 
pressure, and the product was not crystallised. Solvents were removed under reduced 
pressure by vaporisation using a Buchi R-114 rotavapor. A Javac SharkTM high 
vacuum pump was used to remove trace solvents from solid samples. Elemental 
composition of samples was analysed via Perkin Elmer 2400 Series II CHNS/O. 
Optical rotations were measured on a Rudolph Research Analytical Autopol I 
automatic polarimeter. 
Sodium hydride in oil was washed twice with petroleum spirits prior to use. 
Thin layer chromatography was performed using 200 µm silica gel F-254 aluminium-
backed sheets. Preparative TLC was performed using 20×20 cm, 1000 µm thick silica 
gel F-254 glass-backed plates. UV light (254 nm) was used to visualise TLC plates. 
Column chromatography was performed using 40-63 µm silica gel.  
Heated Electro spray ionisation – high resolution mass spectrometry (HESI-
HRMS). The HRMS was determined by Dr. Frankie Busetti at Edith Cowan 
University. A Thermo Scientific Q-Exactive Orbitrap mass spectrometer (Thermo 
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Fisher Scientific Corporation, Waltham, USA) was employed for high accuracy mass 
determination of the compounds. Stock solutions were prepared by dissolving 1 mg of 
compound into 1 mL of DCM. Solutions were diluted down to 10 ng/µL in MeOH 
containing 0.1% formic acid and infused at 3 µL/min into the mass spectrometer using 
a built-in syringe pump. Full calibration of the LTQ Orbitrap XL in the 70-3000 m/z 
range was conducted prior to each measurement with the positive and negative ion 
calibration solutions provided by Thermo Scientific (Australia). Optical lenses were 
optimised with the positive calibration solution prior to each batch of samples. For 
increased mass accuracy on the Q-Exactive Orbitrap mass spectrometer, a plasticizer 
interfering peak present in the background (n-butyl benzenesulfonamide, 
C6H5SO2NH(CH2)3CH3, [M+H]+=214.0896 m/z), was used for the lock mass function. 
The screening analysis was conducted operating the Q-Exactive Orbitrap mass 
spectrometer in full-scan mode from 70-1000 m/z with a mass resolution of 70.000 (@ 
200 m/z). When necessary, samples were also analysed operating the Q-Exactive 
Orbitrap mass spectrometer in HRMS2 mode, where the mass spectrometer was forced 
to isolate the parent compound in the first quadrupole, fragment it in the HCD cell and 
then scan for the product ions in the Orbitrap mass analyser. A mass resolution of 
17.500 (@ 200 m/z) was used for the fragmentation experiments. The possibility for 
NH4+ adducts was confirmed by running a MS/MS on the adducts for a few samples. 
For substance identification the deviation of the measured mass (i.e. parent compound 
and fragments) was compared against the theoretical mass (< 2 ppm, relative error). 
To confirm elemental composition, the measured isotope pattern was also compared 
with that obtained from isotopic simulation. Data was processed using the Xcalibur 
QualBrowser software.  
2.5.2 Functionalisation of the ortho position of the resorcinarene 
2.5.2.1 14,36,56,76-tetrahydroxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (1) 
Resorcinarene (1) was synthesised according to the procedure by 
McIldowie et al.65 To a mixture of 3-methoxyphenol (30.1 g, 0.243 
mol), butanal (22 mL, 17.6 g, 0.245 mol) and dichloromethane (550 
mL) was added boron trifluoride etherate (90 mL, 104 g, 0.729 mol) while in an ice 
bath under nitrogen. The solution turned from orange-yellow to dark red. The ice bath 
was removed and the reaction mixture was allowed to warm to room temperature over 
O OH
C3H7
4
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about 20 minutes. After 2 hours at room temperature, the reaction mixture was 
quenched by adding water (400 mL), producing some white fumes and slight warming. 
The organic layer was separated, and the solvent was removed under reduced pressure 
to give a foamy brown solid as the crude product. The crude product was triturated 
with methanol (~200 mL) to give the product (1) as a white powder (36.9 g, 85%): mp 
256-259 °C (lit.131 257-258 °C); IR 3400 cm-1 (OH phenol); 1H NMR (CDCl3) δ 0.97 
(t, J = 7.4 Hz, 12 H, CH2CH3), 1.30 (apparent sxt, 8 H, CH2CH3), 2.18 (apparent q, 8 
H, CH2CH), 3.83 (s, 12 H, OCH3), 4.30 (t, J = 7.9 Hz, 4 H, CHCH2), 7.23 and 6.34 
(2s, 2 × 4 H, ArH), 7.50 (s, 4 H, OH). 
2.5.2.2 Attempted Rieche formylation of resorcinarene (1) 
The procedure by Bonini et al was applied.128 To a solution of resorcinarene (1) (0.258 
g, 0.362 mmol) in chloroform was added 1,1-dichloromethyl methyl ether (0.18 mL, 
1.23 mmol) followed by tin(IV) chloride (0.86 mL, 1.48 mmol) while in a brine-liquid 
nitrogen bath at -20 °C under nitrogen. Upon warming to room temperature, the 
reaction mixture became somewhat cloudy red-brown with a dark precipitate. The 
reaction mixture gradually became opaque dark brown and then opaque black over 5 
h. The reaction was then quenched with HCl (20 mL, 10%), and a black precipitate 
was observed. The solids were mostly dissolved after an hour of stirring and 
sonicating. The opaque dark red-brown organic layer was separated and the aqueous 
layer was extracted with dichloromethane (3 × 20 mL). The combined organic extracts 
were washed with water (3 × 20 mL), dried (MgSO4) and solvent removed under 
reduced pressure to afford the crude product as a black-brown solid (0.346 g), which 
appeared as a complex mixture by 1H NMR. TLC of the crude product was a complete 
streak. 
2.5.2.3 Attempted Duff formylation of resorcinarene (1) 
The procedure by Szumna and co-workers was applied to resorcinarene (1).130 
Resorcinarene (1) (0.205 g, 0.288 mmol) and hexamethylenetetramine (0.288 g, 2.05 
mmol) were combined in a vial with stirrer bar, followed by trifluoroacetic acid (2 
mL). The vial was capped and shaken vigourously till the solids were largely dissolved 
to produce a clear dark red solution. The reaction mixture was then subjected to 
microwave irradiation at 120 °C for 1 h. The resultant dark yellow-brown mixture was 
added to HCl (15 mL, 1 M) and CHCl3 (15 mL) and stirred rapidly overnight at room 
temperature. The layers were then separated and the aqueous layer was extracted with 
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dichloromethane (6 × 15 mL). The combined organic extracts were dried (MgSO4), 
filtered, and solvent removed under reduced pressure to afford the crude product as a 
dark orange oil (0.462 g). The crude product was filtered through a plug of silica using 
EtOAc (30 mL), and the solvent was removed under reduced pressure to give a dark 
yellow oil (0.137 g). A portion (0.055 g) of the material after the silica plug was 
subjected to preparative TLC (EtOAc – petroleum spirits 30:70). Three fractions were 
collected, which in total were 9 mg. TLC indicated incomplete separation. 1H NMR 
spectroscopy of the fractions could not identify any compounds. 
2.5.2.4 14,36,56,76-tetrahydroxy-16,34,54,74-tetramethoxy-15,35,55,75-
tetra(dimethylaminomethylene)-2,4,6,8-tetrapropylresorcin[4]arene (2) 
This resorcinarene was synthesised based on the report by Buckley et 
al.131 To a mixture of potassium carbonate (0.82 g, 5.95 mmol), 
anhydrous acetonitrile (1 mL) and N,N,N',N'-
tetramethylmethylenediamine (0.57 mL, 4.21 mmol) was carefully 
added acetyl chloride (0.30 mL, 4.21 mmol) with rapidly stirring in an 
ice bath. The resultant white slurry was stirred for 5 minutes under nitrogen. 
Resorcinarene (1) (0.50 g, 0.706 mmol) was then added, together with anhydrous 
acetonitrile (2 mL). The resultant white slurry was subject to microwave irradiation 
for 10 minutes at 110°C. The clear orange mixture was then filtered though cotton 
wool to remove potassium carbonate, and more acetonitrile was added. The filtrate 
was heated until boiling, and then water and triethylamine were added to precipitate 
the product. After allowing the mixture to cool to room temperature, filtration of the 
mixture afforded the previously unreported compound (2) as a white solid (0.46 g, 
70%): mp 221-222 °C; IR 3066 cm-1 (OH); 1H NMR (CDCl3) δ 0.90 (t, J = 7.3 Hz, 12 
H, CH2CH3), 1.25-1.43 (m, 8 H, CH2CH3), 1.70-1.83 (m, 4 H, CH2CH), 1.85-1.96 (m, 
4 H, CH2CH), 2.21 (s, 24 H, NCH3), 3.41 (s, 12 H, OCH3), 3.53, 3.66 (AB, 2 × 4 H, J 
= 13.7 Hz, ArCH2N), 4.49 (t, J = 7.5 Hz, 4 H, CHCH2), 6.73 (s, 4 H, ArH); 13C NMR 
(CDCl3) δ 14.4 (CH2CH3), 21.5 (CH2CH3), 35.7 (CHCH2), 38.3 (CH2CH), 44.4 
(NCH3), 56.3 (br, ArCH2N), 61.2 (OCH3), 113.7 (C, Ar), 125.7 (br, CH, Ar), 127.5, 
127.9, 154.2, 154.4 (C, Ar). Found: C, 70.19; H, 8.90; N, 5.78; C56H84N4O8.H2O; 
requires C, 70.11; H, 9.04%; N, 5.84%. 
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2.5.2.5 Attempted quarternisation and nucleophilic substitution of (2) 
The basis for this synthesis was the procedure by Gutsche and Nam.132 To a suspension 
of partially-dissolved resorcinarene (2) (0.0513 g, 0.0545 mmol) in DMSO-d6 was 
added iodomethane (0.0227 mL, 0.0518 g, 0.365 mmol) in an NMR tube. After 40 
minutes of periodic mixing at room temperature, sodium cyanide (0.030 g, 0.612 
mmol) was added, turning the cloudy reaction mixture a darker yellow colour. The 
reaction was then heated at 80 °C. After 3 hours, 1H NMR spectroscopy of the reaction 
mixture indicated broadening of resorcinarene signals with many peaks. After 3 days, 
1H NMR spectroscopy indicated that the resorcinarene signals had become broader. 
2.5.3 Functionalisation of resorcinarene phenols 
2.5.3.1 14,36,56,76-tetratrifluoromethanesulfonyl-16,34,54,74-tetramethoxy-
2,4,6,8-tetrapropylresorcin[4]arene (3)  
This synthesis was based on the procedure by Heaney and co-
workers.134 Resorcinarene (1) (2.64 g, 3.70 mmol), potassium 
carbonate (3.16 g, 22.86 mmol), N-phenylbis-
(trifluoromethanesulfonimide) (9.08 g, 5.41 mmol) and anhydrous 
acetonitrile (8 mL) were combined in the respective order. The reaction mixture was 
then subject to microwave irradiation at 110 °C for 15 minutes. The reaction mixture 
was allowed to cool to room temperature, then filtered to collect the white crystals 
which were washed with acetonitrile (25 mL), followed by plenty of water. After 
drying in the oven (120 °C), the pure, previously unreported product (3) was obtained 
as white crystals (4.12 g, 90%): mp 129 °C (MeCN); 1H NMR (CDCl3) δ 0.93 (t, J = 
7.3 Hz, 12 H, CH2CH3), 1.33 (apparent sxt, 8 H, CH2CH3), 1.72-1.96 (m, 8 H, 
CH2CH), 3.68 (s, 12 H, OCH3), 4.50 (t, J = 7.5 Hz, 4 H, CHCH2), 6.61 and 6.77 (s, 2 
× 4 H, ArH); 13C NMR (CDCl3) δ 14.10 (CH2CH3), 21.0 (CH2CH3), 36.0 (CHCH2), 
37.1 (CH2CH), 55.5 (OCH3), 103.5 (CH, Ar), 118.7 (q, J = 319.8 Hz, CF3), 126.8 (CH, 
Ar), 127.8, 132.0 (C, Ar), 147.0, 156.2 (C, Ar). Found: C, 46.29; H, 4.05; 
C48H52F12O16S4; requires C, 46.45; H, 4.22%.  
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2.5.3.2 14,36,56,76- tetramethoxy-16,34,54,74-tetranitrile -2,4,6,8-
tetrapropylresorcin[4]arene (4) 
This synthesis was adapted from the procedure by Mattay and co-
workers.133 Tetratriflate resorcinarene (3) (4.12 g, 3.32 mmol), zinc 
cyanide (3.14 g, 26.8 mmol) and oven-dried lithium chloride (1.95 g, 
46.0 mmol) were combined with stirrer bar and placed in an oven at 120 °C overnight. 
The flask with reagents was taken out of the oven and cooled under a stream of 
nitrogen. Anhydrous dimethylformamide (43 mL) was then added, and the mixture 
was de-oxygenated by freeze-pump-thaw procedure three times before adding dark 
orange tetrakistriphenylphosphine palladium(0) (0.784 g, 0.678 mmol), then de-
oxygenated again twice after. The cloudy bright yellow mixture was then heated at 
130 °C under nitrogen. After about 5 minutes of heating, the reaction mixture appeared 
to turn cloudy colourless. Then after 1 hour, the reaction mixture appeared to become 
cloudy yellow-orange. After 2 hours, the cloudy dark yellow reaction mixture was 
allowed to cool, then dichloromethane and sodium hydrogencarbonate solution were 
added to the reaction mixture, and the layers were allowed to settle before separation. 
The dark yellow organic layer was separated, and the aqueous layer was extracted 
twice with dichloromethane. The solvent was removed under reduced pressure from 
the combined organic extracts to give a white-brown solid (4.38 g) as the crude 
product. Purification by column chromatography (EtOAc – DCM 1:99 to 5:95) 
afforded the pure, previously unreported compound (4) as a white solid (2.47 g, 99%): 
mp 300 °C; IR 2223 cm-1 (C≡N); 1H NMR (CDCl3) δ 0.97 (t, J = 7.3 Hz, 12 H, 
CH2CH3), 1.27-1.43 (m, 8 H, CH2CH3), 1.82-2.01 (m, 8 H, CH2CH), 3.77 (s, 12 H, 
OCH3), 4.66 (t, J = 7.5 Hz, 4 H, CHCH2), 6.80, 6.93 (2s, 2 × 4 H, ArH); 13C NMR 
(CDCl3) δ 14.2 (CH2CH3), 20.9 (CH2CH3), 37.3 (CHCH2), 40.4 (CH2CH), 56.1 
(OCH3), 112.1 (C, Ar), 114.1 (CH, Ar), 118.0 (CN), 125.7 (CH, Ar), 138.1, 139.7, 
155.6 (C, Ar). Found: C, 76.64; H, 6.86; N, 7.32; C48H52N4O4; requires C, 76.98; H, 
7.00; N, 7.48%. 
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2.5.3.3 14,36,56,76-tetraformyl-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (5)  
This synthesis was based on the procedure by Mattay and co-workers.133 
To a cloudy colourless mixture of resorcinarene (4) (0.111 g, 0.148 
mmol) in anhydrous tetrahydrofuran (8 mL), was added dropwise 
DIBAL-H in toluene (2.5 mL, 1.02 M, 2.55 mmol), while in an ice bath, with stirring 
under nitrogen. The cloudy colourless solution was stirred in the ice bath, allowing to 
warm to room temperature. After 2 days, the reaction mixture was quenched with 
dilute HCl (10 mL, 1 M) producing bubbles. With a few drops of dilute HCl, the 
mixture turned into a white gel; bubbling and heat produced. With more dilute HCl 
and rapid stirring, the mixture became a cloudy slightly yellow solution. After stirring 
for 2 hours, the quenched reaction mixture was allowed to settle, forming two layers, 
which were separated. The bottom aqueous layer was extracted with dichloromethane 
(3 × 5 mL). The organic layers were combined, dried (MgSO4) and solvent evaporated 
to give the crude product as a slightly yellow solid (0.121 g). The crude product was 
filtered through a short column of silica beginning with dichloromethane, then with 
(EtOAc – DCM 5:95) to give the pure, previously unreported product (5) (0.024 g, 
21%) as a white solid: mp 190 °C; IR 1682 cm-1 (C=O); 1H NMR (CDCl3) δ 0.97 (t, J 
= 7.3 Hz, 12 H, CH2CH3), 1.30-1.47 (m, 8 H,  CH2CH3), 1.89-2.04 (m, 8 H, CH2CH), 
3.71 (s, 12 H, OCH3), 5.11 (t, J = 7.4 Hz, 4 H, CHCH2), 6.95, 7.22 (2s, 2 × 4H, ArH), 
10.30 (s, 4 H, CHO); 13C NMR (CDCl3) δ 14.3 (CH2CH3), 21.1 (CH2CH3), 36.8 
(CHCH2), 37.7 (CH2CH), 55.7 (OCH3), 109.6, 126.7 (CH, Ar), 132.8, 139.6, 140.1, 
154.9, (C, Ar), 191.4 (CHO). HRMS (ESI): calcd. for C48H57O8 as [M + H]+ 761.4048; 
found 761.4044. 
2.5.3.4 14,36,56,76-tetra(aminomethyl)-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (6) 
To a grey slurry of lithium aluminium hydride (0.355 g, 9.35 mmol) in 
anhydrous tetrahydrofuran (35 mL) was added resorcinarene (4) (0.302 
g, 0.403 mmol) while stirring at room temperature. The resultant cloudy 
dark grey mixture was stirred at reflux under nitrogen overnight. Thereafter, the 
mixture was cooled in an ice bath, quenched by slowly adding water (0.355 mL), 
causing vigorous bubbling and fumes, followed by sodium hydroxide (0.355 mL, 
15%), then more water (3 × 0.355 mL). After stirring at room temperature for 1 hour, 
the tetrahydrofuran was removed under reduced pressure. Dichloromethane (50 mL) 
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was added to the white residue with sonicating. The mixture was filtered, and the 
solvent was removed from the clear colourless filtrate to give the pure, previously 
unreported product (6) as a white solid (0.252 g, 82%): mp 207 °C (DCM); IR 3375 
and 3280 (NH2), 1194 cm-1 (C-N); 1H NMR (CDCl3) δ 0.94 (t, J = 7.4 Hz, 12 H, 
CH2CH3), 1.30-1.45 (m, 8 H,  CH2CH3), 1.75-1.87, 1.87-2.00 (2m, 8 H, CH2CH), 3.54, 
3.79 (AB, 2 × 4 H, J = 13.7 Hz, CH2N), 3.68 (s, 12 H, OCH3), 4.37 (t, J = 7.3 Hz, 4 
H, CHCH2), 6.68 and 6.74 (s, 2 × 4 H, ArH); 13C NMR (CDCl3) δ 14.5 (CH2CH3), 
21.4 (CH2CH3), 37.9 (CHCH2), 38.1 (CH2CH), 43.8 (CH2N), 55.4 (OCH3), 110.7, 
126.3 (CH, Ar), 131.7, 134.8, 140.0, 154.7 (C, Ar). HRMS (ESI): calcd. for 
C48H69N4O4 as [M + H]+ 765.5313; found 765.5284.  
2.5.4 Dialdehydecalixarene 
2.5.4.1 25,26,27,28-Tetrahydroxycalixarene (7) 
25,26,27,28-Tetrahydroxycalixarene (7) was prepared by a literature procedure.157 
2.5.4.2 25,27-Dihydroxy-26,28-di-n-propoxycalixarene (8) 
This calixarene was prepared according to literature.128 To a 
mixture of calixarene (7) (1.99 g, 4.70 mmol) and potassium 
carbonate (0.731 g, 5.29 mmol) in acetonitrile (100 mL) was added 
1-bromopropane (3.4 mL, 37.43 mmol). The resultant slightly cloudy white mixture 
was stirred at reflux open to air for 24 hours. The reaction was allowed to cool to room 
temperature. The solvent was removed under reduced pressure and dichloromethane 
(30 mL) was added to the residue. The cloudy white organic layer was washed with 
HCl (3 × 30 mL, 10%), dried (MgSO4), and solvent removed (evaporated) to give a 
white, slightly yellow solid (2.20 g). The solid was recrystallised from chloroform-
methanol to give pure (8) as white crystals (1.74 g, 73%): mp 260-263 °C (lit.69 268-
270 °C); IR 3290 cm-1 (OH phenol); 1H NMR (CDCl3) δ 1.32 (t, J = 7.4 Hz, 6 H, 
CH2CH3), 2.08 (apparent sxt, 4 H, CH2CH3), 3.38, 4.33 (AB, J = 12.9 Hz, 2 × 4 H, 
ArCH2Ar), 3.99 (t, J = 6.3 Hz, 4 H, OCH2), 6.65 (t, J = 7.5 Hz, 2 H, ArH), 6.75 (t, J = 
7.6 Hz, 2 H, ArH), 6.93 (d, J = 7.6 Hz, 4 H, ArH), 7.06 (d, J = 7.5 Hz, 4 H, ArH), 8.29 
(s, 2 H, OH). 
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2.5.4.3 5,17-Diformyl-25,27-dihydroxy-26,28-di-n-propoxycalixarene (9) 
This calixarene was prepared according to literature.128 To 
a solution of calixarene (8) (1.02 g, 2.01 mmol) in 
chloroform (50 mL) was added 1,1-dichloromethyl methyl 
ether (0.48 mL, 0.61 g, 5.3 mmol), followed by tin(IV) 
chloride (2.35 mL, 5.23 g, 20.9 mmol) while at -15°C under nitrogen. The reaction 
mixture immediately turned red, then quickly became pink with a precipitate. The 
reaction mixture was allowed to warm to room temperature, then stirred at room 
temperature under nitrogen for 2 hours. During this time, the reaction mixture turned 
from light-pink to dark pink then to purple. The reaction was then quenched with HCl 
(15 mL, 10%), then stirred till all solids dissolved. The resultant layers were separated, 
and the aqueous phase was extracted with dichloromethane (3 × 15 mL). The combined 
organic extracts were washed with water (3 × 20 mL) dried (CaCl2) and the solvent 
removed under reduced pressure to afford pure (9) as an off-white solid (1.13 g, 
100%): mp. 320-321 °C (CHCl3/MeOH) (lit.69 >320 °C); IR 1670 (C=O), 3159 cm-1 
(OH phenol); 1H NMR (CDCl3) δ 1.33 (t, J = 7.4 Hz, 6 H, CH2CH3), 2.09 (apparent 
sxt, 4 H, CH2CH3), 3.51, 4.31 (AB, J = 13.1 Hz, 2 × 4 H, ArCH2Ar), 4.02 (t, J = 6.2 
Hz, 4 H, OCH2), 6.80 (t, J = 7.6 Hz, 2 H, ArH), 6.97 (d, J = 7.6 Hz, 4 H, ArH), 7.64 
(s, 4 H, ArH), 9.25 (s, 2 H, OH), 9.79 (s, 2 H, CHO). 
2.5.5 Diaminocalixarene method 1 
2.5.5.1 5,17-Dinitro-26,28-dipropoxycalixarene (10) 
To a colourless mixture of calixarene (8) (1.00 g, 1.96 mmol) 
in glacial acetic acid (12 mL) and dichloromethane (10 mL) 
was added nitric acid (3 mL, 70%) while in an ice bath. The 
mixture was stirred in the ice bath open to air, and suddenly turned black after a couple 
of seconds, then to a dark yellow-green colour within a minute. After 30 minutes, the 
reaction mixture was diluted with water (30 mL). The layers were separated, and the 
organic layer was washed with water (3 × 20 mL), dried (MgSO4) and solvent removed 
under reduced pressure to give a dark orange solid as the crude product. The crude 
product was purified by column chromatography (DCM – petroleum spirits 7:3 to 9:1) 
to give pure (10) as a yellow-white solid (0.680 g, 58%): mp 320-345 °C dec (lit.113 
>320 °C dec); IR 3086 cm-1 (OH phenol); 1H NMR (CDCl3) δ 1.33 (t, J = 7.4 Hz, 6 H, 
CH2CH3), 2.09 (apparent sxt, 4 H, CH2CH3), 3.51, 4.30 (AB, J = 13.2 Hz, 2 × 4 H, 
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ArCH2Ar), 4.02 (t, J = 6.2 Hz, 4 H, OCH2), 6.85 (t, J = 7.4 Hz, 2 H, ArH), 7.00 (d, J 
= 7.6 Hz, 4 H, ArH), 8.04 (s, 4 H, ArH), 9.45 (s, 2 H, OH).  
2.5.5.2 Preparation of nitric acid on silica 
Nitric acid on silica (16-20%) was prepared according to a literature procedure.126 
Nitric acid (47 mL, 8 M) and silica gel (20 g) were combined to give a slurry which 
was stirred at room temperature for 2 hours. The slurry was then filtered and allowed 
to air-dry for 40 minutes. 
2.5.5.3 5,17-Dinitro-26,28-dipropoxycalixarene (10) via nitric acid on silica 
Calixarene (8) (0.337 g, 0.663 mmol), nitric acid on silica (1.33 g, ~16%, 0.213 g, 3.39 
mmol) and dichloromethane (12 mL) were combined and stirred at room temperature 
open to air. The white mixture turned light yellow within seconds. After 30 minutes, 
the reaction mixture was filtered with dichloromethane washing, and the solvent was 
evaporated from the filtrate to give a yellow solid as the crude product. Purification by 
column chromatography (DCM – petroleum spirits 7:3 – 9:1) afforded pure (10) white, 
slightly yellow solid (0.242 g, 61%). 
2.5.5.4 5,17-Diamino-26,28-dipropoxycalixarene (11) 
The synthesis was performed according to the procedure by 
Struck et al.113 To a yellow slurry of (10) (0.100 g, 0.167 
mmol) and hydrazine monohydrate (0.374 mL) in methanol 
(25 mL) was added a spatula tip (~0.1 g wet slurry) of Raney nickel. Then, the mixture 
was heated at reflux with rapid stirring, overnight. However, TLC of the reaction 
mixture thereafter indicated remaining starting material. So more hydrazine 
monohydrate (0.374 mL) and Raney nickel (~0.1 g wet slurry) was added to the 
reaction mixture, and reflux continued. TLC after about 6 hours indicated completion 
of the reaction. The cloudy dark green mixture was allowed to cool to room 
temperature, then filtered through celite. The solvent of the yellow filtrate was 
removed under reduced pressure, and the yellowish residue was dissolved in 
dichloromethane (10 mL), instantly turning the yellow solution to a peach, light-red 
colour. The organic solution was washed with NaHCO3 solution (3 × 5 mL), dried 
(MgSO4), and solvent evaporated to give fairly-pure (11) as a light-red solid (0.088 g, 
98%): 1H NMR (CDCl3) δ 1.28 (t, J = 7.4 Hz, 6 H, CH2CH3), 2.06 (apparent sxt, 4 H, 
CH2CH3), 3.25, 4.31 (AB, J = 12.9 Hz, 2 × 4 H, ArCH2Ar), 3.95 (t, J = 6.4 Hz, 4 H, 
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OCH2), 6.46 (s, 4 H, ArH), 6.75 (t, J = 7.5 Hz, 2 H, ArH), 6.93 (d, J = 7.5 Hz, 4 H, 
ArH), 7.64 (s, 2 H, OH). 
2.5.6 Diaminocalixarene method 2 
2.5.6.1 Propylation of calixarene (10) by potassium carbonate and MeCN 
Dinitrodipropoxycalixarene (10) (0.207 g, 0.346 mmol), potassium carbonate (0.643 
g, 4.65 mmol), acetonitrile (10 mL) and 1-bromopropane were combined and the 
yellow reaction mixture was heated at reflux under nitrogen for 12 days. During this 
time, cumulative amounts of sodium iodide (0.434 g, 2.90 mmol), 1-bromopropane 
(2.2 mL, 2.98 g, 24.2 mmol), then iodopropane (1.6 mL, 2.79 g, 16.4 mmol) were 
added to the reaction mixture, while the acetonitrile was also refilled. After this, the 
acetonitrile was evaporated, and the residue was dissolved in dichloromethane and 
water. The layers were separated, and the aqueous layer was extracted with 
dichloromethane (2 × 10 mL). The yellow-coloured combined organic extracts were 
dried (MgSO4) and solvent removed under reduced pressure to give a dark yellow solid 
(0.253 g) as the crude product. The 1H NMR spectrum of the crude product shows it 
to be a mixture of cone144 and partial cone145 propylated products, according to 
literature data.  
2.5.6.2 Attempted propylation of calixarene (10) by sodium hydride and DMF 
Dinitrodipropoxycalixarene (10) (0.201 g, 0.336 mmol), dissolved in anhydrous 
dimethylformamide (12 mL) was added to washed sodium hydride (0.345 g, 60% in 
oil, 0.207 g, 8.63 mmol) and a couple of crystals of imidazole, and the resultant cloudy 
yellow mixture was stirred under nitrogen at room temperature for 30 minutes. 1-
Iodopropane (0.400 mL, 0.697 g, 4.10 mmol) was added, and the reaction mixture was 
stirred overnight at the same conditions. Thereafter, the reaction mixture had turned 
cloudy brown-yellow, and it was quenched with water producing bubbling. After 
stirring at room temperature for 30 minutes, the solvent was removed under reduced 
pressure. The residue was taken up in water and extracted with dichloromethane (3 × 
20 mL). The combined organic extracts were washed with brine, dried (MgSO4), and 
solvent removed under reduced pressure to give a yellow-brown solid (0.188 g) as the 
crude product. The 1H NMR spectrum of the crude product showed it to be the starting 
calixarene (10), essentially intact. 
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2.5.6.3 Propylation of calixarene (10) by sodium carbonate and MeCN 
Dinitrodipropoxycalixarene (10) (0.188 g, 0.314 mmol), sodium carbonate (0.289 g, 
2.73 mmol), acetonitrile (10 mL) and iodopropane (0.368 mL, 0.641 g, 3.77 mmol) 
were combined, and the brown reaction mixture was heated at reflux over 4 days. The 
acetonitrile was then evaporated from the reaction mixture, and the residue was 
extracted with dichloromethane (3 × 10 mL) and dilute HCl (10 mL, 1 M). The 
combined dark brown organic extracts were dried (MgSO4) and solvent removed under 
reduced pressure to give a brown oily residue (0.199 g) as crude product. The 1H NMR 
spectrum of the crude product indicated the absence of starting calixarene (10), with 
cone, partial cone and an unknown product. 
2.5.6.4 Attempted allylation of calixarene (10) with sodium hydride and DMF 
Dinitrodipropoxycalixarene (10) (0.101 g, 0.169 mmol), dissolved in anhydrous 
dimethylformamide (10 mL) was added to washed sodium hydride (0.549 g, 60% in 
oil, 0.329 g, 13.7 mmol) and a couple of crystals of imidazole, and the resultant cloudy 
yellow mixture was stirred under nitrogen at room temperature for 30 minutes. The 
reaction mixture was then cooled in an ice bath, and allyl bromide (0.087 mL, 0.122 
g, 1.01 mmol) was added. The reaction mixture was then allowed to warm to room 
temperature, and then stirred overnight under nitrogen. After, TLC of the reaction 
mixture showed only starting calixarene. Therefore, more allyl bromide (0.217 mL, 
0.303 g, 2.51 mmol) was added to the reaction while in an ice bath. The reaction was 
then stirred over another night at room temperature under nitrogen. Thereafter, the 
reaction mixture was a yellow-brown with white precipitate. TLC of the reaction still 
only showed starting calixarene. After stirring for a total of three days, the reaction 
mixture was a highly-coloured yellow, and was quenched with methanol, producing 
bubbling. Dilute HCl (80 mL, 1 M) was added causing the mixture to lose its yellow 
colour. The mixture was further diluted with water, stirred for a few mins, then filtered. 
The collected solid was dissolved in dichloromethane, washed with dilute HCl (20 mL, 
1 M), dried (MgSO4), filtered, and solvent removed under reduced pressure to give a 
light-brown solid (0.104 g), which was indicated by 1H NMR spectroscopy to be the 
starting calixarene (10), essentially intact. 
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2.5.6.5 Attempted synthesis of cone 5,17-dinitro-26,28-
di((ethoxycarbonyl)methoxy)-25,27-dipropoxycalixarene (12) 
Dinitrodipropoxycalixarene (10) (0.074 g, 0.124 mmol), sodium carbonate (0.125 g, 
1.18 mmol), acetonitrile (7 mL) and ethyl bromoacetate (0.055 mL, 0.083 g, 0.496 
mmol) were combined to give a cloudy pale-yellow mixture, which was heated at 
reflux under nitrogen for up to 5 days (or 67 h). The acetonitrile was boiled off. The 
residue was extracted with HCl (10 mL, 1 M) and dichloromethane (3 × 10 mL). The 
combined organic extracts were dried (MgSO4) and solvent removed under reduced 
pressure to give a yellow solid with crystals (0.123 g) as crude mixture. The crude 
mixture was separated by preparative TLC (DCM 100%) to give, in elution order: 
partial cone calixarene (13) as a white solid (0.022 g, 23%), and previously unreported 
cone calixarene (12) as a white solid (0.039 g, 41%). 
Cone calixarene (12): mp 159-195 °C; IR 1732 and 1754 cm-
1 (C=O ester); 1H NMR (CDCl3) δ 1.03 (t, J = 7.4 Hz, 6 H, 
CH2CH2CH3), 1.29 (t, J = 7.1 Hz, 6 H, OCH2CH3), 1.89 
(apparent sxt, 4 H, CH2CH2CH3), 3.35, 4.69 (AB, J = 13.9 
Hz, 2 × 4 H, ArCH2Ar), 3.79 (t, J = 7.2 Hz, 4 H, OCH2CH2), 
4.22 (q, J = 7.1 Hz, 4 H, OCH2CH3), 4.83 (s, 4 H, OCH2C=O), 6.38 (d, J = 7.5 Hz, 4 
H, ArH), 6.47 (dd, J = 6.7, 1.6 Hz, 2 H, ArH), 7.83 (s, 4 H, ArH); 13C NMR (CDCl3) 
δ 10.6 (CH2CH3), 14.3 (OCH2CH3), 23.3 (CH2CH2CH3), 31.5 (ArCH2Ar), 61.1 
(OCH2CH2), 70.9 (OCH2CH3), 77.4 (OCH2C=O), 123.3, 124.3, 128.6 (CH, Ar), 132.7, 
137.2, 143.0, 155.7, 161.8 (C, Ar), 169.2 (C=O); HRMS (ESI): calcd. for C42H47N2O12 
as [M + H]+ 771.3124; found 771.3112. 
Partial cone calixarene (13): mp 60-80 °C; IR 1732 and 1753 
cm-1 (C=O ester); 1H NMR (CDCl3) δ 1.10 (t, J = 7.4 Hz, 6 H, 
CH2CH3), 1.21 (t, J = 7.1 Hz, 3 H, OCH2CH3),  1.38 (t, J = 7.2 
Hz, 3 H, OCH2CH3), 1.88-1.99 (m, 4 H, CH2CH2CH3), 3.30, 
4.34 (AB, J = 14.3 Hz, 2 × 2 H, ArCH2Ar), 3.59-3.69 (m, 2 H, 
OCH2CH2), 3.80, 3.90 (overlapped AB, J = 13.3 Hz, 2 × 2 H, ArCH2Ar), 3.76-3.85 
(overlapped m, 2 H, OCH2CH2), 3.89, 4.55 (2s, 2 × 2 H, OCH2C=O), 4.02 (q, J = 7.1 
Hz, 2 H, OCH2CH3), 4.34 (q, J = 7.1 Hz, 2 H, OCH2CH3), 6.29 (m, 2 H, ArH), 6.52 
(t, J = 7.6 Hz, 2 H, ArH), 7.08 (dd, J = 7.6, 1.4 Hz, 2 H, ArH), 8.01 and 8.25 (2s, 2 × 
2 H, ArH), 13C NMR (CDCl3) δ 10.8 (CH2CH3), 14.0, 14.4 (OCH2CH3), 23.8 
O2N
O
NO2
OO OPr Pr
OEt EtO
O O
O2N
O O OPr Pr
OEt
O
O2N
O
EtO
O
 88 
 
(CH2CH2CH3), 31.8, 35.2 (ArCH2Ar), 60.8, 61.7 (OCH2CH3), 67.6, 70.7 (OCH2C=O), 
76.8 (OCH2CH2), 122.9, 124.7, 126.0, 129.1, 129.4 (CH, Ar), 130.9, 132.2, 135.3, 
137.2, 142.5, 142.7, 155.8, 161.0, 162.1 (C, Ar), 168.6, 169.5 (C=O); HRMS (ESI): 
calcd. for C42H47N2O12 as [M + H]+ 771.3124; found 771.3102. 
2.5.6.6 Attempted synthesis of cone 5,17-dinitro-26,28-diallyl-25,27-
dipropoxycalixarene (14) 
To a dark brown slurry of dinitrodipropoxycalixarene (10) (0.101 g, 0.169 mmol), 
potassium carbonate (0.229 g, 1.66 mmol) and allyl bromide (1.5 mL, 2.10 g, 17.3 
mmol) was added acetonitrile (5 mL) to give a yellow-brown cloudy mixture, which 
was heated at reflux under nitrogen for 3 days. Thereafter, the solvent had evaporated 
to dryness, and TLC showed absence of starting calixarene. The residue was extracted 
with dichloromethane (3 × 10 mL) and HCl (20 mL, 1 M). The combined organic 
extracts were dried (MgSO4), filtered, and solvent removed under reduced pressure to 
give a light-brown oily solid (0.130 g) as crude mixture. Completion of the phenol 
allylation reaction was verified by the lack of disappearance of signals when a drop of 
D2O as added to the NMR solution of the crude mixture. The crude mixture was 
separated by preparative TLC (DCM – petroleum spirits 80:20) to give, in elution order 
previously unreported products: partial cone calixarene (15) as an off-white solid 
(0.027 g, 24%), cone calixarene (14) as an orange solid (0.006 g, 5%), and 1,3-alternate 
calixarene (16) as a white-yellow solid (0.024 g, 21%). 
Cone calixarene (14): 1H NMR (CDCl3) (impure, only 
relevant signals quoted) δ 1.07 (t, J = 7.4 Hz, 6 H, CH2CH3), 
1.81-2.00 (m, 4 H, CH2CH3), 3.29, 4.45 (AB, J = 13.6 Hz, 2 
× 4 H, ArCH2Ar), 3.75 (t, J = 7.1 Hz, 4 H, OCH2CH2), 4.70 
(d, J = 6.6 Hz, 4 H, OCH2CH), 5.14-5.24 (m, 4 H, CH=CH2), 
6.28-6.39 (overlapped m, 2 H, CH=CH2), 6.31 (d, J = 7.6 Hz, 4 H, ArH), 6.41 (dd, J 
= 6.8 or 1.4 Hz, 2 H, ArH), 7.89 (s, 4 H, ArH); 13C NMR (CDCl3) δ 10.8 (CH3), 23.6 
(CH2CH3), 31.4 (ArCH2Ar), 76.4 (OCH2CH)), 77.4 (OCH2CH2), 118.6 (C=CH2), 
123.0, 124.2, 128.3 (CH, Ar), 132.5 (C, Ar), 134.6 (CH=CH2), 138.2, 142.8, 155.7, 
162.5 (C, Ar); HRMS (ESI): calcd. for C40H43N2O8 as [M + H]+ 679.3014; found 
679.2998. 
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Partial cone calixarene (15): mp 182-184 °C; 1H NMR (CDCl3) 
δ 1.10 (t, J = 7.4 Hz, 6 H, CH2CH3), 1.85-2.03 (m, 4 H, 
CH2CH3), 3.21, 4.11 (AB, J = 13.7 Hz, 2 × 2 H, ArCH2Ar), 
3.55-3.65 (overlapped m, 2 H, OCH2CH), 3.65, 3.80 
(overlapped AB, J = 12.9 Hz, 2 × 2 H, ArCH2Ar), 3.75-3.85 
(overlapped m, 2 H, OCH2CH), 4.03 (dt, J = 6.5, 1.2 Hz, 2 H, OCH2CH), 4.44 (dt, J = 
5.2, 1.6 Hz, 2 H, OCH2CH), 4.82-4.96, 5.33-5.48 (2m, 2 × 2 H, CH=CH2), 5.73 (ddt, 
J = 16.8, 10.3, 6.5 Hz, 1 H, CH=CH2), 6.15 (ddt, J = 17.1, 10.4, 5.1 Hz, 1H, CH=CH2), 
6.29 (m, 2 H, ArH), 6.49 (t, J = 7.6 Hz, 2 H, ArH), 6.94 (dd, J = 7.6, 1.5 Hz, 2 H, 
ArH), 8.02, 8.25 (2s, 2 × 2 H, ArH); 13C NMR (CDCl3) δ 10.9 (CH2CH3), 23.9 
(CH2CH3), 31.1, 35.8 (ArCH2Ar), 73.8, 75.1 (OCH2CH), 76.8 (OCH2CH2), 117.1, 
117.9 (C=CH2), 122.3, 124.4, 126.1, 129.1, 130.1 (CH, Ar), 131.0, 132.0 (C, Ar), 
133.3, 134.6 (CH=CH2), 135.5, 138.4, 142.5, 142.8, 155.7, 162.19, 162.21 (C, Ar) 
(note some signals are coincident); HRMS (ESI): calcd. for C40H46N3O8 as [M + NH4]+ 
696.3279; found 696.3272 (main peak); and calcd. for C40H43N2O8 as [M + H]+ 
679.3014; found 679.3011. 
1,3-alternate calixarene (16): mp 192-205 °C (THF/MeOH); 1H NMR 
(CDCl3) δ 0.99 (t, J = 7.5 Hz, 6 H, CH2CH3), 1.79 (apparent sxt, 4 H, 
CH2CH3), 3.60, 3.72 overlap (AB, J = 14.2 Hz, 2 × 4 H, ArCH2Ar), 
3.70 (overlapped t, J = 7.4 Hz, 4 H, OCH2CH2), 4.21 (dt, J = 4.9, 1.6 
Hz, 4 H, OCH2CH), 5.14-5.28 (m, 4 H, CH=CH2), 5.93 (ddt, J = 17.1, 
10.6, 4.9 Hz, 2 H, CH=CH2), 6.69 (t, J = 7.5 Hz, 2 H, ArH), 6.98 (d, J = 7.5 Hz, 4 H, 
ArH), 7.95 (s, 4 H, ArH); 13C NMR (CDCl3) δ 10.4 (CH2CH3), 23.7 (CH2CH3), 36.5 
(ArCH2Ar), 72.6 (OCH2CH), 74.1 (OCH2CH2), 117.3 (C=CH2), 122.2, 125.7, 131.2 
(CH, Ar), 132.4 (C, Ar), 133.1 (CH=CH2), 135.13, 142.1, 156.3, 161.3 (C, Ar); HRMS 
(ESI): calcd. for C40H43N2O8 as [M + H]+ 679.3014; found 679.2992. 
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2.5.7 Diaminocalixarene method 3 
2.5.7.1 25,26,27,28-Tetrapropoxycalixarene (17) 
The calixarene was prepared as described by Mendez-Arroyo et 
al.151 Calixarene (7) (1.01 g, 2.37 mmol) was added to a mixture 
of washed sodium hydride (1.25 g, 60% in oil, 0.75 g, 31.3 mmol) 
and a few of crystals of imidazole in anhydrous dimethylformamide (50 mL), and the 
resultant off-white slurry was stirred under nitrogen at room temperature for 30 
minutes. Then, 1-bromopropane (1.75 mL, 2.40 g, 19.3 mmol) was added to the slurry, 
and the reaction mixture was stirred under nitrogen at room temperature overnight. 
The reaction mixture was then quenched with methanol (5 mL) producing bubbles. 
The solvent was removed under reduced pressure and the residue was dissolved in 
dichloromethane (40 mL) and dilute HCl (40 mL, 1 M). The layers were separated, 
and the aqueous layer was extracted a further two times with dichloromethane (30 
mL). The combined cloudy yellow organic extracts were dried (MgSO4), and solvent 
removed under reduced pressure to give a yellow solid residue. The yellow solid was 
triturated with methanol (20 mL) to give pure (17) an off-white solid (1.09 g, 78%), 
mp 183-194 °C (lit.158 197-199 °C); 1H NMR (CDCl3) δ 0.99 (t, J = 7.5 Hz, 12 H, 
CH2CH3), 1.92 (apparent sxt, 8 H, CH2CH3), 3.15, 4.46 (AB, J = 13.3 Hz, 2 × 4 H, 
ArCH2Ar), 3.85 (t, J = 7.5 Hz, 8 H, OCH2), 6.52-6.64 (m, 12 H ArH). 
2.5.7.2 5,11,17,23-Tetrabromo-25,26,27,28-tetrapropoxycalixarene (18) 
The calixarene was prepared as described in literature.151 To a 
slightly yellow solution of (17) (0.86 g, 1.46 mmol) partially 
dissolved in butanone (10 mL) was added light-yellow N-
bromosuccinimide (1.68 g, 9.44 mmol). The resultant mixture was dark yellow with a 
white precipitate, which warmed slightly, and within 7 minutes became clear yellow. 
After stirring under nitrogen at room temperature for 24 hours, the reaction was 
stopped by the addition of sodium hydrogensulfite solution (2 mL, 40%), turning the 
mixture cloudy with ppt and slight warming. The quenched reaction mixture was 
stirred for 10 minutes, then extracted with dichloromethane (3 × 20 mL) and dilute 
HCl (20 mL, 1 M). The combined yellow-coloured organic extracts were dried 
(MgSO4) and solvent removed to give a white-yellow solid. The white-yellow solid 
was triturated with methanol (10 mL), then washed with ethanol (3 × 4 mL) to give 
pure (18) as an off-white solid (1.30 g, 98%): mp 272-279 °C (lit.84 280-282 °C); 1H 
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NMR (CDCl3) δ 0.97 (t, J = 7.5 Hz, 12 H, CH2CH3), 1.87 (apparent sxt, 8 H, CH2CH3), 
3.08, 4.35 (AB, J = 13.4 Hz, 2 × 4 H, ArCH2Ar), 3.80 (t, J = 7.6 Hz, 8 H, OCH2), 6.80 
(s, 8 H ArH). 
2.5.7.3 5,17-Dibromo-25,26,27,28-tetrapropoxycalixarene (19) 
The bromine-lithium exchange reaction was conducted 
according to literature procedures.84, 151 To a clear light-yellow 
solution of calixarene (18) (0.422 g, 0.465 mmol) in anhydrous 
tetrahydrofuran (5 mL) was rapidly added butyllithium (1.2 mL, ~1.6 M, 1.9 mmol) 
with rapid stirring while under nitrogen at -84 °C. The solution immediately turned 
dark orange and was stirred for 15 minutes at the same conditions. The reaction 
mixture was quenched with methanol (0.50 mL) and stirred for 10 minutes at the same 
conditions. The reaction mixture was then extracted with dichloromethane (3 × 10 mL) 
and dilute HCl (10 mL, 1 M). The organic extracts were combined, dried (MgSO4) and 
solvent removed under reduced pressure to give an off-white, yellowish crystalline 
solid as the crude product. The crude product was triturated with methanol to give (19) 
as a white, slightly-yellowish solid (0.325 g, 93%): mp 220-238 °C (lit.84 243-245 °C); 
1H NMR (CDCl3) δ 0.99 (t, J = 7.5 Hz, 6 H, CH2CH3), 1.00 (t, J = 7.5 Hz, 6 H, 
CH2CH3), 1.84-1.98 (m, 8 H, CH2CH3), 3.12, 4.41 (AB, J = 13.4 Hz, 2 × 4 H, 
ArCH2Ar), 3.82 (t, J = 7.5 Hz, 4 H, OCH2), 3.84 (t, J = 7.5 Hz, 4 H, OCH2), 6.64 
(apparent  s, 6 H ArH), 6.78 (s, 4 H ArH). 
2.5.7.4 Preparation of anhydrous nitric acid 
Preparation of anhydrous nitric acid: concentrated sulfuric acid (32 mL, 98%) was 
added to potassium nitrate (23 g, 0.23 mol) to give a clear colourless solution, which 
was distilled to give anhydrous nitric acid (12.4 g, 86%) as a yellow liquid. 
2.5.7.5 5,17-Dibromo-22,23-dinitro-25,26,27,28-tetrapropoxycalixarene (20) 
To a mixture of calixarene (19) (0.069 g, 0.0919 mmol), 
claycop (0.109 g) and acetic anhydride (0.276 mL, 0.299 g, 
2.92 mmol) in dichloromethane (4 mL) was added fuming 
anhydrous HNO3 (1 drop) while stirring at room temperature, immediately darkening 
the reaction mixture. After 20 minutes stirring at room temperature open to air, the 
reaction was monitored by TLC, and more anhydrous HNO3 (2 drops) was added as 
necessary. Once the reaction was complete, the turquoise-green reaction mixture was 
OPr PrOO O
H HBrBr
Pr Pr
OPr PrOO O
O2N NO2BrBr
Pr Pr
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filtered, and the filtrate was washed with water (7 mL), turning yellow. The organic 
extract was dried (MgSO4) and solvent evaporated to give a yellow solid (0.092 g) as 
crude product. The crude product was purified by preparative TLC (toluene) to give 
pure, previously unreported product (20) as a mainly colourless solid (0.016 g, 21%), 
which could be recyrstallised to give off-white needles: 273-274 °C (CHCl3/MeOH); 
1H NMR (CDCl3) δ 0.99 (t, J = 7.5 Hz, 6 H, CH2CH3), 1.00 (t, J = 7.5 Hz, 6 H, 
CH2CH3), 1.80-1.98 (m, 8 H, CH2CH3), 3.25, 4.44 (AB, J = 13.7 Hz, 2 × 4 H, 
ArCH2Ar), 3.79 (t, J = 7.5 Hz, 4 H, OCH2), 3.98 (t, J = 7.6 Hz, 4 H, OCH2), 6.76 (s, 4 
H ArH), 7.63 (s, 4 H ArH); 13C NMR (CDCl3) δ 10.2, 10.4 (CH2CH3), 23.3, 23.4 
(CH2CH3), 31.1 (ArCH2Ar), 77.5, 77.6 (OCH2), 115.9 (C, Ar), 124.0, 131.5 (CH, Ar), 
135.7, 136.2, 142.8, 155.3, 162.3 (C, Ar). Found: C, 57.28; H, 5.27; N, 3.34; 
C40H44Br2N2O8; requires C, 57.15; H, 5.28; N, 3.33%. 
2.5.7.6 5,17-Diamino-22,23-dibromo-25,26,27,28-tetrapropoxycalixarene (21) 
The procedure by Timmerman et al. served as a guide.143 To 
a mixture of calixarene (20) (0.106 g, 0.126 mmol), and 
hydrazine monohydrate (0.54 mL) in methanol was added a 
spatula tip (~ 0.1 g wet slurry) of Raney nickel, immediately producing small bubbles. 
The mixture was heated at reflux under nitrogen overnight. The reaction was 
monitored by TLC, and more Raney nickel and hydrazine monohydrate were added as 
necessary. Once the reaction has been completed, the reaction mixture was filtered 
through celite with methanol rinsing, and the solvent was removed under reduced 
pressure from the filtrate. The residue which was dissolved in dichloromethane (20 
mL) and washed with NaHCO3 (3 × 20 mL, 5%). The organic layer was dried (MgSO4) 
and solvent removed under reduced pressure to give pure, previously unreported 
product (21) as a yellow glassy amorphous solid (0.099 g, ~100%) which could not be 
crystallised: 1H NMR (CDCl3) δ 0.97 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.98 (t, J = 7.4 Hz, 
6 H, CH2CH3), 1.78-1.97 (m, 8 H, CH2CH3), 3.01, 4.34 (AB, J = 13.4 Hz, 2 × 4 H, 
ArCH2Ar), 3.32 (br s, 4 H, NH2), 3.74 (t, J = 7.5 Hz, 4 H, OCH2), 3.82 (t, J = 7.6 Hz, 
4 H, OCH2), 5.98 (s, 4 H ArH), 6.87 (s, 4 H ArH); 13C NMR (CDCl3) δ 10.3, 10.5 
(CH2CH3), 23.2 (CH2CH3), 31.0 (ArCH2Ar), 76.88, 76.91 (OCH2), 114.6, 116.0, 
130.8, 134.8, 137.5, 140.7, 149.7, 156.1 (Ar) (note some signals are coincident).  
NH2
OPr
NH2
PrOO O
Br Br
Pr Pr
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3 Distal functionalisation of resorcinarene by selective 
lithiation 
 
 
The work presented in this chapter has been published in a peer reviewed journal cited 
below: 
Tan, D. A.; Mocerino, M., J Incl Phenom Macrocycl Chem 2018, 91 (1), 71-80.  
DOI: 10.1007/s10847-018-0802-4 
 
In this chapter, another strategy towards the key intermediary product of a distally-
functionalised tetramethoxyresorcinarene (Scheme 1.26) is explored. In the literature, 
there exists a few procedures for distally-functionalising resorcinarenes. In the method 
by Shivanyuk et al.,93, 94 a distally-functionalised resorcinarene was directly obtained 
in 53% yield through regioselective tetratosylation of octahydroxyresorcinarene 
(Scheme 1.21). However, this method excludes the tetramethoxyresorcinarene 
because four of the hydroxy groups have already been alkylated. Aside from this work, 
in the literature there is one other main strategy for distally-functionalising a 
resorcinarene – that is by selective lithiation (Scheme 3.1) as reported by Arnott and 
co-workers.111  
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Scheme 3.1 Partially selective distal functionalisation at the wider rim of octamethoxyresorcinarene.  
This direct lithiation method is similar to the selective bromine-lithium exchange by 
Larsen and Jørgensen on calixarenes (Scheme 1.11),84 as well as by Sherburn and co-
workers on cavitands.108-110 But in contrast, the lithiation by Arnott and co-workers is 
not a bromine–lithium exchange, and thus does not require a brominated resorcinarene. 
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In this direct lithiation method, octamethoxyresorcinarene was lithiated using 
butyllithium, then quenched with dimethyldisulfide to give a thioether, which enabled 
elucidation of the result by 1H NMR spectroscopy of the crude mixture. The lithation 
under various conditions was investigated with variation of the reaction solvent, 
number of equivalents of butyllithium, lithiation time and temperature. Using five 
equivalents of butyllithium in THF at a temperature of 40 °C for 2 hours, the best yield 
of 86% for the distal product was achieved, albeit the presence of unreacted starting 
material and mono product. The lithation under these optimal conditions was also 
demonstrated to work with other electrophiles, such as carbon dioxide, to give useful 
functional groups, while still retaining a good yield for the distal product. It was 
hypothesised that the distal selectivity was the result of the randomly-lithiated species 
equilibrating to the distally-lithiated intermediate which was presumably the most 
thermodynamically stable.111 
The first step to prepare tetramethoxyresorcinarene for the lithiation is to protect all 
four hydroxy groups with a protecting group that would be stable under the lithation 
conditions (Scheme 3.2).   
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Scheme 3.2 Investigation into the distal-lithiation of various O-protected resorcinarene derivatives. 
3.1 Benzyl ether 
The protecting group first chosen was the benzyl ether. Benzyl ethers are known to be 
fairly robust, pH stable, and are usually only cleavable by reduction to return the 
alcohol. Furthermore, benzyl bromide is relatively safe to use and was readily 
available. Reaction of the starting resorcinarene (1) with benzyl bromide, sodium 
hydride and tetrahydrofuran furnished the desired tetrabenzyloxyresorcinarene (22) in 
a good yield and purity after recrystallisation (Scheme 3.3). Evidence of the benzyl 
ether was provided by NMR spectroscopy, which showed the benzylic protons as an 
 (1) 
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AB pattern at 4.70 and 4.94 ppm on the 1H NMR spectrum, while the benzylic carbon 
appeared on the 13C NMR spectrum at 71.1 ppm (Appendix A – 21). 
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Scheme 3.3 Protection of resorcinarene phenols with benzyl ethers and attempted distal lithiation. 
With tetrabenzyloxyresorcinarene (22) in hand, the lithiation was then performed 
according to the same conditions as described by Arnott and co-workers, with 
quenching with dimethyldisulfide. Unfortunately, TLC did not show any well-defined 
spots and the 1H NMR spectrum of the quenched reaction mixture indicated the 
resorcinarene peaks as broad humps, with multiple methoxy and aromatic signals. The 
benzyl ether was still apparent by a broad hump from 6.7 to 7.7 ppm. This complex 
mixture suggests that the benzyl ether was not as robust as thought. A protecting group 
that would be more stable under the strongly basic lithiation conditions may perhaps 
provide success.  
3.2 Methoxymethyl ether 
The methoxy methyl (MOM) protecting group, when functionalised to a phenol, is 
known to direct lithiation to the ortho position of the aromatic ring.159, 160 MOM 
protecting groups can be easily removed by acid-catalysed hydrolysis. Therefore, the 
MOM protecting group is an ideal candidate for this application. However, the main 
issue is the safety of methoxymethyl halides,161 which is required for synthesising the 
MOM ether of the phenol. Nevertheless, the reaction of (1) with methoxymethyl 
bromide under standard sodium hydride / THF conditions afforded the target product 
(23) in excellent purity in quantitative yield without any formal purification (Scheme 
3.4). NMR spectroscopy confirmed the MOM ether resorcinarene by an additional 
methoxy peak appearing on both 1H and 13C spectra (Appendix A – 22). The acetal 
was evidenced by the AB at 4.84 and 4.73 ppm on the 1H spectrum, as well as the CH2 
peak at 95.8 ppm on the DEPT-135 spectrum.  
  (1) (22)
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Scheme 3.4 Protection of resorcinarene phenols with methoxymethyl ethers and attempted distal 
lithiation. 
The lithiation was performed on resorcinarene (23) as per the literature, but yielded a 
complex mixture of six compounds as indicated by TLC (Rf(EtOAc/Petrol 4:6) = 0.71, 0.63, 
0.48, 0.38, 0.31, 0. 19, Figure 3.1). Doubling the amount of butyllithium from five to 
ten equivalents also produced the same result, but with the least retained spot on TLC 
becoming darker. The crude products from the reactions with five and ten equivalents 
were combined, and the six compounds were separated sufficiently by preparative 
TLC to enable identification of each compound by 1H NMR spectroscopy. The 
structures of the six compounds were tentatively assigned by analysis of their 1H NMR 
spectra, based principally on symmetry and integration data. The 1H NMR data 
suggested that the six compounds obtained were the five possible products plus the 
starting material (Scheme 3.5). The 1H NMR data (Appendix A – 23), together with 
the isolated yields and assignments are summarised in Table 3.1. 
 
Figure 3.1 TLC (Rf(EtOAc/Petrol 4:6) of the quenched reaction mixture from the lithiation of (23) with 
10 equivalents of butyllithium. 
 
  
 
(1) (23)
      (28) Tetra-SCH3 
 
       (27) Tri-SCH3 
 
       (26) Proximal-SCH3
 
       (25) Distal-SCH3 
       (24) Mono-SCH3 
 
       (1) 
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Scheme 3.5 Lithiation of MOM resorcinarene produces the five possible SCH3 resorcinarene 
products. 
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Table 3.1 Summary of key 1H NMR spectroscopic data of SCH3 resorcinarene products recorded 
in CDCl3. Chemical shifts are listed in ppm. Rf (EtOAc/Petrol 4:6). 
Rf  SCH3 ArH SCH3 resorcinarene 
Symmetry Isolated yield (%) 
0.71 2.34 6.68 Tetra (28) C4 0.9 
0.63 2.28, 2.43* 
6.35, 6.38, 6.42, 6.93, 
6.95 Tri (27) Cs 3.6 
0.48 2.32, 2.39 
6.46, 6.49, 6.53, 6.55, 
6.77, 6.78 Proximal (26) Cs 8.1 
0.38 2.42 6.38, 6.44, 6.94 Distal (25) C2 4.4# 
0.31 2.37 6.48, 6.49, 6.51, 6.59, 6.63, 6.69, 6.70 Mono (24) Cs 27.5# 
0.19 None 6.36, 7.25 (1) C4 14.6 
*Coincidental peaks, integration is double 
#The yields for distal di-SCH3 resorcinarene and mono-SCH3 are not accurate, since both were not 
completely separated.  
The signals in the 1H NMR spectra, which provided clear indicators for assigning the 
products were the SCH3 and the aromatic signals. The distal product (25), having C2 
rotational symmetry, would have half the peaks compared to its asymmetrical 
proximal isomer (26). The appearance of many peaks indicated an absence of 
rotational symmetry in the product. These asymmetrical products – tri (27), proximal 
(26), and mono (24) – could be distinguished from each other by the number of ArH 
and SCH3 signals. For example, tri (27), having three SCH3 replacing three ArH, 
would have three less ArH from the original eight, which would result in five ArH 
peaks. Therefore, based on the number and integration of these signals, together with 
symmetry considerations, the particular SCH3 resorcinarene product could be assigned 
for each spectrum. For all isolated products, the retention of the MOM protecting 
group through the lithiation was confirmed by the pairs of AB doublets around 4.2-5.2 
ppm and the corresponding extra methoxy singlet in all 1H NMR spectra. 
It is clear from the results that distal di-SMe resorcinarene is not the main product. In 
efforts to optimise the yield for the target distal product, the lithiation was attempted 
under milder conditions, at room temperature overnight, but only returned unreacted 
starting resorcinarene. The lithiation was also attempted with sec-butyllithium, a 
stronger base, but yielded similar results as with butyllithium. From the results, it is 
clear that the lithiation of resorcinarene methoxymethyl ether (23) is not a viable 
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method for obtaining a distally-functionalised resorcinarene due to the lack of 
selectivity and difficulty of separation.  
3.3 Ethyl ether 
Finally, for the purpose of simply testing the applicability of the lithation procedure 
on this particular tetramethoxyresorcinarene, the ethyl ether was chosen. The ethyl 
ether would not be readily cleavable to recover the phenol and has no functional value. 
Furthermore, as the methyl and ethyl groups are of similar size, and chirality influence 
would be minimal. However, it was for this similarity that the ethyl ether was chosen; 
to liken the resorcinarene to the literature octamethoxyresorcinarene, while retaining 
its characteristic C4 symmetry. 
The tetraethylation of resorcinarene (1) under standard sodium hydride / THF 
conditions did not proceed to completion despite using up to 30 equivalents of 
iodoethane and subjecting the mixture to reaction again. However, changing the 
reaction solvent to dimethylformamide conveniently furnished the target product (29) 
in good yield and purity (Scheme 3.6). The ethoxy group was confirmed by 1H NMR 
spectroscopy as a multiplet overlapped with the methoxy singlet, and an additional 
triplet in the hydrocarbon region (Appendix A – 25). The methyleneoxy carbon was 
accounted for on the DEPT-135 spectrum by the CH2 peak at 64.9 ppm. 
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Scheme 3.6 Ethylation of resorcinarene phenols and subsequent distal lithiation. 
The ethoxy derivative (29) was then subjected to the same lithiation procedure to give 
a single product along with unreacted starting resorcinarene, as indicated by TLC. The 
product was successfully separated by column chromatography to afford the target 
product (30) in yield of 36%. 1H NMR spectroscopy of the pure product conclusively 
showed a C2-symmetrical resorcinarene product with a single SCH3 peak at 2.42 ppm 
and three peaks in the aromatic region with the same integration (Appendix A – 26). 
 
 
 (29) (30)
(1) 
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The correct number of peaks for target product (30) was present on the 13C NMR 
spectrum, with the SCH3 peak being identified as the peak at 18.3 ppm according to 
HSQC spectroscopy. Therefore, this experiment with the ethoxy functionalised 
resorcinarene proved that the lithiation for octamethoxyresorcinarene was applicable 
to this chiral resorcinarene. However, from this limited investigation it is apparent that 
the phenols needed to be alkylated with a group with close likeness to a methoxy 
group.  
The selective distal lithiation of three novel C4 symmetric O-substituted derivatives of 
tetramethoxyresorcinarene was investigated. These included the benzyloxy, the MOM 
and the ethoxy derivatives of tetramethoxyresorcinarene. Lithiation, followed by 
quenching with dimethyldisulfide gave very different results for the three derivatives. 
The benzyloxy derivative gave a complex mixture that could not be resolved. The 
lithiation on the MOM ether resorcinarene (23) gave a mixture of the five possible 
products, as well as unreacted starting resorcinarene. Separation of the five products 
was not complete, but the isolated compounds were sufficiently pure for tentative 
characterisation. The most abundant product was the mono-SMe (24) which was 
recovered in approximately 28% yield, while the distal-SMe (25) was recovered in a 
minor yield of about 4%. The lithiation with ethoxyresorcinarene (29) selectively 
produced the distal-SMe product (30) in 36%, after separation of unreacted starting 
resorcinarene. This served as a proof of concept that the selective distal lithiation was 
applicable to C4 symmetric tetramethoxyresorcinarene, albeit with an O-substituent 
with close similarity to a methoxy. Perhaps the tetrahydroxy functionality of the 
distal-SMe resorcinarene (30) could be restored by selective removal of the methoxy 
groups to hydroxy groups. The reaction conditions to accomplish this selective 
demethylation has been reported for calixcrowns48 and may be a worthwhile future 
investigation. In conclusion, these results suggest that the selective distal lithiation is 
not very robust, with the distal selectivity being dramatically affected by the 
O-substituents on the resorcinarene. 
  
 101 
 
3.4 Experimental 
3.4.1 General reaction procedure for O-alkylation of resorcinarene (1) 
Resorcinarene (1) (1 eq) was added to a mixture of washed sodium hydride (10-20 eq, 
60% in oil) and a couple of crystals of imidazole in anhydrous tetrahydrofuran, and 
the resultant mixture was stirred under nitrogen at room temperature for 30 minutes. 
To this white slurry was added the relavent alkyl halide (10-20 eq), and the cloudy 
white reaction mixture was stirred overnight at room temperature, under nitrogen. The 
work up and purification is specific for each resorcinarene derivative. 
3.4.1.1 14,36,56,76-tetrabenzyloxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (22) 
The general reaction procedure was applied with resorcinarene (1) 
(0.50 g, 0.703 mmol), sodium hydride (1.07 g, 60% in oil, 0.64 g, 
26.8 mmol), anhydrous tetrahydrofuran (25 mL), and benzyl 
bromide (1.69 mL, 1.21 g, 14.0 mmol). After stirring overnight, 
the reaction mixture was cooled in an ice bath and carefully 
quenched with water, producing bubbles. More water was added, and the solvents were 
removed under reduced pressure (rotavap up to 65°C). The yellow residue was 
dissolved in dichloromethane, and the organic layer was washed with water, separated 
and evaporated to give the crude product as a yellow crystalline solid (0.88 g). The 
crude product was dissolved in minimum dichloromethane; then methanol was added 
so that the product remained dissolved. The yellow solution was gently boiled to 
remove dichloromethane. At a certain point, white crystals formed in the solution, and 
the mixture was immediately taken off the heat and allowed to cool to room 
temperature. More methanol was added, and (22) was collected by vacuum filtration 
as white crystals (0.64 g, 84%): mp 188-189 °C (DCM/MeOH); 1H NMR (CDCl3) δ 
0.91 (t, J = 7.3 Hz, 12 H, CH2CH3), 1.31 (apparent sxt, 8 H, CH2CH3), 1.79-1.96 (m, 
8 H, CH2CH), 3.40 (s, 12 H, OCH3), 4.59 (t, J = 7.4 Hz, 4 H, CHCH2), 4.70, 4.95 (AB, 
J = 11.3 Hz, 8 H, OCH2), 6.37, 6.71 (s, 2 × 4 H, ArH), 7.20-7.35 (overlapped with 
CDCl3, m, ArH); 13C NMR (CDCl3) δ 14.5 (CH2CH3), 21.6 (CH2CH3), 35.9 (CHCH2), 
37.1 (CH2CH), 55.6 (OCH3), 71.1 (OCH2), 97.8, 126.4 (CH, Ar), 126.5 (C, Ar), 127.5, 
127.6, 128.3 (CH, Ar), 137.9, 155.2, 155.8 (C, Ar) (note some signals are coincident). 
Found: C, 80.58; H, 7.69; C72H80O8; requires C, 80.56; H, 7.51%. 
C3H7
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3.4.1.2 14,36,56,76-tetramethoxymethyl-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (23) 
The general reaction procedure was applied with resorcinarene (1) 
(1.00 g, 1.40 mmol), sodium hydride (0.68 g, 60% in oil, 0.409 g, 17.0 
mmol), anhydrous tetrahydrofuran (8 mL), and bromomethyl methyl 
ether (0.345 mL, 1.76 g, 14.1 mmol). After stirring overnight, the 
reaction mixture was then quenched with methanol (2 mL) till bubbling ceased, and 
was then stirred for 45 minutes at room temperature. The solvent was removed under 
reduced pressure, and the residue was dissolved in dichloromethane (30 mL) and dilute 
sodium hydroxide solution (20 mL, 1 M) to give a cloudy light yellow organic layer 
and a clearer dark yellow aq layer. The layers were separated, and the aqueous layer 
was extracted with dichloromethane (10 mL) to give a clear colourless extract. The 
combined cloudy organic extracts were dried (MgSO4), and solvent removed under 
reduced pressure to give pure (23) as a beige-coloured solid (1.36 g, ~100%): mp 149-
150 °C (CHCl3/MeOH); 1H NMR (CDCl3) δ 0.92 (t, J = 7.3 Hz, 12 H, CH2CH3), 1.35 
(apparent sxt, 8 H, CH2CH3), 1.82 (apparent q, 8 H, CH2CH), 3.34 and 3.63 (2s, 2 × 
12 H, OCH3), 4.51 (t, J = 7.5 Hz, 4 H, CHCH2), 4.73, 4.85 (AB, 8 H, J = 6.4 Hz, 
OCH2O), 6.48, 6.66 (s, 2 × 4 H, ArH); 13C NMR (CDCl3) δ 14.4 (CH2CH3), 21.3 
(CH2CH3), 35.3 (CH2CH), 37.4 (CHCH2), 55.7, 55.8 (OCH3), 95.8 (OCH2O), 100.1, 
126.1 (CH, Ar), 127.0, 127.5, 153.6, 155.6 (C, Ar). Found: C, 70.16; H, 8.19; 
C52H72O12; requires C, 70.24; H, 8.16%.  
3.4.1.3 14,36,56,76-tetraethoxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene (29)  
The general reaction procedure was applied with resorcinarene (1) 
(0.101 g, 0.142 mmol), sodium hydride (0.103 g, 60% in oil, 0.062 g, 
2.58 mmol), anhydrous dimethylformamide (25 mL), and iodoethane 
(0.168 mL, 0.328 g, 2.10 mmol). After stirring overnight, the cloudy 
reaction mixture was quenched with water, producing bubbles. Then water (50 mL) 
was added, the white precipitate was filtered, and washed with more water. The filtered 
white precipitate was washed off the funnel with dichloromethane, and the solvent was 
removed under reduced pressure. The resultant residue was placed in an oven (140°C) 
for 5 minutes to remove water, and furnish pure (29) as a white solid (0.106 g, 92%): 
mp 206-208 °C (EtOAc); 1H NMR (CDCl3) δ 0.93 (t, J = 7.3 Hz, 12 H, CH2CH2CH3), 
1.18 (t, J = 7.0 Hz, 12 H, OCH2CH3), 1.37 (m, 8 H, CH2CH3), 1.82 (apparent q, 8 H, 
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OO
4
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CH2CH), 3.59 (s, 12 H, ArOCH3), 3.60-3.69 and 3.85-3.98 (2m, 2 × 4 H, OCH2CH3), 
4.51 (t, J = 7.5 Hz, 4 H, CHCH2), 6.29, 6.63 (s, 2 × 4 H, ArH); 13C NMR (CDCl3) δ 
14.5, 15.0 (CH2CH3), 21.3 (CH2CH3), 35.2 (CHCH2), 37.2 (CH2CH), 55.9 (OCH3), 
64.9 (OCH2), 98.1, 126.1 (CH, Ar), 126.6, 126.8, 155.3, 155.7 (C, Ar). Found: C, 
75.66; H, 9.11; C72H80O8; requires C, 75.69; H, 8.80%.  
3.4.2 Distal lithiation 
3.4.2.1 Attempted synthesis of 14,36,56,76-tetrabenzyloxy-16,34,54,74-
tetramethoxy-15,55-di(methylthio)-2,4,6,8-tetrapropylresorcin[4]arene 
by selective distal lithiation 
The synthesis was performed according to the procedure by Arnott et al.111 To a clear 
colourless solution of resorcinarene benzyl ether (22) (0.050 g, 0.0503 mmol) in 
anhydrous tetrahydrofuran (5 mL) at room temperature was added butyllithium (0.16 
mL, 1.6 M, 0.256 mmol). The clear colourless solution immediately turned bright 
yellow, then dark yellow, then orange, then dark orange. The reaction mixture was 
stirred at 40 °C under nitrogen for 2 h. Upon heating, the reaction mixture became very 
dark opaque brown, eventually turning black after 10 minutes at 40 °C. At the end of 
2 hours, the reaction mixture appeared to be opaque dark brown, perhaps not as black. 
The reaction mixture was then quenched by the addition of dimethyl disulfide (45 μL, 
0.50 mmol), rapidly turning clear light yellow. The quenched reaction mixture was 
then stirred at 40 °C under nitrogen for 3 h. The solvent was evaporated to give a dark 
reddish solid. TLC indicated multiple streaked spots around the baseline that were of 
significantly lower Rf compared to the starting resorcinarene. 1H NMR showed the 
resorcinarene signals as broad humps, indicating decomposition of the resorcinarene. 
3.4.2.2 Synthesis of 14,36,56,76-tetramethoxy-16,34,54,74-tetramethoxymethyl-
15,55-di(methylthio)-2,4,6,8-tetrapropylresorcin[4]arene by selective 
distal lithiation 
The synthesis was performed based on the procedure by Arnott et al.111 To a clear 
colourless solution of resorcinarene methoxymethyl ether (23) (0.0497 g, 0.0559 
mmol) in anhydrous tetrahydrofuran (5 mL) at 40 °C was added dropwise butyllithium 
(0.18 mL, 1.6 M, 0.288 mmol). The clear slightly yellow solution rapidly turned clear 
dark yellow. The reaction mixture was allowed to stir at 40 °C under nitrogen for 2 
hours, appearing to be the same throughout. The reaction mixture was quenched by 
the addition of dimethyldisulfide (0.053 mL, 0.589 mmol), and was stirred under 
nitrogen, at 40 °C for 20 minutes. The tetrahydrofuran solvent was then removed under 
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reduced pressure to give a slightly yellow solid, which appeared as a mixture of 
resorcinarenes by 1H NMR spectroscopy, and of at least five compounds by TLC. The 
synthesis was repeated at the same scale (0.046 g, 0.052 mmol) with double the amount 
of butyllithium (0.33 mL, 1.6 M, 0.528 mmol, 10 eq), giving a similar crude product 
with a sixth spot clearly visible by TLC. The two crude products were combined (0.093 
g) and subjected to preparative TLC (EtOAc – petroleum spirits 40:60). Compounds 
were sufficiently separated to be clearly identified by 1H NMR spectroscopy as: tetra-
SCH3 (28) (0.001 g, 0.9%), tri-SCH3 (27) (0.004 g, 3.6%), proximal-SCH3 (26) (0.009 
g, 8.1%), distal-SCH3 (25) (0.005 g, 4.4%), mono-SCH3 (24) (0.028 g, 27.5%), and 
starting resorcinarene (1) (0.014 g, 14.6%).  
Tetra-SCH3 resorcinarene (28): 1H NMR (only relevant 
signals quoted, CDCl3) δ 0.92 (t, J = 7.3 Hz, 12 H, 
CH2CH3), 1.27-1.38 (m, 8 H, CH2CH3), 1.76-1.91 (m, 8 
H, CH2CH), 2.34 (s, 12 H, SCH3), 3.55, 3.64 (2s, 2 × 12 
H, OCH3), 4.63 (t, J = 7.5 Hz, 4 H, CHCH2), 4.89, 5.04 
(AB, J = 4.8 Hz, 8 H, OCH2O), 6.68 (s, 4 H, ArH). 
 
Tri-SCH3 resorcinarene (27): 1H NMR (only relevant 
signals quoted, CDCl3) δ 0.77-1.02 (m, 12 H, CH2CH3), 
1.19-1.48 (m, 8 H, CH2CH3), 1.59-1.97 (m, 8 H, 
CH2CH), 2.28, 2.43 (2s, 3 H, 6 H, SCH3), 3.25, 3.36, 
3.45, 3.54, 3.64, 3.65, 3.80, 3.85 (8s, 8 × 3 H, OCH3), 
4.20, 4.63 (AB, J = 4.7 Hz, OCH2O), 4.46-4.56, 4.54-
4.62 (m, 2 × 2 H, CHCH2), 4.85, 4.90 (AB, J = 6.7 Hz, 
2 H, OCH2O), 5.00 (d, J = 4.7 Hz, 1 H, OCH2O), 5.05 (d, J = 4.7 Hz, 1 H, OCH2O), 
5.17 (d, J = 4.7 Hz, 1 H, OCH2O), 5.19 (d, J = 4.7 Hz, 1 H, OCH2O), 6.35, 6.38, 6.42, 
6.93, 6.95 (5s, 5 × 1 H, ArH). 
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Proximal-SCH3 resorcinarene (26): 1H NMR (only 
relevant signals quoted, CDCl3) δ 0.87-0.98 (m, 12 H, 
CH2CH3), 1.23-1.45 (m, 8 H, CH2CH3), 1.73-1.92 (m, 8 
H, CH2CH), 2.32, 2.39 (2s, 2 × 3 H, SCH3), 3.31, 3.44, 
3.49, 3.58, 3.65, 3.69 (6s, 3 H, 3 H, 6 H, 6 H, 3 H, 3 H, 
OCH3), 4.37 (d, J = 4.4 Hz, 1 H, OCH2O), 4.45-4.61 (m, 
4 H, CHCH2), 4.70 (d, J = 5.0 Hz, 1 H, OCH2O), 4.85 
(d, J = 4.5 Hz, 1 H, OCH2O), 4.90-4.99 (m, 3 H, OCH2O), 5.04 (s, 2 H, OCH2O), 6.46, 
6.49, 6.53, 6.55, 6.77, 6.78 (6s, 6 × 1 H, ArH). 
Distal-SCH3 resorcinarene (25): 1H NMR (only relevant 
signals quoted, CDCl3) δ 0.91 (t, J = 6.7 Hz, 6 H, 
CH2CH3), 0.94 (t, J = 6.8 Hz, 6 H, CH2CH3), 1.19-1.50 
(m, 8 H, CH2CH3), 1.72-1.97 (m, 8 H, CH2CH), 2.42 (s, 
6 H, SCH3), 3.18, 3.55, 3.65, 3.80 (4s, 4 × 6 H, OCH3), 
4.45-4.56 (m, 4 H, CHCH2), 4.58, 4.73 (AB, J = 6.7 Hz, 
4 H, OCH2O), 4.96, 5.13 (AB, J = 4.7 Hz, 4 H, OCH2O), 
6.38, 6.44, 6.94 (3s, 3 × 2 H). 
 
Mono-SCH3 resorcinarene (24): 1H NMR (only relevant 
signals quoted, CDCl3) δ 0.85-1.00 (m, 12 H, CH2CH3), 
1.27-1.49 (m, 8 H, CH2CH3), 1.72-1.93 (m, 8 H, 
CH2CH), 2.37 (s, 3 H, SCH3), 3.29, 3.32, 3.40, 3.54, 
3.59, 3.62, 3.63, 3.65 (8s, 8 × 3 H, OCH3), 4.46-4.59 (m, 
5 H, CHCH2 + OCH2O), 4.71 (d, J = 6.4 Hz, 1 H, 
OCH2O), 4.76 (d, J = 6.4 Hz, 1 H, OCH2O), 4.83 (d, J 
= 6.4 Hz, 1 H, OCH2O), 4.87 (d, J = 6.4 Hz, 1 H, OCH2O), 4.94 (d, J = 6.4 Hz, 1 H, 
OCH2O), 4.96 (d, J = 6.4 Hz, 1 H, OCH2O), 4.99 (d, J = 6.4 Hz, 1 H, OCH2O), 6.48, 
6.49, 6.51, 6.59, 6.63, 6.69, 6.70 (7s, 7 × 1 H, ArH).  
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3.4.2.3 Synthesis of 14,36,56,76-tetraethoxy-16,34,54,74-tetramethoxy-15,55-
di(methylthio)-2,4,6,8-tetrapropylresorcin[4]arene (30) 
Synthesis was performed according to the procedure by 
Arnott et al.111 To a clear colourless solution of 
resorcinarene ethyl ether (29) (0.050 g, 0.061 mmol) in 
anhydrous tetrahydrofuran (5 mL) at 40 °C was added 
dropwise butyllithium (0.19 mL, 1.6 M, 0.30 mmol). The 
clear colourless solution rapidly turned yellow. The 
reaction mixture was allowed to stir at 40 °C under 
nitrogen for 2 hours, becoming almost clear colourless after 1 h. The clear colourless 
reaction mixture was quenched by the addition of dimethyldisulfide (55 μL, 0.61 
mmol), and was stirred under nitrogen, at 40 °C for 20 minutes. The tetrahydrofuran 
solvent was removed under reduced pressure from the reaction mixture to give the 
crude product as a white to off-white solid which turned light-brownish yellow on 
prolonged exposure to air. The crude product was subjected to column 
chromatography (EtOAc – petroleum spirits 20:80) to afford pure (30) as a clear 
colourless glassy solid (0.020 g, 36%): mp 155 °C (CHCl3/MeOH);  1H NMR (CDCl3) 
δ 0.86-0.97 (m, 12 H, CH2CH3), 1.05 (t, J = 7.0 Hz, 6 H, OCH2CH3), 1.21-1.52 (m, 8 
H, CH2CH2CH3), 1.36 (t, J = 7.0 Hz, 6 H, OCH2CH3), 1.65-1.94 (m, 8 H, CHCH2), 
2.42 (s, 6 H, SCH3), 3.43-3.58 (m, 2 H, OCH2), 3.51 (s, 6 H, OCH3), 3.71-3.83 (m, 2 
H, OCH2), 3.76 (s, 6 H, OCH3), 3.83-3.95, 4.02-4.14 (2m, 2 × 2 H, OCH2), 4.41-4.56 
(m, 4 H, CHCH2), 6.22, 6.36, 6.87 (s, 3 × 2H, ArH); 13C NMR (CDCl3) δ 14.35, 14.37, 
15.0, 16.0 (CH2CH3), 18.3 (SCH3), 21.51, 21.54 (CH2CH3), 36.66, 36.69 (CHCH2), 
37.6, 37.8 (CH2CH), 55.3, 60.7 (OCH3), 64.4, 68.8 (OCH2), 97.4 (CH, Ar), 123.0, 
124.2, 124.4 (C, Ar), 125.9, 126.6 (CH, Ar), 135.6, 135.8, 155.8, 156.0, 156.3, 156.9 
(C, Ar). Found: C, 70.75; H, 8.41; C54H76O8S2; requires C, 70.70; H, 8.35%. 
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4 Direct distal functionalisation of resorcinarene phenols 
In this chapter, another strategy for synthesising the key intermediate of a distally-
functionalised tetramethoxyresorcinarene is reported. As illustrated in Scheme 1.26, a 
distally-functionalised resorcinarene is a key intermediate because it enables the 
resorcinarene to be distally-bridged. The aim of this strategy is to directly distally-
functionalise the resorcinarene via protection of the phenols. In previous work107 
outlined in Scheme 4.1, this was investigated by treating starting heptyl resorcinarene 
(31) with two equivalents of butyllithium to give a resultant precipitate mixture to 
which was added tert-butyldimethylsilyl chloride (TBDMS-Cl).  
OHO
C7H15
4
2 BuLi
THF, 0 °C
2               
THF, RT+
O
O
OHO
O
O
OH O
Si
H15C7
H15C7 C7H15
C7H15
Si
Si
Cl
 
Scheme 4.1 Previous investigation into the direct silylation of resorcinarene phenols.107 
A resorcinarene product was recovered in about 13% yield after partial 
chromatographic separation from unreacted starting resorcinarene. The resorcinarene 
product, having two SiCH3 signals in both 1H and 13C NMR spectra, was initially 
thought to be the proximal di-TBDMS resorcinarene which would possess no 
rotational symmetry.107 However, a closer look at the integration of the 1H NMR 
spectrum clearly showed that each silicone-methyl peak had a relative integration of 
three hydrogens, and the tert-butyl peak was integrating for nine hydrogens. This 
integration pattern strongly suggested that the product was the mono-TBDMS 
resorcinarene, and this was indeed later confirmed by further work, including an NMR 
study which is discussed in the next section. Reaction with up to ten equivalents of 
butyllithium and TBDMS-Cl with propyl resorcinarene (1) still gave the about same 
proportion of mono-TBDMS product to starting resorcinarene as indicated by the 
integration in the 1H NMR spectra of the crude mixtures (Table 4.1). No additional 
products were definitively observed in any of the TLC or 1H NMR spectra of the crude 
mixtures. Interestingly, this lack of reaction appears to contradict a similar 
butyllithium reaction protocol employed by Heaney and co-workers for the 
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tetracamphorsulfonylation of tetramethoxyresorcinarene.66 Nevertheless, the limited 
ability of the resorcinarene to react may be due to the small lithium cation of the 
butyllithium strongly coordinating to the phenoxide anions of the resorcinarene, 
forming a tight ion-pair which results in their decreased solubility and nucleophilicity. 
Therefore, potassium tert-butoxide was investigated as the base.  
Table 4.1  Silylation of resorcinarenes via butyllithium. *Yields were calculated based on 
approximated 1H NMR integration of the crude mixtures. 
OH
O
OHO
O
O
OH O
Si
R
R R
RSiClOHO
R 4
THF
RT, 45 min
BuLi
THF
0 °C - RT
45 min
 
Starting 
resorcinarene 
Eq of 
BuLi/TBDMS-Cl 
Yield %* 
Mono Unreacted starting resorcinarene 
(31) 2 26 74 
(31) 3 28 72 
(1) 2 22 78 
(1) 10.7 29 71 
 
4.1 Silylation with potassium tert-butoxide as base 
4.1.1 TBDMS (tert-butyldimethylsilyl) 
With potassium tert-butoxide as the base, a small-scale test of the silylation reaction 
with TBDMS-Cl in tetrahydrofuran gave a promising TLC. Despite the multiple 
products, the suspected target distal product spot seemed darker than the rest, with all 
products having good chromatographic separation. Therefore, the crude mixture was 
chromatographed, and complete separation of all products was achieved. The 
separated compounds were identified by NMR spectroscopy (Appendix A – 28) to be 
tri- (12%) (35), distal di- (31%) (34), proximal di- (15%) (33), and mono- (28%) (32) 
TBDMS products, as well as starting resorcinarene (10%) (1) (Scheme 4.2).  
R = C3H7 (1) 
R = C7H15 (31) 
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Scheme 4.2 O-Substitution of tetramethoxyresorcinarenes (1) and (31) with two equivalents of 
TBDMS-Cl and potassium tert-butoxide in THF. 
A key indicator enabling identification of the products by NMR spectrsocopy was the 
rotational symmetry of the products, which was evident in the number of peaks in the 
NMR spectra. Compared to the starting resorcinarene, there are many more peaks in 
the NMR spectra of the products, which was a result of a loss of the C4 rotational 
symmetry. A clear indicator of the rotational symmetry of the resorcinarene products 
was the methoxy groups. For products where there was no rotational symmetry – tri, 
R = C3H7 (32) 28% R = C3H7 (33) 15% 
 
R = C3H7 (34) 31% R = C3H7 (35) 12% 
 
R = C7H15 (36) 33% R = C7H15 (37) 12% 
 
R = C7H15 (38) 20% R = C7H15 (39) 6% 
R = C3H7 (1) 
R = C7H15 (31)
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proximal, and mono – the four methoxy groups appear as four separate peaks in both 
1H and 13C NMR spectra. This rotational symmetry rationale enables determination of 
the number of substituted phenols in a resorcinarene product by the number of SiC or 
tert-butyl peaks in the 13C NMR spectrum. However, the distally-subsituted 
resorcinarene product, due to its unique C2 symmetry, can be distinguished from the 
other products by a halving of all peaks. This can be observed in the list of key signals 
of the NMR spectra for the TBDMS resorcinarene products (Table 4.2). The 1H NMR 
integrations of the silyl methyl groups and tert-butyl groups of the TBDMS 
substituents agree with the resorcinarene substitution as determined by rotational 
symmetry arguements.   
Table 4.2 Summary of key NMR spectroscopic data of TBDMS resorcinarene products recorded 
in CDCl3 (Appendix A – 28). Chemical shifts are listed in ppm. Rf (EtOAc/Petrol 4:6).  
Rf Si(CH3)2 SiC SiC(CH3)3 OCH3 TBDMS resorcinarene 1H 13C 13C 1H 13C 1H 13C 
0.87 
-0.10, 
0.07, 
0.15, 
0.19, 
0.26, 
0.28 
-4.28, 
-4.35, 
-4.1, 
-4.0, 
-3.7, 
-3.4 
18.2, 
18.39, 
18.40 
0.84, 
1.04, 
1.02 
25.86, 
25.93, 
26.0 
3.46, 
3.51, 
3.70, 
3.79 
54.8, 
55.3, 
55.5, 
55.7 
Tri 
(35) 
0.76 0.31 -3.7 18.5 1.08 26.0 3.54, 3.87 
55.3, 
55.8 
Distal 
(34) 
0.63 
-0.27, 
0.04, 
0.28, 
0.31 
-4.6, 
-4.1, 
-3.8, 
-3.5 
18.3, 
18.5 
0.85, 
1.07 
25.9, 
26.1 
3.47, 
3.70, 
3.75, 
3.87 
54.9, 
55.1, 
55.6, 
56.0 
Proximal 
(33) 
0.31 0.26, 0.29 
-4.0,  
-3.5 18.6 1.06 26.1 
3.59, 
3.78, 
3.857, 
3.863 
55.4, 
55.9, 
55.99, 
56.04 
Mono 
(32) 
 
It is important to keep in mind the diastereotopic effects on the O-substituents due to 
the influence of the chirality of the resorcinarene. Initially, the NMR spectra for mono-
TBDMS resorcinarene (32) was misinterpreted as being proximal-TBDMS 
resorcinarene (33) due to the two silicon-methyl singlets, which were assumed to 
represent two non-equivalent TBDMS groups. However, synthesis and 
characterisation of tri, distal, proximal and mono TBDMS resorcinarenes has proven 
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that each non-equivalent TBDMS group gives rise to two silicon methyl peaks. This 
phenomenon is general and was also evident for other resorcinarene derivatives 
previously reported. An exception was the distal-TBDMS, which gave only one 
silicon-methyl signal in CDCl3, however this was a solvent effect, since the 
phenomenon was again apparent when the NMR spectrum was recorded in acetone-d6 
(Figure 4.2). This phenomenon was due to the silicon-methyl groups being 
diasteretopic, and therefore non-equivalent. Despite being able to freely rotate, the two 
methyl groups are diastereotopic due to the influence of the chiral centre of the 
resorcinarene. The potential contribution of restricted rotation of the TBDMS group 
was investigated by recording the 1H NMR spectrum at elevated temperatures. If 
restricted rotation played a role in the non-equivalence of the silicon-methyl groups, 
then the corresponding two singlets would coalesce when the NMR spectrum is 
recorded at a higher temperature. The 1H NMR spectrum of distal-TBDMS 
resorcinarene (34) was recorded in DMSO-d6 at room temperature, and also at 77 °C 
(Figure 4.1). The spectra demonstrate a rather minor shift of the silicon-methyl 
singlets, which suggests that restricted rotation was not the principle cause, and that 
the non-equivalence of the silicon-methyl groups was mainly due to the methyl groups 
being diastereotopic. 
 
Figure 4.1 1H NMR study into the possibility of restricted rotation of the TBDMS groups of distal-
TBDMS resorcinarene (34). The upper spectrum was recorded at RT, while the bottom 
spectrum at 77°C. 
In another initially baffling phenomenon, the 1H NMR, recorded for distal-TBDMS 
resorcinarene (34) in CDCl3, gave a rather bizarre and misleading spectrum where all 
peaks associated with the resorcinarene were very broad, except for the triplet of the 
methyl on the end of the propyl chain (Figure 4.2). However, when the 1H NMR was 
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recorded in DMSO-d6 or acetone-d6, all the resorcinarene peaks sharpened to clearly 
show the distal-TBDMS resorcinarene (34) in good purity. Generally, peak broadening 
in NMR spectra is the result of slow oscillation of the atoms of the molecule. 
Therefore, the broad peaks in this case suggests that the oscillation of the resorcinarene 
conformation was slowed down in CDCl3. The unusual solvent effect of the CDCl3 is 
also evident in the fact that the silicon-methyl groups appears as a single peak rather 
than two peaks in both 1H and 13C NMR spectra recorded in CDCl3.  
 
Figure 4.2 1H NMR spectra of distal-TBDMS resorcinarene (34) recorded in CDCl3 (upper 
spectrum), and in acetone-d6 (lower spectrum). *Denotes solvent peaks. 
In the 1H NMR spectra, it is notable that the signals for the resorcinarene benzylic 
methine for some of these TBDMS products have noticeably shifted downfield 
(Figure 4.3). The downfield shift of these peaks points to a de-shielding of the benzylic 
hydogens of the resorcinarene skeleton. These benzylic hydrogens are most likely de-
shielded by diamagnetic anisotropy of an adjacent aromatic ring. This is where the 
magnetic field generated by the circulating π electrons of an aromatic ring causes the 
surrounding magnetic field to be non-uniform, resulting in de-shielding of nearby 
protons that are in planar alignment with the aromatic ring. This de-shielding effect is 
usually only observed for protons which are directly connected to an aromatic ring, 
however for some of these resorcinarenes, the benzylic protons appear to be de-
shielded as well. This could happen by an adjacent aromatic ring being bent outwards 
till it comes into alignment with the benzylic proton. The extent of outward bending 
of the resorcinarene aromatic rings is due to the number and type of O-substituents, as 
evident in their crystal structures shown in Figure 4.6. It can be observed in Figure 
4.3 that the downfield shift of the benzylic methine signal is greater for the mono-
TBDMS (32) than the tri-TBDMS (35) resorcinarene. Perhaps the aromatic rings for 
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the tri-TBDMS (35) have been flattened out too much such that it is no longer in planar 
alignment with the benzylic hydrogen. 
 
Figure 4.3 1H NMR spectra of mono-TBDMS (32) (top) and tri-TBDMS (35) (bottom) illustrating 
the downfield shift of the resorcinarene benzylic methine peak. 
With the resorcinarene products definitively identified by NMR spectroscopy, it was 
encouraging that the distal target product was obtained in 31% yield, the highest-
yielding product. Although 31% yield is relatively low, the key intermediate of a 
distally-functionalised chiral resorcinarene was delivered in a single-step, in practical 
amounts by a simple reaction. The starting resorcinarene (1) for this reaction can be 
easily synthesised in bulk, enabling scaling-up of the reaction. The work involved in 
this reaction was significantly less compared to that of the other strategies that have 
been explored and have returned overall unsuccessful results. Taking all these factors 
into consideration, this relatively low-yielding reaction becomes an attractive pathway 
to explore. To optimise the yield of the target distal product, and to determine the effect 
of the reaction conditions, the resorcinarene silylation reaction with TBDMS was 
explored with variation to the: reaction solvent, base, and length of the resorcinarene 
alkyl chain. 
Since mono-TBDMS resorcinarene (32) was yielded in 28%, being the second-most 
abundant product, the number of equivalents of potassium tert-butoxide and TBDMS-
Cl were increased from two to three, with the aim of converting more mono to distal. 
With three equivalents, the reaction in tetrahydrofuran gave a crude mixture with a 
TLC that indicated a faint spot for the target distal product, while two spots at higher 
Rf were significantly darker (Figure 4.4). This suggests that the distal product was 
reacting more readily and being converted to the tri. The impact of the reaction solvent 
was briefly explored by repeating the reaction, with three equivalents, in 
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dimethylformamide; the resultant TLC indicated that the target distal product was a 
minor product. The same reaction in acetonitrile mostly returned starting 
resorcinarene.  
 
Figure 4.4 TLC analysis of various silylation reaction conditions of resorcinarene (1) with 
potassium tert-butoxide as base and TBDMS-Cl. Two equivalents of the base and 
TBDMS-Cl gives the best selectivity for distal target product (34). 
Therefore, from this brief investigation, the reaction in tetrahydrofuran with two 
equivalents of base and silylating agent appears to provide the best conditions for 
yielding the target distal product against other products. Further investigation of the 
reaction conditions with sodium hydride as base did not give a better yield of the distal 
product. The isolated yields of this reaction are reported in Table 4.3. 
Table 4.3 O-Substitution of resorcinarenes (1) and (31) with TBDMS and various bases in THF. 
Starting 
resorcinarene Base (eq) 
% Yield 
Starting 
resorcinarene Mono Proximal Distal Tri 
(1) KOtBu (2.1) 10 28 15 31 12 
(1) NaH (2.0) 18 37 12 23 7 
(31)* KOtBu (2.0) 22 33 12 20 6 
(31)* KOtBu (3.0) 19 21 17 13 27 
*Average of two experiments 
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To test if the alkyl chain of the resorcinarene had an impact on the yields of the 
products, heptyl resorcinarene (31) was subjected to the silylation reaction under the 
best conditions as determined for propyl resorcinarene (1). The silylation of heptyl 
resorcinarene (31) under these conditions produced a mixture of products which were 
separated by preparative TLC. Employing the same rotational symmetry interpretation 
of the NMR spectra (Appendix A – 34), the products were identifed to be the tri- (39), 
distal di- (38), proximal di- (37) and mono- (36) TBDMS resorcinarene products 
(Table 4.4). 
Table 4.4 Summary of key NMR spectroscopic data of TBDMS heptyl resorcinarene products 
recorded in CDCl3 (Appendix A – 34). Chemical shifts are listed in ppm.  
Rf (EtOAc/Petrol 3:7).  
Rf Si(CH3)2 SiC SiC(CH3)3 OCH3 TBDMS resorcinarene 1H  13C  13C 1H 13C 1H  13C  
0.77 
-0.12, 
0.05, 
0.13, 
0.18, 
0.24, 
0.26, 
-4.4, 
-4.3, 
-4.1, 
-4.0, 
-3.7, 
-3.4 
18.2, 
18.4 
0.82, 
1.01, 
1.02 
25.9, 
25.9, 
26.0 
3.42, 
3.48, 
3.68, 
3.77 
54.8, 
55.3, 
55.5, 
55.7 
Tri 
(39) 
0.68 0.30 -3.8 18.5 1.08 26.0 3.53, 3.87 
55.3, 
55.9 
Distal 
(38) 
0.50 
-0.31, 
0.01, 
0.25, 
0.29 
-4.6, 
-4.2, 
-3.8, 
-3.5 
18.3, 
18.5 
0.82, 
1.05 
25.9, 
26.1 
3.44, 
3.68, 
3.73, 
3.88 
54.8, 
55.1, 
55.6, 
56.0 
Proximal 
(37) 
0.25 0.24, 0.29 
-4.0, 
-3.5 18.6 1.06 26.1 
3.58, 
3.78, 
3.85, 
3.86 
55.4, 
55.9, 
55.97, 
56.05 
Mono 
(36) 
 
The reaction of the heptyl resorcinarene (31) with two equivalents of potassium tert-
butoxide and TBDMS-Cl, afforded inferior selectivity for the distal product (38) 
compared to that of the propyl resorcinarene (1). Nevertheless, with the heptyl 
resorcinarene, the distal product was delivered in a greater yield than the tri (39) and 
the proximal (37) products, but not the mono (36) product (Table 4.3). Therefore, with 
the aim to convert more mono to distal, the equivalents of potassium tert-butoxide and 
TBDMS-Cl were increased from two to three. However, with three equivalents, the 
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distal product became the least abundant, with tri becoming the major product. This 
appears to be the same result for the propyl resorcinarene (Figure 4.4), the distal 
product was being converted to the tri product more readily than the mono and 
proximal products, thus suggesting that the distal product was the most reactive. 
During attempts to crystallise the heptyl products, it was discovered that the products 
were decomposing in chloroform solution, though it had been pre-treated with 
potassium carbonate. It appears that the silyl ethers of the longer-chain resorcinarenes 
were more labile. The instability of the silyl ethers was especially evident for the 
proximal-TBDMS resorcinarene (37), where satisfactory NMR spectra could not be 
readily acquired. The 1H NMR spectrum of a solution of (37) in potassium carbonate-
treated CDCl3 confirmed the product in good purity, albeit a small silanol peak at 0.10 
ppm. After leaving this solution at ambient conditions overnight, the 1H NMR 
spectrum (Figure 4.5) showed a small amount of mono-TBDMS (36), which was 
clearly evidenced by the methoxy peaks. 
 
Figure 4.5 1H NMR spectra of a solution of proximal-TBDMS resorcinarene (37) in CDCl3 shows 
some decomposition to the mono-TBDMS resorcinarene (36) after leaving overnight at 
RT. 
After recording the NMR spectra of proximal-TBDMS (37) in CDCl3, the CDCl3 was 
evaporated, and the slightly-hydrolysed product was dissolved in acetone-d6 to test its 
stability in a different solvent. After two weeks, it was clear that the proximal product 
was very slowly hydrolysing in the acetone-d6. This observed lability was surprising 
as it seems unlikely that the longer alkyl chain could be the cause. This apparent 
lability was not further investigated since efforts were focused on advancing the main 
investigation. In summary, the silylation of the heptyl resorcinarene (31) with 
TBDMS-Cl, afforded inferior selectivity for the distal product, compared to the propyl 
resorcinarene (1), as well as more labile products which were prone to decomposition. 
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Crystals suitable for single crystal X-ray diffraction analysis were obtained for all 
TBDMS resorcinarene derivatives (Table 4.5). The structures were determined by 
A/Prof. Chiara Massera from the University of Parma, Italy.  
Table 4.5 Crystallisation solvents for single crystals of TBDMS resorcinarene derivatives for X-
ray diffraction analysis. 
Resorcinarene Crystallisation solvent 
Mono-TBDMS (32) DCM-MeOH 
Prox-TBDMS (33) MeCN 
Distal-TBDMS (34) THF-MeOH 
Tri-TBDMS (35) Chloroform-MeOH 
 
Analysis of these single crystals by X-ray diffraction confirmed the NMR assignment 
of the TBDMS resorcinarene derivatives at the solid state (Appendix B – 3). These 
crystal structures, shown in Figure 4.6, clearly show the expected crown conformation 
of the resorcinarenes. As anticipated, the mono-TBDMS resorcinarene (32) has the 
most crown-like conformation due to the increased number of hydrogen bonds, as well 
as the lower steric bulk. 
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Figure 4.6 Crystal structures of TBDMS resorcinarenes. Colour code: C, grey; O, red; Si, yellow. 
Hydrogen atoms have been omitted for clarity. For ORTEP view see Appendix B – 11. 
More substituents cause greater distortion of the resorcinarene crown conformation, 
generally in the form of a pinching of the crown conformation to a boat conformation. 
A boat conformation is where a distal pair of aromatic rings become flattened out, 
often due to the steric bulk of a substituent, causing the other distal pair of aromatic 
rings to be pinched together being roughly vertical and parallel to each other. Distal-
TBDMS resorcinarene (34) has a fairly symmetrical crown conformation that is 
slightly pinched, while much asymmetric distortion is apparent for prox-TBDMS 
resorcinarene (33). Of these partially-substituted resorcinarenes, the conformation of 
tri-TBDMS resorcinarene (35) was observed to be the most boat-like, owing to its 
Mono-TBDMS (32) 
Prox-TBDMS (33)
Distal-TBDMS (34)
Tri-TBDMS (35)
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greater substitution. It is notable that even with one substituent, mono-TBDMS 
resorcinarene (32) begins to adopt the boat conformation. In this case, the aromatic 
ring bearing the substituent is being bent outwards due to the steric bulk of the TBDMS 
group, which in turn causes the distal aromatic ring to also be bent outwards, 
presumably to alleviate ring strain on the macrocycle. With the distal aromatic ring 
being extended outwards, it may become more reactive than the proximal pair of 
aromatic rings since it is now relatively sterically unhindered. Perhaps this boat 
conformation explains the observed selectivity for the distal-TBDMS resorcinarene 
product (34). 
Attempts to crystallise the TBDMS heptyl resorcinarene products tri- (39), proximal- 
(37), mono- (36) by slow diffusion of methanol into a solution of the product in 
chloroform, resulted in the colourless solutions turning to a yellow-orange colour. TLC 
showed multiple product spots, which were indicative of decomposition of the 
products. Of the TBDMS heptyl products, only distal (38) could be crystallised, while 
the other products formed glassy solids. The crystals of distal-TBDMS heptyl 
resorcinarene (38), obtained from EtOAc-MeOH, were suitable for single crystal X-
ray diffraction analysis (Appendix B – 6). The crystal structure (Figure 4.7), shows 
that the longer heptyl groups on the narrower rim do not have much impact on the 
conformation of the resorcinarene. 
 
Figure 4.7 Crystal structure of TBDMS heptyl resorcinarene (38). For ORTEP view see Appendix 
B – 14. 
The crystal packing of the propyl resorcinarene derivatives generally follows that of 
the distal-TBDMS propyl (34). The crystal packing of distal-TBDMS (34) is irregular 
compared to the heptyl (38) derivative (Figure 4.8). With the heptyl, the 
resorcinarenes are regularly arranged in a head-to-head / tail-to-tail packing along the 
c-axis direction. However, for the propyl resorcinarene, this head-to-head / tail-to-tail 
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packing alternates along the b-axis rather than being uniform as with the heptyl. This 
difference in packing is the result of the longer alkyl chains of the heptyl resorcinarene 
which make a uniform packing along the b-axis more favourable. This observation is 
consistent with the work by Nissinen and co-workers who reported the uniformed 
layered packing for bis-crown resorcinarenes with alkyl chains that were pentyl or 
longer.106 
 
Figure 4.8 Crystal packing of the distal-TBDMS resorcinarenes: propyl (34) along the a-axis (left) 
and heptyl (38) along the b-axis (right). The tails and the heads of the resorcinarene 
molecules are represented in green and orange, respectively. 
In the investigation so far, a set of optimum reaction conditions for the silylation of 
tetramethoxyresorcinarene has been determined. Next, the O-substitution of 
resorcinarene (1) with a few other bulky protecting groups was investigated, and where 
practicable, the products were separated by preparative TLC for characterisation and 
determination of the yield.  
4.1.2 TBDPS (tert-butyldiphenylsilyl) 
The silylation with TBDPS, was investigated because of its similarity to TBDMS, both 
being silyl protecting groups. TBDPS, however, having two phenyl groups instead of 
methyl groups, may perhaps have a greater steric bulk and thus increase the steric 
repulsion and favour the formation of the distal product. The silylation of resorcinarene 
(1) with two equivalents of potassium tert-butoxide and TBDPS-Cl in tetrahydrofuran 
produced three resorcinarene products, which were separated by preparative TLC. 
Characterisation by NMR spectroscopy (Appendix A – 40) revealed the products to 
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be the distal di- (42), proximal di- (41) and mono- (40) TBDPS resorcinarene products 
(Scheme 4.3). A resorcinarene product, suspected to be tri-TBDPS resorcinarene (43), 
was observed but had co-eluted and was not separated. 
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Scheme 4.3 O-Substitution of resorcinarene (1) with two equivalents of TBDPS-Cl and potassium 
tert-butoxide in THF. 
In the NMR spectra, the signals from the phenyl groups of the TBDPS substituents 
could not be definitively distinguished from the aromatic signals from the 
resorcinarene macrocycle. The clear indicators of rotational symmetry were provided 
(1)
(40) 32% (41) 7% 
  
(42) 16% (43) 0% 
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by the signals from the silyl tert-butyl group and the methoxy groups (Table 4.6), thus 
enabling assignment of the TBDPS resorcinarenes by NMR spectroscopy as per the 
same rationale described for the TBDMS derivatives. Regarding proximal-TBDPS 
resorcinarene (41), the signals in the aliphatic region of the 1H NMR spectrum were 
broad and overlapping, hence making accurate assignment unclear. However, the 
correct number of peaks were present in the aliphatic region of the 13C NMR spectrum, 
thus confirming (41) in good purity. It is notable that the peaks for the resorcinarene 
benzylic methine have shifted downfield as far as 5.1 ppm in some instances – a 1.0 
ppm shift. Additionally, a non-resorcinarene product that eluted before the distal, was 
isolated. Comparison of the 1H NMR spectrum of this product, with the literature,162 
determined it to be TBDPS-OH which most likely originated from the hydrolysis of 
unreacted TBDPS-Cl. 
Table 4.6 Summary of key NMR spectroscopic data of TBDPS resorcinarene products recorded in 
CDCl3 (Appendix A – 40). Chemical shifts are listed in ppm. Rf (EtOAc/Petrol 4:6).  
Rf SiC SiC(CH3)3 OCH3 CHCH2 TBDPS resorcinarene 13C 1H 13C 1H 13C 1H 
0.76  
0.79, 
1.11, 
1.18 
 
2.80, 
3.08, 
3.15, 
3.54 
 
4.16, 
^4.78, 
5.03 
Suspected tri 
(not separated 
from TBDPS-
OH*) 
0.61 19.8 1.20 26.7 3.17, 3.46 
55.1, 
55.5 
4.18, 
5.11 
Distal 
(42) 
0.47 19.2, 19.7 
0.79, 
1.16 
26.4, 
26.7 
2.92, 
2.97, 
3.51, 
3.88 
54.3, 
55.0, 
55.1, 
56.0 
4.04, 
4.34, 
4.92, 
5.12 
Proximal 
(41) 
0.29 19.8 1.19 26.8 
3.11, 
3.41, 
3.76, 
3.89 
55.0, 
55.7, 
55.9, 
56.1 
4.13, 
4.25, 
4.34, 
5.14 
Mono 
(40) 
^Integration is doubled 
*TBDPS-OH was identified by comparison of the 1H NMR spectrum to literature162 
The isolated yields of the TBDPS resorcinarene products from the silylation reaction 
are listed in Table 4.7. With two equivalents of potassium tert-butoxide and TBDPS-
Cl, the silylation did not proceed far, as starting resorcinarene and mono-TBDPS (40) 
were the main components, while no tri-TBDPS resorcinarene was detected. 
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Therefore, the number of equivalents of potassium tert-butoxide and TBDPS-Cl were 
increased from two to three. With three equivalents, there was significantly more 
resorcinarene silylation, and the distal-TBDPS (42) was afforded as the major product 
in 25% yield. An additional resorcinarene product that eluted before distal (42), but 
co-eluted with the TBDPS-OH was also observed by 1H NMR spectroscopy. The 1H 
NMR spectrum of the co-eluted material (Appendix A – 44) showed that this was 
most likely the tri-TBDPS resorcinarene product (Table 4.6).  
Table 4.7 O-Substitution of resorcinarene (1) with two and three equivalents of TBDPS and 
potassium tert-butoxide in THF. 
KOtBu % Yield Starting resorcinarene Mono Proximal Distal Tri 
2.0 eq 39 32 7 16 0 
3.0 eq Trace 12 9 25 ~22* 
*Not separated from TBDPS-OH; yield calculated based on approximated 1H NMR integration. 
The assignment of the reaction products mono-TBDPS (40) and distal-TBDPS (42) 
were confirmed at the solid state through X-ray diffraction analysis on single crystals 
(Appendix B – 5). Crystals of good quality were obtained for mono-TBDPS (40) by 
crystallisation from DCM-petroleum spirits, and also for distal-TBDPS (42) from 
chloroform-MeOH. As shown in Figure 4.9, the conformations of both mono-TBDPS 
(40) and distal-TBDPS (42) appear much like their TBDMS counterparts. The main 
difference is the aromatic rings bearing the substituents are slightly more flattened out, 
indicating a slightly greater steric bulk of TBDPS compared to the TBDMS groups. 
As a result, the crown conformation of the distal-TBDPS (42) is slightly more pinched 
compared to its TBDMS counterpart. 
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Figure 4.9 Crystal structures of mono-TBDPS (40) resorcinarene (top) and distal-TBDPS (42) 
resorcinarene (bottom). Colour code: C, grey; O, red; Si, yellow. Hydrogen atoms have 
been omitted for clarity. For ORTEP view see Appendix B – 13. 
The investigation into the silylation of resorcinarene (1) with three equivalents of 
TBDPS-Cl and potassium tert-butoxide delivered the distal product in best yield of 
25%. However, this is inferior compared to the silylation with TBDMS-Cl, which 
produces the distal product in a higher yield of 31%. 
4.1.3 Benzyl ether 
The selective O-substitution of resorcinarene (1) was further explored with benzyl 
ether protecting groups. Benzyl ethers were chosen because of their common 
availability and chemical stability but also, in this case, their difference from a silyl 
ether while retaining some steric bulk and compatibility with the reaction conditions. 
In Section 3.1, the tetrabenzyl derivative of resorcinarene (1) was prepared by 
treatment of excess base and benzyl bromide. This investigation aims to only use two 
equivalents of base and benzyl bromide to evaluate the possibility of partially-selective 
distal O-substitution. Therefore, the optimum set of reaction conditions with 
resorcinarene (1) and two equivalents of benzyl bromide and potassium tert-butoxide 
similarly produced multiple products, which were separated by preparative TLC. 
Analysis of the separated products by NMR spectroscopy (Appendix A – 44) 
identified them as mono- (44), proximal di- (45), distal di- (46), tri- (47) and tetra- (22) 
benzyl ether resorcinarenes (Scheme 4.4). 
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Scheme 4.4 O-Substitution of resorcinarene (1) with two equivalents of benzyl bromide and 
potassium tert-butoxide in THF. Yields are averages from two experiments. 
As with the silyl ether resorcinarene derivatives, the same rotational symmetry 
interpretation provided the basis for identification of the benzyloxyresorcinarene 
products by NMR spectroscopy (Table 4.8). The number of benzylic methylene peaks 
around 71 ppm in the DEPT-135 spectra provided a clear indicator of the number of 
benzyl ether substituents on a resorcinarene. For products without symmetry – mono-
OBn (44), proximal-OBn (45) and tri-OBn (47) – the number benzylic methylene 
peaks equated to the number of benzyl ether substituents. 
  
(1) (44) 18% 
 
 (45) 18% (46)  15%
 
 (47) 18% (22) 3%
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Table 4.8 Summary of key NMR spectroscopic data of benzyloxyresorcinarene products recorded 
in CDCl3 (Appendix A – 44). Chemical shifts are listed in ppm. Rf (EtOAc/Petrol 4:6). 
Rf PhCH2O OCH3 CHCH2 Benzyloxy resorcinarene 13C  1H  13C  
0.82 71.1 3.40 55.6 4.59 Tetra (22) 
0.68 
71.0, 
71.1, 
71.2 
3.37, 3.41, 
3.46, 3.79 
55.4, 55.6, 
56.0* 
4.26, 
4.56-4.64, 
4.68-4.76 
Tri (47) 
0.52 71.1 3.48, 3.89 55.3, 56.1 4.21-4.42, 4.91-5.06 Distal (46) 
0.38 71.0, 71.1 
3.43, 3.47, 
3.77, 3.84 
55.3, 55.4, 
55.9, 56.0 
4.26, 4.30, 
4.82-4.98 Proximal (45) 
0.30 71.0 3.38, 3.80, 3.84, 3.85 
55.2, 55.9, 
56.0, 56.2 
4.24-4.34, 
5.00-5.06 Mono (44) 
*HSQC shows two coincidental peaks 
However, in the 1H NMR spectra, the benzylic methylene group appears around 5 ppm 
as an AB pair, due to diastereotopic effects, which obscures and complicates the 
appearance of the peaks, particularly for asymmetrical proximal-OBn (45) and tri-OBn 
(47). Oddly, for tri-OBn (47), some of the AB peaks had shifted from 5.1 ppm as low 
as 4.43 ppm. To further obscure the AB peaks for proximal-OBn (45) and tri-OBn 
(47), of some peaks of the benzylic methine resorcinarene macrocycle were shifted 
downfield to around 4.9 ppm, in a similar fashion that was observed for the silyl 
resorcinarene derivatives. The mingling and overlap of the peaks of the two different 
benzylic protons are apparent in the HSQC spectra shown in Figure 4.10. The HSQC 
spectrum of tri-OBn (47) also shows two coincidental methoxy peaks at 56.0 ppm in 
the 13C NMR spectrum. 
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Figure 4.10 HSQC NMR spectra of proximal-OBn (45) (left) and tri-OBn (47) (right). The overlap 
of the peaks of benzylic methines and methylenes in the 1H NMR spectra have been 
highlighted.  
As shown in Table 4.9, the reaction with two equivalents of benzyl bromide and 
potassium tert-butoxide gave a rather inconsistent spread of product yields. The mono-
OBn (44) and starting resorcinarene (1) could not be fully separated because of co-
elution. Nevertheless, in both reactions with two equivalents, distal-OBn (46) was 
afforded in a yield of 15%, and was clearly not a major product.  
Table 4.9 O-Substitution of resorcinarene (1) with two equivalents of benzyl bromide and 
potassium tert-butoxide in THF. 
KOtBu % Yield Starting resorcinarene Mono Proximal Distal Tri Tetra 
2.0 eq 26* 25* 17 15 11 <1 
2.0 eq 5^ 11^ 18 15 25 6 
*Co-eluted and not separated; yield calculated based on approximated 1H NMR integration 
^Trace of the other material 
Crystallisation of the proximal-OBn (45) and tri-OBn (47) products was not 
successful, with both forming brown glassy solids. Single crystals suitable for X-ray 
diffraction analysis could be obtained for distal-OBn (46) from chloroform-MeOH 
(Appendix B – 6). The crystal structure of distal-OBn (46), shown in Figure 4.11, 
PhCH2O PhCH2O 
PhCH PhCH 
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confirms its assignment. The boat conformation is again apparent, but with slight 
distortion caused by the benzyl ether substituents.  
 
Figure 4.11 Crystal structure of distal-OBn (46) resorcinarene from three different angles. For 
ORTEP view see Appendix B – 14. 
From the investigations of protecting groups, bases, reaction solvents, and a 
resorcinarene with a longer hydrocarbon chain, the original conditions with 
resorcinarene using potassium tert-butoxide and TBDMS-Cl in tetrahydrofuran still 
gave the best yield of the distally-functionalised resorcinarene. The reason for the 
observed selectivity for the distal product may be due to the increased reactivity of the 
distal aromatic ring which may be more exposed as the mono O-functionalised 
resorcinarene begins to adopt the boat conformation. Notably, in all cases, the 
chromatographic elution order was always the same: tri, distal, proximal, then mono. 
Under the original conditions, the reaction was scaled up (1 g), and the products were 
isolated in essentially the same yields as the small scale. In the chromatography of 
larger scale reactions (7 g), once the distal target product (34) had eluted, all remaining 
compounds were flushed out with EtOAc, and were thus unseparated. A reaction with 
9.8 grams of starting resorcinarene (1) delivered the distal target product (34) in 31% 
yield, the same yield as the small scale. The starting resorcinarene could be 
conveniently recovered from the significant quantity of by-product mixture by 
subjecting it to TBDMS hydrolysis conditions as outlined in Section 4.2.2. This ability 
to conveniently convert the by-products back to starting resorcinarene is an advantage 
to the practicality of this synthesis as there is no large wastage of resorcinarene 
material.  
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4.2 Replacement of TBDMS protecting groups 
Since the distal functionalisation of the chiral resorcinarene was accomplished in the 
form of distal-TBDMS resorcinarene (34), the resorcinarene should be ready for distal 
bridging with a crown ether. However, initial attempts to bridge (34) with tetraethylene 
glycol ditosylate163 according to the procedure by Nissinen et al.103 gave a complex 
mixture. A search of the literature revealed that the conditions of caesium carbonate 
and dimethylformamide were in fact a proven method for deprotecting TBDMS-
protected phenols.164 Therefore, the TBDMS protecting groups needed to be replaced 
with a protecting group that is more base-stable.  
4.2.1 Replacement of TBDMS protecting groups with methanesulfonates 
The protecting group first chosen was the methanesulfonate. Methanesulfonates can 
be removed by base-catalysed hydrolysis, but should be stable under the conditions for 
bridging, since carbonate is a weak base. In previous work, tetra-protection of the 
starting resorcinarene was conveniently accomplished in high yields and in good 
purity.107 The synthetic plan for the replacement of the silyl ether groups with 
methanesulfonates is outlined in Scheme 4.5. For the removal of the TBDMS 
protecting groups from resorcinarene (48), hydrolysis by caesium carbonate and 
dimethylformamide at 90 °C was chosen. These reaction conditions, being the same 
conditions for the bridging reaction, were chosen to also test the stability of the 
methanesulfonate esters under the conditions for bridging. If the methanesulfonates 
were also hydrolysed together with the TBDMS groups, at this step, then the 
methanesulfonate groups would be also be unstable in the next step, under the reaction 
conditions for bridging, and thus would be an unsuitable protecting group. 
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Scheme 4.5 Replacement of TBDMS protecting groups with methanesulfonates. 
Resorcinarene (34) was subjected to the standard reaction conditions107 of 
triethylamine and methanesulfonyl chloride to afford a product that had rather 
ambiguous NMR spectra. At first sight, the 1H and 13C NMR spectra (Appendix A – 
50) indicated absence of the methyl of the methanesulfonate, thus suggesting starting 
material was obtained. However, TLC indicated a spot with Rf above the starting 
resorcinarene, and IR showed no OH stretch. An HRMS spectrum was obtained which 
recorded a main peak for the target product. Furthermore, single crystals of the 
product, which were obtained from chloroform-MeOH, were analysed by X-ray 
diffraction (Appendix B – 7). The crystal structure shown in Figure 4.13 clearly 
evidenced the product as the target product (48), which takes on a boat conformation 
that is similar to its precursor, distal-TBDMS resorcinarene (34). On closer inspection 
of the NMR spectra, it was realised that the broad peak at 1.95 ppm on the 1H spectrum 
gave an integration which did not fit in with the CH2 multiplet it was partially-
overlapped with. A closer look at this inconsistency by HSQC and DEPT-135 
spectroscopy clearly showed that this broad peak was coupling to a carbon that was 
not a CH2 (Figure 4.12); close inspection of the DEPT-135 spectrum, showed that the 
peak it was coupling to was partially-overlapped with the resorcinarene methine peak.  
(48) (34) 
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Figure 4.12 HSQC NMR spectrum of resorcinarene (48). In the DEPT-135 spectrum, the peak for 
the methyl of the methanesulfonate is coincidental with the methine peak of the 
resorcinarene at 35.6 ppm. 
 
Figure 4.13 Crystal structure of resorcinarene (48). Colour code: C, grey; O, red; Si, yellow; S, gold. 
Hydrogen atoms have been omitted for clarity. For ORTEP view see Appendix B – 15. 
Resorcinarene (48) was then subjected to the caesium carbonate / DMF hydrolysis to 
give a mixture which appeared by TLC to have not starting resorcinarene, but three 
product spots. The 1H NMR spectrum of the crude product showed no signals at low 
ppm, evidencing complete removal of the TBDMS groups. However, multiple peaks 
were present at ~2.7 ppm which suggested multiple methanesulfonate resorcinarene 
products. From these results, it was concluded that the methanesulfonate esters were 
also hydrolysing, but at a slower rate compared to the TBDMS groups. Therefore, the 
methanesulfonate protecting group was not sufficiently stable under the conditions for 
bridging, and a more base-stable protecting group is required.  
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4.2.2 Replacement of TBDMS protecting groups with benzyl ethers 
The benzyl ether protecting group is pH stable and cleavable by hydrogenation, and is 
therefore a suitable candidate. The synthetic strategy would now be to benzylate the 
two distal phenols of (34), then hydrolyse the TBDMS groups to give a distal benzyl 
ether resorcinarene which would then be ready for bridging (Scheme 4.6). 
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Scheme 4.6 Replacement of TBDMS protecting groups with benzyl ethers. 
The benzylation on distal-TBDMS resorcinarene (34) was performed similarly to the 
general procedure described in Section 3.4.1. After removal of minor by-products by 
chromatography, the target distal-TBDMS distal-OBn resorcinarene product (49) was 
afforded in a good yield and confirmed by NMR spectroscopy (Appendix A – 52). 
The presence of the benzyl ether functional group was immediately apparent on the 
13C NMR spectrum by the single peak at 71.3 ppm, representing the benzylic carbon. 
The HSQC spectrum demonstrated that this peak was coupling to two peaks at 4.44 
and 4.78 ppm on the 1H NMR spectrum representing the diastereotopic benzylic 
protons, with the former peak appearing as a broad hump which overlapped with a 
benzylic methine peak of the resorcinarene. The retention of the TBDMS groups on 
the resorcinarene could be identified by two silicon-methyl signals at low chemical 
(34) (49) 
(46)  
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shift on both the 1H and 13C NMR spectra. These signals, together with the two 
methoxy peaks on the 1H NMR spectrum, confirmed the retention of C2 symmetry of 
the resorcinarene; all four peaks had the same integration of six protons, and were 
broader than usual. However, on the 13C NMR spectrum, only one methoxy peak was 
apparent rather than the anticipated two. HSQC showed that this peak was coupled to 
the two methoxy peaks on the 1H NMR spectrum, therefore implying that the two 
anticipated methoxy peaks on the 13C NMR spectrum were in fact coincidental in that 
one observed peak. The resorcinarene aromatic protons appeared as three broad peaks 
on the 1H NMR spectrum at 6.33, 6.36, 7.07 ppm, rather than the expected four peaks. 
The fourth missing peak has probably overlapped with the two peaks at 6.33 and 6.36 
ppm to give a total integration for six protons. 
The structure assignment of distal-TBDMS distal-OBn resorcinarene (49) was 
confirmed at the solid state by X-ray diffraction analysis (Appendix B – 7) on single 
crystals that were readily obtained from slow evaporation from dichloromethane. As 
evident in the crystal structure (Figure 4.14), the resorcinarene takes on a boat 
conformation much similar to that of tri-TBDMS resorcinarene (35) (Figure 4.6) 
where the bulky TBDMS groups have pushed out a pair of distal aromatic rings till 
they are almost completely horizontal. 
 
Figure 4.14 Crystal structure of resorcinarene (49). Colour code: C, grey; O, red; Si, yellow. 
Hydrogen atoms have been omitted for clarity. For ORTEP view see Appendix B – 15. 
One of the minor by-products of the benzylation reaction isolated by chromatography, 
was indicated by 1H NMR spectroscopy to be asymmetrical tri benzyl ether mono 
TBDMS resorcinarene, thus evidencing that a small amount of TBDMS hydrolysis 
was occurring. Running the benzylation at reflux produced the target product with 
significant amounts of by-products. Two of the by-products were isolated by 
preparative TLC, and were apparent by 1H NMR spectroscopy to be the tri benzyl ether 
mono TBDMS resorcinarene as before, and also a di benzyl ether mono TBDMS mono 
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OH resorcinarene (Figure 4.15). These by-products were likely caused by some 
hydrolysis of the TBDMS groups with sodium hydroxide,165 which is produced when 
the sodium hydride reacts with water, especially during the quenching of the reaction 
with water. These by-products, although limited, are undesirable because they, 
necessitate chromatographic separation, and also reduce the yield of target product 
while wasting the distal-TBDMS resorcinarene (34). In an effort to have a clean 
reaction without by-products, the benzylation reaction was investigated under various 
conditions which are summarised in Table 4.10. 
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Figure 4.15 Suspected structures of two by-products from the benzylation of distal-TBDMS 
resorcinarene (34). 
 
Table 4.10  Benzylation of distal-TBDMS resorcinarene (34) under various reaction conditions. 
Benzylation reaction conditions Outcome 
NaH, THF, RT, quench with water Target product (49) with minor by-products 
NaH, THF, reflux, quench with water Significant by-products 
NaH, THF, RT, quench with methanol Many significant by-products 
KOtBu, THF, RT Tetrabenzyl ether resorcinarene (22) with no target product 
Diisopropylethylamine, DCM, RT No reaction 
NaH, THF, RT, quench with HCl 10% Target product (49) with minor by-products 
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When the sodium hydride was quenched with methanol instead of water, a mixture 
with a TLC which showed many compounds was produced; this was a far worse result 
compared with quenching with water. It seems that sodium methoxide is a better 
TBDMS hydrolysis agent compared to sodium hydroxide, most likely due to its 
increased solubility and nucleophilicity in tetrahydrofuran. Another strategy to avoid 
the TBDMS hydrolysis by-products is to perform the benzylation using potassium tert-
butoxide in tetrahydrofuran, which are the same conditions for silylation. However, 
benzylation of (34) under these conditions produced tetrabenzyl ether resorcinarene 
(22) and no target product as confirmed by TLC and 1H NMR spectroscopy. The 
benzylation was also attempted under similar conditions as the methanesulfonylation 
with a non-nucleophilic amine as base such as diisopropylethylamine, but no reaction 
was observed by TLC, and starting resorcinarene was recovered. 
It was thought that the deprotection of the TBDMS ethers could be accomplished in 
the same pot, during the quenching of the benzylation reaction by quenching the 
sodium hydride with hydrochloric acid solution. This would avoid a separate reaction 
for the TBDMS deprotection, and could also lead to an easier purification without the 
need for column chromatography. Using hydrochloric acid to quench the sodium 
hydride, as well as to deprotect the TBDMS ethers, would also prevent reaction of the 
resultant phenols of (49) with the excess benzyl bromide.  
When the benzylation reaction was quenched with hydrochloric acid (10%), TLC after 
15 minutes, showed mainly diOBn diTBDMS resorcinarene (49), but no de-silylated 
resorcinarene (46). After stirring overnight, the TLC indicated the presence of 
resorcinarene (46), with an intermediate spot, and a trace of precursor resorcinarene 
(49). Therefore, to force the TBDMS hydrolysis to completion, concentrated 
hydrochloric acid (32%) was added and the quenched reaction mixture was heated at 
reflux. After 2 hours, TLC indicated that the reaction was complete. The TLC of the 
crude product showed that the target de-silylated resorcinarene (46) was the main 
product, but minor by-products were also present, suggesting that the benzylation was 
still not a clean reaction. Compared to the original water-quenching of the benzylation 
reaction, the chromatographic separation of this quenching with concentrated 
hydrochloric acid appears to be more difficult. Therefore, Scheme 4.6 still provides 
the best synthetic path. Nonetheless, this investigation has shown that the TBDMS 
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ethers are fairly stable under acidic conditions. Thus, quenching the benzylation 
reaction with dilute hydrochloric acid would pose the least risk to unwanted TBDMS 
ether hydrolysis, and benzylation of the subsequent phenol. This benzylation reaction 
is scalable and was performed at a 4-gram scale to give a yield of 80% of the target 
resorcinarene (49).  
For the removal of the TBDMS protecting groups of (49), the simple base-hydrolysis 
procedure by Davies et al.165 was employed. After work up, a white solid was obtained 
which smelled like a silyl derivative. The 1H NMR spectrum of this showed the target 
product (46) with two large impurity peaks at 0.11 and 0.93 ppm, indicating the 
impurity to be a TBDMS derivative, most likely tert-butyldimethylsilanol, the 
hydrolysis by-product. After some experimentation, it was discovered that the smell 
disappears after repeated addition of methanol and removal under reduced pressure. 
The 1H NMR spectrum of the material after this treatment indicates that the peaks 
associated with the impurity are absent leaving the target product (46) in good purity. 
The suspected tert-butyldimethylsilanol impurity probably formed an azeotrope with 
methanol and was removed together with the methanol. This deprotection reaction was 
scalable with a 3.9-gram reaction yielding the target product (46) in 97%. 
The success of the TBDMS removal was evidenced by the appearance of an OH stretch 
in the IR spectrum. The complete removal of the TBDMS protecting groups was 
indicated by the absence of peaks at low chemical shift in both 1H and 13C NMR 
spectra. The retention of the benzyl ether was clearly identified by the benzylic peak 
at 71.1 ppm in the 13C NMR spectrum, as well as the AB pair at 5.10 and 5.14 ppm in 
the 1H NMR spectrum. This, as well as the two prominent methoxy peaks in both the 
1H and 13C NMR spectra confirm retention of C2 symmetry. Moreover, the NMR 
spectra matched that of product (46) that was obtained from the direct benzylation of 
resorcinarene (1). 
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In the work so far, the key intermediate of a distally-protected tetramethoxy-
resorcinarene has been accomplished in the form of the distal-OBn resorcinarene (46). 
The distal selectivity of this key compound was obtained by direct silylation of the 
starting resorcinarene. However, two additional synthetic steps were necessary, since 
the silyl groups of the distal-TBDMS resorcinarene (34) were unstable under the 
bridging reaction conditions. Nevertheless, the overall synthetic procedure to 
accomplish distal-OBn resorcinarene (46) is practical and has been demonstrated to 
work on a multi-gram scale. This key intermediate now enables the installation of a 
bridge over the resorcinarene cavity via O-alkylation of the remaining two 
resorcinarene hydroxy groups. 
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4.3 Experimental 
4.3.1 X-ray crystallography 
Crystal structures were determined by A/Prof. Chiara Massera from the University of 
Parma, Italy. Intensity data and cell parameters were recorded at 190(2) K on a Bruker 
ApexII diffractometer (MoK radiation  = 0.71073 Å) and at 298(2) K on a Bruker 
Smart Breeze at the University of Parma, or at 100(2) K at the ELETTRA Synchrotron 
Light Source (CNR Trieste, Basovizza, Trieste, Italy). 
4.3.2 Phenol silylation of resorcinarenes via butyllithium 
A representative procedure with 10.7 equivalents is given. To a solution of 
resorcinarene (0.225 g, 0.316 mmol, 1 eq) in anhydrous tetrahydrofuran (10 mL) was 
added butyllithium (2.5 mL, 1.35 M, 3.38 mmol, 10.7 eq) while at 0 °C under nitrogen. 
The resultant cloudy mixture with white precipitate was stirred at room temperature 
under nitrogen for 45 minutes. TBDMS-Cl (0.507 g, 3.36 mmol, 10.7 eq) was added 
with anhydrous tetrahydrofuran (~1 mL), and the reaction mixture was stirred at the 
same conditions for 45 minutes. During this time, the cloudy mixture became clear. 
The tetrahydrofuran was then removed under reduced pressure, and the residue was 
dissolved in ether and dilute HCl (1 M). The layers were separated, and the organic 
layer was washed with brine, dried (MgSO4), filtered, and solvent removed under 
reduced pressure to give a yellow to orange-brown oil as the crude product. The 1H 
NMR spectrum and TLC of the crude product indicated mostly starting material with 
some mono-TBDMS resorcinarene product. 
4.3.3 General procedure for the distal phenol substitution of resorcinarenes 
via KOtBu and THF 
To potassium tert-butoxide (2 eq) was added resorcinarene (1) or (31) (1 eq) with 
anhydrous tetrahydrofuran (5 mL) to give an initially cloudy pink mixture, which 
turned beige while stirring at room temperature under nitrogen for 45 minutes. The 
respective derivitising agent (2 eq) was then added to the mixture, rapidly turning it 
clear. After stirring at room temperature under nitrogen for 2 hours, the solvent was 
removed under reduced pressure to give a brown solid which was dissolved in 
dichloromethane and washed with dilute HCl (1 M). The aqueous layer was extracted 
with dichloromethane, and the combined organic extracts were dried (MgSO4), 
filtered, and solvent removed under reduced pressure. The resultant crude solid was 
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subjected to preparative TLC to give the pure resorcinarenes. The beige products were 
recrystallised from the appropriate solvents to give white crystals for analysis.  
4.3.3.1 14,36,56,76-tetrahydroxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetraheptylresorcin[4]arene (31) 
Resorcinarene (31), that was synthesised in previous work107 was used. 
4.3.3.2 tert-Butyldimethylsilyl ether (TBDMS) 
The general procedure was applied with potassium tert-butoxide (23.0 mg, 0.205 
mmol, 2.06 eq), resorcinarene  (1) (71.0 mg, 0.0996 mmol, 1.00 eq), anhydrous 
tetrahydrofuran (5 mL) and TBDMS-Cl (30.3 mg, 0.201 mmol, 2.02 eq) in petroleum 
spirits (0.1 mL) to give a mixture which was subjected to preparative TLC (EtOAc – 
petroleum spirits 40:60) to give pure, previously unreported resorcinarenes: tri (35) 
(13 mg, 12%), distal (34) (29 mg, 31%), proximal (33) (14 mg, 15%), mono (32) (23 
mg, 28%) as beige solids as well as remaining resorcinarene (1) (7 mg, 10%) in 
respective elution order. 
Mono-TBDMS resorcinarene (32): m.p. 255-256 °C 
(DCM/MeOH); IR 3420 cm-1 (OH phenol); 1H NMR 
(CDCl3) δ 0.26, 0.29 (2s, 2 × 3 H, Si(CH3)2), 0.87-1.03 
(m, 12 H, CH2CH3), 1.06 (s, 9 H, SiC(CH3)3), 1.11-
1.42 (m, 8 H, CH2CH3), 1.72-1.89, 1.93-2.08, 2.05-
2.28 (3m, 1 H, 1 H, 6 H, CH2CH), 3.59, 3.78, 3.857, 
3.863 (4s, 4 × 3 H, OCH3), 4.22-4.36 (m, 3 H, CHCH2), 4.81 (t, J = 7.9 Hz, 1 H, 
CHCH2), 6.23, 6.29, 6.41 (3s, 1 H, 2 H, 1 H, ArH), 6.99 (overlapped, br s, 2 H, OH), 
7.03, 7.11 (2s, 2 × 1 H, ArH), 7.21 (overlapped, br s, 1 H, OH), 7.22, 7.33 (2s, 2 × 1 
H, ArH); 13C NMR (CDCl3) δ -4.0, -3.5 (Si(CH3)2), 14.16, 14.20, 14.6 (CH2CH3), 18.6 
(SiC(CH3)3), 21.05, 21.12, 21.14, 21.3 (CH2CH3), 26.1 (SiC(CH3)3), 32.5, 32.8, 32.9, 
33.0 (CHCH2), 36.0, 36.7, 37.1, 39.4 (CH2CH), 55.4, 55.9, 56.0, 56.0 (OCH3), 99.4, 
99.6, 100.2, 101.7 (CH, Ar), 121.9, 123.1 (C, Ar), 123.3, 123.4 (CH, Ar), 124.2, 124.4, 
125.1, 125.2 (C, Ar), 125.3, 126.8 (CH, Ar), 130.3, 151.8, 152.4, 152.8, 153.1, 153.40, 
153.44, 154.3, 156.6 (C, Ar) (note some signals are coincident). Found: C, 72.46; H, 
8.37; C50H70O8Si; requires C, 72.60; H, 8.53%. 
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Proximal-TBDMS resorcinarene (33): m.p. 211 °C 
(MeCN); IR 3490 cm-1 (OH phenol); 1H NMR 
(CDCl3) δ -0.27, 0.04, 0.28, 0.31 (4s, 4 × 3 H, 
Si(CH3)2), 0.85 (s, 9 H, SiC(CH3)3), 0.85-0.94, 0.94-
1.03 (2m, 2 × 6 H, CH2CH3), 1.07 (s, 9 H, SiC(CH3)3), 
1.14-1.46 (m, 8 H, CH2CH3), 1.68-1.94, 1.97-2.13 
(2m, 2 × 4 H, CH2CH), 3.47, 3.70, 3.75, 3.87 (4s, 4 × 
3 H, OCH3), 4.18, 4.31 (2t, J = 7.4 Hz, 2 × 1 H, CHCH2), 4.57-4.70 (m, 2 H, CHCH2), 
6.18, 6.19, 6.34, 6.45, 6.48, 6.82, 7.16, 7.23 (8s, 8 × 1 H, ArH); 13C NMR (CDCl3) δ -
4.6, -4.1, -3.8, -3.5 (Si(CH3)2), 14.28, 14.29, 14.6 (CH2CH3), 18.3, 18.5 (SiC(CH3)3, 
21.1, 21.3, 21.6 (CH2CH3), 25.9, 26.1 (SiC(CH3)3), 33.0, 33.9 (CHCH2), 34.4, 35.1 
(br, CHCH2), 36.4, 36.6 (CH2CH), 38.9, 39.2 (br, CH2CH), 54.9, 55.1, 55.6, 56.0 
(OCH3), 99.0, 100.1, 101.4, 102.5 (CH, Ar), 121.3, 123.1 (br), 124.3 (C, Ar), 124.7 
(CH, Ar), 125.2 (C, Ar), 125.5 (br, CH, Ar), 125.6 (C, Ar), 125.7 (CH, Ar), 126.1 (C, 
Ar), 127.1 (CH, Ar), 128.7 (br), 151.2, 152.1, 152.7, 153.0, 153.5, 154.0, 154.7, 156.9 
(C, Ar) (note some signals are coincident). Found: C, 71.49; H, 9.01; C56H84O8Si2; 
requires C, 71.44; H, 8.99%. 
Distal-TBDMS resorcinarene (34): m.p. 236-237 
°C (CHCl3/MeOH); IR 3470 cm-1 (OH phenol); 
1H NMR (CDCl3) δ 0.31 (br s, 12 H, Si(CH3)2), 
0.88 (t, J = 7.3 Hz, 6 H, CH2CH3), 0.90-1.02 (m, 
6 H, CH2CH3), 1.07-1.47 (m, 8 H, CH2CH3), 1.08 
(br s, 18 H, SiC(CH3)3), 1.62-1.88, 1.70-1.97, 
1.85-2.10, 1.93-2.30 (4m, 4 × 2 H, CH2CH), 3.54, 3.87 (2br s, 2 × 6 H, OCH3), 4.28, 
4.72 (2 br s, 2 × 2 H, CHCH2), 6.01, 6.20, 6.35, 6.76 (4br s, 4 × 2 H, ArH), 7.25 
(overlapped with CHCl3, br s, 2 H, OH); 13C NMR (CDCl3) δ -3.7 (Si(CH3)2), 14.3, 
14.5 (CH2CH3), 18.5 (SiC(CH3)3), 21.0, 21.4 (CH2CH3), 26.0 (SiC(CH3)3), 33.5 
(CHCH2), 36.9, 39.5 (CH2CH), 55.3, 55.8 (OCH3), 99.5, 101.1 (CH, Ar), 120.8, 123.6, 
124.4 (C, Ar), 124.6, 127.5 (CH, Ar), 130.6, 151.8, 153.1, 153.4, 156.7 (C, Ar) (note 
some signals are coincident); 1H NMR (DMSO-d6) δ -0.11, 0.09 (2s, 2 × 6 H, 
Si(CH3)2), 0.79 (t, J = 7.3 Hz, 6 H, CH2CH3), 0.82 (t, J = 7.3 Hz, 6 H, CH2CH3), 0.89 
(s, 18 H, SiC(CH3)3), 1.02-1.32 (m, 8 H, CH2CH3), 1.50-1.80 (m, 8 H, CH2CH), 3.51, 
3.60 (2s, 2 × 6 H, OCH3), 4.39-4.53 (m, 4 H, CHCH2), 6.16, 6.30, 6.55, 6.83 (4s, 4 × 
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2 H, ArH), 8.74 (s, 2 H, OH); 13C NMR (20% CDCl3 in DMSO-d6) δ -4.9, -4.3 
(Si(CH3)2), 13.9, 14.0 (CH2CH3), 17.7 (SiC(CH3)3), 20.7, 20.9 (CH2CH3), 25.4 
(SiC(CH3)3), 33.8, 34.2 (CHCH2), 37.4, 38.0 (CH2CH), 54.6, 55.2 (OCH3), 98.3, 102.0 
(CH, Ar), 122.3, 122.6, 125.0, 125.3 (C, Ar), 125.6, 126.3 (CH, Ar), 150.9, 152.8, 
154.6, 154.8 (C, Ar); 1H NMR (Acetone-d6) δ 0.05, 0.19 (2s, 2 × 6 H, Si(CH3)2), 0.87 
(t, J = 7.4 Hz, 6 H, CH2CH3), 0.92 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.99 (s, 18 H, 
SiC(CH3)3), 1.16-1.27, 1.27-1.40 (2m, 2 × 4 H, CH2CH3), 1.68-1.82, 1.82-1.98 (2m, 2 
H, 6 H, CH2CH), 3.64, 3.66 (2s, 2 × 6 H, OCH3), 4.52 (t, J = 7.6 Hz, 2 H, CHCH2), 
4.68 (t, J = 7.7 Hz, 2 H, CHCH2), 6.32, 6.90, 7.04 (3s, 4 H, 2 H, 2 H, ArH), 7.27 (s, 2 
H, OH); 13C NMR (Acetone-d6) δ -4.1, -3.7 (Si(CH3)2), 14.5, 14.6 (CH2CH3), 18.8 
(SiC(CH3)3), 21.9, 22.2 (CH2CH3), 26.2 (SiC(CH3)3), 35.27, 35.30 (CHCH2), 38.2, 
39.5 (CH2CH), 55.4, 56.1 (OCH3), 99.6, 103.2 (CH, Ar), 123.6, 124.9, 126.1 (C, Ar), 
126.6 (CH, Ar), 127.5 (C, Ar), 127.9 (CH, Ar), 152.7, 154.1, 155.9, 156.6 (C, Ar). 
HRMS (ESI): calcd. for C56H85O8Si2 as [M + H]+ 941.5778; found 941.5781. Found: 
C, 71.05; H, 9.15; C56H84O8Si2; requires C, 71.44; H, 8.99%. 
Tri-TBDMS resorcinarene (35): m.p. 261-262 °C 
(CHCl3/MeOH); IR 3544 cm-1 (OH phenol); 1H 
NMR (CDCl3) δ -0.10, 0.07, 0.15, 0.19, 0.26, 
0.28, (6s, 6 × 3 H, Si(CH3)2), 0.84-0.98 (m, 12 H, 
CH2CH3), 0.84, 1.04, 1.02 (3s, 3 × 9 H, 
SiC(CH3)3), 1.19-1.48 (m, 8 H, CH2CH3), 1.66-
2.02 (m, 8 H, CH2CH), 3.46, 3.51, 3.70, 3.79 (4s, 
4 × 3 H, OCH3), 4.22 (t, J = 6.7 Hz, 1 H, CHCH2), 4.42-4.50, 4.48-4.56 (2m, 1 H, 2 
H, CHCH2), 6.14, 6.21 (2s, 2 × 1 H, ArH), 6.30 (br s, 2 H, ArH), 6.33, 6.54, 6.96, 6.99 
(4s, 4 × 1 H, ArH); 13C NMR (CDCl3) δ -4.3, -4.3, -4.1, -4.0, -3.7, -3.4 (Si(CH3)2), 
14.37, 14.44, 14.5, 14.6 (CH2CH3), 18.2, 18.39, 18.40 (SiC(CH3)3), 21.2, 21.6, 21.6, 
21.7 (CH2CH3), 25.86, 25.93, 26.0 (SiC(CH3)3), 34.7, 35.6, 36.00, 36.04 (CHCH2), 
37.2, 37.3, 37.70, 37.73 (CH2CH), 54.8, 55.3, 55.5, 55.7 (OCH3), 99.5, 101.4, 101.7, 
103.0 (CH, Ar), 121.0, 123.5, 124.3, 124.5, 125.2 (C, Ar), 126.0, 126.2, 126.4 (CH, 
Ar), 127.4 (CCH, Ar), 127.7 (CH, Ar), 128.0, 129.6, 151.2, 152.1, 152.4, 154.2, 154.9, 
155.8, 156.7 (C, Ar) (note some signals are coincident). Found: C, 70.51; H, 9.69; 
C62H98O8Si3; requires C, 70.54; H, 9.36%. 
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The procedure was repeated on a larger scale with resorcinarene (1) (1.24 g, 1.74 
mmol, 1.00 eq), anhydrous tetrahydrofuran (50 mL), potassium tert-butoxide (0.390 
g, 3.48 mmol, 2.00 eq), TBDMS-Cl (0.524 g, 3.47 mmol, 2.00 eq), and after column 
chromatography (EtOAc – petroleum spirits 5:95 to 40:60), gave pure resorcinarenes: 
tri (35) (0.267 g, 14%), distal (34) (0.403 g, 25%), proximal (33) (0.217 mg, 13%), 
mono (32) (0.356 g, 25%) as beige solids as well as remaining resorcinarene (1) (0.167 
mg, 13%) in respective elution order. 
The procedure was repeated on a larger scale with resorcinarene (1) (6.99 g, 9.80 
mmol, 1.00 eq), anhydrous tetrahydrofuran (210 mL) potassium tert-butoxide (2.20 g, 
19.6 mmol, 2.00 eq), TBDMS-Cl (2.97 g, 19.7 mmol, 2.01 eq), and after column 
chromatography (EtOAc – petroleum spirits 10:90 to 15:85), gave pure resorcinarenes 
tri (35) (1.73 g, 17%), and distal (34) (2.63 g, 28%) in respective elution order; the 
remaining compounds were not separated. 
4.3.3.3 TBDMS with Sodium Hydride 
Sodium hydride (60% in oil) was washed three times with petroleum spirits while 
under nitrogen in a schlenk flask. The residue petroleum spirits was evaporated under 
a stream of nitrogen. To the sodium hydride (10 mg, 0.417 mmol, 2.01 eq) was added 
resorcinarene (1) (148 mg, 0.208 mmol, 1.00 eq), a crystal of imidazole, and anhydrous 
tetrahydrofuran (5 mL) to produce a gently-bubbling, slightly-cloudy solution. After 
stirring for 30 minutes at room temperature under nitrogen, the solution gradually 
become completely cloudy white. Then, TBDMS-Cl (63 mg, 0.416 mmol, 2.00 eq) 
was added with anhydrous tetrahydrofuran (2 mL), and the cloudy white mixture was 
stirred overnight at room temperature under nitrogen, although TLC monitoring of the 
reaction mixture indicated that the reaction had finished within 3 hours. The reaction 
mixture was then filtered through a pad of silica and washed with EtOAc (10 mL). 
Removal of the solvent under reduced pressure gave the crude product as a yellowish 
solid (192 mg). About half the crude product (95 mg) was subjected to preparative 
TLC (EtOAc – petroleum spirits 35:65) to give pure resorcinarenes: tri (35) (8 mg, 
7%), distal (34) (22 mg, 23%), proximal (33) (12 mg, 12%), mono (32) (31 mg, 37%) 
as beige solids as well as remaining starting resorcinarene (1) (13 mg, 18%) in 
respective order. 
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4.3.3.4 tert-Butyldiphenylsilyl ether (TBDPS) 
The general procedure was applied with resorcinarene (1) (112 mg, 0.157 mmol, 1.00 
eq), anhydrous tetrahydrofuran (5 mL) potassium tert-butoxide (0.035 g, 0.312 mmol, 
1.99 eq) and TBDPS-Cl (0.0817 mL, 86.4 mg, 0.3143 mmol, 2.00 eq), the mixture was 
stirred overnight, concentrated, and half of the residue was then subjected to 
preparative TLC (EtOAc – petroleum spirits 30:70) to give pure, previously 
unreported resorcinarenes: distal (42) (15 mg, 16%), proximal (41) (6.8 mg, 7%), 
mono (40) (24 mg, 32%), and unreacted resorcinarene (1) (11 mg, 39%) in respective 
elution order. 
Mono-TBDPS resorcinarene (40): m.p. 260-261 °C 
(CHCl3/MeOH); IR 3437 cm-1 (OH phenol); 1H NMR 
(CDCl3) δ 0.74-1.06 (m, 12 H, CH2CH3), 1.08-1.50 
(m, 8 H, CH2CH3), 1.19 (s, 9 H, SiC(CH3)3), 1.82-1.97, 
1.99-2.17, 2.17-2.32 (3m, 1 H, 5 H, 2 H, CH2CH), 
3.11, 3.41, 3.76, 3.89 (4s, 4 × 3 H, OCH3), 4.13 (t, J = 
7.7 Hz, 1 H, CHCH2), 4.25 (t, J = 7.8 Hz, 1 H, 
CHCH2), 4.34 (t, J = 7.8 Hz, 1 H, CHCH2), 5.14 (t, J = 8.1 Hz, 1 H, CHCH2), 5.86, 
6.24, 6.43 (3s, 1 H, 2 H, 1 H, ArH), 6.82 (br s, 1 H, OH), 7.00, 7.10 (2s, 2 H, 1 H, 
ArH), 7.29-7.48 (m, 9 H, ArH, OH), 7.66-7.73, 7.74-7.84 (2m, 2 × 2H, ArH); 13C NMR 
(CDCl3) δ 14.1, 14.2, 14.7 (CH2CH3), 19.8 (SiC(CH3)3), 20.9, 21.14, 21.15, 21.5 
(CH2CH3), 26.8 (SiC(CH3)3), 32.5, 32.6, 32.8, 33.0 (CHCH2), 35.7, 36.7, 37.1, 39.7 
(CH2CH), 55.0, 55.7, 55.9, 56.1 (OCH3), 99.2, 99.2, 100.3, 102.8 (CH, Ar), 121.7, 
122.9 (C, Ar), 122.9, 123.3 (CH, Ar), 124.1, 124.2, 125.0, 125.3 (C, Ar), 125.5 (CH, 
Ar), 125.5 (C, Ar), 126.8 , 127.88, 127.90 (CH, Ar), 129.6 (C, Ar), 129.9 (CH, Ar), 
133.3, 133.5 (C, Ar), 135.70, 135.73 (CH, Ar), 151.5, 152.27, 152.31, 153.26, 153.33, 
153.4, 154.4, 156.5 (C, Ar) (note some signals are coincident). Found: C, 75.53; H, 
7.76; C60H74O8Si; requires C, 75.75; H, 7.84%. 
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Proximal-TBDPS resorcinarene (41): m.p. 137-138 
°C (MeOH); IR 3455 cm-1 (OH phenol); 1H NMR 
(CDCl3) δ 0.79 (s, 9 H, SiC(CH3)3), 0.85-1.03 (m, 12 
H, CH2CH3), 1.16 (s, 9 H, SiC(CH3)3), 1.23-1.52 (m, 
8 H, CH2CH3), 1.67-1.78, 1.80-1.93, 1.94-2.22 (3m, 
5 H, 2 H, 1 H, CH2CH), 2.92, 2.97, 3.51, 3.88 (4s, 4 
× 3 H, OCH3), 4.04 (t, J = 7.6 Hz, 1 H, CHCH2), 4.34 
(t, J = 7.6 Hz, 1 H, CHCH2), 4.88-4.98, 5.08-5.17 
(2m, 2 × 1 H, CHCH2), 5.68, 5.90, 6.29, 6.42, 6.65, 6.92 (6s, 6× 1 H, ArH), 7.05-7.14 
(m, 4 H, ArH), 7.21-7.47 (overlapped with CHCl3, m, 11 H, ArH), 7.63-7.74 (m, 5 H, 
ArH), 7.83-7.89 (m, 2 H, ArH); 13C NMR (CDCl3) δ 14.2, 14.26, 14.27, 14.8 
(CH2CH3), 19.2, 19.7 (SiC(CH3)3), 21.0, 21.1, 21.3, 21.8 (CH2CH3), 26.4, 26.7 
(SiC(CH3)3), 32.8, 33.70, 33.75 (br), 34.8 (CHCH2), 36.3, 36.6, 39.8, 40.1 (CH2CH), 
54.3, 55.0, 55.1, 56.0 (OCH3), 99.1, 100.3, 102.1, 102.6 (CH, Ar), 121.4, 123.3, 124.0 
(C, Ar), 124.7, 125.2, 125.4 (CH, Ar), 125.4, 125.7 (C, Ar), 126.8 (CH, Ar), 126.9 (C, 
Ar), 127.70, 127.71, 127.9, 127.9, 129.56, 129.57, 129.79, 129.84 (CH, Ar), 133.0, 
133.1, 134.32, 134.35 (C, Ar), 135.6, 135.68, 135.73, 135.75 (CH, Ar), 151.0, 152.0, 
152.9, 153.0, 153.2, 153.5, 154.1, 157.0 (C, Ar) (note some signals are coincident). 
HRMS (ESI): calcd. for C72H92O8Si2 as [M]+ 1188.6331; found 1188.6310. 
Distal-TBDPS resorcinarene (42): m.p. 270-271 
°C (CHCl3/MeOH); IR 3479 cm-1 (OH phenol); 
1H NMR (CDCl3) δ 0.94 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 0.95 (t, J = 7.3 Hz, 6 H, CH2CH3), 
1.19-1.63 (m, 8 H, CH2CH3), 1.20 (s, 18 H, 
SiC(CH3)3), 1.80-1.93, 1.93-2.07, 2.07-2.20 (3m, 
2 H, 4 H, 2 H, CH2CH), 3.17, 3.46 (2s, 2 × 6 H, 
OCH3), 4.18 (t, J = 7.5 Hz, 2 H, CHCH2), 5.11 (t, J = 7.9 Hz, 2 H, CHCH2), 5.90, 6.20, 
6.30, 6.90 (4s, 4 × 2 H, ArH), 7.31-7.52 (m, 14 H, ArH, OH), 7.79 (d, J = 7.7 Hz, 8 H, 
ArH); 13C NMR (CDCl3) δ 14.2, 14.7 (CH2CH3), 19.8 (SiC(CH3)3), 21.0, 21.6 
(CH2CH3), 26.7 (SiC(CH3)3), 33.0, 33.1 (CHCH2), 36.8, 40.0 (CH2CH), 55.1, 55.5 
(OCH3), 99.0, 102.3 (CH, Ar), 120.6, 123.7 (C, Ar), 124.3 (CH, Ar), 124.3 (C, Ar), 
127.3, 127.9, 127.9 (CH, Ar), 129.9 (C, Ar), 129.9, 130.0 (CH, Ar), 133.0, 133.7, 
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135.7, 135.8 (CH, Ar), 151.3, 152.4, 153.4, 156.7 (C, Ar). Found: C, 76.40; H, 8.06; 
C76H92O8Si2; requires C, 76.73; H, 7.79%. 
4.3.3.5 Benzyl ether 
The general procedure was applied with resorcinarene (1) (76 mg, 0.107 mmol, 1.00 
eq), anhydrous tetrahydrofuran (6 mL) potassium tert-butoxide (24 mg, 0.214 mmol, 
2.01 eq) and benzyl bromide (0.0254 mL, 36.5 mg, 0.213 mmol, 2.00 eq). After 
reaction overnight, the tetrahydrofuran solvent was evaporated, and the residue was 
filtered through a short plug of silica eluting with EtOAc. The EtOAc was evaporated, 
and the residue was subjected to preparative TLC (EtOAc – petroleum spirits 40:60) 
to give pure resorcinarenes: tetra (22) (6.5 mg, 6%), tri (47) (26 mg, 25%), distal (46) 
(14 mg, 15%), proximal (45) (17 mg, 18%), and mono (44) co-eluted with unreacted 
resorcinarene (1) in respective elution order. The co-eluted mono and starting 
resorcinarene was mostly separated by another preparative TLC (EtOAc – DCM 5:95) 
to give mono (44) (9 mg, 11%) and resorcinarene (1) (4 mg, 5%). Tri (47) and proximal 
(45) resorcinarenes formed brown oils which could not be crystallised. The 1H NMR 
spectrum of the first-eluting product matched that of the tetra-OBn resorcinarene (22) 
which is described in Section 3.4.1.1. All other OBn resorcinarenes are previously 
unreported. 
Mono-OBn resorcinarene (44): mp 220-224 °C 
(MeCN); IR 3413 cm-1 (OH phenol); 1H NMR (only 
relevant signals quoted, CDCl3) δ 0.85-1.03 (m, 12 H, 
CH2CH3), 1.15-1.38 (m, 8 H, CH2CH3), 1.92-2.02, 
2.08-2.25 (2m, 2 H, 6 H, CH2CH), 3.38, 3.80, 3.84, 
3.85 (4s, 4 × 3 H, OCH3), 4.24-4.34 (m, 3 H, CHCH2), 
5.00-5.06 (m, 1 H, CHCH2), 5.01, 5.07 (AB, J = 12.0 Hz, 2 H, CH2Ph), 6.21, 6.31, 
6.38, 6.39 (4s, 4 × 1 H, ArH), 7.09, 7.17 (2br s, 2 × 1 H, OH), 7.18, 7.19, 7.22 (3s, 3 × 
1 H, ArH), 7.24 (br s, 1 H, OH), 7.27-7.33, 7.34-7.41, 7.46-7.53 (3m, 2 H, 2 H, 2 H, 
ArH); 13C NMR (only relevant signals quoted, CDCl3) δ 14.1, 14.2, 14.3 (CH2CH3), 
21.06, 21.09, 21.1, 21.2 (CH2CH3), 31.7, 32.86, 32.88, 33.0 (CHCH2), 36.2, 36.5, 36.7, 
39.0 (CH2CH), 55.2, 55.9, 56.0, 56.2 (OCH3), 71.0 (OCH2Ph), 97.0, 99.5, 99.6, 100.1 
(CH, Ar), 122.3 (C, Ar), 123.56 (CH, Ar), 123.64, 123.9, 124.5 (C, Ar), 124.7 (CH, 
Ar), 124.9, 125.1, 125.9 (C, Ar), 126.1, 127.0, 127.6, 128.6 (CH, Ar), 128.9, 138.0, 
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152.6, 152.9, 153.3, 153.4, 153.7, 154.1, 155.3, 156.2 (C, Ar) (note some signals are 
coincident). HRMS (ESI): calcd. for C51H63O8 as [M + H]+ 803.4517; found 803.4497. 
Proximal-OBn resorcinarene (45): IR 3447 cm-1 (OH 
phenol); 1H NMR (CDCl3) δ 0.84-1.02 (m, 12 H, 
CH2CH3), 1.12-1.42 (m, 8 H, CH2CH3), 1.77-2.01, 
2.03-2.19 (2m, 2 × 4 H, CH2CH), 3.43, 3.47, 3.77, 
3.84 (4s, 4 × 3 H, OCH3), 4.26 (t, J = 7.7 Hz, 1 H, 
CHCH2), 4.30 (t, J = 7.7 Hz, 1 H, CHCH2), 4.80, 4.89 
(AB, J = 11.6 Hz, 2 H, CH2Ph), 4.82-4.98 (m, 2 H, 
CHCH2), 5.03, 5.07 (AB, J = 12.0 Hz, 2 H, CH2Ph), 
6.21, 6.34, 6.36, 6.42, 6.86, 7.04, 7.18 (7s, 7 × 1 H, ArH), 7.26-7.33, 7.34-7.41, 7.46-
7.53 (3m, 6 H, 3 H, 2 H, ArH); 13C NMR (CDCl3) δ 14.2, 14.38, 14.40 (CH2CH3), 
21.1 (CH2CH3), 33.1, 33.5 (CHCH2), 36.6, 39.2 (br, CH2CH), 55.3, 55.4, 55.9, 56.0 
(OCH3), 71.0, 71.1 (OCH2Ph), 97.2, 97.4, 99.2, 100.0 (CH, Ar), 121.9, 124.3 (C, Ar), 
124.4 (br, CH, Ar), 124.8, 125.1 (C, Ar), 125.2 (br, CH, Ar), 125.4 (C, Ar), 125.8 (CH, 
Ar), 127.1 (C, Ar), 127.1, 127.48, 127.52, 127.6, 128.4, 128.5 (CH, Ar), 137.7, 138.4, 
152.4, 152.6, 153.8, 154.1, 154.9 (br), 155.4 (br), 155.8, 156.5 (C, Ar) (note some 
signals are coincident). HRMS (ESI): calcd. for C58H69O8 as [M + H]+ 893.4987; found 
893.4913. 
Distal-OBn resorcinarene (46): m.p. 202-203 
°C (CHCl3/MeOH); IR 3368 cm-1 (OH 
phenol); 1H NMR (CDCl3) δ 0.91 (t, J = 7.2 
Hz, 6 H, CH2CH3), 0.99 (t, J = 7.2 Hz, 6 H, 
CH2CH3), 1.14-1.44 (m, 8 H, CH2CH3), 1.82-
2.01, 2.03-2.23 (2m, 2 × 4 H, CH2CH), 3.48, 
3.89 (2s, 2 × 6 H, OCH3), 4.21-4.42, 4.91-5.06 (2m, 2 × 2 H, CHCH2), 5.10, 5.14 (AB, 
J = 12.1 Hz, 4 H, CH2Ph), 6.22, 6.48, 7.04 (3s, 3 × 2 H, ArH), 6.57 (br s, 2 H, ArOH), 
7.28-7.37 (m, 4 H, ArH), 7.41 (t, J = 7.4 Hz, 4 H, ArH), 7.57 (d, J = 7.1 Hz, 4 H, ArH); 
13C NMR (CDCl3) δ 14.2, 14.3 (CH2CH3), 21.0, 21.1 (CH2CH3), 32.2, 33.1 (CHCH2), 
36.8, 39.5 (CH2CH), 55.3, 56.1 (OCH3), 71.1 (CH2Ph), 96.9, 99.3 (CH, Ar), 121.3 (C, 
Ar), 124.1 (CH, Ar), 124.7, 124.9 (C, Ar), 127.0, 127.1, 127.6, 128.5 (CH, Ar), 129.2, 
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138.1, 153.2, 153.4, 155.1, 156.4 (C, Ar). Found: C, 77.67; H, 7.66; C58H68O8; requires 
C, 78.00; H, 7.67%. 
Tri-OBn resorcinarene (47): IR 3476cm-1 (OH 
phenol); 1H NMR (CDCl3) δ 0.81-1.01 (m, 12 
H, CH2CH3), 1.18-1.48 (m, 8 H, CH2CH3), 
1.74-2.06 (m, 8 H, CH2CH), 3.37, 3.41, 3.46, 
3.79 (4s, 4 × 3 H, OCH3), 4.26 (t, J = 7.3 Hz, 1 
H, CHCH2), 4.45, 4.76 (AB, J = 11.2 Hz, 2 H, 
CH2Ph), 4.56-4.64 (m, 1 H, CHCH2), 4.68-4.76 
(m, 2 H, CHCH2), 4.99 (d, J = 11.8 Hz, 1 H, 
CH2Ph), 5.00 (d, J = 11.8 Hz, 1 H, CH2Ph), 5.08 (d, J = 11.8 Hz, 1 H, CH2Ph), 5.10 
(d, J = 11.8 Hz, 1 H, CH2Ph), 6.19, 6.27, 6.39, 6.47, 6.50, 6.64, 7.03 (7s, 7 × 1 H, 
ArH), 7.04-7.08 (m, 2 H, ArH), 7.09 (s, 1 H, ArH), 7.17-7.24, 7.27-7.42, 7.43-7.50 
(3m, 3 H, 7 H, 4 H, ArH + OH); 13C NMR (CDCl3) δ 14.3, 14.41, 14.45, 14.5 
(CH2CH3), 21.1, 21.3, 21.4 (CH2CH3), 34.5, 34.8, 35.2 (CHCH2), 37.1, 37.4, 37.5, 
38.1 (CH2CH), 55.4, 55.6, 56.0 (OCH3), 71.0, 71.1, 71.2 (OCH2Ph), 96.8, 97.6, 98.7, 
99.4 (CH, Ar), 121.2, 124.3, 124.5, 125.3, 125.4 (C, Ar), 125.69, 125.73, 126.0, 
127.28, 127.32 (CH, Ar), 127.35 (C, Ar), 127.5 (CH, Ar), 127.61 (C, Ar), 127.64, 
127.7 (CH, Ar), 128.1 (C, Ar), 128.2, 128.50, 128.52 (CH, Ar), 128.9, 137.7, 138.0, 
138.3, 152.5, 154.4, 154.7, 155.4, 155.6, 155.7, 156.1, 156.6 (C, Ar) (note some 
signals are coincident). HRMS (ESI): calcd. for C65H74O8 as [M]+ 982.5384; found 
982.5373. 
4.3.3.6 Heptyl TBDMS 
General procedure with potassium tert-butoxide (21.9 mg, 0.195 mmol, 2.01 eq), 
resorcinarene (31) (92.5 g, 0.0987 mmol, 1.00 eq), anhydrous tetrahydrofuran (5 mL) 
and a solution of TBDMS-Cl in petroleum spirits (0.081 mL, 0.37 g/mL, 29.7 mg, 
0.197 mmol) gave a mixture which was subjected to preparative TLC (EtOAc – 
petroleum spirits 30:70) to give pure, previously unreported resorcinarenes: tri (39) (7 
mg, 6%), distal (38) (25 mg, 22%), proximal (37) (15 mg, 13%), mono (36) (34 mg, 
33%) as colourless solids as well as remaining resorcinarene (31) (19 mg, 21%) in 
respective elution order. All products were colourless solids but, only distal (38) could 
be crystallised. 
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To assess repeatability, the same reaction was repeated at a similar scale to give: tri 
(39) (6%), distal (38) (19%), proximal (37) (12%), mono (36) (33%), starting 
resorcinarene (31) (23%). 
Mono-TBDMS heptyl (36): IR 3434 cm-1 (OH 
phenol); 1H NMR (CDCl3) δ 0.24, 0.29 (2s, 2 × 3 H, 
Si(CH3)2), 0.80-0.95 (m, 12 H, CH2CH3), 1.06 (s, 9 H, 
SiC(CH3)3), 1.16-1.45 (m, 40 H, (CH2)5CH3), 1.73-
1.87, 1.91-2.26 (2m, 1 H, 7 H, CH2CH), 3.58, 3.78, 
3.85, 3.86 (4s, 4 × 3 H, OCH3), 4.17-4.31 (m, 3 H, 
CHCH2), 4.78 (t, J = 8.0 Hz, 1 H, CHCH2), 6.22, 6.28, 6.41 (3s, 1 H, 2 H, 1 H, ArH), 
6.97 (overlapped, br s, 2 H, OH), 7.00, 7.09 (2s, 2 × 1 H, ArH), 7.21 (overlapped, br 
s, 2 H, ArH + OH), 7.32 (s, 1 H, ArH); 13C NMR (CDCl3) δ -4.0, -3.5 (Si(CH3)2), 14.3 
(CH2CH3), 18.6 (SiC(CH3)3), 22.8 (CH2), 26.1 (SiC(CH3)3), 28.0, 28.1, 28.2, 28.3, 
29.48, 29.50, 29.56, 29.57, 29.7, 29.9, 30.2, 32.02, 32.05, 32.1 (CH2), 32.7, 33.1, 33.3, 
33.4 (CHCH2), 34.0, 34.7, 35.0, 37.2 (CH2CH), 55.4, 55.9, 55.97, 56.05 (OCH3), 99.4, 
99.6, 100.2, 101.6 (CH, Ar), 121.9, 123.1 (C, Ar), 123.2, 123.4 (CH, Ar), 124.2, 124.5 
(C, Ar), 125.2 (CH, Ar), 125.3, 125.4 (C, Ar), 126.7 (CH, Ar), 130.4, 151.8, 152.3, 
152.8, 153.1, 153.4, 154.3, 156.6 (C, Ar) (note some signals are coincident); HRMS 
(ESI): calcd. for C66H103O8Si as [M + H]+ 1051.7417; found 1051.7410. 
Proximal-TBDMS heptyl (37): IR 3478 cm-1 (OH 
phenol); 1H NMR (CDCl3 Impure, only relevant 
signals quoted) δ -0.31, 0.01, 0.25, 0.29 (4s, 4 × 3 H, 
Si(CH3)2), 0.82 (s, 9 H, SiC(CH3)3), 0.84-0.92 (m, 12 
H, CH2CH3), 1.05 (s, 9 H, SiC(CH3)3), 1.11-1.47 (m, 
40 H, (CH2)5CH3), 1.66-1.93, 1.93-2.16 (2m, 2 × 4 H, 
CH2CH), 3.44, 3.68, 3.73, 3.88 (4s, 4 × 3 H, OCH3), 
4.11 (t, J = 7.6 Hz, 1 H, CHCH2), 4.26 (t, J = 7.5 Hz, 1 H, CHCH2), 4.52-4.66 (m, 2 
H, CHCH2), 6.15, 6.16 (overlapped 2s, 2 × 1 H, ArH), 6.18 (br s, 1 H, OH), 6.32 (s, 1 
H, ArH), 6.40 (br s, 2 H, ArH + OH), 6.47, 7.14, 7.20 (3s, 3 × 1 H, ArH); 13C NMR 
(CDCl3) δ -4.6, -4.2, -3.8, -3.5 (Si(CH3)2), 14.25, 14.27, 14.29 (CH2CH3), 18.3, 18.5 
(SiC(CH3)3), 22.80, 22.83, 22.9 (CH2), 25.9, 26.1 (SiC(CH3)3), 28.02, 28.03, 28.2, 
28.5, 29.4, 29.46, 29.49, 29.52, 29.85, 29.91, 29.93, 30.3, 32.06, 32.11, 32.2 (CH2), 
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33.3 (CHCH2), 34.5 (CH2CH), 54.8, 55.1, 55.6, 56.0 (OCH3), 99.0, 100.1, 101.4, 102.5 
(CH, Ar), 121.4, 123.1, 124.4 (C, Ar), 124.7, 125.3, 125.6 (CH, Ar), 125.7, 126.0, 
127.1, 127.2, 128.8, 151.2, 152.1, 152.7, 153.0, 153.5, 154.0, 154.6, 156.9 (C, Ar) 
(note some signals are coincident); HRMS (ESI): calcd. for C72H117O8Si2 as [M + H]+ 
1165.8281; found 1165.8271. 
Distal-TBDMS heptyl (38): mp 142 °C 
(EtOAc/MeOH); IR 3459 cm-1 (OH phenol); 1H 
NMR (CDCl3) δ 0.30 (br s, 12 H, Si(CH3)2), 0.86  
(t, J = 6.9 Hz, 12 H, CH2CH3), 1.08 (br s, 18 H, 
SiC(CH3)3), 1.15-1.45 (m, 40 H, (CH2)5CH3), 
1.66-1.80, 1.78-1.90, 1.88-2.02, 2.00-2.18 (4m, 4 
× 2 H, CH2CH), 3.53, 3.87 (2br s, 2 × 6 H, OCH3), 4.24, 4.69 (2 br s, 2 × 2 H, CHCH2), 
5.77-6.11 (br s, 1 H, OH), 6.18, 6.35, 6.74, (3br s, 3 × 2 H, ArH), 7.25 (overlapped 
with CHCl3 br s, 2 H, ArH); 13C NMR (CDCl3) δ -3.8 (Si(CH3)2), 14.3 (CH2CH3), 18.5 
(br, SiC(CH3)3), 22.8 (CH2), 26.0 (SiC(CH3)3), 27.9, 28.4, 29.5, 29.9, 30.2, 32.1 (CH2), 
33.8 (CHCH2), 34.7, 37.3 (CH2CH), 55.3, 55.9 (OCH3), 99.5, 101.2 (CH, Ar), 120.7, 
123.7, 124.4 (C, Ar), 124.7, 127.4 (CH, Ar), 130.6, 151.8, 153.1, 153.3, 156.7 (C, Ar) 
(note some signals are coincident) 1H NMR (Acetone-d6) δ 0.08, 0.21 (2s, 2 × 6 H, 
Si(CH3)2), 0.82-0.92 (m, 12 H, CH2CH3), 1.01 (s, 18 H, SiC(CH3)3), 1.12-1.45 (m, 40 
H, (CH2)5CH3), 1.68-1.83, 1.84-2.01 (2m, 2 H, 6 H, CH2CH), 3.63, 3.68 (2s, 2 × 6 H, 
OCH3), 4.50 (t, J = 7.4 Hz, 2 H, CHCH2), 4.69 (t, J = 7.7 Hz, 2 H, CHCH2), 6.31, 6.33, 
6.94, 7.03 (4s, 4 × 2 H, ArH), 7.24 (s, 2 H, OH); 13C NMR (Acetone-d6) δ -4.0, -3.7 
(Si(CH3)2), 14.416, 14.421 (CH2CH3), 18.8 (SiC(CH3)3), 23.36, 23.38 (CH2), 26.3 
(SiC(CH3)3), 28.8, 29.1, 30.1, 30.2, 30.58, 30.62, 32.7, 32.8 (CH2), 35.4 (CHCH2), 
35.9, 37.3 (CH2CH), 55.4, 56.1 (OCH3), 99.5, 103.1 (CH, Ar), 123.4, 124.8, 126.2 (C, 
Ar), 126.6 (CH, Ar), 127.7 (C, Ar), 127.9 (CH, Ar), 152.6, 154.0, 155.8, 156.6 (C, Ar) 
(note some signals are coincident); HRMS (ESI): calcd. for C72H117O8Si2 as [M + H]+ 
1165.8281; found 1165.8272. 
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Tri-TBDMS resorcinarene heptyl (39): IR 3536 
cm-1 (OH phenol); 1H NMR (CDCl3) δ -0.12, 
0.05, 0.13, 0.18, 0.24, 0.26, (6s, 6 × 3 H, 
Si(CH3)2), 0.82 (s, 9 H, SiC(CH3)3), 0.82-0.89 (m, 
12 H, CH2CH3), 1.01, 1.02  (2s, 2 × 9 H, 
SiC(CH3)3), 1.12-1.44 (m, 40 H, (CH2)5CH3), 
1.66-1.99 (m, 8 H, CH2CH), 3.42, 3.48, 3.68, 3.77 
(4s, 4 × 3 H, OCH3), 4.10-4.24, 4.35-4.46, 4.44-4.52 (3m, 1 H, 1 H, 2 H, CHCH2), 
6.11, 6.19, 6.24 (br), 6.28, 6.31, 6.50, 6.95 (br), 6.97 (br), (8s, 8 × 1 H, ArH); 13C NMR 
(CDCl3) δ -4.4, -4.3, -4.1, -4.0, -3.7, -3.4 (Si(CH3)2), 14.27, 14.29 (CH2CH3), 18.2, 
18.4, (SiC(CH3)3), 22.8, 22.9 (CH2), 25.87, 25.95, 26.0 (SiC(CH3)3), 28.1, 28.6, 28.7, 
29.45, 29.47, 29.50, 29.53, 30.0, 30.1, 30.3, 32.17, 32.25, 34.7 (br) (CH2), 34.8 (br, 
CHCH2), 35.0 (br), 35.4 (CH2), 35.8, 36.3 (CHCH2), 54.8, 55.3, 55.5, 55.7 (OCH3), 
99.5, 101.3, 101.7, 103.0 (CH, Ar), 121.1, 123.5 (br), 124.3, 124.5, 125.2 (br) (C, Ar), 
125.9, 126.2, 126.4 (br, CH, Ar), 127.6 (C, Ar), 127.7 (br, CH, Ar), 128.2 (br), 129.8 
(br), 151.2, 151.3, 152.1, 152.4, 154.2, 154.9, 155.8, 156.7 (C, Ar) (note some signals 
are coincident); HRMS (ESI): calcd. for C78H131O8Si3 as [M + H]+ 1279.9146; found 
1279.9132. 
4.3.4 Replacement of TBDMS protecting groups 
4.3.4.1 14,56-di-tert-butyldimethylsilylether-36,76-dimethanesulfonyl-16,34,54,74-
tetramethoxy-2,4,6,8-tetrapropylresorcin[4]arene (48) 
To a clear solution of resorcinarene (34) (0.127 g, 
0.135 mmol) and triethylamine (0.226 mL, 0.164 
g, 1.62 mmol) dissolved in dichloromethane (10 
mL) was added methanesulfonyl chloride (0.084 
mL, 0.124 g, 1.62 mmol), while in an ice bath. 
The resultant clear yellow solution was stirred at 
room temperature under nitrogen for 1 h. The 
reaction mixture was then washed with dilute HCl (15 mL, 1 M) and the aqueous layer 
was extracted with dichloromethane (3 × 5 mL). The combined organic extracts were 
dried (MgSO4), filtered, and solvent removed under reduced pressure to give a yellow-
white solid (0.155 g). A portion of the material (0.098 g) was triturated by heating with 
methanol, allowing to cool to room temperature, then filtering off the resultant yellow 
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solution from the pure, previously unreported product (48) which was collected as a 
white solid (0.078 g, 98%) then washed with methanol: mp 257-258 °C 
(CHCl3/MeOH); 1H NMR (CDCl3) δ 0.25, 0.31 (2s, 2 × 6 H, Si(CH3)2), 0.91 (t, J = 
7.3 Hz, 6 H, CH2CH3), 0.92 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.04 (s, 18 H, SiC(CH3)3), 
1.17-1.44 (m, 8 H, CH2CH3), 1.68-1.93 (m, 8 H, CH2CH), 1.95 (br s, 6 H, SO2CH3), 
3.55, 3.80 (2s, 2 × 6 H, OCH3), 4.49-4.62 (m, 4 H, CHCH2), 6.31 (br s, 2 H, ArH), 
6.39 (s, 2 H, ArH), 6.85 (s, 2 H, ArH), 7.21 (br s, 2 H, ArH); 13C NMR (CDCl3) δ -
4.1, -3.6 (Si(CH3)2), 14.3, 14.5 (CH2CH3), 18.4 (SiC(CH3)3), 21.1, 21.5 (CH2CH3), 
25.9 (SiC(CH3)3), 34.8 (CHCH2), 35.6, 35.7 (CHCH2 + SO2CH3), 37.5, 37.6 (CH2CH), 
55.3, 55.6 (2 × OCH3), 101.7, 103.2 (CH, Ar), 126.4, 126.7 (C, Ar), 126.8 (CH, Ar), 
127.8, 130.2, 147.4, 151.9, 155.2, 155.6 (C, Ar) (note some signals are coincident). 
HRMS (ESI): calcd. for C58H89O12S2Si2 as [M + H]+ 1097.5328; found 1097.5296. 
4.3.4.2 Attempted synthesis of 14,56-dimethanesulfonyl-16,34,54,74-
tetramethoxy-2,4,6,8-tetrapropylresorcin[4]arene-36,76-diol 
Slighlty impure resorcinarene (48) (57 mg, 0.052 mmol) was combined with caesium 
carbonate (62 mg, 0.19 mmol) and non-anhydrous dimethylformamide (4 mL), then 
heated at 90°C open to air, overnight. After overnight, the reaction mixture was a 
cloudy brown solution. The reaction mixture was diluted with water (80 mL) and 
filtered, but no solids were collected. Brine (20 mL) was added to the filtrate, and 
extracted with ether (3 × 15 mL). The combined ether extracts were washed with brine 
(10 mL), dried (MgSO4), filtered, and solvent removed under reduced pressure to give 
a yellow oil which smelled like TBDMS-OH. Methanol (~15 mL) was added and 
removed under reduced pressure; after repeating a second time, a yellow-brown solid 
(0.041 g) was recovered. The material was then filtered through a plug of silica with 
EtOAc to give a yellow-brown solid (0.031 g). TLC and 1H NMR analysis of the 
product indicated it to contain multiple methanesulfonate resorcinarene compounds. 
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4.3.4.3 14,56-dibenzyloxy-36,76-di-tert-butyldimethylsilylether-16,34,54,74-
tetramethoxy-2,4,6,8-tetrapropylresorcin[4]arene (49) 
Resorcinarene (34) (4.07 g, 4.32 mmol) was 
added to a mixture of washed sodium hydride 
(1.81 g, 60% in oil, 1.09 g, 45.3 mmol) and a 
couple of crystals of imidazole in anhydrous 
tetrahydrofuran (150 mL), and the resultant 
mixture was stirred under nitrogen at room 
temperature for 10 minutes. To this off-white 
slurry was added benzyl bromide (5.2 mL, 7.48 
g, 43.7 mmol), and the reaction mixture was 
stirred overnight at room temperature, under nitrogen. The reaction mixture was then 
cooled in an ice bath and carefully quenched with dilute HCl (1 M), producing bubbles. 
The solvents were removed under reduced pressure from the clear orange yellow 
solution, and the residue was dissolved in dichloromethane (70 mL) and water (70 
mL). The layers were separated, and the the cloudy off-white aqueous layer was 
extracted with dichloromethane (20 mL). The combined organic layers were dried 
(MgSO4), filtered, and solvent removed under reduced pressure to give a yellow liquid 
residue. The residue was triturated with methanol to give a slightly yellow solid, which 
was further purified by column chromatography (DCM – petroleum spirits 50:50) to 
give pure, previously unreported product (49) as a white solid (3.86 g, 80%): mp 218-
219 °C (DCM); 1H NMR (CDCl3) δ 0.20, 0.32 (2s, 2 × 6 H, Si(CH3)2), 0.90-0.99 (m, 
12 H, CH2CH3), 1.06 (s, 18 H, SiC(CH3)3), 1.24-1.54 (m, 8 H, CH2CH3), 1.77-1.99 
(m, 8 H, CH2CH), 3.38, 3.63 (2s, 2 × 6 H, OCH3), 4.27-4.55 (m, 4 H, CH2Ph and 
CHCH2), 4.55-4.65 (m, 2 H, CHCH2), 4.78 (br d, J = 10.7 Hz, 2 H, CH2Ph), 6.18-6.50 
(m, 6 H, ArH), 6.93-7.25 (m, 6 H, ArH), 7.27-7.37 (m, 6 H, ArH); 13C NMR (CDCl3) 
δ -4.1, -3.4 (Si(CH3)2), 14.5, 14.6 (CH2CH3), 18.4 (SiC(CH3)3), 21.6, 21.8 (CH2CH3), 
26.0 (SiC(CH3)3), 35.9, 36.6 (CHCH2), 37.1 (CH2CH), 55.4 (2 × OCH3), 71.3 
(CH2Ph), 98.5, 101.9 (CH, Ar), 124.8 (C, Ar), 126.4, 126.8, 127.5, 128.2 (CH, Ar), 
137.8, 151.3, 155.0, 155.7, 156.1 (C, Ar) (note some signals are coincident). Found: 
C, 75.01; H, 8.55; C70H96O8Si2; requires C, 74.95; H, 8.63%. 
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4.3.4.4 14,56-dibenzyloxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene-36,76-diol (46) 
To a solution of (49) (3.86 g, 3.44 mmol) 
dissolved in tetrahydrofuran (30 mL) was 
added a solution of sodium hydroxide (1.48 g, 
37.0 mmol) dissolved in methanol (20 mL). 
The slightly cloudy colourless reaction mixture 
was stirred at room temperature overnight 
under nitrogen. The solvent was removed under 
reduced pressure, and the residue dissolved in dichloromethane (50 mL) and dilute 
HCl (50 mL, 1 M). The layers were separated, and the aqueous layer was extracted 
with dichloromethane (50 mL). The combined cloudy organic extracts were dried 
(MgSO4), filtered, and solvent removed under reduced pressure to give a white solid 
which smelled like a silyl derivative (probably tert-butyldimethylsilanol). Methanol 
(20 mL) was added to the product, and then removed under reduced pressure; this 
process was repeated up to 10 times until the smell disappeared to give (46) as a white-
beige solid (2.97 g, 97%). NMR data was consistent with (46) as described earlier. 
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5 Synthesis and investigation of crown resorcinarenes as 
enantioselective membrane carriers 
The synthesis of distal-OBn resorcinarene (46) has provided the key intermediate that 
enables the installation of a bridge on distal positions of the resorcinarene (Scheme 
5.1). The goal of the distal bridge is to partially-enclose the resorcinarene cavity to 
enable binding of smaller guest molecules through intermolecular interactions. Crown 
ethers were chosen as the bridge due to their well-known ability to act as hydrogen-
bond acceptors. Their availability in various lengths, also enables the synthesis of 
various sizes of crown resorcinarenes, which would have different binding affinities 
for a guest molecule. The binding interactions and various sizes of the crown 
resorcinarenes are vital factors for their potential to act as enantioselective membrane 
carriers for chiral guest molecules. 
 
Scheme 5.1 Distal-OBn resorcinarene (46) enables the installation of a bridge on distal positions of 
the resorcinarene. 
5.1 Synthesis of distal crown resorcinarenes  
Distal-OBn resorcinarene (46) was reacted with 2.1 equivalents of tetra(ethylene 
glycol)-ditoluenesulfonate (50) with caesium carbonate in dimethylformamide, as per 
the procedure described by Nissinen and co-workers.103 The reaction was successful 
with the target distally-bridged crown-5 resorcinarene product (53) being isolated in a 
yield of 26%. Since the tetra(ethylene glycol)ditoluenesulfonate (50) has two reactive 
sites, it is possible to form oligomers which would consist of multiple resorcinarenes 
intermolecularly-bridged by the tetraethylene glycol. With this in mind, the reaction 
was conducted at more dilute concentrations of 1 mg/mL, resulting in significantly 
improved yields of about 55%. When the reaction concentration was doubled to 2 
mg/mL, the yield only decreased by about 5%. Therefore, at larger scales, the reaction 
was conducted at 2 mg/mL for the reason of minimising the volume of 
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dimethylformamide solvent, which becomes troublesome to remove at large volumes. 
After experimentation with various methods, it was found that large volumes (0.5 L) 
of dimethylformamide were most conveniently removed under high vacuum using a 
rotary evaporator. Resorcinarenes with crown-6 (54) and crown-7 (55) bridges were 
also synthesised through similar reaction conditions as summarised in Table 5.1. The 
use of alternative reaction solvents such as acetonitrile and acetone were also explored 
but resulted in significantly lower yields of the target product. Reaction using a 
carbonate base with a different cation, such as potassium carbonate, drastically 
decreased the yield, which could be due to the poorer solubility of potassium carbonate 
in dimethylformamide, however no unreacted starting resorcinarene was apparent by 
TLC. The caesium cation was possibly acting as a better template for the crown ether 
to facilitate its intramolecular coupling to the resorcinarene. In the literature, 15-
crown-5 and 18-crown-6 have been demonstrated to bind caesium ions in 
dimethylformamide, with the latter forming a more stable complex.166 This templating 
effect may explain the greater yields recorded for the crown-7 resorcinarene (55) 
which has a crown ether that is analogous to the 18-crown-6. In these investigations, 
slightly more (2.5 eq) ethylene glycol ditosylate was generally required to ensure 
complete reaction of the starting resorcinarene, as was monitored by TLC. The crude 
product was purified by column chromatography, with good chromatographic 
separation. The work up and purification of the crown-7 resorcinarene (55) was 
slightly more difficult, likely due to the greater hydrophilicity of the overall product. 
The phase separation during the work up was not as good, requiring more time to 
separate. Product (55) could be purified by filtering through a plug of silica, followed 
by trituation with methanol. However, a small amount of the product could not be 
recovered from the methanol filtrate, due to it having slight solubility in methanol. The 
trituation was not successful when performed immediately after the silica plug; this 
may be caused by trace residue solvents which enhance the solubility of the product in 
methanol.  
  
 156 
 
Table 5.1 Investigation into the bridging of (46) with crown 5-7 ethers at various conditions. 
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Resorcinarene 
crown 
Ethylene 
glycol 
(2.5 eq) 
Base Solvent 
Concentration of 
reaction mixture 
(mg/mL) 
Yield 
(%) 
(53) Tetra-  (n = 1) 
Cs2CO3 DMF 4.2 26 
Cs2CO3 DMF 1 52-58 
Cs2CO3 DMF 2 48-50 
(54) Penta-  (n = 2) 
Cs2CO3 DMF 1 49-66 
Cs2CO3 DMF 2 36 
K2CO3 MeCN 1 20 
Cs2CO3 MeCN 1 40 
Cs2CO3 Acetone 1 38 
(55) Hexa-  (n = 3) 
Cs2CO3 DMF 1 50-51 
Cs2CO3 DMF 2 66-70 
Cs2CO3 DMF 3 61-62 
 
The key evidence that the target dibenzyloxy crown resorcinarene products (53), (54) 
and (55) were obtained was provided by NMR spectroscopy (Appendix A – 56). The 
retention of C2 symmetry for all three products was confirmed by the two prominent 
methoxy peaks in both 1H and 13C spectra. The three resorcinarenes, despite having 
very similar NMR spectra, were all unambiguously distinguished by the number of 
peaks in the 71 ppm region of the 13C NMR spectra. In this region, the oxygen-carbons 
of the newly-installed crown ether bridge were evident, having half the number of 
peaks due to the C2 symmetry of the crown resorcinarene. A signal for the benzylic 
carbon of the benzyl ether is also present in this region, and was differentiated by 
HSQC spectroscopy. The crown ether bridge is also evident on the 1H NMR spectrum, 
(46) 
n = 1 (53) 
n = 2 (54) 
n = 3 (55) 
n = 1 (50) 
n = 2 (51) 
n = 3 (52) 
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but appeared as complicated overlapping multiplets, which roughly had the expected 
integration. The possibility that these crown resorcinarene products could be dimers 
from intermolecular bridging was refuted by the fact that there were no doubling of 
peaks in the 1H NMR spectra as would be expected if two chiral resorcinarenes had 
combined. Nevertheless, for confirmation, dibenzyloxy crown-5 resorcinarene (53) 
was analysed by HRMS which recorded a main peak which corresponded to the mass 
of the intramolecularly bridged product. Furthermore, the dibenzyloxy crown 
resorcinarene products (53), (54) and (55) were confirmed at the solid state by X-ray 
diffraction on single crystals (Appendix B – 8), respectively obtained from: DCM-
petroleum spirits, THF-MeOH, and DCM-petroleum spirits. Overall, the crystal 
structures showed that these resorcinarene derivatives had a very similar basket shape 
(Figure 5.1).  
 
Figure 5.1 Overall view of crystal structures of benzyloxy crown resorcinarenes. For ORTEP view 
see Appendix B – 16. 
The two distally-bridged aromatic rings are pinched together, causing the two other 
aromatic rings to be pushed outwards from the cavity. Figure 5.2 shows that these 
aromatic rings bearing the benzyl ether groups, have been flattened out with an obtuse 
angle beyond horizontal for all three resorcinarenes. From this view, it is apparent that 
crown-6 resorcinarene (54) has a slightly distorted conformation compared to the other 
resorcinarenes, perhaps because of the odd number of ethylene glycol subunits in the 
crown-5 ether bridge. 
  
(53)    (54)            (55) 
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Figure 5.2 Crystal structures of benzyloxy crown resorcinarenes highlighting the obtuse angle of 
the benzyloxy aromatic rings. 
As shown in Figure 5.3, all three benzyloxy crown resorcinarenes have different 
lengths of crown ethers, however they have all adopted essentially the same boat 
conformation, where the pair of bridged aromatic rings have been pinched together till 
they are vertical and parallel to each other. The overall shape of the resorcinarene 
cavity appears to be largely unaffected by the length of the crown ether bridge. The 
ability for the flexible crown ethers to fold is especially evident in these crystal 
structures of the crown resorcinarenes in the solid state. The crown ether bridge is 
folded to a greater extent for the crown-7 resorcinarene (55). The flexibility of the 
crown ether renders the overall cavity of the crown resorcinarene to be more flexible 
and less well-defined. This could be a factor in the ability for the crown resorcinarene 
to contain guest molecules. 
 
Figure 5.3 Crystal structures of benzyloxy crown resorcinarenes highlighting the cavity and boat 
conformation. 
In the crystal structures of the three benzyloxy crown resorcinarenes – (53), (54), (55) 
– only (55) had a solvent molecule present in the crystal lattice. In the crystal structure 
of the crown-7 resorcinarene (55), a molecule of dichloromethane from the 
crystallisation solvent has complexed within the crown ether bridge mainly through 
interactions between the oxygens of the crown ether and hydrogens of the 
dichloromethane (Figure 5.4). This confirms the ability for the crown ether to complex 
smaller molecules. However, since this was only observed for the crown resorcinarene 
derivative with the largest crown, this suggests that a longer crown ether bridge on the 
(53)      (54)               (55) 
(53)      (54)    (55) 
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resorcinarene may provide a better receptor. Nevertheless, these observations in the 
solid state are not an accurate representation of the solution state, but rather provide a 
general guide to the complexation in solution. These crown resorcinarenes will be 
applied in solution, where there should be greater flexibility of the resorcinarene boat 
conformation, which may increase the capacity of the cavity for the containment of 
smaller guest molecules.    
 
Figure 5.4 Crystal structure of benzyloxy crown-7 resorcinarene (55) demonstrating the 
complexation of dichloromethane in the crown ether bridge. A spacefill model is shown 
on the right. 
Having accomplished the synthesis of distally-bridged crown resorcinarenes in three 
sizes, the examination of these products as potential membrane carriers for chiral drugs 
could commence. However, for the possibility of enantioselective transport, the crown 
resorcinarenes would need to be obtained as a single enantiomer. The plan for 
separating the enantiomers of the crown resorcinarene was to convert the enantiomers 
into diastereomers, separate the diastereomers, then remove the chiral moiety. 
Therefore, the attachment of a chiral moiety to the enantiomers of the crown 
resorcinarenes is required to convert them to diastereomers. As discussed in the next 
section, Section 5.2, this is most conveniently accomplished at this stage, the final 
stage of synthesis. A convenient method to attach a chiral moiety to the crown 
resorcinarenes would be to remove the benzyl ether protecting group, then attach the 
chiral moiety by esterification of the resultant phenol.  
The first attempts to remove the benzyl ether groups by reduction using Pd/C with 
either hydrazine or hydrogen gas did not show any reaction by TLC. Work up of the 
reaction mixture and 1H NMR spectroscopy of the resultant material confirmed only 
unreacted starting material. Therefore, a Birch-style reduction, using sodium metal and 
liquid ammonia, was employed. Under these harsher reduction conditions, the 
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debenzylation of the three crown resorcinarenes (53), (54), (55), was completed in 30 
minutes, and after work up, the respective target products (56), (57), (58) were 
afforded in good purity and in quantitative yield (Scheme 5.2). Poor phase separation 
in the DCM/water work up was again encountered with the crown-7 resorcinarene 
(58). This was most likely due to its increased hydrophilicity. It was discovered that 
washing out the soluble salts with water, while collecting the water-insoluble product 
by filtration provided a more effective and convenient work up procedure. 
n
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Scheme 5.2 Removal of benzyl ether protecting groups from crown resorcinarenes. 
The complete removal of the benzyl ethers was clearly apparent on the 1H NMR 
spectra (Appendix A – 62) for each of the crown resorcinarenes where the multiplets 
in the aromatic region associated with the benzyl ether were absent. In the aromatic 
region, there were only four singlets with the same integration, which represented the 
aromatic protons of the C2-symmetrical resorcinarene macrocycle. The absence of the 
benzylic carbon peak at 71 ppm in the 13C NMR spectra for the crown resorcinarenes 
provided further confirmation of the removal of the benzyl ethers.  
In the 1H NMR spectra of the three dihydroxy crown resorcinarenes, discreet 
multiplets ranging from 1.3-4.3 were apparent. These multiplets were indeed the 
methylenes of the crown ether bridge as confirmed on the HSQC spectrum (Figure 
5.5), which showed them coupling to peaks at 70 ppm in the 13C NMR spectrum. 
Although some of these multiplets were overlapped, it was evident on the HSQC 
spectra that the number of these methylene multiplets for the dihydroxy crown 
resorcinarenes (56), (57), (58) were eight, ten and twelve respectively. However in the 
13C NMR spectra, the number of peaks around 70 ppm for the crown ether methylenes 
n = 1 (53) 
n = 2 (54) 
n = 3 (55) 
n = 1 (56) 
n = 2 (57) 
n = 3 (58) 
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were half, as expected for a C2-symmetrical resorcinarene. This non-equivalence of 
the protons of the crown ether bridge may have been a result of diastereotopicity, but 
not observed for the benzyloxy crown resorcinarenes. 
 
Figure 5.5 HSQC spectrum recorded in CDCl3 of resorcinarene (56) demonstrating that the 
methylene peaks of the crown ether appear in the 1H NMR spectrum as discreet 
multiplets over a wide chemical shift. 
However, when the 1H NMR spectra of the crown resorcinarenes were recorded in 
DMSO-d6, the wide-ranging discreet multiplets became lumped together (Figure 5.6). 
Moreover, the two signals for the benzylic methine of the resorcinarene macrocycle 
have coalesced into one.  
 
Figure 5.6 1H NMR spectra of resorcinarene (56) recorded in CDCl3 (top) and DMSO-d6 (bottom). 
The coalescing of the signals has been highlighted. *Denotes solvent peaks.  
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This indicates that the phenomenon of the wide-ranging multiplets was dependent on 
the solvent used to record the 1H NMR spectrum. Unlike the benzyloxy counterparts, 
the dihydroxy crown resorcinarenes have two hydroxy groups which are able to from 
hydrogen bonds. In CDCl3, these two hydroxy groups could form intramolecular 
hydrogen bonds to the oxygens of methoxy groups on proximal aromatic rings. 
Formation of these hydrogen bonds would increase rigidity of the overall crown 
resorcinarene, which may explain the appearance of the discreet multiplets in the 1H 
NMR spectrum recorded in CDCl3. However, in DMSO-d6, a solvent which is able to 
accept hydrogen bonds, the intramolecular hydrogen bonds would be disrupted by the 
solvent, leading to greater flexibility and mobility of the crown resorcinarene. This 
could explain the lumping and coalescing of peaks in the 1H NMR spectrum recorded 
in DMSO-d6.   
Single crystals of dihydroxy crown resorcinarene (57) were obtained from DCM-
petroleum spirits. Analysis of the single crystals of (57) by X-ray diffraction confirmed 
the assignment at the solid state (Appendix B – 9). As evident in the crystal structure 
(Figure 5.7), the dihydroxy crown resorcinarene (57) has a similar basket shape to the 
dibenzyloxy counterpart. However, the dihydroxy crown resorcinarene appears to take 
on a more crown-like conformation where the non-bridged aromatic rings, have folded 
towards the cavity as a result of losing the steric bulk of the benzyl ether groups. This 
in turn causes the bridged aromatic rings to become slightly bent out of the cavity and 
are no longer vertical like in its benzyloxy precursor. Therefore, the cavity of the 
dihydroxy crown resorcinarene is wider in comparison to its benzyloxy precursor.  
 
Figure 5.7 Crystal structure of dihydroxy crown-6 resorcinarene (57). For ORTEP view see 
Appendix B – 17. 
The crown ether bridge of the dihydroxy crown-6 resorcinarene (57) is also noticeably 
closer to the resorcinarene cavity, compared to its benzyloxy precursor (54). This could 
be explained by the bending out of the bridged aromatic rings which pulls the crown 
ether bridge closer to the cavity, while the presence of free hydroxy groups would also 
 163 
 
form intramolecular hydrogen bonds with the crown ether bridge. With the crown ether 
bridge being closer to the cavity, the spacefill models (Figure 5.8) of the solid-state 
crystal structure shows that half of the cavity has become sterically inaccessible. 
However, in solution, this may not necessarily be the case, as the crown ether bridge 
should be mobile and flexible in solution. In terms of overall flexibility of the cavity, 
the cavity of the dihydroxy resorcinarene (57) would likely be less flexible than its 
benzyloxy precursor (54), due to the intramolecular hydrogen bonding.  
 
Figure 5.8 Side and top views in spacefilling mode of the dihydroxy crown-6 resorcinarene (57) 
(top) and dibenzyloxy crown-6 resorcianrene (54) (bottom) from their crystal structures. 
Outlined in yellow is the crown ether bridge which renders half of the cavity for (57) 
sterically inaccessible. Propyl chains have been omitted for clarity. 
In the crystal structure of dihydroxy crown-6 resorcinarene (57), water molecules were 
found to reside within the crystal lattice, with nothing being complexed within the 
resorcinarene cavity. The overall crystal packing was driven by hydrogen bonds 
between the free hydroxy group of the resorcinarene and the water molecules in the 
lattice. The resorcinarene molecules are connected through strong water-mediated 
hydrogen bonds involving the hydroxy groups O2B, whilst also directly interacting 
through O2D-H∙∙∙O2D weak intermolecular bonds (Figure 5.9). The resorcinarene 
molecules are packed in a head-to-head / tail-to-tail manner that is similar to the other 
resorcinarene derivatives.  
(57) 
 
 
 
(54) 
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Figure 5.9  Crystal packing of dihydroxy crown-6 resorcinarene (57). Hydrogen atoms have been 
omitted for clarity, and water molecules are represented as red spheres of arbitrary 
radius. 
5.2 Diastereomic resolution of tetramethoxyresorcinarene 
Having accomplished the synthesis of the distally-bridged resorcinarene products (56), 
(57) and (58), the investigation focused on obtaining these final products as their single 
enantiomers. The single resorcinarene enantiomers would enable enantioselective 
membrane transport to be examined.  
Enantioseparation by diastereomic resolution requires the attachment of a chiral 
moiety, followed by separation of the diastereomers, then removal of the chiral moiety. 
Therefore, the chiral moiety needs to be attached by a cleavable link, such as an ester, 
to facilitate its removal once the diastereomers are resolved. With this requirement in 
mind, esterification of the phenols provides the most convenient linkage for the 
attachment and removal of a chiral moiety.  
The chiral resolution of racemic tetramethoxyresorcinarene derivatives has been 
reported by Heaney and co-workers through conversion to camphorsulfonate 
diastereomers, which were separated by column chromatography.66 Hydrolysis of the 
diastereomers, gave the separated enantiomers in overall yields of 12-41% (Scheme 
5.3, Table 5.2, Table 5.3). In particular, the enantiomers of starting resorcinarene (1) 
were separated in an overall yield of 41% for the S enantiomer, and 18% for the R 
enantiomer. This significant discrepancy between the yields for the two enantiomers 
was attributed to the chromatographic process, since the NMR spectra of the crude 
material indicated formation of the diastereomers in equal proportions. However, in 
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one case (Table 5.2, reaction 2), diastereomers of tetracamphorsulfonates and 
tricamphorsulfonates were isolated in a 4:1:1:4 ratio, which suggested some 
enantiorecognition in the diastereomer formation, which may be due to steric bulk. It 
was also noted that diastereomers of resorcinarene derivatives with R groups bulkier 
than methyl on the 16,34,54,74 alkyloxy positions of the resorcinarene were easier to 
separate (Table 5.3, reaction 2 & 3). However, with bulky alkoxy groups, the reaction 
did not proceed further than di-substitution, despite the use of excess camphorsulfonyl 
chloride (Table 5.2 reaction 4 & 5). The incomplete tetra-substitution was again 
thought to be the result of the increased steric hindrance due to the bulky alkoxy 
groups. This result was perhaps unfortunate, since theoretically, more chiral moieties 
would amplify the diastereomic differences and improve diastereomer separation. 
Nevertheless, it is rather interesting that a proximally-functionalised resorcinarene was 
formed selectively from the various other possible products. Note, in the original 
paper, these compounds were assigned as distal however, close inspection of the NMR 
data suggests that the proximal dicamphorsulfonate regioisomers were obtained. 
The absolute configurations for some of the single resorcinarene enantiomers were 
also determined by X-ray crystallography on the corresponding separated 
diastereomers.66 The camphorsulfonate moiety, having a known absolute 
configuration, provided an internal reference that enabled the absolute configuration 
of the resorcinarene to be determined.6 Therefore, the absolute configuration of the 
single resorcinarene enantiomer can be inferred from its corresponding diastereomer, 
however its designation will flip as the removal of the camphorsulfonate groups 
reverses the priority. In the work by Heaney and co-workers, the faster-eluting 
diastereomer always had a R absolute configuration, and a more positive specific 
rotation. 
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Scheme 5.3 Chiral resolution of axially-chiral resorcinarene derivatives by chromatographic 
separation of respective camphorsulfonate diastereomers, followed by hydrolysis of the 
corresponding diastereomer.66 
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Table 5.2 Synthesis of various camphorsulfonate resorcinarene diastereomers by pyridine reflux.66  
CS-Cl (Camphorsulfonyl chloride)  AC (Absolute configuration)  *Incorrectly assigned in the original paper 
  
Diastereomer synthesis Diastereomer hydrolysis 
Reaction CS-Cl eq Camphorsulfonate Diastereomer AC Alkyl R Yield (%) Enantiomer AC Yield (%) 
1 8 Tetra 2R,4R,6R,8R n-C3H7 CH3 46 S 89 Tetra 2S,4S,6S,8S n-C3H7 CH3 23 R 78 
2 12 
Tetra 2R,4R,6R,8R n-C5H11 CH3 23 S 65 
Tetra 2S,4S,6S,8S n-C5H11 CH3 5.5 R 64 
Tri 2R,4R,6R,8S n-C5H11 CH3 4.8   
Tri 2S,4S,6S,8R n-C5H11 CH3 18   
3 8.1 Tetra 2R,4R,6R,8R n-C7H15 CH3 39 S 84 Tetra 2S,4S,6S,8S n-C7H15 CH3 17 R 70 
4 2 Tetra 2R,4R,6R,8R n-C11H23 CH3 38 S 79 Tetra 2S,4S,6S,8S n-C11H23 CH3 20 R 60 
5 3.9 Proximal* 2R,4R,6S,8S n-C5H11 CH(CH3)2 34   Proximal 2S,4S,6R,8R n-C5H11 CH(CH3)2 30   
6 12 Proximal 2R,4R,6S,8S n-C5H11 c-C5H9 23   Proximal 2S,4S,6R,8R n-C5H11 c-C5H9 23   
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Table 5.3 Synthesis of various camphorsulfonate resorcinarene diastereomers by butyllithium/THF.66  
  
Diastereomer synthesis Diastereomer hydrolysis 
Reaction BuLi Eq 
CS-Cl 
Eq Camphorsulfonate 
Diastereomer 
AC Alkyl R 
Yield 
(%) 
Enantiomer 
AC Yield (%) 
1 8.1 10.1 Tetra 2R,4R,6R,8R n-C5H11 CH3 33 S 65 Tetra 2S,4S,6S,8S n-C5H11 CH3 33 R 64 
2 2 2 
Mono 2S,4R,6R,8R n-C5H11 CH(CH3)2 25 S 89 
Mono 2R,4S,6S,8S n-C5H11 CH(CH3)2 24 R 82 
Proximal* 2R,4R,6S,8S n-C5H11 CH(CH3)2 8 S 82 
Proximal 2S,4S,6R,8R n-C5H11 CH(CH3)2 8 R 83 
3 2 2 
Mono 2S,4R,6R,8R n-C5H11 c-C5H9 23 S 75 
Mono 2R,4S,6S,8S n-C5H11 c-C5H9 22 R 78 
Proximal 2R,4R,6S,8S n-C5H11 c-C5H9 10 S 72 
Proximal 2S,4S,6R,8R n-C5H11 c-C5H9 10 R 76 
4 8.1 10.2 Proximal 2R,4R,6S,8S n-C5H11 CH(CH3)2 41   Proximal 2S,4S,6R,8R n-C5H11 CH(CH3)2 41   
5 8 10 Proximal 2R,4R,6S,8S n-C5H11 c-C5H9 28   Proximal 2S,4S,6R,8R n-C5H11 c-C5H9 28   
6 8 8 Tetra 2R,4R,6R,8R n-CH2CH(CH3)2 CH3 26 S 80 Tetra 2S,4S,6S,8S n-CH2CH(CH3)2 CH3 24 R 74 
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Table 5.3 (continued) Synthesis of various camphorsulfonate resorcinarene diastereomers by butyllithium/THF.66 
R camphorsulfonate R enantiomer  CS-Cl (Camphorsulfonyl chloride)  AC (Absolute configuration) *Incorrectly assigned in the original paper  
 
 
Diastereomer synthesis Diastereomer hydrolysis 
Reaction BuLi Eq 
CS-Cl 
Eq Camphorsulfonate 
Diastereomer 
AC Alkyl R 
Yield 
(%) 
Enantiomer 
AC Yield (%) 
7 8 8 Tetra
R 2R,4R,6R,8R n-CH2CH(CH3)2 CH3 36 R 78 
TetraR 2S,4S,6S,8S n-CH2CH(CH3)2 CH3 35   
8 1.2 1.3 
Mono 2S,4R,6R,8R n-C5H11 CH3 25   
Mono 2R,4S,6S,8S n-C5H11 CH3 25   
Proximal* 2R,4R,6S,8S n-C5H11 CH3 9 S 70 
Proximal 2S,4S,6R,8R n-C5H11 CH3 9 R 70 
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To obtain single enantiomers of the crown resorcinarenes, it is possible to perform the 
diastereomic resolution on starting resorcinarene (1), as demonstrated in the work by 
McIldowie and co-workers. However, the three steps to synthesise, separate, then 
cleave the diastereomers involves a significant amount of work, and thus the resultant 
enantio-pure material significantly increases in value. In view of this, it would be ideal 
to perform the three steps after all low-yielding steps, or at the end of synthesis. In the 
scheme to synthesise the crown resorcinarenes, there are three opportunities where the 
resorcinarene has free phenols to accommodate the attachment of a chiral moiety 
(Scheme 5.4).  
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Scheme 5.4 Opportunities for making diastereomers via phenols during the synthesis of crown 
resorcinarenes for chiral resolution. 
Separating the enantiomers at the end of synthesis would be advantageous if both 
enantiomers and diastereomers of the final product are required. However, a possible 
disadvantage would be if the yield from the three steps involved in the diastereomic 
 (34) (49) 
(46) 
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separation is low, because it would mean wastage of valuable product from the five-
step synthesis. Considering these advantages and disadvantages, resolving the 
diastereomers of the crown resorcinarenes after the five-step synthesis, appears to be 
the most attractive option, and therefore this was investigated first. Moreover, since 
the diastereomers of the crown resorcinarenes will be synthesised, they would also be 
worth investigating as potential enantioselective membrane carriers.  
5.2.1 Diastereomers of crown resorcinarenes 
Camphorsulfonate diastereomers of the crown resorcinarenes were synthesised (Table 
5.4) using the sulfonylation procedure in Section 4.3.4.1 with camphorsulfonyl 
chloride and triethylamine. The reaction proceeded smoothly, with the 1H NMR 
spectrum of the crude material clearly showing doubling of the key resorcinarene 
signals which provided strong evidence of the successful formation of the 
diastereomers. The 1H NMR spectrum also indicated that the crude product was a fairly 
pure material, since no other resorcinarene peaks were apparent, other than the 
expected diastereomers. The yields for the isolated diastereomer mixture were often 
quantitative. To separate the diastereomers, preferential solubility in various solvents 
was investigated, but yielded no success. It was discovered from a TLC screen of 
various chromatographic solvent systems, that the chromatographic separation of the 
diastereomers was very close but could be achieved by developing the same TLC plate 
in MeOH-DCM (2:98) three times. Using this solvent system via preparative TLC, all 
resorcinarene diastereomer mixtures were successfully separated in sufficient 
quantities. The diastereomic separation for these crown resorcinarene derivatives 
appeared to be very similar, with separation for the crown-5 resorcinarene being 
slightly better, and the separation slightly worse for the crown-7 resorcinarene where 
a small amount of co-eluted diastereomers could not be separated.  
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Table 5.4 Preparation, yield and specific rotation of camphorsulfonate resorcinarene 
diastereomers. 
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Resorcinarene n Yield Specific rotation (c ~1.00) 
(59a) 1 50% +48.0° 
(59b) 1 48% -11.8° 
(60a) 2 40% +46.5° 
(60b) 2 39% -16.5° 
(61a) 3 34% +56.6 
(61b) 3 22% -22.1° 
 
n = 1 (59a) 
n = 2 (60a) 
n = 3 (61a) 
 
n = 1 (59b) 
n = 2 (60b) 
n = 3 (61b) 
 
n = 1 (56) 
n = 2 (57) 
n = 3 (58) 
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Confirmation of the attachment of the camphorsulfonate group to the resorcinarene 
was clearly provided by the C=O absorbance stretch in the IR spectrum. The separation 
of the diastereomers was unambiguously confirmed by the 1H NMR spectra (Figure 
5.10) which showed complete separation of the doubled peaks. The 13C NMR spectra 
(Appendix A – 72) provided better evidence regarding the identity of the products; a 
peak around 214 ppm was recorded which is ascribed to the carbonyl carbon of the 
camphorsulfonate. The correct number of signals were observed in all 13C NMR 
spectra for the separated diastereomers. The retention of the crown ether was 
represented by the signals around 70 ppm. The complicated overlapped multiplets of 
the camphorsulfonate moiety in the 1H NMR spectra of the diastereomers were 
assigned by HSQC, DEPT-135 and 13C NMR spectra. Analysis of the diastereomers 
by polarimetry showed that the first-eluting diastereomer always had a positive 
rotation, while the second-eluting diastereomer always had a negative rotation. This 
observation follows the trend observed by Heaney and co-workers for chiral 
tetramethoxyresorcinarenes.66 An example of the specific rotation for a pair of 
separated diastereomers (60a) and (60b) was +46.5° and -16.5° respectively. 
 
Figure 5.10 1H NMR spectra recorded in CDCl3 of the diastereomeric mixture (top), first-eluting 
diastereomer (60a) (middle), and second-eluting diastereomer (60b) bottom. 
The crystallisation of diastereomers (60a) and (60b) was examined but it was only 
possible to form crystals as a diastereomic mixture. Once the diastereomers were fully 
separated, crystallisation was no longer successful, with the separated diastereomers 
only forming oily, glassy solids. The diastereomeric mixture (60a) and (60b) was 
crystallised from ethanol, and the crystal structure was determined by X-ray diffraction 
on a single crystal (Appendix B – 10). The crystal structure (Figure 5.11) confirms 
the structure of the diastereomers, which adopt the boat conformation. The distal pair 
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of aromatic rings bearing the sterically-bulky camphorsulfonate groups have been 
flattened out near horizontal, in a similar manner to the tri-TBDMS resorcinarene (35). 
 
Figure 5.11 Crystal structure of a diastereomer of camphorsulfonate crown-6 resorcinarene (60a) or 
(60b), obtained from a crystal of both diastereomers. Colour code: C, grey; O, red; S, 
gold. Hydrogen atoms have been omitted for clarity. For ORTEP view see Appendix B 
– 18. 
The crystal packing of the diastereomeric mixture reveals that the two diastereomers 
have packed together in a manner that is complementary to the chirality of the 
resorcinarene. As shown in Figure 5.12 the resorcinarenes do not pack head-to-head / 
tail-to-tail, but the two diastereomers interlock together via the camphorsulfonate 
substituents. The tendency for a diastereomer to pack in an interlocking, 
complementary manner with the other diastereomer, may be responsible for the 
difficulty in crystallising the separated diastereomers. 
 
Figure 5.12 Crystal packing of resorcinarene diastereomers (60a) and (60b) crystallised from 
ethanol. Colour code: resorcinarene macrocycle, orange; crown ether, red; propyl tails, 
green; camphorsulfonate, dark-blue and light-blue for the two different diastereomers. 
However, with a trace amount of the other diastereomer present from slightly co-eluted 
material, the crystallisation was difficult but was successful from diethyl ether. 
Perhaps the trace of the other diastereomer provided a complementary crystal packing 
which enabled a crystal of the diastereomeric mixture to form. This diastereomeric 
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crystal may have acted as a seed crystal which enabled the pure diastereomer to 
crystallise. These crystals of slightly co-eluted diastereomers (60a) and (60b), 
obtained from ether, were analysed by X-ray crystallography to determine the absolute 
configuration of the separated camphorsulfonate resorcinarenes. Disappointingly, 
analysis of the crystals of (60b) revealed that both diastereomers were still present in 
the unit cell. The co-crystallisation of these diastereomers was rather surprising, since 
the co-crystallisation of covalent diastereomers is reportedly a rare occurrence.167 An 
alternative method for the determination of the absolute configuration of chiral 
resorcinarenes has been reported by Neri and co-workers168, 169 using electronic 
circular dicroism with comparison of the spectra with computational predictions. 
Samples of separated diastereomers (59a) and (59b) were sent to Neri’s group for 
determination of absolute configuration, with results still outstanding. In lieu of these 
results, the absolute configuration of these crown resorcinarene camphorsulfonates has 
been tentatively assigned based on the similar work by McIldowie and co-workers,66 
who consistently recorded a R configuration and more positive specific rotation for the 
faster-eluting diastereomer. 
Although the camphorsulfonylation reaction proceeded smoothly to give clean 
products in quantitative yield, the reaction was capricious, particularly on scaling up. 
A smooth reaction was indicated by a TLC showing the target diastereomers with 
minimal baseline. Moreover, the aromatic region of the 1H NMR spectrum of the crude 
product clearly showed doubled resorcinarene peaks with an almost-flat baseline. 
Unsuccessful reactions could be distinguished by the appearance of spots near the 
baseline on TLC, as wells as lumps of peaks in the aromatic region of the 1H NMR 
spectra. These observations point to the formation of undesirable material which 
results in significant reduction of the yield of the target diastereomers, therefore 
rendering the reaction unsuccessful. To recify this inconsistency on reaction scale-up, 
the triethylamine addition was performed with cooling of the reaction mixture in an 
ice bath, as well as decreasing the concentration of the reaction mixture; unfortunately 
these measures were of no effect. The reaction appeared to be the most reliable on a 
small 20 mg scale, which therefore necessitated multiple small-scale reactions to 
obtain the required quantities of diastereomers. For some reaction products, a small 
amount of impurity co-elutes with the diastereomeric mixture. This impurity was 
visible as small peaks in the aromatic region of the 1H NMR spectrum, and appears to 
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be a resorcinarene-based by-product. Removal of this impurity was challenging but 
could be partially removed by repeatedly subjecting the material to preparative TLC 
with MeOH-toluene (5:95). 
5.2.2 Diastereomers of synthetic intermediates of crown resorcinarene  
Although the camphorsulfonate diastereomers of the crown resorcinarenes have been 
synthesised and separated, in hope of finding better diastereomic separation, the 
synthesis of diastereomers of intermediates during the crown resorcinarene synthesis 
was explored. Such resorcinarene diastereomers would not be considered as potential 
membrane carriers but would serve as a better method to synthesise single enantiomers 
of the crown resorcinarenes. 
Making diastereomers of the distal-TBDMS resorcinarene (34) has the potential for 
the chiral moiety to also serve as the replacement protecting group for the TBDMS. 
This would be an advantage as it would integrate the diastereomer formation and 
hydrolysis into the synthetic procedure (Scheme 5.5), which would enable enantio-
pure crown resorcinarenes to be synthesised without additional synthetic steps. 
Furthermore, it would also provide three possible intermediates at which the 
diastereomers could be separated. However, if a cleavable chiral moiety such as a 
camphorsulfonate were to function as a replacement protecting group for the TBDMS, 
it needs to be stable under the Cs2CO3/DMF conditions for bridging. This was a cause 
for concern since the methanesulfonate group was hydrolysing under these conditions 
(Section 4.2.1). Nevertheless, the camphorsulfonate group, being bulkier, may be 
more resilient to hydrolysis, and thus this was investigated. 
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Scheme 5.5 Potential modification of the synthetic procedure where the chiral moiety could also 
function as the protecting group that replaces the TBDMS. 
Distal-TBDMS resorcinarene (34) was subjected to the general camphorsulfonylation 
procedure. Despite using a vast excess of 16 equivalents of camphorsulfonyl chloride, 
the TLC of the reaction mixture still showed a spot of equal retention to the starting 
resorcinarene. Nevertheless, the reaction was worked up, and a crude product of at 
least four compounds by TLC was obtained. However, the 1H NMR spectrum of the 
crude material showed no starting resorcinarene, but the key resorcinarene peaks were 
doubled which suggested the formation of diastereomers. The four UV-active spots 
were separated by preparative TLC, but only the highest-Rf spot contained the mixture 
of the resorcinarene diastereomers (62) in a combined yield of 50%, without the other 
impurities (Appendix A – 86). Experimentation of chromatographic solvent systems 
 
(62)
(34) 
 178 
 
yielded no separation of the purified diastereomer mixture (62). Inspite of the low 
yield, difficult purification, and unsuccessful diastereomer separation, it was thought 
that purification and separation of the diastereomers may be easier after hydrolysis of 
the TBDMS protecting groups. Therefore, a crude diastreomeric mixture of (62) was 
subjected to hydrolysis via Cs2CO3/DMF to also test the stability of the 
camphorsulfonate esters under the conditions for bridging. The 1H NMR of the 
hydrolysis crude product indicated removal of the TBDMS groups, but the 
resorcinarene signals appeared as a complex mixture. Unfortunately, this indicates that 
the camphorsulfonates, like the methanesulfonates (Section 4.2.1), were also 
hydrolysing under the Cs2CO3/DMF reaction conditions used for bridging. 
Consequently, the idea of forming camphorsulfonate diastereomers on distal-TBDMS 
resorcinarene (34), then utilising the camphorsulfonate groups as protecting groups for 
the bridging reaction was proven to be unsuccessful on account of the low yield, 
unsuccessful diastereomer separation, and instability of the camphorsulfonate groups. 
The final, and least attractive opportunity for making diastereomers in the synthetic 
scheme is to make diastereomers of the dibenzyloxyresorcinarene (46). This is the least 
attractive opportunity because dibenzyloxyresorcinarene (46) is the precursor for the 
lower-yielding bridging reaction. Nevertheless, the potential for easier diastereomer 
separation was the motivation for investigating the synthesis of camphorsulfonates of 
this resorcinarene. Dibenzyloxyresorcinarene (46) was subjected to the general 
camphorsulfonylation procedure to give a crude mixture which was chromatographed 
by preparative TLC which delievered the purified diastereomers in a combined yield 
of 78%. The characteristic doubling of peaks in the 1H NMR spectrum (Appendix A 
– 87) confirmed the successful synthesis and isolation of the diastereomers. 
Experimentation with chromatographic solvent systems unfortunately yielded no 
resolution of the diastereomers. Therefore, the formation of diastereomers on the 
crown resorcinarene final product, as was first investigated, provides the best method 
for the synthesis and separation of the resorcinarene diastereomers in sufficient 
quantities. 
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5.3 Synthesis of bis-crown resorcinarenes 
Since bis-crown resorcinarenes can be simply synthesised by a single step 
procedure,102, 103 bis-crown resorcinarene derivatives were also synthesised (Figure 
5.13). These bis-crown resorcinarenes would be assessed as membrane carriers for 
comparison. Compared to the distally-bridged crown resorcinarenes, these bis crown 
resorcinarenes have a more open cavity, and thus are expected to be inferior membrane 
carriers.  
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Figure 5.13  Synthesis of bis-crown resorcinarenes. 
The successful synthesis of the target bis-crown resorcinarenes was demonstrated by 
the expected C2 symmetry of the product. This was apparent by the doubling of the 
peaks in the aromatic region of the 1H NMR spectrum (Appendix A – 87), from two 
to four, compared to the starting resorcinarene. The C2 symmetry also rendered the 
two crown ether moieties to be equivalent, with the sixteen carbons for bis-crown-5 
resorcinarene (63) appearing as eight CH2 peaks around 70 ppm in the DEPT-135 
spectrum. 
5.4 Membrane transport experiments 
Having accomplished the synthesis and separation of the camphorsulfonate 
diastereomers of crown 5-7 resorcinarenes in sufficient amounts, the investigation 
progressed to examining all synthesised crown resorcinarenes as membrane carriers 
for an appropriate chiral drug. The resorcinarene which demonstrates the greatest 
membrane transport will be obtained as single enantiomers via hydrolysis of the 
corresponding separated diastereomers. Then both single enantiomers would be 
examined as membrane carriers to determine if there was any enantioselectivity in the 
membrane transport. As discussed in Section 1.1.6, the membrane-based separation 
 
n = 1 (50)
n = 2 (51)
n = 3 (52)
n = 1 (63) 23% 
n = 2 (64) 8.6%
n = 3 (65) 16% 
(1) 
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technique was chosen for the many advantages such as its simplicity, low cost, 
continuous operation, industrial scalability, and applicability to calixarenes.  
Since the membrane carrier is a crown resorcinarene, the guest racemic drug 
theoretically needs to have functional groups and a shape which would complement 
binding with the host resorcinarene crown. Regarding functional groups, aromatic 
rings are able to π-stack with other aromatic rings, as well as bind with ammonium 
species through electrostatic interactions. On the other hand, crown ethers are known 
to form hydrogen bonds through the multiple oxygen atoms which act as hydrogen 
bond acceptors. Based on this theoretical reasoning, a starting point for a racemic drug 
would be one with an ionisable amine group which could bind in the crown ether or in 
the electron-rich resorcinarene cavity. Additionally, having an aromatic ring would 
provide potential for π-stacking inside the resorcinarene cavity, while also enabling 
the transport rate of the drug to be monitored by UV-vis spectroscopy. Regarding 
shape, the racemic drug should not be bulky, but should be linear so that it can fit into 
the crown resorcinarene, which has a crown conformation. The chiral centre of the 
drug should also be fairly close to the functional groups that would bind with the 
resorcinarene to enable maximum chiral interaction between host and guest that should 
lead to chiral recognition.  
In terms of structure and functional groups, salbutamol (Figure 5.14) may be a suitable 
racemic drug candidate for this membrane transport investigation. salbutamol is 
significant because it is the common drug used to treat asthma and chronic obstructive 
pulmonary diseases. It works by relaxing the constricted airway muscles, causing 
dilation of the airway, allowing the patient to breathe. In vitro studies of (S)-salbutamol 
suggest it produces pro-inflammatory effects,8 as well as muscle-spasm effects which 
undermines the therapeutic muscle-relaxing effect of the (R) enantiomer.9, 10 However, 
these advantages of enantio-pure (R)-salbutamol (Levosalbutamol) over racemic 
salbutamol has not been clearly evidenced in various clinical studies, which have 
yielded contradictory results. Some clinical studies have concluded that (R)-
salbutamol provides no advantage in effectiveness and safety over racemic 
salbutamol,170, 171 while others have suggested otherwise.172, 173 This is due to the 
presence of many factors in a clinical setting and therefore the clinical advantages of 
(R)-salbutamol over racemic salbutamol is still being studied and debated. One 
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definitive factor limiting the use of (R)-salbutamol is the significantly greater cost 
compared to racemic salbutamol. In one clinical study, the total cost of treatment was 
$8003 with (R)-salbutamol, versus $5772 with racemic salbutamol, a 38% increase.171 
The additional expense is attributed to the additional steps required for 
enantioresolution, which is accomplished by the diastereomic crystallisation of an 
intermediate in the synthesis of (R)-salbutamol.174  
OH
OH
OH
NH OH
OH
OH
NH
 
Figure 5.14 The structures of (R)-salbutamol (left) and (S)-salbutamol (right). 
Studies regarding the diffusion of salbutamol across a membrane are present in the 
literature. Corrigan and co-workers have discovered that the diffusion of salbutamol 
sulfate can be enhanced by the application of an electric current across the membrane, 
with the quantity of salbutamol diffusing across being proportional to the current 
density applied.175 In further work, Corrigan and co-workers have shown that 
salbutamol sulfate diffused through hydrophobic membranes at a slower rate 
compared to hydrophilic membranes.176 The effect of the counter anion on the 
diffusion of salbutamol was briefly investigated by Patel et al.,177 who showed that a 
hydrophobic anion (1-hydroxy-2-napthoic acid), instead of the standard hydrophilic 
sulfate anion, decreased the diffusion of salbutamol across a regenerated cellulose 
membrane. In spite of the examples in the literature, the membrane transport of 
salbutamol that is facilitated by a membrane carrier appears to be an unprecedented 
investigation. 
The membrane transport of salbutamol was investigated through a bulk liquid 
dichloromethane membrane in a U-tube apparatus. UV-visible spectrometry was used 
to monitor the appearance of salbutamol in the receiving phase. In particular, the 
absorbance at 224 nm was monitored, since it provides a more accurate estimate of 
salbutamol at very low concentrations (<0.01 mg/mL),178 which was the case for all 
experiments. Because of the many variables involved, much experimentation was 
required to develop a reliable method from the running of the transport experiments to 
the monitoring of the appearance of salbutamol by UV-visible spectrometry.  
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Preliminary investigations into some factors of the membrane transport of salbutamol 
indicated that: 
 A blank membrane solvent of chloroform compared to dichloromethane 
exhibited a significantly faster rate of salbutamol self-transport, thus 
dichloromethane appears to be better membrane solvent. 
 A source phase of 1 M HCl compared to water caused a significant increase of 
the salbutamol transport with resorcinarene (57) in dichloromethane. This 
observation confirms the initial assumption that the chloride salt is transported 
better than the more hydrophilic sulfate salt that the salbutamol comes in.  
 U-tube glassware of slightly different dimensions (±5 mm) may have an impact 
on the membrane transport, as suggested by some limited evidence. 
 A receiving phase of 1 M HCl compared to water showed a slightly lower rate 
of transport with resorcinarene (57) in dichloromethane. This was an 
anticipated result because a HCl receiving phase already contains ions, and so 
it would receive ions less readily compared to a receiving phase that is pure 
water (empty of ions). 
 Conducting the membrane transport experiments in a warm water bath to 
increase the rate of transport appears to give erratic results. 
 Monitoring of the transport by conductivity gave erratic results. A consistent 
result could not be established in an experiment with a blank dichloromethane 
membrane and a 1 M HCl source phase. The erratic results were likely due to 
the passive diffusion of HCl through the dichloromethane membrane. 
 Too much crown resorcinarene in the dichloromethane membrane caused it to 
precipitate over time, and float through to the top of the aqueous layers. A 
concentration of about 1.5 mg/mL of the crown resorcinarene appeared to be 
the ideal amount, however a little precipitation was still observed, particularly 
for dihydroxy crown-7 resorcinarene (58). 
These factors could be further investigated, however at this stage, a protocol that would 
give reasonably consistent results was required. After much experimentation, a 
protocol for the experiments was established using dichloromethane (20 mL) as the 
membrane solvent, with crown resorcinarene (~30 mg, 0.0277 mmol), salbutamol in 5 
equivalents, a source phase of HCl (5 mL, 1 M), and a receiving phase of MilliQ water 
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(5 mL). With these conditions, the fifteen crown resorcinarene derivatives (Table 5.5) 
were monitored over a week for the ability to carry salbutamol hydrochloride across a 
bulk liquid dichloromethane membrane. The results of the investigation into the 
membrane transport of salbutamol with the resorcinarene derivatives are shown in 
Figure 5.15 (Appendix C – 1). These results were an average of multiple replicate 
experiments. Comparison of the absorbance at 224 nm with a literature calibration 
curve178 enabled approximation of the amount of salbutamol present in the receiving 
phase. With five equivalents of salbutamol to resorcinarene, the salbutamol in the 
receiving phase was very low; less than 0.1% of the salbutamol was transported after 
a week. The results would have a greater certainty if the salbutamol was transported 
in a greater amount. Therefore, to increase the amount of salbutamol transported to the 
receiving phase, all experiments were conducted with double the equivalents of 
salbutamol to resorcinarene. With 10 equivalents (Appendix C – 17), there was more 
salbutamol being transported as indicated by an increase in UV-vis absorbance 
(Figure 5.16), however the transport yield of salbutamol was still very low, still being 
less than 0.1% after a week. Moreover, after running the experiments with 10 
equivalents of salbutamol for a week, a white precipitate appears at the source phase 
– membrane interface. This was also apparent for the blank dichloromethane 
membrane, leading to the conclusion that the salbutamol is slowly precipitating over 
time. Nevertheless, this precipitation was observed after a week and should not affect 
the results during the week.  
Table 5.5 List of resorcinarenes investigated as membrane carriers for salbutamol hydrochloride. 
 Crown-5n = 1 
Crown-6
n = 2 
Crown-7
n = 3 
nO
O
OO
O
O
O O
H7C3
H7C3C3H7
C3H7
O
O
O
R
R
R = Bn (53) (54) (55) 
R = H (56) (57) (58) 
R = 
camphorSO2 (59a) (60a) (61a) 
R = 
camphorSO2 (59b) (60b) (61b) 
Bis-crown (63) (64) (65) 
Parent resorcinarene (1) was also investigated. 
 
  
184
 
Figure 5.15 Comparison of resorcinarenes as membrane carriers with 5 equivalents of salbutamol hydrochloride. Averages of replicate experiments. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 1 2 3 4 5 6 7
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
2
4
 
n
m
Days
Crown‐5
0 1 2 3 4 5 6 7Days
Crown‐6
0 1 2 3 4 5 6 7Days
Crown‐7
● (53) 
● (56) 
● (59a)
● (59b)
● (63) 
● (54) 
● (57)  
● (60a)  
● (60b)  
● (64) 
● (1) 
● Blank DCM
● (55) 
● (58) 
● (61a) 
● (61b) 
● (65) 
  
185
  
Figure 5.16  Comparison of resorcinarenes as membrane carriers with 10 equivalents of salbutamol hydrochloride. Averages of replicate experiments. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 1 2 3 4 5 6 7
A
b
s
o
r
b
a
n
c
e
 
a
t
 
2
2
4
 
n
m
Days
Crown‐5
0 1 2 3 4 5 6 7Days
Crown‐6
0 1 2 3 4 5 6 7Days
Crown‐7
   ● (53) 
● (56) 
● (59a)
● (59b)
● (63) 
● (54) 
● (57)  
● (60a)  
● (60b)  
● (64) 
● (1) 
● Blank DCM
● (55) 
● (58) 
● (61a) 
● (61b) 
● (65) 
● (58) outlier 
 186 
 
The UV-vis analysis of the receiving phases of the membrane transport experiments 
have shown that all crown resorcinarenes were enhancing the membrane transport of 
salbutamol to different extents compared to the blank dichloromethane control. Even 
the parent resorcinarene (1) appeared to be enhancing the salbutamol transport, albeit 
having a rather negligible enhancement, as expected. Across all the crown 
resorcinarenes, the best transporters generally appear to be the dibenzyl and dihydroxy 
crown resorcinarenes, followed by the camphorsulfonate diastereomers, then the bis-
crown resorcinarenes. The bis-crown resorcinarenes were expected to be the poorest 
transporters because of their open cavities. The crown-5 resorcinarenes diastereomers 
(59a) and (59b) were an exception, being the worst transporters in their class. This 
may be due to the relatively small cavity of the crown-5 resorcinarene being obstructed 
by the bulky camphorsulfonate group. In terms of size, crown-6 resorcinarenes 
generally appeared to be better transporters, which may suggest that a resorcinarene 
with this crown offers a better fit for salbutamol. Generally, the transport between 
resorcinarene diastereomers appears to be noticeably different. In particular, the 
enhancement in transport appears to switch between crown-5 resorcinarenes (59a) and 
(59b) when the equivalents of salbutamol were changed from 5 to 10.  
As shown in the preliminary membrane transport experiments, there were many 
variables involved in the setup, running, and analyses of these experiments. 
Considering this, together with the low level of salbutamol present, the uncertainties 
of these results are likely to be relatively high. Therefore, care was taken to identify 
and minimise unwanted variables. To assess the repeatability of the experiments, each 
experiment was replicated till consistent results were apparent. For most experiments, 
this was accomplished after two or three replicates, however, more variation was 
encountered for some experiments. These variations could be due to some 
undiscovered factor, or could be inherent to the particular resorcinarene derivative.  
For example, the experiment with resorcinarene (58) with 10 equivalents of salbutamol 
(Figure 5.16) produced a set of results which had a lower transport than with the blank 
dichloromethane. These were deemed to be outliers, which may have been caused by 
an undiscovered entity. All things considered, reasonably consistent results were 
obtained from these experiments, and these results provide a general, qualitative 
indicator of the trends. 
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Despite the uncertainties, a definitive observation in all these results is that a small 
amount of salbutamol was being transported across the membrane. Over an entire 
week, less than 0.1% of the salbutamol was transported by the membrane carrier as 
well as through passive diffusion. In comparison, Adhikari et al.,28 reported the a best 
transport yield of 11% over 8.3 days for their system. This lack of transport of 
salbutamol by the crown resorcinarenes suggests that there was insufficient binding of 
the salbutamol to the resorcinarene. The salbutamol may have been carried across the 
membrane by weak association to the crown resorcinarene, rather than by being carried 
within its cavity. Perhaps the anticipated hydrogen bonding and π-stacking did not 
provide sufficient binding interactions needed for the binding and transportation of 
salbutamol. The examples of membrane carriers for organic molecules in the literature, 
mentioned in Section 1.2.3, often possess acid functionalities such as a carboxylic 
acid,57 a phosphonic acid,28, 52 or a boronic acid.56 This is because the acid functionality 
facilitates stronger electrostatic binding interactions as well as maintaining charge 
balance by proton exchange. The inclusion of an acid functionality on the crown 
resorcinarene would be a next synthetic step in its investigation as a potential 
membrane carrier. On the other hand, the size of the resorcinarene cavity, its 
conformation, and the arrangement of the functional groups about the resorcinarene 
may not have provided a good fit for salbutamol. As a basic starting point, it was 
roughly speculated that salbutamol would bind within the cavity of the resorcinarene, 
however currently, no definitive evidence exists to determine if and how this would 
happen. Therefore, the binding of salbutamol with the resorcinarene needs to be 
investigated in a more informative way that would shed light to how the binding 
occurs. This information would enable more efficient design of the membrane 
transport experiment and the synthesis of a membrane carrier with a complimentary 
shape and functional-group arrangment. 
5.4.1 NMR titrations of crown resorcinarenes with salbutamol sulfate 
It would be ideal if the binding of the salbutamol and resorcinarene could be observed 
as a crystal structure, since that would provide a clear picture of the interaction. An 
attempt to obtain crystals of an inclusion complex was however, unsuccessful. 
Therefore, NMR spectroscopy, was utilised for the possibility to provide binding 
information, as well as a screening method for combinations of host and guest. 
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To probe the binding interactions of the dibenzyloxy and dihydroxy crown 
resorcinarenes with salbutamol, 1H NMR titrations of the crown resorcinarenes with 
salbutamol sulfate were conducted in DMSO-d6. In this titration, salbutamol sulfate 
was added in increments of up to 12 equivalents to a solution of the crown 
resorcinarene, while monitoring by 1H NMR spectroscopy. The titration of dihydroxy 
crown-6 resorcinarene (57) at first glance appeared to demonstrate binding of the 
salbutamol and resorcinarene, as indicated by significant shifting of the salbutamol 
peaks in the 1H NMR spectra (Figure 5.17).  
 
Figure 5.17 1H NMR spectra of the titration of dihydroxy crown-6 resorcinarene (57) with 
salbutamol sulfate in DMSO-d6. 
Initially, it was thought that this confirmed the result from the membrane transport 
experiments of resorcinarene (57) being one of the best salbutamol membrane carriers. 
However, in the titration spectra, the peaks of the resorcinarene were mostly unmoved. 
The resorcinarene peak with the greatest shift was the peak originally at 6.43 ppm, 
which shifted to 6.47 ppm after the addition of 12 equivalents of salbutamol sulfate 
(Figure 5.18). This shift of 0.04 ppm was a meager shift compared to the work by 
Adhikari et al. In their work, the best membrane carrier and guest combination 
produced a shift of about 0.1 ppm in the peaks of the calixarene host with 2 equivalents 
of the guest.28 
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Figure 5.18 Expansion of the 1H NMR titration shown in Figure 5.17. The resorcinarene peak with 
the greatest shift is highlighted.  
The titrations of the crown-5 and crown-7 derivatives of the dihydroxyresorcinarenes 
yielded similar results (Figure 5.19). It was puzzling that significant shifts were 
consistently observed for the salbutamol peaks, while only a small shift was observed 
for the resorcinarene peak.  
 
Figure 5.19 Comparison of the greatest-shifted resorcinarene peak from 1H NMR titrations of 
salbutamol sulfate with dihydroxy crown 5-7 resorcinarenes in DMSO-d6. 
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A search of the literature revealed a very helpful article by Thordarson179 who cautions 
of the possibility for guests to aggregate in solution, and to examine this by performing 
trial titrations of the guest alone over a large range of concentrations. Therefore, the 
titration of salbutamol sulfate alone in DMSO-d6 was performed, and the results 
(Figure 5.20) demonstrate that the salbutamol peaks were shifting with increasing 
concentration, confirming the suspicion of aggregation of salbutamol sulfate in 
solution. Therefore, the consistently observed shifts in the salbutamol peaks were an 
invalid indicator of the interaction of salbutamol with the resorcinarene. Nevertheless, 
the relatively small shift of the resorcinarene peak is still a valid indicator which shows 
a small interaction of the resorcinarene with salbutamol in dimethylsulfoxide. 
 
Figure 5.20 1H NMR spectra of the titration of salbutamol sulfate alone in DMSO-d6. 
1H NMR titrations were also performed for dibenzyloxy crown 5-7 resorcinarenes 
(53), (54), (55) with salbutamol sulfate in DMSO-d6. The usual shifts were observed 
for the salbutamol peaks, however the resorcinarene peaks remained completely 
unmoved even with up to 12 equivalents of salbutamol sulfate. The apparent lack of 
interaction in the 1H NMR titration seems contradictory to the membrane transport 
results which shows similar salbutamol transport by both dibenzyloxy and dihydroxy 
derivatives of the crown resorcinarene. However, these 1H NMR titrations, being 
conducted in DMSO-d6, may not be an accurate representation of the membrane 
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transport process which was conducted in dichloromethane. Dimethylsulfoxide was 
used for these 1H NMR titrations for the sake of solublility of the salbutamol sulfate. 
Unlike dichloromethane, dimethylsulfoxide is a coordinating solvent which may 
solvate the salbutamol and prevent its interaction with the resorcinarene. In fact, as 
shown in Figure 5.6, a change of the NMR solvent from CDCl3 to DMSO-d6 resulted 
in a significant difference in the 1H NMR spectra of the dihydroxy crown 
resorcinarenes. The conformation of the resorcinarenes appears to be impacted by the 
solvent, and thus this may provide some supporting evidence for the hypothesis that 
the observed lack of binding in the 1H NMR titrations could be due to the solvating 
effect of the dimethylsulfoxide solvent. Further NMR titration work is required to 
ascertain these suspicions. 
5.4.2 Investigation of crown resorcinarenes as enantioselective membrane 
carriers for the chiral resolution of salbutamol 
Although there was only less than 0.1 mg of salbutamol present in the receiving phase, 
this amount is sufficient for analysis by chiral HPLC to determine if there was any 
enantioselectivity in the salbutamol membrane transport. Of all the resorcinarenes 
examined as membrane carriers, the dihydroxy crown-6 resorcinarene (57) appears to 
be one of the best membrane carriers for salbutamol. Therefore, to examine if 
resorcinarene (57) could enantioselectively transport salbutamol, the enantiomers of 
resorcinarene (57) need to be separated. This could be achieved by simple base-
catalysed hydrolysis of the sulfonate esters of the corresponding crown-6 
resorcinarene diastereomers (60a) and (60b) which have already been separated. As 
per the procedure by McIldowie and co-workers,66 the separated diastereomers (60a) 
and (60b) were both subjected to hydrolysis (Scheme 5.6), delivering the 
corresponding single enantiomers (57a) and (57b) in essentially quantitative yield in 
good purity after work up.  
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Scheme 5.6 Synthesis of single enantiomers of dihydroxy crown-6 resorcinarene (57a) and (57b) via 
hydrolysis of the separated diastereomers (60a) and (60b). 
The single enantiomers (57a) and (57b) were both confirmed by 1H NMR 
spectroscopy, with both having identical spectra which matched the spectrum of 
racemic (57). The two products were also confirmed to be enantiomers of each other 
with both giving opposite specific rotations of essentially the same magnitude.  
The two single enantiomers (57a) and (57b) were then examined as enantioselective 
membrane carriers under the same conditions with 3.7 equivalents of salbutamol. After 
5 days, the receiving phases were analysed by chiral HPLC, but unfortunately revealed 
equal proportions of both salbutamol enantiomers (Figure 5.21).  
(57a), [α]D -20.2° (60a)
(60b) (57b), [α]D +21.4° 
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Figure 5.21 HPLC chromatograms of the receiving phases from the membrane transport of 
salbutamol with resorcinarene single enantiomers (57a) (top) and (57b) (middle). The 
bottom trace is of salbutamol sulfate for reference. 
The six separated diastereomers, being optically active, were also examined as 
enantioselective membrane carriers. The receiving phases from the earlier membrane 
transport experiments with the separated diastereomers were analysed by chiral HPLC 
but were also revealed to contain the salbutamol enantiomers in equal proportions. The 
chromatograms for the membrane transport experiments with 10 equivalents of 
salbutamol appeared to contain more baseline impurity peaks compared to the 
experiments with 5 equivalents. Nevertheless, the chromatograms for both 5 and 10 
equivalents of salbutamol demonstrated that there was no enantioselective transport 
by any of the separated diastereomers. The lack of enantioselective membrane 
transport by these enantio-pure chiral cavities (57a) and (57b), including the six 
diastereomers, may be due to the crown resorcinarene being too flexible, and thus able 
to flex and accommodate both enantiomers. This lack of enantioselectivity may also 
be due to the salbutamol associating on the outside of crown resorcinarene without 
engaging with the chirality of the crown resorcinarene cavity. 
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In this chapter, the synthesis of distally-bridged crown 5-7 resorcinarenes from 
distally-functionalised resorcinarene (46) was described. Camphorsulfonate 
diastereomers of the three sizes of crown resorcinarenes were also synthesised and 
separated. Moreover, bis-crown 5-7 resorcinarenes were synthesised for comparison 
of their membrane transport capabilities. All fifteen of these crown resorcinarenes 
were then investigated as membrane carriers for salbutamol, with all of them 
exhibiting salbutamol transport to various degrees. Although, the transport yield of 
salbutamol for these crown resorcinarenes was very low, this was the first 
demonstration of a bulk liquid membrane carrier for salbutamol. This indicates that 
the binding interactions between the crown resorcinarenes and salbutamol were not 
sufficiently strong. Perhaps stronger interactions, such as electrostatic interactions via 
a carboxylic acid functionality on the resorcinarene, is needed. However, these 
functional groups that facilitate binding need to be located and arranged on the 
resorcinarene in a manner which provides a good fit for salbutamol. Therefore, the 
interaction of these crown resorcinarene derivatives with salbutamol was briefly 
investigated via NMR titrations, which suggested a small binding for the dihydroxy 
crown resorcinarenes. Despite the low transport yield, the enantioselective transport 
of salbutamol was investigated by performing the membrane transport with single 
enantiomers of one the best membrane carriers. Analysis of the receiving phase by 
chiral HPLC unfortunately indicated no separation of the salbutamol enantiomers. 
Perhaps the salbutamol did not bind to the resorcinarene in a way which was impacted 
by the chirality of the resorcinarene. Or perhaps the crown resorcinarene was 
conformationally too flexible and able to accommodate both salbutamol enantiomers. 
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5.5 Experimental 
5.5.1 General procedure for the synthesis of poly(ethylene glycol) 
ditoluenesulfonates 
The synthesis was performed according to the literature.163 To a solution of 
poly(ethylene glycol) (1 eq) and p-toluenesulfonyl chloride (2 eq) dissolved in 
dichloromethane was added powdered potassium hydroxide (8 eq) in many small 
portions while in an ice bath. The potassium hydroxide was added over 30 minutes to 
keep the temperature of the reaction mixture below 5°C. The reaction mixture was 
then stirred at 0°C open to air for 3 hours. After, water was added to the reaction 
mixture, and the layers were separated. The aqueous layer was extracted twice with 
dichloromethane. The combined organic extracts were washed with water, dried 
(MgSO4), filtered, and the solvent removed under reduced pressure to give the product 
as a mainly colourless oil. 
5.5.1.1 Tetra(ethylene glycol)ditoluenesulfonate (50) 
The general procedure was applied with tetra(ethylene 
glycol) (10.0 g, 0.0515 mol) and p-toluenesulfonyl 
chloride (19.5 g, 0.102 mol), dichloromethane (50 mL), 
and potassium hydroxide (23.4 g, 0.417 mol) to give 
(50) (16.1 g, 62%) as a mainly colourless oil: 1H NMR (CDCl3) δ 2.44 (s, 6 H, CH3), 
3.54-3.57 (m, 6 H, OCH2), 3.63-3.74 (m, 6 H, OCH2), 4.12-4.20 (m, 4 H, OCH2), 7.31-
7.36 (AA’BB’, 4 H, ArH), 7.76-7.82 (AA’BB’, 4 H, ArH). 
5.5.1.2 Penta(ethylene glycol)ditoluenesulfonate (51) 
The general procedure was applied with 
penta(ethylene glycol) (5.01 g, 0.021 mol), 
toluenesulfonyl chloride (8.1 g, 0.043 mol), 
dichloromethane (25 mL) and potassium 
hydroxide (9.5 g, 0.169 mol) to give (51) (7.34 g, 64%) as a mainly colourless oil: 1H 
NMR (CDCl3) δ 2.44 (s, 6 H, CH3), 3.58 (s, 6 H, OCH2), 3.61-3.73 (m, 10 H, OCH2), 
3.13-4.18 (m, 4 H, OCH2), 7.31-7.36 (AA’BB’, 4 H, ArH), 7.77-7.82 (AA’BB’, 4 H, 
ArH); 13C NMR (CDCl3) δ 21.8 (CH3), 68.8, 69.4, 70.7, 70.7, 70.9 (OCH2), 128.1, 
130.0, 133.2, 144.9 (C, Ar). 
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5.5.1.3 Hexa(ethylene glycol)ditoluenesulfonate (52) 
According to the procedure by Ouchi et al.,180 
to a solution of hexaethylene glycol (3.0 g, 
0.011 mol) and sodium hydroxide (1.20 g, 
0.03 mol) dissolved in water (50 mL) was 
added dropwise a solution of p-toluenesulfonyl chloride (3.78 g, 0.0198 mol) in 
tetrahydrofuran (50 mL), while keeping the temperature below 5°C in an ice bath. The 
reaction mixture was stirred at 0-5°C in an ice bath for 2 hours, then poured on to ice-
cold water and extracted with dichloromethane (2 × 70 mL). The organic extracts were 
washed with water (2 × 70 mL), then with brine, dried (MgSO4), filtered and solvent 
removed under reduced pressure to give a colourless, slightly yellow oil (2.26 g), 
which was shown to be the partially-reacted monotoluenesulfonate intermediate by 
NMR spectroscopy. Therefore, the monotoluenesulfonate intermediate was re-
subjected to reaction using the general procedure as described earlier, using potassium 
hydroxide (1.22 g, 0.0217 mol) and p-toluenesulfonyl chloride (1.01 g, 0.0053 mol) in 
dichloromethane (30 mL). The presence of excess p-toluenesulfonyl chloride in the 
product was removed by filtration through silica, first with dichloromethane to elute 
the toluenesulfonyl chloride, then with EtOAc to elute (52) (2.28 g, 36%) in good 
purity: 1H NMR (CDCl3) δ 2.44 (s, 6 H, CH3), 3.58 (s, 8 H, OCH2), 3.61 (br s, 8 H, 
OCH2), 3.66-3.71, 4.11-4.19 (2m, 2 × 4 H, OCH2), 7.31-7.36 (AA’BB’, 4 H, ArH), 
7.77-7.82 (AA’BB’, 4 H, ArH); 13C NMR (CDCl3) δ 21.8 (CH3), 68.8, 69.4, 70.7, 70.7, 
70.8, 70.9 (OCH2), 128.1, 130.0, 133.2, 144.9 (C, Ar). 
5.5.2 General procedure for the synthesis of crown resorcinarenes 
To a clear solution of resorcinarene (46) (1 eq), caesium carbonate (8 eq) in anhydrous 
dimethylformamide was added poly(ethylene glycol) ditosylate (2.5 eq). The mainly 
clear colourless reaction mixture was heated at 90°C under nitrogen overnight. The 
dimethylformamide was removed under reduced pressure and dichloromethane was 
added to the residue. After washing with brine twice, the organic layer was dried 
(MgSO4), filtered, and solvent removed under reduced pressure to give a dark brown 
residue as the crude product. The crude was purified by column chromatography to 
give the target product. 
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5.5.2.1 Dibenzyloxy crown-5 resorcinarene (53) 
The general procedure for the synthesis of 
crown resorcinarenes was applied with 
resorcinarene (46) (1.03 g, 1.15 mmol), 
caesium carbonate (3.04 g, 9.33 mmol), 
anhydrous dimethylformamide (600 mL), 
and tetra(ethylene glycol) ditosylate (50) 
(0.975 mL, 1.21 g, 2.41 mmol). Column 
chromatography (EtOAc – DCM 2:8), afforded (53) as a slightly yellow solid (0.595 
g, 49%). For analysis, the slightly yellow solid was recrystallised by diffusion from 
CHCl3/MeOH to give the previously unreported product (53) as white plates and 
needles: mp 193 °C (CHCl3/MeOH); 1H NMR (CDCl3) δ 0.896 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 0.904 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.16-1.53 (m, 8 H, CH2CH3), 1.69-2.04 
(m, 8 H, CH2CH), 3.13-3.32 (m, 8 H, CH2O), 3.38-3.50 (m, 5 H, CH2O), 3.44 (s, 6 H, 
OCH3), 3.50-3.58 (m, 3 H, CH2O), 3.86 (s, 6 H, OCH3), 4.50-4.58, 4.64-4.73 (2m, 2 
× 2 H, CHCH2), 5.21 (s, 4 H, CH2Ph), 6.20, 6.54, 6.56 (3s, 3 × 2 H, ArH), 7.25 
(overlapped with CHCl3, s, 2 H, ArH), 7.29-7.36 (m, 2 H, ArH), 7.37-7.43 (m, 4 H, 
ArH), 7.54-7.60 (m, 4 H, ArH); 1H NMR (DMSO-d6) δ 0.81 (t, J = 7.3 Hz, 6 H), 0.83 
(t, J = 7.3 Hz, 6 H), 1.01-1.23, 1.17-1.40 (2m, 2 × 4 H, CH2CH3), 1.55-1.88 (m, 8 H, 
CH2CH), 3.07-3.21 (m, 4 H, OCH2), 3.21-3.37 (overlapped with HDO, m, 10 H, 
OCH2), 3.38 (s, 6 H, OCH3), 3.38-3.56 (m, 6 H, OCH2), 3.84 (s, 6 H, OCH3), 4.33-
4.44, 4.44-4.54 (2m, 2 × 2 H, CHCH2), 5.23 (apparent s, 4 H, CH2Ph), 5.99, 6.64, 6.73, 
7.05 (4s, 2 × 2 H, ArH), 7.30-7.37, 7.38-7.47, 7.51-7.59 (3m, 2 H, 4 H, 4 H, ArH); 13C 
NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 21.3, 21.4 (CH2CH3), 35.2, 35.3 (CHCH2), 
37.5, 37.5 (CH2CH), 55.3, 56.2 (OCH3), 70.4, 70.6, 71.08 (OCH2C), 71.14 (OCH2Ph), 
71.8 (OCH2C), 97.5, 103.3 (CH, Ar), 125.3, 125.5 (C, Ar), 125.8, 126.7, 127.2, 127.6, 
128.5 (CH, Ar), 129.0, 129.2, 138.4, 154.4, 155.0, 156.2, 157.2 (C, Ar). Found: C, 
75.11; H, 7.54; C66H82O11; requires C, 75.4; H, 7.86%. HRMS (ESI): calcd. for 
C66H83O11H as [M + H]+ 1051.5930; found 1051.5913. 
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5.5.2.2 Dibenzyloxy crown-6 resorcinarene (54) 
The general procedure for the synthesis of 
crown resorcinarenes was applied with (46) 
(0.503 g, 0.563 mmol), caesium carbonate 
(1.59 g, 4.88 mmol), anhydrous 
dimethylformamide (500 mL), and 
penta(ethylene glycol) ditosylate (51) (0.615 
mL, 0.775 g, 1.42 mmol). Column 
chromatography (EtOAc – DCM 2:8) afforded the previously unreported product (54) 
(0.349 g, 57%) as a white solid: mp 181-182°C (CHCl3/MeOH); 1H NMR (CDCl3) δ 
0.90 (t, J = 7.2 Hz, 6 H, CH2CH3), 0.91 (t, J = 7.2 Hz, 6 H, CH2CH3), 1.15-1.54 (m, 8 
H, CH2CH3), 1.66-2.02 (m, 8 H, CH2CH), 3.17-3.33 (m, 6 H, CH2O), 3.33-3.40 (m, 4 
H, CH2O) 3.41 (s, 6 H, OCH3), 3.42-3.58 (m, 10 H, CH2O), 3.86 (s, 6 H, OCH3), 4.47-
4.57, 4.63-4.73 (2m, 2 × 2 H, CHCH2), 5.19, 5.22 (AB, J = 12.6 Hz, 4 H, CH2Ph), 
6.17, 6.43, 6.53, (3s, 3 × 2 H, ArH), 7.26 (overlapped with CHCl3, 2 H, ArH), 7.32 (t, 
J = 7.3 Hz, 2 H, ArH), 7.40 (t, J = 7.4 Hz, 4 H, ArH), 7.57 (d, J = 7.3 Hz, 4 H, ArH); 
1H NMR (DMSO-d6) δ 0.82 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.84 (t, J = 7.4 Hz, 6 H, 
CH2CH3), 1.02-1.23, 1.16-1.40 (2m, 2 × 4 H, CH2CH3), 1.54-1.89 (m, 8 H, CH2CH), 
3.06-3.15 (m, 2 H, OCH2), 3.20-3.46 (overlapped with HDO, m, 16 H, OCH2), 3.35 
(s, 6 H, OCH3), 3.46-3.56 (m, 2 H, OCH2), 3.83 (s, 6 H, OCH3), 4.35-4.45, 4.47-4.58 
(2m, 2 × 2 H, CHCH2), 5.21, 5.24 (AB, J = 12.8 Hz, 4 H, CH2Ph), 6.03, 6.47, 6.72, 
7.09 (4s, 4 × 2 H, ArH), 7.29-7.37, 7.39-7.46, 7.53-7.60 (3m, 2 H, 4 H, 4 H, ArH); 13C 
NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 21.3, 21.4 (CH2CH3), 35.1, 35.2 (CHCH2), 
37.48, 37.49 (CH2CH), 55.5, 56.2 (OCH3), 70.3, 70.55, 70.64, 70.80, 70.84 (OCH2C), 
71.2 (OCH2Ph), 97.5, 101.7 (CH, Ar), 124.9, 125.1 (C, Ar), 125.8, 126.5, 127.3, 127.6, 
128.5 (CH, Ar), 129.1, 129.4, 138.5, 154.4, 154.9, 156.3, 156.9 (C, Ar). Found: C, 
74.51; H, 7.86; C68H86O12; requires C, 74.56; H, 7.91%. 
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5.5.2.3 Dibenzyloxy crown-7 resorcinarene (55) 
The general procedure for the synthesis of 
crown resorcinarenes was applied with (46) 
(0.502 g, 0.562 mmol), caesium carbonate 
(2.50 g, 7.67 mmol), anhydrous 
dimethylformamide (250 mL), and 
hexa(ethylene glycol) ditosylate (52) (0.568 
mL, 0.697 g, 1.18 mmol). After the removal 
of the dimethylformamide, brine (100 mL) was added to the residue, and extracted 
with dichloromethane (2 × 50 mL). The combined organic extracts were dried 
(MgSO4), filtered, and solvent removed under reduced pressure to give a solid (0.836 
g) as crude product. The crude product was filtered through a plug of silica using 
dichloromethane (10 mL), then EtOAc (250 mL), and the solvent was removed under 
reduced pressure to give a yellow oil (0.547 g), which was left open to air overnight. 
The yellow oil was triturated with methanol to give the previously unreported product 
(55) (0.452 g, 70 %) as a white crystalline solid: mp 136°C (CHCl3/MeOH); 1H NMR 
(CDCl3) δ 0.88 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.91 (t, J = 7.4 Hz, 6 H, CH2CH3), 1.18-
1.53 (m, 8 H, CH2CH3), 1.64-2.01 (m, 8 H, CH2CH), 3.06-3.14, 3.14-3.22 (2m, 2 × 2 
H, CH2O), 3.35-3.44 (m, 2 H, CH2O), 3.40 (s, 6 H, OCH3), 3.44-3.70 (m, 18 H, CH2O), 
3.85 (s, 6 H, OCH3), 4.47-4.54, 4.60-4.70 (2m, 2 × 2 H, CHCH2), 5.18, 5.22 (AB, J = 
12.4 Hz, 4 H, CH2Ph), 6.11, 6.34, 6.52, 7.23 (4s, 4 × 2 H, ArH), 7.29-7.36, 7.37-7.43, 
7.54-7.60 (3m, 2 H, 4 H, 4 H, ArH); 1H NMR (DMSO-d6) δ 0.81 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 0.85 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.05-1.22, 1.21-1.39 (2m, 2 × 4 H, 
CH2CH3), 1.53-1.68, 1.65-1.88 (2m, 2 H, 6 H, CH2CH), 3.05-3.20 (m, 4 H, OCH2), 
3.23-3.33 (overlapped with HDO, m, 2 H, OCH2), 3.35 (s, 6 H, OCH3), 3.35-3.47, 
3.47-3.58 (m, 15 H, 3 H, OCH2), 3.84 (s, 6 H, OCH3), 4.33-4.44, 4.47-4.58 (2m, 2 × 2 
H, CHCH2), 5.20, 5.24 (AB, J = 12.3 Hz, 4 H, CH2Ph), 6.01, 6.40, 6.72 , 7.08 (4s, 4 × 
2 H, ArH), 7.30-7.37, 7.39-7.46, 7.53-7.60 (3m, 2 H, 4 H, 4 H, ArH); 13C NMR 
(CDCl3) δ 14.4, 14.5 (CH2CH3), 21.3, 21.4 (CH2CH3), 35.2, 35.4 (CHCH2), 37.3, 37.4 
(CH2CH), 55.6, 56.1 (OCH3), 70.1, 70.4, 70.8, 70.86, 70.87, 71.0 (OCH2C), 71.2 
(OCH2Ph), 97.3, 101.5 (CH, Ar), 124.9, 125.0 (C, Ar), 125.8, 126.5, 127.2, 127.6, 
128.5 (CH, Ar), 129.1, 129.5, 138.4, 154.3, 154.9, 156.4, 156.7 (C, Ar). Found: C, 
72.54; H, 7.72; C70H90O13.H2O; requires C, 72.64; H, 8.01%. 
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5.5.3 General procedure of the reduction of benzyl ethers 
To a solution of benzyloxy crown resorcinarene dissolved in tetrahydrofuran was 
added anhydrous ammonia, which was condensed with EtOAc/liquid nitrogen. 
Sodium metal was then added to the colourless solution till a dark blue colour persisted 
throughout the solution for 30 minutes. The dark blue reaction mixture was then 
quenched with a spatula tip of ammonium chloride, and the solvents were allowed to 
evaporate to dryness. The residue was taken up in water, and the undissolved solids 
were collected by filteration. The solids were washed off the funnel with 
dichloromethane, and the solvent was removed under reduced pressure. The resultant 
residue was placed in an oven (140°C) for 5 minutes to remove water, and furnish the 
dihydroxy crown resorcinarene as a beige solid in good purity. 
5.5.3.1 Dihydroxy crown-5 resorcinarene (56) 
The general procedure was applied with (53) (0.342 g, 
0.352 mmol), tetrahydrofuran (10 mL), and anhydrous 
ammonia (~50 mL), to give the pure, previously 
unreported product (56) (0.288 g, 100%) as a white 
solid: mp 259-260 °C (CHCl3/MeOH); IR 3380 cm-1 
(OH phenol); 1H NMR (CDCl3) δ 0.91 (t, J = 7.4 Hz, 6 
H, CH2CH3), 0.96 (t, J = 7.4 Hz, 6 H, CH2CH3), 1.12-
1.37 (m, 8 H, CH2CH3), 1.38-1.48 (m, 2 H, CH2O), 1.81-1.97 (m, 4 + 2 H, CH2CH + 
CH2O), 1.97-2.04 (m, 2 H, CH2O), 2.05-2.17 (m, 4 H, CH2CH), 2.60-2.69, 2.87-2.97, 
3.53-3.62 (3m, 3 × 2 H, CH2O), 3.72, 3.84 (2s, 2 × 6 H, OCH3), 3.86-3.93 (m, 2 H, 
CH2O), 4.15 (t, J = 8.0 Hz, 2 H, CHCH2), 4.26-4.36 (m, 2 H, CH2O), 4.81 (t, J = 8.0 
Hz, 2 H, CHCH2), 6.37, 6.44, 6.84, 7.46 (4s, 4 × 2 H, ArH); 1H NMR (DMSO-d6) δ 
0.83 (t, J = 7.2 Hz, 6 H), 0.85 (t, J = 7.2 Hz, 6 H), 1.03-1.25, 1.16-1.41 (2m, 2 × 4 H, 
CH2CH3), 1.54-1.81 (m, 8 H, CH2CH), 3.06-3.21, 3.21-3.29, 3.33-3.45 (3m, 4 H, 2 H, 
6 H, OCH2), 3.38 (s, 6 H, OCH3), 3.45-3.56 (m, 4 H, OCH2), 3.78 (s, 6 H, OCH3), 
4.27-4.39 (m, 4 H, CHCH2), 5.84, 6.44, 6.63, 6.99 (4s, 4 × 2 H, ArH), 8.88 (s, 2 H, 
OH); 13C NMR (CDCl3) δ 14.2, 14.4 (CH2CH3), 20.9, 20.9 (CH2CH3), 32.1, 33.9 
(CHCH2), 36.7, 39.1 (CH2CH), 55.6, 55.7 (OCH3), 68.7, 69.6, 69.8, 70.5 (OCH2), 
98.0, 99.4, 123.5 (CH, Ar), 123.7, 124.6 (C, Ar), 126.3 (CH, Ar), 127.4, 127.6, 152.0, 
154.1, 155.1, 155.8 (C, Ar). Found: C, 71.79; H, 8.26; C52H70O11; requires C, 71.70; 
H, 8.10%. 
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5.5.3.2 Dihydroxy crown-6 resorcinarene (57) 
The general procedure was applied with (54) (0.393 g, 
0.359 mmol), tetrahydrofuran (30 mL), and anhydrous 
ammonia (~90 mL), to give (57) good purity as a beige 
solid (0.340 g, 100%). For analysis, the beige solid was 
recrystallised from hot ethanol to give the pure 
previously unreported product (57) as white crystals: 
mp 250-251 °C (CHCl3/MeOH); IR 3428 cm-1 (OH 
phenol); 1H NMR (CDCl3) δ 0.92 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.96 (t, J = 7.4 Hz, 6 
H, CH2CH3), 1.14-1.36 (m, 8 + 2 H, CH2CH3 + CH2O), 1.80-1.87 (m, 2 H, CH2O), 
1.88-1.99 (m, 4 H, CH2CH), 1.99-2.20 (m, 4 + 2 H, CH2CH + CH2O), 2.67-2.78, 2.96-
3.07, 3.12-3.23, 3.52-3.60, 3.67-3.74 (5m, 5 × 2 H, CH2O), 3.75,  3.84 (2s, 2 × 6 H, 
OCH3), 3.89-3.99 (m, 2 H, CH2O), 4.10-4.25 (m, 2 + 2 H, CHCH2 + CH2O), 4.86 (t, J 
= 8.1 Hz, 2 H, CHCH2), 6.24, 6.40 (2s, 4 × 2 H, ArH), 6.74 (br s, 2 H, OH), 6.89, 7.50 
(2s, 4 × 2 H, ArH); 1H NMR (DMSO-d6) δ 0.83 (t, J = 7.4 Hz, 6 H, CH2CH3), 0.85 (t, 
J = 7.4 Hz, 6 H, CH2CH3), 1.01-1.42 (m, 8 H, CH2CH3), 1.52-1.81 (m , 8 H, CH2CH), 
3.08-3.17, 3.17-3.25, 3.32-3.52 (3m, 2 H, 2 H, 16 H, CH2O), 3.35,  3.77 (2s, 2 × 6 H, 
OCH3), 4.28-4.39 (m, 4 H, CHCH2), 5.9, 6.4, 6.5, 7.0 (4s, 4 × 2 H, ArH), 8.9 (s, 2 H, 
OH); 13C NMR (CDCl3) δ 14.2, 14.5 (CH2CH3), 20.9, 21.0 (CH2CH3), 31.9, 33.8 
(CHCH2), 36.9, 39.3 (CH2CH), 55.5, 55.6 (OCH3), 67.9, 69.4, 69.5, 69.9, 71.1 
(OCH2), 95.9, 99.3 (CH, Ar), 123.2, 123.92 (C, Ar), 123.93, 126.2 (CH, Ar), 127.2, 
127.4, 151.9, 154.2, 155.2, 156.0. 13C NMR (DMSO-d6) δ 14.0, 14.2 (CH2CH3), 20.88, 
20.90 (CH2CH3), 34.6, 34.9 (CHCH2), 36.3, 36.8 (CH2CH), 55.2, 55.5 (OCH3), 69.4, 
69.9, 70.0, 70.4 (OCH2), 98.5, 101.9 (CH, Ar), 123.2, 123.4, 125.07 (C, Ar), 125.13, 
125.3 (CH, Ar), 125.8 (C, Ar), 152.3, 154.1, 155.9, 156.4 (C, Ar) (note some signals 
are coincident). Found: C, 69.47; H, 8.27; C54H74O12.H2O; requires C, 69.50; H, 
8.21%. 
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5.5.3.3 Dihydroxy crown-7 resorcinarene (58) 
The general procedure was applied with (0.572 g, 0.502 
mmol), tetrahydrofuran (30 mL), and anhydrous 
ammonia (~90 mL), to give (58) in good purity as an 
off-white solid (0.470 g, 98%). For analysis, the off-
white solid was triturated with acetone to give the pure 
previously unreported product (58) as a white solid: mp 
209-210 °C (MeCN); IR 3397 cm-1 (OH phenol); 1H 
NMR (CDCl3) δ 0.90 (t, J = 7.3 Hz, 6 H, CH2CH3), 0.96 (t, J = 7.4 Hz, 6 H, CH2CH3), 
1.10-1.37 (m, 8 H, CH2CH3), 1.80-1.99, 2.01-2.19 (2m, 2 × 4 H, CH2CH), 2.30-2.40, 
2.40-2.50, 2.59-2.74, 2.86- 2.96, 2.99-3.10, 3.27-3.38, 3.55-3.73, (7m, 2 H, 4 H, 4 H, 
2 H, 2 H, 2 H, 4 H, CH2O), 3.76, 3.82 (2s, 2 × 6 H, OCH3), 3.84-3.93 (m, 2 H, CH2O), 
4.10-4.23 (m, 2 + 2 H, CH2O + CHCH2), 4.86 (t, J = 8.1 Hz, 2 H, CHCH2), 6.34, 6.40, 
6.92, 7.47 (4s, 4 × 2 H, ArH); 1H NMR (DMSO-d6) δ 0.84 (t, J = 7.3 Hz, 6 H, CH2CH3), 
0.85 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.04-1.23, 1.19-1.39 (2m, 2 × 4 H, CH2CH3), 1.51-
1.65, 1.61-1.81 (2m, 2 H, 6 H, CH2CH), 3.05-3.17 (m, 4 H, OCH2), 3.22-3.35 
(overlapped with HDO, m, OCH2), 3.35 (s, 6 H, OCH3), 3.38-3.54 (m, 20 H, OCH2), 
3.77 (s, 6 H, OCH3), 4.26-4.40 (m, 4 H, CHCH2), 5.85, 6.39, 6.43, 7.02 (4s, 4 × 2 H, 
ArH), 8.88 (s, 2 H, OH). 13C NMR (CDCl3) δ 14.2, 14.4 (CH2CH3), 20.9, 21.0 
(CH2CH3), 31.8, 33.8 (CHCH2), 36.8, 39.5 (CH2CH), 55.5, 55.7 (OCH3), 67.7, 69.7, 
70.1, 70.2, 70.4, 70.7 (OCH2), 96.7, 99.3 (CH, Ar), 123.2 (C, Ar), 124.1 (CH, Ar), 
124.2 (C, Ar), 126.1 (CH, Ar), 127.3 , 152.0, 154.2, 155.5, 155.8 (C, Ar) (note some 
signals are coincident). Found: C, 68.77; H, 8.59; C56H78O13.H2O; requires C, 68.83; 
H, 8.25%. 
5.5.4 General procedure for the camphorsulfonylation of resorcinarenes 
The synthetic procedure was adapted from that of (48) in Section 4.3.4.1. (1S)-(+)-
camphorsulfonic acid (10 eq) and thionyl chloride were heated at reflux for 1 h. The 
thionyl chloride was evaporated under nitrogen to give a white crystalline solid, 
assumed to be (1S)-(+)-camphorsulfonyl chloride. To the freshly-prepared (1S)-(+)-
camphorsulfonyl chloride was added resorcinarene (1 eq), dichloromethane and 
triethylamine (16 eq). The reaction mixture was stirred under nitrogen at room 
temperature for 1 h. The work up and purification is specific for each resorcinarene 
derivative. 
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5.5.4.1 Dicamphorsulfonate crown-5 resorcinarene (59a) and (59b) 
The general procedure was applied with resorcinarene (1S)-(+)-camphorsulfonyl acid 
(57 mg, 0.245 mmol) and thionyl chloride (1 mL), crown-5 resorcinarene (56) (20 mg, 
0.023 mmol), dichloromethane (3 mL) and triethylamine (0.052 mL, 0.072 mg, 0.709 
mmol). The reaction mixture was stirred under nitrogen at room temperature for 40 
minutes, then washed with dilute HCl (5 mL, 1 M). The layers separated, and the 
aqueous phase extracted with dichloromethane (5 mL). The combined yellow organic 
extracts were dried (CaCl2) and solvent removed under reduced pressure to give an 
off-white solid (56 mg). The crude material was subjected to repeated preparative TLC 
(MeOH – DCM 2:98), with the same plate being developed two to three times, to give 
the previously unreported diastereomers (59a) (14 mg, 50%) and (59b) (13 mg, 48%). 
Crown-5 camphorsulfonate 
resorcinarene (59a): IR 1749 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.90 (t, J 
= 7.3 Hz, 6 H, CH2CH3), 0.94 (s, 6 H, 
CH3 camph), 0.96 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.19-1.42 (m, 6 H, 
CH2CH3), 1.21 (s, 6 H, CH3 camph), 
1.42-1.55 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.66-1.91 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.91-2.06 (m, 2 H, CH2CH), 1.99 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.06-
2.15 (m, 2 H, CH2 camph), 2.13-2.19 (m, 2 H, CH camph), 2.44 (ddd, J = 18.5, 4.4, 
3.4 Hz, 2 H, CH2 camph), 2.57-2.72 (m, 2 H, CH2 camph), 3.14-3.22, 3.22-3.33, 3.36-
3.57 (3m, 2 H, 6 H, 8 H, CH2O), 3.39 (s, 6 H, OCH3), 3.41, 3.96 (AB, J = 14.9 Hz, 4 
H, SCH2), 3.91 (s, 6 H, OCH3), 4.32-4.41, 4.51-4.59 (2m, 2 × 2 H, CHCH2), 6.19, 
6.56, 6.98, 7.19 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.3, 14.5 (CH2CH3), 19.9, 
20.2 (CCH3, camph), 21.3, 21.4 (CH2CH3), 25.4, 27.1 (CH2, camph), 35.2, 36.3 
(CHCH2), 37.07, 37.12 (CH2CH), 42.7 (CH2C=O, camph), 43.1 (CH, camph), 48.1 
(CCH3, camph), 49.1 (SCH2, camph), 55.3, 56.2 (OCH3), 58.4 (CC=O, camph), 70.5, 
70.6, 71.1, 71.8 (OCH2), 103.2, 103.6, (CH, Ar), 124.0, 124.7 (C, Ar), 125.3, 127.0 
(CH, Ar), 131.1, 135.1, 145.4, 154.9, 156.5, 157.6 (C, Ar), 214.2 (C=O); [α]D +48.0 
(c 1.02, CHCl3); HRMS (ESI): calcd. for C72H102NO17S2 as [M + NH4]+ 1316.6584; 
found 1316.6527 (main peak); and calcd. for C72H99O17S2 as [M + H]+ 1299.6318; 
found 1299.6270. 
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Crown-5 camphorsulfonate 
resorcinarene (59b): IR 1748 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.90 (t, J = 
7.3 Hz, 6 H, CH2CH3), 0.934 (s, 6 H, 
CH3 camph), 0.95 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.19-1.41 (m, 6 H, 
CH2CH3), 1.20 (s, 6 H, CH3 camph), 
1.41-1.54 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.66-1.90 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.90-2.03 (m, 2 H, CH2CH), 1.99 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.06-
2.15 (m, 2 H, CH2 camph), 2.13-2.19 (m, 2 H, CH camph), 2.43 (ddd, J = 18.5, 4.4, 
3.4 Hz, 2 H, CH2 camph), 2.60-2.71 (m, 2 H, CH2 camph), 3.17-3.34 (m, 8 H, CH2O), 
3.35, 4.01 (AB, J = 14.9 Hz, 4 H, SCH2), 3.36-3.43 (m, 2 H, CH2O), 3.42 (s, 6 H, 
OCH3), 3.43-3.58 (m, 6 H, CH2O), 3.91 (s, 6 H, OCH3), 4.32-4.40, 4.51-4.59 (2m, 2 
× 2 H, CHCH2), 6.17, 6.61, 7.00, 7.17 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.3, 
14.5 (CH2CH3), 19.9, 20.2 (CCH3, camph), 21.3, 21.4 (CH2CH3), 25.5, 27.1 (CH2, 
camph), 35.4, 36.4 (CHCH2), 36.9, 37.1 (CH2CH), 42.7 (CH2C=O, camph), 43.0 (CH, 
camph), 48.1 (CCH3, camph), 48.8 (SCH2, camph), 55.2, 56.2 (OCH3), 58.4 (CC=O, 
camph), 70.5, 70.6, 71.2, 72.1 (OCH2), 103.3, 103.7, (CH, Ar), 123.6, 124.7 (C, Ar), 
125.4, 126.9 (CH, Ar), 130.9, 135.3, 145.5, 154.9, 156.6, 157.8 (C, Ar), 214.2 (C=O); 
[α]D -11.8 (c 1.02, CHCl3); HRMS (ESI): calcd. for C72H102NO17S2 as [M + NH4]+ 
1316.6584; found 1316.6526 (main peak); and calcd. for C72H99O17S2 as [M + H]+ 
1299.6318; found 1299.6258. 
5.5.4.2 Dicamphorsulfonate crown-6 resorcinarene (60a) and (60b) 
The general camphorsulonylation procedure was applied with (1S)-(+)-
camphorsulfonyl acid (0.258 g, 1.11 mmol) and thionyl chloride (3 mL), crown-6 
resorcinarene (57) (0.100 g, 0.109 mmol), dichloromethane (7 mL) and triethylamine 
(0.244 mL, 0.177 g, 1.75 mmol). The reaction mixture was stirred under nitrogen at 
room temperature for 50 minutes, then washed with dilute HCl (10 mL, 1 M). The 
layers separated, and the aqueous phase extracted with dichloromethane (5 mL). The 
combined yellow organic extracts were dried (CaCl2) and solvent removed under 
reduced pressure to give an off-white solid (0.240 g). The crude material was subjected 
to column chromatography (silica: 23 × 25 mm). The impurity was first eluted with 
EtOAc – petroleum spirits (25 mL, 50:50), then the diastereomer mixture was eluted 
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with EtOAc (75 mL, 100%). The EtOAc was evaporated to give the diastereomer 
mixture as an off-white solid (0.143 g). This material was subjected to preparative 
TLC (MeOH – DCM 2:98), with the same plate being developed three times, to give 
the previously unreported diastereomers (60a) (0.058 g, 40%) and (60b) (0.057 g, 
39%), along with unseparated diastereomer mixture (0.009 g, 6%). 
Crown-6 camphorsulfonate 
resorcinarene (60a): IR 1747 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.91 (t, J = 
7.3 Hz, 6 H, CH2CH3), 0.94 (s, 6 H, 
CH3 camph), 0.96 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.21 (s, 6 H, CH3 camph), 
1.22-1.44 (m, 6 H, CH2CH3), 1.43-
1.57 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.66-1.92 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.92-2.05 (m, 2 H, CH2CH), 1.99 (d, J = 18.4 Hz, 2 H, CH2 camph), 2.06-
2.16 (m, 2 H, CH2 camph), 2.12-2.20 (m, 2 H, CH camph), 2.44 (ddd, J = 18.4, 4.4, 
3.4 Hz, 2 H, CH2 camph), 2.59-2.72 (m, 2 H, CH2 camph), 3.14-3.46 (m, 10 H, CH2O), 
3.37 (s, 6 H, OCH3), 3.42, 3.97 (AB, J = 14.9 Hz, 4 H, SCH2), 3.46-3.59 (m, 10 H, 
CH2O), 3.91 (s, 6 H, OCH3), 4.31-4.40, 4.47-4.58 (2m, 2 × 2 H, CHCH2), 6.16, 6.42, 
6.95, 7.19 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 19.9, 20.2 
(CCH3, camph), 21.2, 21.4 (CH2CH3), 25.4, 27.1 (CH2, camph), 35.1, 36.3 (CHCH2), 
37.06, 37.11 (CH2CH), 42.7 (CH2C=O, camph), 43.1 (CH, camph), 48.1 (CCH3, 
camph), 49.2 (SCH2, camph), 55.5, 56.2 (OCH3), 58.4 (CC=O, camph), 70.2, 70.4, 
70.6, 70.8, 70.8 (OCH2), 101.1, 103.5 (CH, Ar), 123.5, 124.0 (C, Ar), 125.2, 126.8 
(CH, Ar), 131.2, 135.3, 145.4, 154.8, 156.6, 157.2 (C, Ar), 214.2 (C=O); [α]D +46.5 
(c 1.11, CHCl3); HRMS (ESI): calcd. for C74H103O18S2 as [M + H]+ 1343.6580; found 
1343.6564. 
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Crown-6 camphorsulfonate 
resorcinarene (60b): IR 1748 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.90 (t, J = 
7.3 Hz, 6 H, CH2CH3), 0.94 (s, 6 H, 
CH3 camph), 0.95 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.20 (s, 6 H, CH3 camph), 
1.21-1.43 (m, 6 H, CH2CH3), 1.43-
1.57 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.63-1.91 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.91-2.04 (m, 2 H, CH2CH), 1.98 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.05-
2.13 (m, 2 H, CH2 camph), 2.13-2.19 (m, 2 H, CH camph), 2.43 (ddd, J = 18.5, 4.7, 
3.4 Hz, 2 H, CH2 camph), 2.59-2.71 (m, 2 H, CH2 camph), 3.18-3.34 (m, 6 H, CH2O), 
3.36, 4.02 (AB, J = 14.9 Hz, 4 H, SCH2), 3.39 (s, 6 H, OCH3), 3.40-3.46, 3.46-3.60 
(2m, 4 H, 10 H, CH2O), 3.90 (s, 6 H, OCH3), 4.31-4.40, 4.48-4.57 (2m, 2 × 2 H, 
CHCH2), 6.14, 6.45, 6.97, 7.17 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.4, 14.5 
(CH2CH3), 19.9, 20.2 (CCH3, camph), 21.3, 21.4 (CH2CH3), 25.5, 27.1 (CH2, camph), 
35.2, 36.3 (CHCH2), 37.0, 37.1 (CH2CH), 42.7 (CH2C=O, camph), 43.1 (CH, camph), 
48.1 (CCH3, camph), 49.0 (SCH2, camph), 55.4, 56.2 (OCH3), 58.4 (CC=O, camph), 
70.3, 70.58, 70.62, 70.7, 70.8 (OCH2), 101.2, 103.6 (CH, Ar), 123.2, 123.9 (C, Ar), 
125.2, 126.7 (CH, Ar), 131.1, 135.3, 145.4, 154.9, 156.6, 157.3 (C, Ar), 214.2 (C=O); 
[α]D -16.5 (c 1.10, CHCl3); HRMS (ESI): calcd. for C74H103O18S2 as [M + H]+ 
1343.6580; found 1343.6565. 
5.5.4.3 Dicamphorsulfonate crown-7 resorcinarene (61a) and (61b) 
The general procedure was applied with resorcinarene (1S)-(+)-camphorsulfonyl acid 
(0.050 g, 0.215 mmol) and thionyl chloride (1 mL), crown-7 resorcinarene (58) (0.020 
g, 0.021 mmol), dichloromethane (3 mL) and triethylamine (0.047 mL, 0.034 g, 0.337 
mmol). The reaction mixture was stirred under nitrogen at room temperature for 1 
hour, then washed with dilute HCl (5 mL, 1 M). The layers separated, and the aqueous 
phase extracted with dichloromethane (5 mL). The combined yellow organic extracts 
were dried (CaCl2) and solvent removed under reduced pressure to give an off-white 
solid (0.046 g). The crude material was subjected to column chromatography (silica: 
23 × 25 mm). The impurity was first eluted with acetone – DCM (20 mL, 10:90), then 
the diastereomer mixture was eluted with acetone – DCM (60 mL, 30:70). The solvent 
was removed under reduced pressure to give the diastereomer mixture as a solid (0.027 
O
O
O O
O
O
OO
C3H7 H7C3
H7C3C3H7
O
S
O
O O
S
O
O
O
O
O
O
 207 
 
g). This material was subjected to repeated preparative TLC (MeOH – DCM 2:98), 
with the same plate being developed two to three times, to give the previously 
unreported diastereomers (61a) (9.7 mg, 34%), (61b) (6.3 g, 22%), along with 
unseparated diastereomer mixture (4.2 mg, 15%). 
Crown-7 camphorsulfonate 
resorcinarene (61a): IR 1748 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.92 (t, J 
= 7.3 Hz, 6 H, CH2CH3), 0.94 (s, 6 H, 
CH3 camph), 0.95 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.21 (s, 6 H, CH3 camph), 
1.22-1.43 (m, 6 H, CH2CH3), 1.43-
1.56 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.60-1.91 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.91-2.06 (m, 2 H, CH2CH), 1.98 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.06-
2.16 (m, 2 H, CH2 camph), 2.12-2.20 (m, 2 H, CH camph), 2.44 (ddd, J = 18.5, 4.5, 
3.4 Hz, 2 H, CH2 camph), 2.59-2.71 (m, 2 H, CH2 camph), 3.06-3.16, 3.17-3.27 (2m, 
2 H, 2 H, CH2O), 3.36 (s, 6 H, OCH3), 3.37-3.46 (m, 2 H, CH2O), 3.42, 3.97 (AB, J = 
14.9 Hz, 4 H, SCH2), 3.46-3.63 (2m, 4 H, 18 H, CH2O), 3.91 (s, 6 H, OCH3), 4.31-
4.40, 4.48-4.57 (2m, 2 × 2 H, CHCH2), 6.12, 6.31, 6.95, 7.18 (4s, 4 × 2 H, ArH); 13C 
NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 19.9, 20.1 (CCH3, camph), 21.2, 21.4 
(CH2CH3), 25.4, 27.1 (CH2, camph), 35.2, 36.3 (CHCH2), 37.0, 37.1 (CH2CH), 42.7 
(CH2C=O, camph), 43.1 (CH, camph), 48.1 (CCH3, camph), 49.2 (SCH2, camph), 
55.5, 56.1 (OCH3), 58.4 (CC=O, camph), 70.0, 70.2, 70.8, 70.88, 70.95, 71.1 (OCH2), 
100.8, 103.5 (CH, Ar), 123.3, 124.3 (C, Ar), 125.3, 126.8 (CH, Ar), 131.2, 135.4, 
145.3, 154.8, 156.7, 157.0 (C, Ar), 214.2 (C=O); [α]D +56.6 (c 0.99, CHCl3); HRMS 
(ESI): calcd. for C76H110NO19S2 as [M + NH4]+ 1404.7108; found 1404.7069 (main 
peak); and calcd. for C76H107O19S2 as [M + H]+ 1387.6842; found 1387.6809.  
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Crown-7 camphorsulfonate 
resorcinarene (61b): IR 1748 cm-1 
(C=O); 1H NMR (CDCl3) δ 0.91 (t, J 
= 7.3 Hz, 6 H, CH2CH3), 0.94 (s, 6 H, 
CH3 camph), 0.94 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 1.20 (s, 6 H, CH3 camph), 
1.22-1.44 (m, 6 H, CH2CH3), 1.44-
1.56 (m, 2 + 2 H, CH2CH3 + CH2 camph), 1.60-1.89 (m, 6 + 2 H, CH2CH + CH2 
camph), 1.89-2.03 (m, 2 H, CH2CH), 1.98 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.03-
2.16 (m, 2 H, CH2 camph), 2.12-2.20 (m, 2 H, CH camph), 2.44 (ddd, J = 18.5, 4.4, 
3.4 Hz, 2 H, CH2 camph), 2.59-2.71 (m, 2 H, CH2 camph), 3.06-3.15, 3.19-3.27 (2m, 
2 H, 2 H, CH2O), 3.37, 4.01 (AB, J = 14.9 Hz, 4 H, SCH2), 3.38 (s, 6 H, OCH3), 3.39-
3.47, 3.47-3.66 (2m, 2 H, 18 H, CH2O), 3.90 (s, 6 H, OCH3), 4.31-4.40, 4.48-4.57 (2m, 
2 × 2 H, CHCH2), 6.11, 6.33, 6.97, 7.17 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.4, 
14.5 (CH2CH3), 19.9, 20.1 (CCH3, camph), 21.2, 21.4 (CH2CH3), 25.5, 27.1 (CH2, 
camph), 35.3, 36.4 (CHCH2), 36.9, 37.2 (CH2CH), 42.7 (CH2C=O, camph), 43.1 (CH, 
camph), 48.1 (CCH3, camph), 49.1 (SCH2, camph), 55.4, 56.1 (OCH3), 58.4 (CC=O, 
camph), 70.1, 70.3, 70.8, 70.9, 71.0, 71.1 (OCH2), 100.8, 103.6 (CH, Ar), 123.0, 124.2 
(C, Ar), 125.4, 126.7 (CH, Ar), 131.0, 135.5, 145.3, 154.8, 156.6, 157.1 (C, Ar), 214.1 
(C=O); [α]D -22.1 (c 0.99, CHCl3); HRMS (ESI): calcd. for C76H110NO19S2 as [M + 
NH4]+ 1404.7108; found 1404.7064 (main peak); and calcd. for C76H107O19S2 as [M + 
H]+ 1387.6842; found 1387.6790. 
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5.5.4.4 Dicamphorsulfonate diTBDMS resorcinarene diastereomeric mixture 
(62) 
The general camphorsulonylation 
procedure was applied with distal-
TBDMS resorcinarene (34) (0.052 g, 
0.0552 mmol), freshly-prepared (1S)-(+)-
camphorsulfonyl chloride (0.226 g, 0.901 
mmol), triethylamine (0.185 mL, 0.132 g, 
1.33 mmol), and dichloromethane (6 mL). 
The clear, slightly yellow reaction mixture 
was stirred under nitrogen at room 
temperature for 1 h. The reaction mixture was then washed with dilute HCl (10 mL, 1 
M), and the aqueous layer was extracted with dichloromethane (5 mL). The combined 
organic extracts were dried (MgSO4) and solvent removed under reduced pressure to 
give a glassy yellow solid (0.180 g) as crude product. A portion (0.119 g) of the crude 
product was subjected to preparative TLC (EtOAc – toluene 1:9) to give the purified 
diastereomic mixture (62) as a solid (0.025 g, 50%). The diastereomers could not be 
separated. 1H NMR (only key signals quoted, CDCl3) δ -0.12, -0.11, 0.10, 0.11 (4s, 4 
× 6 H, Si(CH3)2), 1.17, 1.19 (2s, 2 × 6 H, CH3 camph), 1.965 (d, J = 18.5 Hz, 2 H, CH2 
camph), 1.968 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.42 (apparent ddd, 4 H, CH2 camph), 
2.54-2.66 (m, 4 H, CH2 camph), 3.27, 3.30, 3.84, 3.85 (2AB, J = 15.0 Hz, 2 × 4 H, 
SCH2), 3.94, 3.50, 3.71, 3.72 (4s, 4 × 6 H, OCH3), 4.36-4.47, 4.49-4.61 (2m, 2 × 4 H, 
CHCH2), 6.15, 6.17, 6.63, 6.67 (4s, 4 × 2 H, ArH), 6.70-6.80 (m, 2 H, ArH), 6.83, 6.85 
(2s, 2 × 2 H, ArH). 
5.5.4.5 Attempted synthesis of dicamphorsulfonate resorcinarene  
Crude resorcinarene diastreomer mixture (62) (0.196 g) was combined with caesium 
carbonate (0.068 g, 0.209 mmol) and non-anhydrous dimethylformamide (4 mL), then 
heated at 90°C open to air. After 45 minutes, the reaction was diluted with brine (20 
mL) and extracted with diethyl ether till the organic extract was colourless and the 
aqueous layer was a slight yellow colour. The combined organic extracts were washed 
with brine, dried (MgSO4), filtered, and solvent removed under reduced pressure to 
give a brown oily residue (0.147 g). 1H NMR spectroscopy indicated a complex 
mixture of resorcinarenes was obtained. 
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5.5.4.6 Dicamphorsulfonate dibenzyloxyresorcinarene diastereomeric mixture 
The general camphorsulfonylation 
procedure was applied with distal-
benzyloxyresorcinarene (46) (0.044 g, 
0.0493 mmol), freshly-prepared (1S)-(+)-
camphorsulfonyl chloride (0.122 g, 0.487 
mmol), triethylamine (0.110 mL, 0.0798 
g, 0.789 mmol), and dichloromethane (3 
mL). The clear, slightly yellow reaction 
mixture was stirred under nitrogen at room 
temperature. After 1 hour 15 minutes, the reaction mixture was washed with dilute 
HCl (20 mL, 1 M). The layers were separated, and the aqueous phase was extracted 
with dichloromethane (5 mL). The combined yellow organic extracts were dried 
(MgSO4) and solvent removed under reduced pressure to give a colourless glassy solid 
(0.112 g) as the crude product. The crude product was subjected to preparative TLC 
(THF – petroleum spirits 3:7) to give the purified diastereomers as a crystalline white 
solid (0.051 g, 78%). The diastereomers could not be separated. 1H NMR (only key 
signals quoted, CDCl3) δ 1.20, 1.22 (2s, 2 × 6 H, CH3 camph), 1.98 (d, J = 18.5 Hz, 2 
H, CH2 camph), 1.99 (d, J = 18.5 Hz, 2 H, CH2 camph), 2.44 (apparent ddd, 4 H, CH2 
camph), 2.60-2.72 (m, 4 H, CH2 camph), 3.33, 3.34 (2s, 2 × 6 H, OCH3), 3.38, 3.40, 
3.97 , 4.01 (2AB, J = 14.9 Hz, 2 × 4 H, SCH2), 3.559, 3.562 (2s, 2 × 6 H, OCH3), 4.40-
4.49, 4.49-4.58 (2m, 2 × 4 H, CHCH2), 6.238, 6.244, 6.29, 6.34, 6.91, 6.93 (6s, 6 × 2 
H, ArH), 6.96-7.04 (m, 8 H, ArH), 7.09, 7.10 (2s, 2 × 2 H, ArH), 7.24-7.31 (m, 4 H, 
ArH), 7.32-7.38 (m, 8 H, ArH). 
5.5.5 Bis-crown resorcinarenes 
5.5.5.1 Bis-crown-5 resorcinarene (63) 
The general procedure for the synthesis of crown 
resorcinarenes was applied with resorcinarene (1) 
(0.419 g, 0.588 mmol), caesium carbonate (1.84 g, 
5.65 mmol), tetra(ethylene glycol) ditosylate (50) 
(0.595 mL, 0.739 g, 1.47 mmol), and anhydrous 
dimethylformamide (30 mL). After stirring at 90°C 
under nitrogen for 3 days, the solvent was removed under reduced pressure, and the 
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brown residue solid was taken up in water (50 mL) and filtered. The filtered solid was 
then purified by column chromatography (EtOAc 100%) to give the previously 
unreported product (63) as a white-yellow solid (0.138 g, 23%). For analysis, the 
white-yellow solid was recrystallised from CHCl3/MeOH to give pure (63) as white 
crystals: mp 159-177 °C (CHCl3/MeOH); 1H NMR (CDCl3) δ 0.89 (t, J = 7.3 Hz, 6 H, 
CH2CH3), 0.92 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.16-1.52 (m, 8 H, CH2CH3), 1.65-1.97 
(m, 8 H, CH2CH), 3.08-3.18, 3.26-3.50 (m, 2 H, 6 H, CH2O), 3.39 (s, 6 H, OCH3), 
3.50-3.79 (m, 12 H, CH2O), 3.79 (t, J = 4.1 Hz, 4 H, CH2O), 3.88-4.02 (m, 4 H, CH2O), 
3.92 (s, 6 H, OCH3), 4.27 (dt, J = 12.0, 4.1 Hz, 2 H, CH2O), 4.38-4.59 (m, 2 + 4 H, 
CH2O + CHCH2), 5.92, 6.08, 6.73, 7.18 (4s, 4 × 2 H, Ar); 13C NMR (CDCl3) δ 14.4, 
14.5 (CH2CH3), 21.5 (CH2CH3), 35.7, 35.8 (CHCH2), 36.7, 37.2 (CH2CH), 55.7, 56.0 
(OCH3), 69.0, 69.5, 70.1, 70.8, 70.9, 71.1, 71.5, 71.7 (OCH2), 97.8, 98.5 (CH, Ar), 
123.0, 123.9 (C, Ar), 126.1, 126.8 (CH, Ar), 128.5, 129.2, 154.4, 155.0, 156.0, 156.5 
(C, Ar) (note some signals are coincident); HRMS (ESI): calcd. for C60H88NO14 as [M 
+ NH4]+ 1046.6199; found 1046.6178 (main peak); and calc. for C60H85O14 as [M + 
H]+ 1029.5934; found 1029.5901. 
5.5.5.2 Bis-crown-6 resorcinarene (64) 
The general procedure for the synthesis of crown 
resorcinarenes was applied with resorcinarene 
(1) (0.451 g, 0.633 mmol), caesium carbonate 
(1.64 g, 5.03 mmol), penta(ethylene glycol) 
ditosylate (51) (0.686 mL, 0.864 g, 1.58 mmol), 
and anhydrous dimethylformamide (40 mL). 
After stirring at 90°C under nitrogen for 3 days, 
the solvent was removed under reduced pressure, and the brown residue solid was 
taken up in water (50 mL) and filtered. The filtered solid was then purified by column 
chromatography (acetone – DCM 40:60) to give the previously unreported product 
(64) as a glassy yellow solid (0.061 g, 8.6%). For analysis, the glassy yellow solid was 
recrystallised from CHCl3/MeOH to give pure (64) as large colourless crystals: mp 
125-126 °C (CHCl3/MeOH); 1H NMR (CDCl3) δ 0.91 (t, J = 7.3 Hz, 6 H, CH2CH3), 
0.92 (t, J = 7.3 Hz, 6 H, CH2CH3), 1.17-1.35, 1.35-1.51 (2m, 2 × 4 H, CH2CH3), 1.66-
1.81, 1.81-1.95 (2m, 2 × 4 H, CH2CH), 3.15-3.24, 3.25-3.39 (m, 2 H, 6 H, CH2O), 3.40 
(s, 6 H, OCH3), 3.42-3.50 (m, 2 H, CH2O), 3.56-3.61 (m, 4 H, CH2O), 3.61-3.80 (m, 
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16 H, CH2O), 3.91 (s, 6 H, OCH3), 3.93-4.02 (m, 6 H, CH2O), 4.22 (dt, J = 10.7, 3.9 
Hz, 2 H, CH2O), 4.32-4.40 (m, 2 H, CH2O), 4.40-4.53 (m, 4 H, CHCH2), 5.94, 6.09, 
6.58, 7.18 (4s, 4 × 2 H, ArH); 13C NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 21.4 
(CH2CH3), 35.6, 35.7 (CHCH2), 36.6, 37.0 (CH2CH), 55.7, 55.8 (OCH3), 69.2, 69.9, 
70.2, 70.4, 70.88, 70.89, 71.1, 71.3, 71.40, 71.43 (OCH2), 97.0, 98.4 (CH, Ar), 123.0, 
123.5 (C, Ar), 126.1, 126.5 (CH, Ar), 128.7, 129.2, 154.6, 155.0, 156.1, 156.6 (C, Ar) 
(note some signals are coincident); HRMS (ESI): calcd. for C64H92O16 as [M]+ 
1116.6380; found 1116.6344; and calc. for C64H93O16 as [M + H]+ 1117.6458; found 
1117.6406.  
5.5.5.3 Bis-crown-7 resorcinarene (65) 
The general procedure for the synthesis 
of crown resorcinarenes was applied with 
resorcinarene (1) (0.310 g, 0.435 mmol), 
caesium carbonate (1.14 g, 3.49 mmol), 
hexa(ethylene glycol) ditosylate (52) 
(0.517 mL, 0.634 g, 1.07 mmol), and 
anhydrous dimethylformamide (30 mL). 
After stirring at 90°C under nitrogen for 3 days, the solvent was removed under 
reduced pressure, and the brown residue solid was taken up in dichloromethane and 
filtered. The filtrate was then subjected to column chromatography (acetone – DCM 
50:50), followed by preparative TLC (acetone – DCM 40:60). The mostly-pure 
product was then recrystallised from CHCl3/MeOH to give the pure, previously 
unreported product (65) as off-white crystals (0.066 g). The mother liquor from the 
recrystallisation was subjected to preparative TLC (acetone – DCM 40:60) to recover 
more pure product (0.018 g), giving total (65) (0.084 g, 16%): mp 132 °C 
(CHCl3/MeOH); 1H NMR (CDCl3) δ 0.90 (t, J = 7.3 Hz, 6 H, CH2CH3), 0.91 (t, J = 
7.3 Hz, 6 H, CH2CH3), 1.18-1.35, 1.33-1.50 (2m, 2 × 4 H, CH2CH3), 1.64-1.80, 1.80-
1.95 (2m, 2 × 4 H, CH2CH), 3.11-3.24, 3.30-3.48 (m, 4 H, 6 H, CH2O), 3.40 (s, 6 H, 
OCH3), 3.56 (apparent t, 4 H, CH2O), 3.59-3.81 (m, 25 H, CH2O), 3.87-3.96 (m, 3 H, 
CH2O), 3.89 (s, 6 H, OCH3), 3.97-4.05 (m, 2 H, CH2O), 4.15-4.24, 4.24-33 (2m, 2 H, 
2 H, CH2O), 4.39-4.46, 4.46-4.53 (2m, 2 × 2 H CHCH2), 5.96, 6.09, 6.54, 7.16 (4s, 4 
× 2 H, ArH); 13C NMR (CDCl3) δ 14.4, 14.5 (CH2CH3), 21.41, 21.44 (CH2CH3), 35.5, 
35.6 (CHCH2), 36.8, 37.1 (CH2CH), 55.80, 55.84 (OCH3), 69.0, 69.6, 69.9, 70.4, 70.7, 
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70.78, 70.81, 70.86, 70.95, 71.0, 71.08, 71.13 (OCH2), 97.1, 98.5 (CH, Ar), 123.5, 
123.8 (C, Ar), 126.1, 126.4 (CH, Ar), 128.8, 129.4, 154.6, 155.1, 156.1, 156.5 (C, Ar); 
HRMS (ESI): calcd. for C88H104NO18 as [M + NH4]+ 1222.7248; found 1222.7235. 
5.5.6 General procedure for the hydrolysis of camphorsulfonate resorcinarene 
diastereomers 
The procedure by McIldowie and co-workers served as a guide.66 Diastereomerically-
pure camphorsulfonate resorcinarene (1 eq) was combined with sodium hydroxide (56 
eq), ethanol, and water. The resultant clear solution was heated at reflux under nitrogen 
overnight. The ethanol was evaporated, and the white residue was acidified with dilute 
HCl (10 mL, 1 M), then extracted with dichloromethane (3 × 3 mL). The combined 
organic extracts were dried (MgSO4) and solvent evaporated to give the enantio-pure 
resorcinarene. 
5.5.6.1 Enantio-pure crown-6 resorcinarene (57a)  
The general procedure was applied with resorcinarene (60a) (0.058 g, 0.0432 mmol), 
sodium hydroxide (0.097 g, 2.43 mmol), ethanol (5 mL) and water (2 mL) to give the 
previously unreported product (57a) (0.041 g, 100%) as an off-white solid: [α]D -20.2 
(c 1.10, CHCl3); mp 251-252 °C (CHCl3/MeOH). The 1H NMR spectrum matched that 
of racemic crown-6 resorcinarene (57). 
5.5.6.2 Enantio-pure crown-6 resorcinarene (57b) 
The general procedure was applied with resorcinarene (60b) (0.057 g, 0.0424 mmol), 
sodium hydroxide (0.010 g, 2.50 mmol), ethanol (5 mL) and water (2 mL) to give the 
previously unreported product (57b) (0.038 g, 98%) as a light-yellow solid: [α]D +21.4 
(c 1.08, CHCl3); mp 252-253 °C (CHCl3/MeOH). The 1H NMR spectrum matched that 
of racemic crown-6 resorcinarene (57). 
5.5.7 General method for the NMR titration of resorcinarenes with salbutamol 
sulfate 
Resorcinarene (5.2 µmol, ~ 5 mg) was weighed into an NMR tube, then DMSO-d6 
(0.5 mL) was added, followed by sonicating and heating with a heat gun to dissolve 
the resorcinarene. Resorcinarene (53) could not be entirely dissolved. After recording 
the 1H NMR spectrum, the appropriate amount of salbutamol sulfate was weighed in 
a micro spatula and directly added to the NMR tube. The salbutamol sulfate was 
dissolved with heating with a heat gun, and the 1H NMR spectrum recorded. The 
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process of adding salbutamol sulfate, dissolving and recording the 1H NMR spectrum 
was repeated for the appropriate number of data points. 
5.5.8 General method for membrane transport experiments 
Membrane transport experiments were performed at ambient conditions in a glass U-
tube with dimensions as shown in Figure 5.22. The source phase consisted of 
salbutamol sulfate (5 & 10 eq) dissolved in HCl (5 mL, 1 M) solution. MilliQ water (5 
mL) was used for the receiving phase. The membrane consisted of the resorcinarene 
crown derivative (1 eq, Table 5.6) dissolved in dichloromethane (20 mL), and was 
mixed with a stirrer bar (1 × 0.7 cm). The stirrer bar was rotated at 500 RPM using a 
magnetic stirrer. The U-tubes were kept upright ontop of the stirrer plate by placing 
together in an appropriately-sized box. 
 
Figure 5.22 Schematic of the U-tube apparatus used for the membrane transport experiments. 
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Table 5.6 Masses of crown resorcinarene membrane carriers. Two sets of experiments were 
conducted with the salbutamol being in 5 and 10 equivalents with respect to the 
resorcinarene. 
 
 
The membrane transport of salbutamol was monitored by UV-vis spectrometry using 
a GBC UV/VIS 916 UV-vis spectrometer scanning from 200-400 nm at a speed of 480 
nm/min and step size of 1 nm. The experimental procedure to monitor the membrane 
transport is illustrated in Figure 5.23. The receiving phase is first transferred to a vial 
using a Pasteur pipette to ensure thorough mixing of the receiving phase. Then the 
receiving phase is transferred to a cuvette that has been checked to have a zero UV-vis 
reading. The UV-vis spectrum of the receiving phase is recorded, then the receiving 
phase solutions are returned back to the U-tube, and the membrane transport 
experiment continued. The same procedure is repeated for the next analysis the 
following day. This procedure was carefully repeated for all membrane transport 
analyses to ensure best consistency and reproducibility of the results. 
Resorcinarene crown 0.0277 mmol (mg) 
diOBn crown-5 (53) 29 
diOBn crown-6 (54) 31 
diOBn crown-7 (55) 32 
diOH crown-5 (56) 25 
diOH crown-6 (57) 25 
diOH crown-7 (58) 27 
DicamphorSO2 crown-5 (59a) 36 
DicamphorSO2 crown-5 (59b) 36 
DicamphorSO2 crown-6 (60a) 38 
DicamphorSO2 crown-6 (60b) 38 
DicamphorSO2 crown-7 (61a) 39 
DicamphorSO2 crown-7 (61b) 39 
Bis-crown-5 (63) 17a 30 
Bis-crown-6 (64) 17b 31 
Bis-crown-7 (65) 17c 33 
Parent resorcinarene (1) 20 
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Figure 5.23 Analysis procedure for the membrane transport of salbutamol. 
The membrane transport experiments were reset according to the following work up 
procedure. The bulk of the source and receiving aqueous phases were first removed by 
Pasteur pipette, then the remainder of the aqueous phase was removed via a separatory 
funnel. The organic phase was dried (CaCl2), then the dichloromethane solvent was 
evaporated till the desired volume of 20 mL was achieved. 
5.5.9 Investigation procedure of enantio-pure crown resorcinarenes as 
enantioselective membrane carriers for the chiral resolution of salbutmol 
The receiving phase of membrane transport experiments with single enantiomer or 
diastereomer crown resoricnarenes was analysed by chiral HPLC by first transferring 
the receiving phase (~5 mL) from the U-tube into a vial (20 mL), then completely 
removing the water by freeze drying. The residue white solid was dissolved in a couple 
of drops of methanol, then filtered through a plug of PTFE filter paper, into a 300 µL 
Qsert vial for HPLC. The success of the salbutamol chiral resolution by the 
resorcinarene membrane carrier was determined using an Agilent 1200 series HPLC, 
equipped with an Astec® Chirobiotic-T® column under literature181 conditions listed 
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in the following Table 5.7. This procedure was performed on a replicate membrane 
transport experiment for confirmation of the result. 
Table 5.7 HPLC column conditions for the analysis of salbutamol enantioseparation.181 
Column Astec Chirobiotic-T, 25 cm × 4.6 mm I.D., 5 µm 
particles  
Column temperature Room temperature 
Mobile phase 15 mM ammonium formate in methanol 
Flow rate 1 mL/min 
Injection 10 µL 
Detector UV, 220 nm 
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6 Conclusions and future work 
In this project, three different strategies to synthesise a distally-functionalised 
tetramethoxyresorcinarene were explored. As summarised in Scheme 6.1, these were: 
calixarene rigid bridge, selective lithiation, and direct functionalisation of the 
resorcinarene phenols. The calixarene rigid bridge strategy yielded inconclusive 
results in the imine coupling of the resorcinarene to the calixarene. The strategy as a 
whole was realised to be impractical due to the many synthetic steps involved. The 
investigation into the selective lithiation of tetramethoxyresorcinarene indicated that 
the lithiation reaction was only applicable to a derivative of the resorcinarene with 
limited functionality.  
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Scheme 6.1 Summary of the three different strategies to synthesise a distally-functionalised 
tetramethoxyresorcinarene. 
(1)
(30)
 
(57) 
 219 
 
Fortunately, the direct functionalisation of the resorcinarene phenols provided the 
breakthrough. Although all other partially-functionalised resorcinarene products were 
produced, the target distally-functionalised tetramethoxyresorcinarene was the major 
product and was isolated in gram-quantities through this simple, single-step reaction. 
This key intermediate enabled the distal-bridging of tetramethoxyresorcinarene which 
was accomplished with crown ethers of three different lengths. The interesting basket-
shape architecture of these crown resorcinarenes, and their boat conformation, is 
evident in their crystal structures, which were obtained through X-ray diffraction on 
single crystals. The diastereomers of the crown 5-7 resorcinarenes were synthesised 
and separated, enabling the single enantiomers of the crown resorcinarenes to be 
obtained.  
These distally-bridged crown resorcinarenes were investigated and were shown to be 
membrane carriers for salbutamol hydrochloride to various extents, albeit a very low 
transport yield. In spite of the low level of transport, the single enantiomers for one of 
the best membrane carriers were obtained from the hydrolysis of the corresponding 
separated diastereomers. These single enantiomers were examined for the potential to 
act as enantioselective membrane carriers for salbutamol. Analysis of the receiving 
phases by chiral HPLC unfortunately revealed no enantioseparation of the salbutamol 
by these single crown resorcinarene enantiomers. This was also the case for the 
separated crown resorcinarene diastereomers. Nevertheless, this work is a proof of 
concept and the first demonstration of a bulk liquid membrane carrier for salbutamol. 
With further investigation into the optimisation of the chiral resorcinarene and 
membrane transport conditions, the transport yield could be improved, and 
enantioselective transport may be a possibility. 
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6.1 Project refinement 
6.1.1 Potential methods to enhance the enantioselectivity of the chiral 
resorcinarene 
The lack of enantioselective transport by these enantio-pure chiral cavities may be 
caused by conformational flexibility, which would allow both crown resorcinarene 
enantiomers to flex and accommodate both enantiomers of salbutamol. Therefore, it is 
of interest to make the chiral cavity of the resorcinarene more rigid. This could be 
accomplished by adding some rigidity to the flexible crown ether bridge by 
incorporation of an aromatic spacer, as per the strategy by Sansone et al. (Figure 
1.13).92 In the literature, the synthesis of a crown ether moiety with an aromatic spacer 
has been accomplished in two steps in an overall yield of 55% (Scheme 6.2).182  
OH
OH
+ O
OH
Cl
Cs2CO3
DMF
55%
K2CO3
DMF
TsCl
TEA
DCM
O
O
TsO
O
O
TsO
O
OH
OO
O
OH
O O
H7C3C3H7
C3H7 H7C3
O
O
O
O
 
Scheme 6.2 Proposed synthesis of a crown resorcinarene with a rigid aromatic spacer. 
Another method for making the cavity of the crown resorcinarene more rigid would 
be to connect the proximal aromatic rings with a short bridge, thereby converting the 
resorcinarene into a partial cavitand. This would not only rigidify the resorcinarene 
cavity, but also make it better defined as the aromatic rings would be prevented from 
bending out. It was for this reason of conformational rigidity that Duggan and co-
workers utilised a cavitand as a scaffold for their boronic acid membrane carriers.56 To 
bridge the proximal aromatic rings with a short bridge, complete demethylation of the 
resorcinarene is first required (Scheme 6.3). This should be possible through the 
procedure employed by Casnati et al.48 for the demethylation of a crown calixarene.    
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Scheme 6.3 Proposed synthesis of a chiral crown partial cavitand from a crown resorcinarene. 
Other than making the cavity more rigid, another method to enhance the chirality of 
the cavity may be to increase the steric bulk of the methoxy substituents which endow 
the cavity with chirality. Substituents such as isobutyl groups may give a greater 
expression of the chirality of the resorcinarene cavity in terms of steric bulk. The 
notion is that a chirality of greater steric bulk would increase steric hinderance and 
hence would prevent the other enantiomer of a guest molecule from binding with the 
resorcinarene. Some literature precedence of this idea may be offered by the work by 
Heaney and co-workers in separating camphorsulfonate diastereomers of the chiral 
resorcinarene (Scheme 5.3). In their work, a better separation was found for 
camphorsulfonate diastereomers with bulkier alkoxy groups.66 Perhaps the bulkier 
alkoxy groups increased the steric bulk of the resorcinarene chirality, which was 
responsible for the greater differences between their diastereomers.  
There are two possible strategies to convert the methoxy groups to a bulkier alkoxy 
group. The first strategy would be to construct the resorcinarene macrocycle from a 
subunit with a bulky alkoxy group such as an isopropoxy or cyclopentyl group.183 
However, the different alkoxy group may impact the partial distal selectivity of the 
silylation reaction – this would be an interesting investigation in itself (Scheme 6.6).  
  
(57) 
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The second strategy for obtaining a bulkier alkoxy group on the resorcinarene would 
be to alkylate the phenols of a dihydroxy crown resorcinarene with a bulky alkyl group 
(Scheme 6.4). The subsequent product could be demethylated to convert the four 
methoxy groups to phenols to increase functionality. However, if demethylation was 
required, the bulky alkoxy group needs to be unreactive under the harsh conditions for 
demethylation, which therefore excludes isopropoxy or cyclopentyl groups. 
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Scheme 6.4 A possible strategy for the synthesis of a crown resorcinarene with a bulkier alkoxy 
group. 
6.1.2 The need for more informative studies for enantioselective binding 
In this work, the combination of a crown resorcinarene host and salbutamol guest was 
investigated based on a general idea of the possible complimentary intermolecular 
interactions. However, there is a need for greater, more specific insight into how the 
chiral binding would occur. This knowledge would better enable the synthetic design 
of the resorcinarene membrane carrier, as well as enable more likely host-guest 
combinations to be investigated. Some knowledge of the binding could be provided 
by NMR titrations of the host and guest, as was briefly investigated with the crown 
resorcinarenes with salbutamol. However, more work is needed to develop this NMR 
titration technique to study salbutamol binding. In particular, the NMR solvent needs 
to be changed from dimethylsulfoxide, to a non-coordinating solvent like chloroform. 
(57) 
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For the reason of solubility, changing the solvent to chloroform would necessitate 
changing the sulfate counter anion of salbutamol to something more hydrophobic.  
Computational modelling of the binding would be of great assistance to predicting and 
understanding the binding between host and guest, as well as the influence of chirality. 
Since enantioselective binding is dependent on size and shape, computational 
modelling would be an ideal tool to visualise this event. In particular, the impact on 
enantioselective binding by the functional groups which endow the resorcinarene 
cavity with chirality could be better explored by a computational model. Factors such 
as the number, size, type and placement of these groups about the wider rim of the 
resorcinarene (as such in the resorcinarenes shown in Scheme 6.3) are of interest. 
6.1.3 Further investigation of membrane transport 
Regarding the membrane transport experiments, there remains much to be 
investigated. The membrane transport with these crown resorcinarenes could be 
performed on molecules other than salbutamol. Perhaps it would be helpful to study 
the transport of simple analogues of salbutamol, such as amino acids, to prove that 
something could be transported in substantial quantities by these crown resorcinarenes. 
This would enable establishment of the membrane transport procedures, as well as 
better understanding of the binding. 
Regarding the investigation of crown resorcinarenes as potential membrane carriers 
for salbutamol, it would be of interest to conduct the membrane transport experiments 
using various sizes of crown ethers as membrane carriers. This would show if crown 
ethers alone could act as membrane carriers for salbutamol, and also provide a control 
experiment for the membrane transport mediated the crown resorcinarenes. 
As discussed in this project, there are many variables and factors to be considered with 
the membrane transport experiments. There is still room for experimentation and 
improvement of the conditions for these experiments.  
The ideal counter anion for minimising passive transport of the salbutamol through a 
blank membrane is the sulfate anion. However, the great hydrophilicity of the sulfate 
anion also prevents it from being carried across the membrane by a membrane carrier. 
This was the rationale for replacing the salbutamol anion from a sulfate to a chloride 
in the membrane transport experiments of this project. However, the trade off for 
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having a less hydrophilic counter anion was an increase in the passive transport of 
salbutamol, which is undesirable. This conundrum could be solved by installation of a 
counter anion onto the membrane carrier that would provide a counter anion for the 
salbutamol during transport through the organic membrane, while also assisting in the 
binding of the salbutamol to the membrane carrier via electrostatic interactions. 
Furthermore, a membrane carrier with a counter anion functionality would also enable 
an overall charge balance of the source and receiving phases through an exchange of 
H+, as per the work by Adhikari et al.28 (Error! Reference source not found.). 
Counter anion functional groups such as carboxylates could be installed on the chiral 
crown resorcinarene by a two-step procedure beginning with selective O-alkylation 
with ethyl bromoacetate, followed by hydrolysis of the ester (Scheme 6.5). 
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Scheme 6.5 The crown resorcinarene could be functionalised with a carboxylate to act as a counter 
anion for the membrane transport of salbutamol. 
The passive transport of salbutamol could also be minimised by the choice of 
membrane solvent. Preliminary investigations in this project have suggested that less 
passive transport of salbutamol was occurring in dichloromethane than in chloroform. 
Perhaps this could be due to chloroform having a slightly stronger net dipole compared 
to dichloromethane. A more non-polar membrane solvent is desirable, since it should 
minimise passive transport, while still being able to dissolve the membrane carrier. 
Nevertheless, a membrane solvent which enables unambiguous results is sufficient, 
(57) 
 225 
 
since the ultimate goal would be to perform the membrane transport experiments with 
a solid supported membrane,15, 26 which would make an organic solvent in a bulk liquid 
membrane redundant. 
6.1.4 Further optimisation of resorcinarene distal functionalisation 
In the silylation of resorcinarene (1), the effect of the base, O-substituent, and reaction 
solvent was investigated. However, the potential impact of the reaction temperature, 
concentration and deprotonation time would be worth investigating. By adjusting these 
reaction conditions, it may be possible to increase the yield of the distally-
functionalised resorcinarene.  
Further experimentation of the distal functionalisation with other protecting groups 
may possibly give a better yield of the distally-functionalised product. In particular, 
protecting groups that are also stable under the Cs2CO3/DMF bridging conditions 
would be desirable to avoid the additional steps of replacing the TBDMS group. 
Potential candidates for this investigation could be a 2-(trimethylsilyl)ethoxymethyl 
ether, or an isopropyl ether, or a tert-butyl ether.  
6.2 Project extention 
In this work, the silylation was investigated on resorcinarenes with propyl and heptyl 
chains. It would be interesting to further investigate the impact of the resorcinarene 
alkyl chain on the proportions of the partially-functionalised products, particularly 
with a resorcinarene of short chain-length (Scheme 6.6). Additionally, the impact of 
the alkoxy group of the resorcinarene is completely unknown, since only 
tetramethoxyresorcinarenes were examined in this work. The silylation could be 
investigated on isopropoxy- and cyclopentyl- analogues of the chiral resorcinarene 
which are known in the literature.183 Perhaps, for this investigation, a HPLC separation 
method could be employed for a rapid preliminary determination of the proportions of 
the partially-silylated resorcinarene products.  
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Scheme 6.6 Potential further investigation into the impact of the resorcinarene alkyl chain and 
alkoxy group on the proportions of partially-silylated products. 
A different approach to modifying the chiral resorcinarene to be a potential membrane 
carrier would be to install a tri-armed bridge over the cavity of the resorcinarene 
(Figure 6.1). The synthesis of this product should be readily accomplished, since only 
one intramolecularly bridged product is possible. 
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Figure 6.1 A tri-armed bridged resorcinarene may be a potential membrane carrier. 
6.3 New directions 
In this project, the groundwork for the synthesis of partially-functionalised chiral 
resorcinarenes has been laid. The optimisation of the yield of other partially-
functionalised chiral resorcinarene products could be investigated with the goal of 
exploring a different avenue and application of the chiral resorcinarene. The ability to 
readily obtain practical amounts of partially-functionalised chiral resorcinarenes opens 
up new directions for research. The synthesis of chiral partial cavitands could be 
possible in the same manner as with the crown resorcinarene in Scheme 6.3. In this 
case, ethyl ethers could provide a more convenient group which is inert to the 
demethylation conditions (Scheme 6.7). In this strategy, the chirality of the 
resorcinarene cavity is preserved by O-alkylation of a partially-functionalised 
resorcinarene with ethoxy groups. Subsequent removal of all other O-substituents by 
hydrolysis and demethylation would furnish a chiral resorcinarene with neighbouring 
hydroxy groups that could accept a cavitand bridge. The synthesis of a chiral cavitand 
from an axially-chiral resorcinarene as such would be unprecedented, since most 
axially-chiral cavitands have been synthesised from octahydroxyresorcinarene. Chiral 
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cavitands are of current interest because of their ability for enantioselective 
complexation.184, 185 
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Scheme 6.7 Possible synthesis of a chiral partial cavitand from a partially-functionalised chiral 
resorcinarene. 
Referring back to Scheme 6.6, a resorcinarene alkoxy group that would be of great 
synthetic utility would be one which is readily cleavable, such as a benzyloxy or 
isopropoxy group. A readily-cleavable group as such would not require the non-
selective cleavage conditions as a methoxy group otherwise would. This would open 
up new synthetic opportunities such as the possibility for greater functionality in the 
potential partial cavitand synthesis (Scheme 6.7), through the use of alternative groups 
other than ethyl ethers. 
The ability to obtain distal-benzyloxyresorcinarene (46) (Figure 6.2) in gram 
quantities opens up many possibilities for the installation of various other bridges and 
functionalities at the distal positions of the chiral resorcinarene. Other than increasing 
the rigidty of the bridge as in Scheme 6.2, different functionalisations could be 
incorporated into the bridge, depending on the target application. For instance, an 
amino crown ether could be installed as the bridge to target carboxylate guests. Other 
than the formation of an ether linkage, other bridging linkages, such as the formation 
of a triazole by ‘click’ chemistry, could be explored.  
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Figure 6.2 Distal-benzyloxyresorcinarene (46) provides the key intermediate that enables other 
distal bridging or functionalisations of the tetramethoxyresorcinarene. 
A different avenue which could be explored for the chiral resorcinarene is its utilisation 
as a catalyst with potential enantioselectivity. In the literature, there are current 
investigations into calixarenes186 and resorcinarenes187 as potential catalysts.  
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Appendix A - 1 
 
2 Distal functionalisation of resorcinarene by a calixarene 
rigid bridge 
Synthesis of tetraamino- and tetraformyl- resorcinarenes via the 
ortho position 
(1) 14,36,56,76-tetrahydroxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
1.  
 
Appendix A1.1 (1) 1H NMR spectrum recorded in CDCl3. 
(2) 14,36,56,76-tetrahydroxy-16,34,54,74-tetramethoxy-15,35,55,75-
tetra(dimethylaminomethylene)-2,4,6,8-tetrapropylresorcin[4]arene 
2.  
 
Appendix A2.1 (2) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A2.2 (2) 13C NMR spectrum recorded in CDCl3. 
 
 
Appendix A - 2 
 
 
Appendix A2.3 (2) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A2.4 (2) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A2.5 (2) IR spectrum. 
 
Synthesis of tetraamino- and tetraformyl- resorcinarenes via 
phenols 
(3) 14,36,56,76-tetratrifluoromethanesulfonyl-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
3.  
 
Appendix A3.1 (3) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A3.2 (3) 13C NMR spectrum recorded in CDCl3. 
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Appendix A3.3 (3) DEPT-135 NMR spectrum recorded in CDCl3. 
(4) 14,36,56,76- tetramethoxy-16,34,54,74-tetranitrile -2,4,6,8-
tetrapropylresorcin[4]arene 
4.  
 
Appendix A4.1 (4) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A4.2 (4) 13C NMR spectrum in CDCl3. 
 
Appendix A4.3 (4) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A4.4 (4) HMBC NMR spectrum recorded in CDCl3. 
 
Appendix A4.5 (4) IR spectrum. 
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(5) 14,36,56,76-tetraformyl-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
5.  
 
Appendix A5.1 (5) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A5.2 (5) 13C NMR spectrum. 
 
Appendix A5.3 (5) DEPT-135 NMR spectrum recorded in CDCl3. 
(6) 14,36,56,76-tetra(amminomethyl)-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
6.  
 
Appendix A6.1 (6) 1H NMR spectrum recorded in CDCl3. 
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Appendix A6.2 (6) 13C NMR spectrum in CDCl3. 
 
Appendix A6.3 (6) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A6.4 (6) IR spectrum. 
Synthesis of a calixarene as a rigid bridge 
(8) 25,27-Dihydroxy-26,28-di-n-propoxycalixarene 
7.  
 
Appendix A7.1 (8) 1H NMR spectrum recorded in CDCl3. 
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Appendix A7.2 (8) IR spectrum. 
(9) 5,17-Diformyl-25,27-dihydroxy-26,28-di-n-propoxycalixarene 
8.  
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Appendix A8.1 (9) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A8.2 (9) IR spectrum. 
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(10) 5,17-Dinitro-26,28-dipropoxycalixarene 
9.  
 
Appendix A9.1 (10) 1H NMR spectrum recorded in CDCl3. 
(11) 5,17-Diamino-26,28-dipropoxycalixarene 
10.  
 
Appendix A10.1 (11) 1H NMR spectrum recorded in CDCl3. 
 
(12) di((ethoxycarbonyl)methoxy) calixarene cone 
11.  
 
Appendix A11.1 (12) 1H NMR spectrum recorded in CDCl3. 
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Appendix A11.2 (12) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A11.3 (12) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A11.4 (12) HSQC NMR spectrum recorded in CDCl3. 
 
 
Appendix A - 11 
 
 
Appendix A11.5 (12) IR spectrum. 
 
(13) di((ethoxycarbonyl)methoxy) calixarene partial cone 
12.  
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Appendix A12.1 (13) 1H NMR spectrum recorded in CDCl3. 
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Appendix A12.2 (13) 13C NMR spectrum. 
 
Appendix A12.3 (13) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A12.4 (13) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A12.5 (13) IR spectrum. 
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Appendix A13.1 (14) 1H NMR spectrum recorded in CDCl3. 
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Appendix A13.2 (14) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A13.3 (14) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A13.4 (14) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A13.5 (14) COSY NMR spectrum recorded in CDCl3. 
 
(15) Allyl calixarene partial cone 
14.  
 
Appendix A14.1 (15) 1H NMR spectrum recorded in CDCl3. 
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Appendix A14.2 (15) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A14.3 (15) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A14.4 (15) HSQC NMR spectrum recorded in CDCl3. 
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(16) Allyl calixarene 1,3-alternate 
15.  
 
Appendix A15.1 (16) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A15.2 (16) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A15.3 (16) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A15.4 (16) HSQC NMR spectrum recorded in CDCl3. 
 
 
(17) 25,26,27,28-Tetrapropoxycalixarene 
16.  
 
Appendix A16.1 (17) 1H NMR spectrum recorded in CDCl3. 
(18) 5,11,17,23-Tetrabromo-25,26,27,28-tetrapropoxycalixarene 
17.  
 
Appendix A17.1 (18) 1H NMR spectrum recorded in CDCl3. 
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(19) 5,17-Dibromo-25,26,27,28-tetrapropoxycalixarene 
18.  
 
Appendix A18.1 (19) 1H NMR spectrum recorded in CDCl3. 
(20) 5,17-Dibromo-22,23-dinitro-25,26,27,28-tetrapropoxycalixarene 
19.  
 
Appendix A19.1 (20) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A19.2 (20) 13C NMR spectrum. 
 
Appendix A19.3 (20) DEPT-135 NMR spectrum recorded in CDCl3. 
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(21) 5,17-Diamino-22,23-dibromo-25,26,27,28-tetrapropoxycalixarene 
20.  
 
Appendix A20.1 (21) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A20.2 (21) 13C NMR spectrum recorded in CDCl3. 
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3 Distal functionalisation of resorcinarene by selective 
lithiation 
(22) 14,36,56,76-tetrabenzyloxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
21.  
 
Appendix A21.1 (22) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A21.2 (22) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A21.3 (22) DEPT-135 NMR spectrum recorded in CDCl3. 
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(23) 14,36,56,76-tetramethoxymethyl-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
22.  
 
Appendix A22.1 (23) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A22.2 (23) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A22.3 (23) DEPT-135 NMR spectrum recorded in CDCl3. 
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(24) - (28) Lithiation of  14,36,56,76-tetramethoxymethyl-16,34,54,74-tetramethoxy-
2,4,6,8-tetrapropylresorcin[4]arene (23) 
23.  
 
Appendix A23.1 (28) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A23.2 (27) 1H NMR spectrum recorded in CDCl3. 
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Appendix A23.3 (26) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A23.4 (25) 1H NMR spectrum recorded in CDCl3. 
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Appendix A23.5 (24) 1H NMR spectrum recorded in CDCl3. 
(29) 14,36,56,76-tetraethoxy-16,34,54,74-tetramethoxy-2,4,6,8-
tetrapropylresorcin[4]arene 
1.  
 
Appendix A1.1 (29) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A1.2 (29) 13C NMR spectrum recorded in CDCl3. 
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Appendix A1.3 (29) DEPT-135 NMR spectrum recorded in CDCl3. 
(30) Synthesis of 14,36,56,76-tetraethoxy-16,34,54,74-tetramethoxy-15,55-
di(methylthio)-2,4,6,8-tetrapropylresorcin[4]arene 
2.  
 
Appendix A2.1 (30) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A2.2 (30) 13C NMR spectrum recorded in CDCl3. 
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Appendix A2.3 (30) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A2.4 (30) HSQC NMR spectrum recorded in CDCl3. 
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4 Direct distal functionalisation of resorcinarene phenols 
TBDMS 
(32) Mono TBDMS 
3.  
 
Appendix A3.1 (32) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A3.2 (32) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A3.3 (32) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A3.4 (32) HSQC NMR spectrum recorded in CDCl3. 
 
(33) Proximal TBDMS 
4.  
 
Appendix A4.1 (33) 1H NMR spectrum recorded in CDCl3. 
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Appendix A4.2 (33) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A4.3 (33) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A4.4 (33) HSQC NMR spectrum recorded in CDCl3.  
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(34) Distal TBDMS 
5.  
 
Appendix A5.1 (34) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A5.2 (34) 1H NMR spectrum recorded in DMSO-d6. 
 
Appendix A5.3 (34) 1H NMR spectrum recorded in acetone-d6. 
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Appendix A5.4 (34) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A5.5 (34) 13C NMR spectrum recorded in acetone-d6. 
 
Appendix A5.6 (34) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A5.7 (34) DEPT-135 NMR spectrum in recorded acetone-d6. 
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Appendix A5.8 (34) HSQC NMR spectrum recorded in CDCl3. 
 
(35) Tri TBDMS 
6.  
 
Appendix A6.1 (35) 1H NMR spectrum recorded in CDCl3. 
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Appendix A6.2 (35) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A6.3 (35) DEPT-135 NMR spectrum recorded in CDCl3. 
TBDMS heptyl 
(36) Mono TBDMS heptyl 
7.  
 
Appendix A7.1 (36) 1H NMR spectrum recorded in CDCl3. 
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Appendix A7.2 (36) 1H NMR spectrum recorded in CDCl3 with D2O exchange. 
 
Appendix A7.3 (36) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A7.4 (36) DEPT-135 NMR spectrum recorded in CDCl3. 
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(37) Proximal TBDMS heptyl 
8.  
 
Appendix A8.1 (37) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A8.2 (37) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A8.3 (37) DEPT-135 NMR spectrum recorded in CDCl3. 
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(38) Distal TBDMS heptyl 
9.  
 
Appendix A9.1 (38) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A9.2 (38) 1H NMR spectrum recorded in acetone-d6. 
 
Appendix A9.3 (38) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A9.4 (38) 13C NMR spectrum recorded in acetone-d6. 
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Appendix A9.5 (38) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A9.6 (38) DEPT-135 NMR spectrum recorded in acetone. 
 
(39) Tri TBDMS heptyl 
10.  
 
Appendix A10.1 (36)  1H NMR spectrum recorded in CDCl3. 
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Appendix A10.2 (36)  13C NMR spectrum recorded in CDCl3. 
 
Appendix A10.3 (36)  DEPT-135 NMR spectrum recorded in CDCl3. 
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TBDPS 
(40) Mono TBDPS 
11.  
 
Appendix A11.1 (40) 1H NMR spectrum. 
 
Appendix A11.2 (40) 13C NMR spectrum. 
 
Appendix A11.3 (40) DPET-135 NMR spectrum. 
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Appendix A11.4 (40) HSQC NMR spectrum. 
(41) Proximal TBDPS 
12.  
 
Appendix A12.1 (41) 1H NMR spectrum. 
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Appendix A12.2 (41) 13C NMR spectrum. 
 
Appendix A12.3 (41) DEPT-135 NMR spectrum. 
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(42) Distal TBDPS 
13.  
 
Appendix A13.1 (42) 1H NMR spectrum. 
 
Appendix A13.2 (42) 13C NMR spectrum. 
 
Appendix A13.3 (42) DEPT-135 NMR spectrum. 
  
 
 
Appendix A - 44 
 
(43) Tri TBDPS 
14.  
 
Appendix A14.1 (43) 1H NMR spectrum. 
Benzyl ether 
(44) Mono benzyl ether 
15.  
 
 
Appendix A15.1 (44) 1H NMR spectrum recorded in CDCl3. 
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Appendix A15.2 (44) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A15.3 (44) DEPT-135 NMR spectrum recorded in CDCl3. 
(45) Proximal benzyl ether 
16.  
 
Appendix A16.1 (45) 1H NMR spectrum recorded in CDCl3. 
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Appendix A16.2 (45) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A16.3 (45) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A16.4 (45) HSQC NMR spectrum recorded in CDCl3. 
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(46) Distal benzyl ether 
17.  
 
Appendix A17.1 (46) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A17.2 (46) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A17.3 (46) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A17.4 (46) HSQC NMR spectrum recorded in CDCl3. 
(47) Tri benzyl ether 
18.  
 
Appendix A18.1 (47) 1H NMR spectrum recorded in CDCl3. 
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Appendix A18.2 (47) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A18.3 (47) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A18.4 (47) COSY NMR spectrum recorded in CDCl3. 
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Appendix A18.5 (47) HSQC NMR spectrum recorded in CDCl3. 
Replacement of TBDMS protecting groups 
(48) 14,56-di-tert-butyldimethylsilylether-36,76-dimethanesulfonyl-16,34,54,74-
tetramethoxy-2,4,6,8-tetrapropylresorcin[4]arene  
19.  
 
Appendix A19.1 (48) 1H NMR spectrum recorded in CDCl3. 
 
 
Appendix A - 51 
 
 
Appendix A19.2 (48) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A19.3 (48) HSQC NMR spectrum recorded in CDCl3. 
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(49) 14,56-dibenzyloxy-36,76-di-tert-butyldimethylsilylether-16,34,54,74-
tetramethoxy-2,4,6,8-tetrapropylresorcin[4]arene  
20.  
 
Appendix A20.1 (49) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A20.2 (49) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A20.3 (49) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A20.4 (49) HSQC NMR spectrum recorded in CDCl3. 
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5 Synthesis of crown resorcinarenes 
Poly(ethylene glycol)ditoluenesulfonate 
(50) Tetra(ethylene glycol)ditoluenesulfonate 
21.  
 
Appendix A21.1 (50) 1H NMR spectrum recorded in CDCl3. 
(51) Penta(ethylene glycol)ditoluenesulfonate 
22.  
 
Appendix A22.1 (51) 1H NMR spectrum recorded in CDCl3. 
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Appendix A22.2 (51) 13C NMR spectrum recorded in CDCl3. 
(52) Hexa(ethylene glycol)ditoluenesulfonate 
23.  
 
Appendix A23.1 (52) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A23.2 (52) 13C NMR spectrum recorded in CDCl3. 
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Dibenzyloxy crown resorcinarenes 
(53) Dibenzyloxy crown-5 resorcinarene 
24.  
 
Appendix A24.1 (53) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A24.2 (53) 1H NMR spectrum recorded in DMSO-d6. 
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Appendix A24.3 (53) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A24.4 (53) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A24.5 (53) HSQC NMR spectrum recorded in CDCl3. 
 
 
Appendix A24.6 (53) HMBC NMR spectrum recorded in CDCl3. 
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(54) Dibenzyloxy crown-6 resorcinarene 
25.  
 
Appendix A25.1 (54) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A25.2 (54) 1H NMR spectrum recorded in DMSO-d6. 
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Appendix A25.3 (54) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A25.4 (54) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A25.5 (54) HSQC NMR spectrum recorded in CDCl3. 
 
(55) Dibenzyloxy crown-7 resorcinarene 
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26.  
 
Appendix A26.1 (55) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A26.2 (55) 1H NMR spectrum recorded in DMSO-d6. 
 
Appendix A26.3 (55) 13C NMR spectrum recorded in CDCl3. 
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Appendix A26.4 (55) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A26.5 (55) HSQC NMR spectrum recorded in CDCl3. 
Dihydroxy crown resorcinarenes 
(56) Dihydroxy crown-5 resorcinarene 
27.  
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Appendix A27.1 (56) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A27.2 (56) 1H NMR spectrum recorded in DMSO-d6. 
 
Appendix A27.3 (56) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A27.4 (56) DEPT-135 spectrum recorded in CDCl3. 
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Appendix A27.5 (56) COSY spectrum recorded in CDCl3. 
 
Appendix A27.6 (56) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A27.7 (56) HMBC NMR spectrum recorded in CDCl3. 
 
Appendix A27.8 (56) IR spectrum. 
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(57) Dihydroxy crown-6 resorcinarene 
28.  
 
Appendix A28.1 (57) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A28.2 (57) 1H NMR spectrum recorded in DMSO-d6. 
 
Appendix A28.3 (57) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A28.4 (57) 13C NMR spectrum recorded in DMSO-d6. 
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Appendix A28.5 (57) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A28.6 (57) DEPT-135 spectrum recorded in DMSO-d6. 
 
Appendix A28.7 (57) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A28.8 (57) HMBC NMR spectrum recorded in CDCl3. 
 
Appendix A28.9 (57) IR spectrum. 
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(58) Dihydroxy crown-7 resorcinarene 
29.  
 
Appendix A29.1 (58) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A29.2 (58) 1H NMR spectrum recorded in DMSO-d6. 
 
Appendix A29.3 (58) 13C NMR spectrum recorded in CDCl3. 
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Appendix A29.4 (58) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A29.5 (58) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A29.6 (58) HMBC NMR spectrum recorded in CDCl3.  
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Camphorsulfonate crown resorcinarene diastereomers 
(59a) Dicamphorsulfonate crown-5 resorcinarene 
30.  
 
Appendix A30.1 (59a) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A30.2 (59a) 13C NMR spectrum recorded in CDCl3. 
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Appendix A30.3 (59a) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A30.4 (59a) HSQC NMR spectrum (expansion) recorded in CDCl3. 
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Appendix A30.5 (59a) HSQC NMR spectrum recorded in CDCl3. 
 
(59b) Dicamphorsulfonate crown-5 resorcinarene 
31.  
 
Appendix A31.1 (59b) 1H NMR spectrum recorded in CDCl3. 
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Appendix A31.2 (59b) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A31.3 (59b) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A31.4 (59b) HSQC NMR spectrum (expansion) recorded in CDCl3. 
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Appendix A31.5 (59b) HSQC NMR spectrum recorded in CDCl3. 
 
(60a) Dicamphorsulfonate crown-6 resorcinarene 
32.  
 
Appendix A32.1 (60a) 1H NMR spectrum recorded in CDCl3. 
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Appendix A32.2 (60a) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A32.3 (60a) DEPT-135 spectrum recorded in CDCl3. 
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Appendix A32.4 (60a) HSQC NMR spectrum (expansion) recorded in CDCl3. 
 
 
Appendix A32.5 (60a) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A32.6 (60a) IR spectrum. 
 
(60b) Dicamphorsulfonate crown-6 resorcinarene 
33.  
 
Appendix A33.1 (60b) 1H NMR spectrum recorded in CDCl3. 
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Appendix A33.2 (60b) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A33.3 (60b) DEPT-135 spectrum recorded in CDCl3. 
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Appendix A33.4 (60b) HSQC NMR spectrum (expansion) recorded in CDCl3. 
 
 
Appendix A33.5 (60b) HSQC NMR spectrum recorded in CDCl3. 
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Appendix A33.6 (60b) IR spectrum. 
 
(61a) Dicamphorsulfonate crown-7 resorcinarene 
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Appendix A34.1 (61a) 1H NMR spectrum recorded in CDCl3. 
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Appendix A34.2 (61a) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A34.3 (61a) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A34.4 (61a) HSQC NMR spectrum (expansion) recorded in CDCl3. 
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Appendix A34.5 (61a) HSQC NMR spectrum recorded in CDCl3. 
 
(61b) Dicamphorsulfonate crown-7 resorcinarene 
35.  
 
Appendix A35.1 (61b) 1H NMR spectrum recorded in CDCl3. 
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Appendix A35.2 (61b) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A35.3 (61b) DEPT-135 spectrum recorded in CDCl3. 
 
Appendix A35.4 (61b) HSQC NMR spectrum (expansion) recorded in CDCl3. 
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Appendix A35.5 (61b) HSQC NMR spectrum recorded in CDCl3. 
 
(62) Diastereomeric mixture of dicamphorsulfonate diTBDMS resorcinarene 
36.  
 
Appendix A36.1 Diastereomeric mixture (62) 1H NMR spectrum recorded in CDCl3. 
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Diastereomeric mixture of dicamphorsulfonate dibenzyloxy resorcinarene 
37.  
 
Appendix A37.1 Diastereomeric mixture dicamphorsulfonate dibenzyloxy resorcinarene 1H NMR 
spectrum recorded in CDCl3. 
Bis-crown resorcinarenes 
(63) Bis-crown-5 resorcinarene 
38.  
 
Appendix A38.1 (63) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A38.2 (63) 13C NMR spectrum recorded in CDCl3. 
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Appendix A38.3 (63) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A38.4 (63) HSQC NMR spectrum recorded in CDCl3. 
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(64) Bis-crown-6 resorcinarene 
39.  
 
Appendix A39.1 (64) 1H NMR spectrum recorded in CDCl3. 
 
Appendix A39.2 (64) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A39.3 (64) DEPT-135 NMR spectrum recorded in CDCl3. 
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Appendix A39.4 (64) HSQC NMR spectrum recorded in CDCl3. 
 
(65) Bis-crown-7 resorcinarene 
40.  
 
Appendix A40.1 (65) 1H NMR spectrum recorded in CDCl3. 
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Appendix A40.2 (65) 13C NMR spectrum recorded in CDCl3. 
 
Appendix A40.3 (65) DEPT-135 NMR spectrum recorded in CDCl3. 
 
Appendix A40.4 (65) HSQC NMR spectrum recorded in CDCl3. 
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Appendix B - 1 
General experimental information 
Crystal structures of the compounds were determined by X-ray diffraction methods by 
A/Prof. Chiara Massera from the University of Parma, Italy.  
For the samples Mono-TBDMS (32), Prox-TBDMS (33), Distal-TBDMS (34), Mono-
TBDPS (40), Distal-TBDPS (42), Distal-OBn (46), Distal-TBDMS (38), diOBn 
diTBDMS (49), diOBn crown-6 (54), diOBn crown-7 (55) and diOH crown-6 (57) 
intensity data and cell parameters were recorded at 190(2) K on a Bruker ApexII 
diffractometer (MoK radiation  = 0.71073 Å) equipped with a CCD area detector 
and a graphite monochromator.  
For diMeSO2 diTBDMS (48) intensity data and cell parameters were recorded at 
298(2) K on a Bruker Smart Breeze. 
For dicamphorsulfonate crown-6 (60) intensity data and cell parameters were recorded 
at 190(2) K on a Bruker D8 Venture PhotonII diffractometer (CuK radiation  = 
1.54178 Å).  
All raw frame data acquired on Bruker instruments were processed using the programs 
SAINT and SADABS to yield the reflection data files.1-3  
For Tri-TBDMS (35) and for diOBn crown-5 (53), intensity data and cell parameters 
were recorded at 100(2) K at the ELETTRA Synchrotron Light Source (CNR Trieste, 
strada statale 14, Area Science Park, 34149, Basovizza, Trieste, Italy), and the raw 
frame data were processed using the program package CrysAlisPro 1.171.38.41.4  
All structures were solved by Direct Methods using the SIR97 program5 and refined 
on Fo2 by full-matrix least-squares procedures, using the SHELXL-2014/7 program6 
in the WinGX suite v.2014.1.7 
The crystals of Tri-TBDMS (35), Mono-TBDPS (40) and Distal-TBDPS (42) 
diffracted poorly, but the data were good enough to establish the crystal and molecular 
structure of the products.  
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All non-hydrogen atoms were refined with anisotropic atomic displacements, unless 
in cases where disorder was present (solvent, alkyl chains, etc.). The hydrogen atoms 
were included in the refinement at idealized geometry (C-H 0.96, 0.93 and 0.98 Å for 
methyl, aromatic and methylenic H atoms, respectively) and refined “riding” on the 
corresponding parent atoms. The weighting schemes used in the last cycle of 
refinement were w = 1/ [2Fo2 + (0.0391P)2], w = 1/ [2Fo2 + (0.0672P)2 + 0.6860P], 
w = 1/ [2Fo2 + (0.0764P)2 + 2.4161P], w = 1/ [2Fo2 + (0.4203P)2], w = 1/ [2Fo2 + 
(0.1289P)2], w = 1/ [2Fo2 + (0.0P)2], w = 1/ [2Fo2 + (0.0897P)2 + 0.9194P], w = 1/ 
[2Fo2 + (0.1210P)2 + 2.9812P], w = 1/ [2Fo2 + (+ 1.4916P)2+ 1.4759P], w = 1/ [2Fo2 
+ (0.0948 P)2+ 2.2146P], w = 1/ [2Fo2 + (0.1816 P)2 + 4.6366 P], w = 1/ [2Fo2 + 
(0.4158P)2], w = 1/ [2Fo2 + (0.0721P)2 + 1.4916P], w = 1/ [2Fo2 + (0.3255P)2] and 
w = 1/ [2Fo2 + (0.1593P)2 + 0.2094P], where P = (Fo2 + 2Fc2)/3, for Mono-TBDMS 
(32), Prox-TBDMS (33), Distal-TBDMS (34), Tri-TBDMS (35), Mono-TBDPS (40), 
Distal-TBDPS (42), Distal-OBn (46), Distal-TBDMS (38), diMeSO2 diTBDMS (48), 
diOBn diTBDMS (49), diOBn crown-5 (53), diOBn crown-6 (54), diOBn crown-7 
(55), diOH crown-6 (57) and dicamphSO2 crown-6 (60) respectively.  
For diOBn crown-6 (54) the calculated molar mass, density and absorption coefficient 
include two disordered water molecules per cell which do not appear in the final files 
because of the refinements carried out with data subjected to SQUEEZE.8 
Crystal data and experimental details for data collection and structure refinement are 
reported in the following Table B1 to Table B7. 
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Crystal data and structure refinement  
Table B1 Crystal data and structure refinement information for compounds Mono-TBDMS (32) 
and Prox-TBDMS (33). 
Compound Mono-TBDMS (32) Prox-TBDMS (33) 
empirical formula C50H70O8Si C56H84O8Si2 
M 827.15 941.41 
crys syst Triclinic Triclinic 
space group P-1 P-1 
a/Å 11.467(3) 13.582(1) 
b/Å 14.222(4) 14.896(1) 
c/Å 16.757(5) 16.117(2) 
/° 103.940(5) 109.063(2) 
/° 109.484(6) 99.137(2) 
/° 98.901(6) 111.256(2) 
V/Å3 2416.5(12) 2726.3(4) 
Z 2 2 
ρ /g cm–3 1.137 1.147 
 /mm–1 0.098 0.116 
F(000) 896 1024 
total reflections 13171 39382 
unique reflections (Rint) 8088 (0.0547) 13777 (0.0810) 
observed reflections [Fo>4σ(Fo)] 4083 8068 
GOF on F2a 1.013 1.007 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0611, 0.1108 0.0606, 0.1403 
largest diff. peak and hole (eÅ–3) 0.291, -0.338 1.182, -0.723 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2.  
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Table B2 Crystal data and structure refinement information for compounds Distal-TBDMS (34) 
and Tri-TBDMS (35). 
Compound Distal-TBDMS (34) Tri-TBDMS (35) 
empirical formula C56H84O8Si2 C62H98O8Si3 
M 941.41 1055.67 
crys syst monoclinic Monoclinic 
space group P21/n P21/n 
a/Å 14.039(2) 29.220(5 
b/Å 26.618(3) 10.963(2) 
c/Å 14.620(2) 41.528(8) 
/° - - 
/° 93.690(2) 103.399(9) 
/° - - 
V/Å3 5452.0(12) 12941(4) 
Z 4 8 
ρ /g cm–3 1.147 1.084 
 /mm–1 0.116 0.089 
F(000) 2048 4608 
total reflections 58411 195561 
unique reflections (Rint) 9328 (0.1197) 41455 (0.0581) 
observed reflections [Fo>4σ(Fo)] 4915 27378 
GOF on F2a 1.002 1.024 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0610, 0.1431 0.1497, 0.4188 
largest diff. peak and hole (eÅ–3) 0.712, -0.316 5.387, -1.175 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2. 
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Table B3 Crystal data and structure refinement information for compounds Mono-TBDPS (40) 
and Distal-TBDPS (42). 
Compound Mono-TBDPS (40) Distal-TBDPS (42) 
empirical formula C60H74O8Si∙2H2O C76H91O8Si2∙ ½ H2O 
M 987.31 1198.68 
crys syst Monoclinic Triclinic 
space group C 2/c P-1 
a/Å 26.098(9) 14.161(6) 
b/Å 18.207(9) 14.414(6) 
c/Å 25.589(9) 18.256(7) 
/° - 104.816(9) 
/° 99.641(7) 95.977(9) 
/° - 98.881(9) 
V/Å3 11987(8) 3519(2) 
Z 8 2 
ρ /g cm–3 1.094 1.131 
 /mm–1 0.092 0.104 
F(000) 4256 1290 
total reflections 24615 28261 
unique reflections (Rint) 8716 (0.2574) 8541 (0.3872) 
observed reflections [Fo>4σ(Fo)] 2934 2587 
GOF on F2a 1.001 0.826 
R indices [Fo>4σ(Fo)]bR1, wR2 0.1049, 0.2409 0.00950, 0.2160 
largest diff. peak and hole (eÅ–3) 1.038, -0.347 0.952, -0.293 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2. 
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Table B4 Crystal data and structure refinement information for compounds Distal-OBn (46) and 
Distal-TBDMS (38). 
Compound Distal-OBn (46) Distal-TBDMS (38) 
empirical formula C58H68O8 C58H68O8 
M 893.12 1165.82 
crys syst Triclinic Triclinic 
space group P-1 P-1 
a/Å 15.559(2) 12.635(1) 
b/Å 16.121(2) 14.113(1) 
c/Å 21.417(2) 20.164(2) 
/° 77.881(2) 90.250(1) 
/° 71.290(2) 95.111(1) 
/° 80.371(2) 96.340(1) 
V/Å3 4945.6(10) 3559.0(5) 
Z 4 2 
ρ /g cm–3 1.199 1.088 
 /mm–1 0.078 0.100 
F(000) 1920 1280 
total reflections 70215 36741 
unique reflections (Rint) 24690 (0.0372) 11379 (0.0494) 
observed reflections [Fo>4σ(Fo)] 16183 7897 
GOF on F2a 1.005 1.001 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0555, 0.1495 0.0682, 0.1892 
largest diff. peak and hole (eÅ–3) 0.745, -0.475 0.979,  -0.563 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2. 
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Table B5 Crystal data and structure refinement information for compounds diMeSO2 diTBDMS 
(48) and diOBn diTBDMS (49). 
Compound diMeSO2 diTBDMS 
(48) 
diOBn diTBDMS 
(49) 
empirical formula C58H88O12S2Si2 C70H96O8Si2 
M 1097.58 1121.64 
crys syst Triclinic Triclinic 
space group P-1 P-1 
a/Å 12.490(2) 14.0561(6) 
b/Å 13.875(3) 14.2020(6) 
c/Å 19.606(2) 17.9849(8) 
a/° 77.472(2) 87.243(1) 
b/° 86.473(2)  69.162(1) 
g/° 74.004(2) 81.920(1) 
V/Å3 3188.4(9) 3322.1(2) 
Z 2 2 
ρ /g cm–3 1.143 1.121 
m /mm–1 0.175 0.105 
F(000) 1184 1216 
total reflections 39204 41481 
unique reflections (Rint) 13119 (0.0441) 13880 (0.0335) 
observed reflections [Fo>4σ(Fo)] 8350 10354 
GOF on F2a 1.008 1.006 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0755, 0.2159 0.0597, 0.1627 
largest diff. peak and hole (eÅ–3) 1.333, -0.492 2.060, -0.739 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2.  
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Table B6 Crystal data and structure refinement information for compounds diOBn crown-5 (53) 
and diOBn crown-6 (54). 
Compound diOBn crown-5 (53) diOBn crown-6 (54). 
empirical formula C66H82O11 C68H88O13 
M 1051.31 1113.38 
crys syst Monoclinic Triclinic 
space group P21/n P-1 
a/Å 19.1720(2) 12.1540(4) 
b/Å 24.7360(3) 14.4487(5) 
c/Å 24.7452(3) 19.1555(6) 
/°  77.867(2) 
/° 104.106(1) 79.263(2) 
/°  88.568(2) 
V/Å3 11381.3(2) 3230.8(2) 
Z 8 2 
ρ /g cm–3 1.227 1.144 
 /mm–1 0.053 0.078 
F(000) 4528 1200 
total reflections 221915 33942 
unique reflections (Rint) 39506 (0.0739) 13197 (0.0393) 
observed reflections [Fo>4σ(Fo)] 34102 7513 
GOF on F2a 1.004 1.027 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0838, 0.2400 0.1316, 0.4296 
largest diff. peak and hole (eÅ–3) 2.364, -0.965 1.429, -0.932 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2.  
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Table B7 Crystal data and structure refinement information for compounds diOBn crown-7 (55), 
and diOH crown-6 (57). 
Compound diOBn crown-7 (55) diOH crown-6 (57) 
empirical formula C71H92O13Cl2 C54H76O13 
M 1224.34  933.14 
crys syst Monoclinic Triclinic 
space group P21/n P-1 
a/Å 12.155(1) 10.9616(5) 
b/Å 50.046(5) 14.3251(7) 
c/Å 12.350(1) 16.7964(7) 
/°  97.860(3) 
/° 119.407(2) 99.661(3) 
/°  100.439(3) 
V/Å3 6544.6(10) 2518.7(2) 
Z 4 2 
ρ /g cm–3 1.243 1.230 
 /mm–1 0.162 0.087 
F(000) 2624 1008 
total reflections 33428 27939 
unique reflections (Rint) 10277 (0.0743) 12502 (0.0459) 
observed reflections [Fo>4σ(Fo)] 5958 5588 
GOF on F2a 1.008 1.016 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0563, 0.1326 0.1295, 0.3990 
largest diff. peak and hole (eÅ–3) 0.233, -0.407 1.506, -0.656 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2. 
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Table B8 Crystal data and structure refinement information for compound dicamphSO2 crown-6 
(60). 
Compound dicamphSO2 crown-6 
(60) 
empirical formula C78H112O19.Si2∙ ½ H2O 
M 1426.80 
crys syst Triclinic 
space group P 1 
a/Å 15.4379(8) 
b/Å 15.8165(8) 
c/Å 17.7024(8) 
/° 70.226(2) 
/° 72.490(2) 
/° 84.648(2) 
V/Å3 3878.9(3) 
Z 2 
ρ /g cm–3 1.222 
 /mm–1 1.184 
F(000) 1538 
total reflections 65317 
unique reflections (Rint) 27089 (0.0399) 
observed reflections [Fo>4σ(Fo)] 25856 
GOF on F2a 1.006 
R indices [Fo>4σ(Fo)]bR1, wR2 0.0642, 0.1834 
largest diff. peak and hole (eÅ–3) 0.690, -0.477 
 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections and 
p the number of parameters. bR1 = Σ║Fo│-│Fc║/Σ│Fo│, wR2 = [Σ[w(Fo2-
Fc2)2]/Σ[w(Fo2)2]]1/2. 
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ORTEP view of crystal structures  
For all crystal structures, the hydrogen atoms of the alkyl chains have been omitted for 
clarity. 
 
Figure B1 ORTEP view (20% probability level) of Mono-TBDMS resorcinarene (32).  
 
Figure B2 ORTEP view (20% probability level) of Prox-TBDMS resorcinarene (33).  
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Figure B3 ORTEP view (20% probability level) of Distal-TBDMS resorcinarene (34).  
 
Figure B4 ORTEP view (20% probability level) of Tri-TBDMS resorcinarene (35). One of two 
independent molecules. 
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Figure B5 ORTEP view (20% probability level) of Mono-TBDPS resorcinarene (40). The 
hydrogen atoms of the water molecules could not be located in the difference 
Fourier map.  
 
Figure B6 ORTEP view (20% probability level) of Distal-TBDPS resorcinarene (42). The 
hydrogen atoms of the water molecules could not be located in the difference 
Fourier map. 
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Figure B7 ORTEP view (20% probability level) of Distal-OBn resorcinarene (46). One of two 
independent molecules. 
 
Figure B8 ORTEP view (20% probability level) of Distal-TBDMS resorcinarene (38).  
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Figure B9 ORTEP view (20% probability level) of DiMeSO2 diTBDMS resorcinarene (48). 
 
Figure B10 ORTEP view (20% probability level) of DiOBn diTBDMS resorcinarene (49). 
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Figure B11 ORTEP view (20% probability level) of DiOBn crown-5 resorcinarene (53). 
 
Figure B12 ORTEP view (20% probability level) of DiOBn crown-6 resorcinarene (54). 
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Figure B13 ORTEP view (20% probability level) of DiOBn crown-7 resorcinarene (55). 
 
Figure B14 ORTEP view (20% probability level) of DiOH crown-6 resorcinarene (57). 
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Figure B15 ORTEP view (20% probability level) of Dicamphorsulfonate crown-6 resorcinarene 
(60) diastereomeric mixture crystallised from diethyl ether. One of two independent 
molecules. 
 
  
 
 
Appendix B - 19 
References 
1. SADABS Bruker Analytical X-ray Systems: Madison, Wisconsin, USA, 2004. 
2. Sheldrick, G. M. SADABS v2.03: Area-Detector Absorption Correction, 
University of Göttingen: Germany, 1999. 
3. SAINT Software Users Guide, Version 6.0, Bruker Analytical X-ray Systems: 
Madison, Wisconsin, USA, 1999. 
4. CrysAlisPro 1.171.38.41, Rigaku Oxford Diffraction: 2015. 
5. Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacovazzo, C.; 
Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R., J. Appl. Cryst 
1999, 32, 115-119. 
6. Sheldrick, G., Acta Crystallographica Section A 2008, 64 (1), 112-122. 
7. Farrugia, L., J. Appl. Crystallogr. 2012, 45 (4), 849-854. 
8. van der Sluis, P.; Spek, A. L., Acta Crystallographica Section A 1990, 46 (3), 
194-201. 
 

 
 
 
 
 
 
Appendix C 
Membrane Transport 
UV-Vis Data 
 
Appendix C 
 
The membrane transport of salbutamol was monitored by UV-vis spectrometry using 
a GBC UV/VIS 916 UV-vis spectrometer scanning from 200-400 nm at a speed of 
480 nm/min and step size of 1 nm. Each experiment was repeated in multiple runs 
for consistency. 
An example of the UV-vis spectra from one run is given on page 1. 
For each spectrum, the absorbance at 224 nm was plotted against time to give the 
amount of salbutamol present in the receiving phase over the course of the run. This 
data for every run is presented in a graph for each experiment. For some 
experiments, the consistent runs without outliers, were selected for the average to be 
calculated – these selected runs are presented in a second graph. 
The experiments were conducted using salbutamol in 5 equivalents (pages 2-16) and 
10 equivalents (pages 17-27). 
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